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PREFACE
This thesis is the compilation of published and unpublished work on probing
the role of sulfenylation in redox regulation of protein kinases. Hydrogen peroxide
(H2O2) functions as a secondary messenger to regulate signal transduction networks,
largely through modification of specific cysteine residues in redox-sensitive target
proteins. Cysteine sulfenic acid (sulfenylation) is a reversible modification and is the
direct product of the reaction between H2O2 and a protein thiolate. Sulfenylation has
emerged as a central mechanism utilized by proteins to detect changes in the cellular
redox balance, and is also correlated with disease states associated with chronic H2O2
levels.
In Chapter 1, we present a historical overview of EGFR and signal-mediated pro-
duction of H2O2 as well as the molecular mechanisms involved in redox regulation of
this pathway. We begin by highlighting studies linking EGFR activation to endoge-
nous H2O2 production and examine the effects of redox modulation on downstream
signaling pathways. Finally, we discuss recent examples that identify direct oxidation
of EGFR and how these discoveries form the basis for understanding redox-based
kinase signaling and development of therapeutic strategies. This work has been pub-
lished as a review: Truong, T. H. and Carroll, K. S. (2012). "Redox Regulation
of Epidermal Growth Factor Receptor Signaling through Cysteine Oxidation." Bio-
chemistry. 51 (50), 9954-9965.
In Chapter 2, we present the development and application of an approach that
allows relative quantification of sulfenic acids using a pair of light and heavy isotope
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labeled probes (DAz-2 and d6-DAz-2) in conjunction with a complementary acid-
cleavable linker (Yn-ACL). This method can be used to directly map sites of cysteine
oxidation and compare sulfenylation levels in normal and disease states. This work
has been published as: Truong, T. H., Garcia, F. J., Seo, Y. H. and Carroll, K.
S. (2011). "Isotope-coded chemical reporter and acid-cleavable affinity reagents for
monitoring protein sulfenic acids." Bioorg. Med. Chem. Lett. 21 (17), 5015-5020.
In Chapter 3, we report the development and application of a new alkyne-based
probe (DYn-2) for detection of sulfenic acids. These studies demonstrate EGF-
mediated signaling induces endogenous H2O2 production and dynamic changes in
global protein sulfenylation in A431 cells. Three protein tyrosine phosphatases (SHP2,
PTEN, and PTP1B) were observed to undergo ligand-dependent oxidation and ex-
hibit a unique sulfenylation profile in situ. In addition, EGFR was identified as a
direct target of signal-derived H2O2 at its active site cysteine (Cys797), which en-
hances its inherent kinase activity. This work has been published as: Paulsen, C.
E., Truong, T. H., Garcia, F. J., Homann, A., Gupta V., Leonard, S. E., Carroll,
K. S. (2011). "Peroxide-dependent sulfenylation of the EGFR catalytic site enhances
kinase activity." Nat. Chem. Biol. 8 (1), 57-64.
In Chapter 4, we perform molecular characterization of EGFR sulfenylation to
delineate the role of Cys797 and determine its effect on receptor activity. Mutation
of this residue abrogates kinase activation, sulfenylation, and decreases its affinity for
ATP. Moreover, oxidation affects the propensity of Cys797 to undergo sulfenylation
in oncogenic EGFR mutants and affects the potency of inhibitors that target this
residue in its reduced thiolate form. Additionally, we explore the possibility that other
kinases harboring a structurally homologous cysteine to Cys797 may be subjected to
redox-based regulation through this residue. This work is currently in preparation
for publication.
In Chapter 5, we report the development of a panel of first-generation nucleophilic
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RSOH-targeted inhibitors and evaluate compound potency and selectivity towards
Cys797 in response to concomitant EGFR oxidation. We demonstrate our nucle-
ophilic compounds are capable of potent inhibition towards EGFR under oxidizing
conditions and occur through partial irreversible mechanisms. Our work provides
proof of principle and indicates that the propensity of EGFR Cys797 to undergo
sulfenylation can be exploited to develop new classes of inhibitors. This work is
current in preparation for publication.
Chapter 6 is a discussion of future directions for the continued study of the molec-
ular mechanisms underlying redox-based regulation of protein kinases and the devel-
opment of redox-based nucleophilic inhibitors towards EGFR.
Appendix 1 is a collection of protocols that presents a series of methods utilizing
the application of sulfenic acid probes for in vitro and in situ detection of sulfenyl
modifications. This work has been published as: Truong, T. H. and Carroll, K. S.
(2012). "Bioorthogonal Chemical Reporters for Analyzing Protein Sulfenylation in
Cells." Curr. Protoc. Chem. Biol. 4, 101-122.
Appendix 2 is a comprehensive discussion of the molecular mechanisms involved
in redox regulation of protein kinases and downstream signaling pathways. This work
has been published as a review: Truong, T. H. and Carroll, K. S. (2013). "Redox
Reguation of Protein Kinases." Crit. Rev. Biochem. Mol. Biol. 48 (4), 332-356.
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ABSTRACT
Probing the Role of Sulfenylation in Redox Regulation of Protein Kinases
by
Thu H. Truong
Co-Chairs: Kate S. Carroll and Anna K. Mapp
Hydrogen peroxide (H2O2) functions as a secondary messenger to regulate intracel-
lular signaling cascades, largely through the modification of specific cysteine residues
within redox-sensitive targets such as protein kinases. Oxidation can influence kinase
activity in physiology and pathology, but the molecular mechanisms underlying these
events remain largely unknown. In the present study, we present the development and
application of chemical tools to detect and quantify changes in sulfenic acid forma-
tion (sulfenylation). These tools were used to demonstrate epidermal growth factor
(EGF)-mediated signaling induces global and dynamic changes in protein sulfeny-
lation. Three protein tyrosine phosphatases (PTPs) were shown to undergo EGF-
dependent oxidation and exhibit a unique sulfenylation profile in cells, suggesting the
extent of sulfenylation may be related to differences in subcellular locations of target
proteins. In addition, epidermal growth factor receptor (EGFR) was identified as a
direct target of signal-derived H2O2 at its active site cysteine (Cys797). Sulfenyla-
tion of EGFR Cys797 enhances its intrinsic tyrosine kinase activity, and subsequent
work has demonstrated mutation of this residue abrogates EGFR autophosphory-
lation, sulfenylation, and decreases its affinity for ATP. These results highlight the
xxii
importance of Cys797 with respect to EGFR function during normal cell signaling.
Nine additional kinases harbor a cysteine residue that is structurally homologous to
Cys797, and we present evidence that these kinases may be similarly regulated by
oxidation of this residue. EGFR is mutated or amplified in a number of human car-
cinomas, and the proximity of Cys797 in the kinase domain potentially renders it
more sensitive to oxidation in oncogenic mutants as shown by our data. Interestingly,
EGFR Cys797 serves as a therapeutic target for covalent inhibitors that react with
the reduced residue through electrophilic Michael addition. Oxidation of Cys797 al-
ters the potency of current EGFR inhibitors that cannot recognize the kinase in its
sulfenyl form. We report the development of a panel of first-generation nucleophilic
RSOH-targeted inhibitors and evaluate compound potency towards EGFR Cys797
in response to concomitant oxidation. Collectively, the results of this thesis provide
novel insight into how oxidative modification of kinases affects signal transduction
pathways and have broad implications for therapeutics in disease states.
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CHAPTER I
Redox Regulation of Epidermal Growth Factor
Receptor Signaling Through Cysteine Oxidation
1.1 Abstract
Epidermal growth factor receptor (EGFR) exemplifies the family of receptor tyro-
sine kinases that mediate numerous cellular processes including growth, proliferation
and differentiation. Moreover, gene amplification and EGFR mutations have been
identified in a number of human malignancies, making this receptor an important
target for the development of anticancer drugs. In addition to ligand-dependent ac-
tivation and concomitant tyrosine phosphorylation, EGFR stimulation results in the
localized generation of H2O2 by NADPH-dependent oxidases. In turn, H2O2 func-
tions as a secondary messenger to regulate intracellular signaling cascades, largely
through the modification of specific cysteine residues within redox-sensitive protein
targets, including Cys797 in the EGFR active site. In this review, we highlight recent
advances in our understanding of the mechanisms that underlie redox regulation of
EGFR signaling and how these discoveries may form the basis for development of new
therapeutic strategies to target this and other H2O2-modulated pathways.
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1.2 Redox Regulation of EGFR Signaling Through Cysteine
Oxidation
Activation of receptor tyrosine kinases (RTKs) by their respective extracellular
ligands (e.g. growth factors) initiates signaling cascades that regulate cellular prolif-
eration, differentiation, migration, and survival (1). Among the 58 RTKs identified in
the human genome, epidermal growth factor (EGF) receptor (EGFR) has served as
the quintessential model for understanding RTK biology in physiological signaling and
cancer. EGFR, also known as HER1 (or erbB1), is a transmembrane protein grouped
into a subfamily that consists of three additional, closely related receptors: HER2
(erbB2), HER3 (erbB3), and HER4 (erbB4). EGFR is comprised of a glycosylated
extracellular ligand-binding domain, a transmembrane domain, and an intracellular
domain containing its tyrosine kinase core. In response to ligand (e.g. EGF) binding,
EGFR forms homo- or heterodimers with other HER family members, followed by
autophosphorylation of key tyrosine residues located within the tyrosine kinase do-
main (2). Once activated, EGFR relays the signal through a variety of downstream
intracellular signaling cascades, including the Ras/mitogen activated protein kinase
(MAPK) pathway or the phosphatidylinositol 3 kinase (PI3K)/Akt pathway. Since
its discovery (3–6), EGFR has been widely studied in regards to its physiologic and
pathological settings. In particular, EGFR and related family members have been
found to be mutated or amplified in a number of human lung and breast cancers,
rendering them an attractive target for the development of therapeutics (7–9).
Beginning in the 1990s, data from several research groups demonstrated that
EGF binding to EGFR triggered the production of endogenous hydrogen peroxide
(H2O2) in cells (Figure 1.1) (10, 11). Moreover, it was also established that other
growth factors [FGF (12), PDGF (13), VEGF (14), insulin (15)], cytokines [TNF-
α (12, 16), interleukin-1 (16)], and angiotensin II (17) stimulate H2O2 generation.
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Although chronic exposure to high concentrations of H2O2 can lead to a cellular
condition known as oxidative stress, cells can also utilize H2O2 as a secondary mes-
senger to regulate physiological signal transduction (18–21). H2O2 modulates signal-
ing pathways largely through the modification of specific cysteine residues located
within redox-sensitive protein targets (Figure 1.2A). The direct product of the reac-
tion between H2O2 and a protein thiolate (RS−) is sulfenic acid (RSOH). Such protein
sulfenylation is reversible by thiol-disulfide oxidoreductases of the thioredoxin (Trx)
superfamily throughout the intracellular milieu and thus, constitutes a facile switch
for modulating protein function, akin to phosphorylation. Associated regulatory re-
dox modifications of cysteine include sulfenamides, nitrosothiols, disulfides, sulfinic,
and sulfonic acids (Figure 1.2B). Over the last several years, an increasing number
of studies have demonstrated important functional roles for protein sulfenic acids in
cell signaling (22–26). In particular, kinases and phosphatases are both known to
undergo cysteine-based redox regulation (27, 28) and the collective efforts of many
researchers have established that these enzymes are regulated by endogenous H2O2
produced during EGF-mediated cell signaling (29).
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Figure 1: EGFR Timeline (Version 3)
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during EGF signaling. (85)
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Figure 1.1: EGFR Timeline. Timeline outlining key events and discoveries relating to redox
regulation of EGFR signaling through cysteine oxidation.
In this review, we present a historical overview of EGFR and ligand-mediated
production of H2O2 as well as the molecular mechanisms involved in redox regulation
of this signaling pathway (Figure 1.1). We begin by highlighting early studies linking
EGFR activation to EGF-induced H2O2 production. Subsequently, we address the ef-
fects of redox modulation on two major pathways downstream of EGFR, Ras/MAPK
and PI3K/Akt. Additionally, we discuss the interplay between H2O2-mediated inac-
tivation of protein tyrosine phosphatases (PTPs) and kinase activation on net cellular
levels of tyrosine (Tyr) phosphorylation. Key enzymes involved in the generation and
metabolism of H2O2 within EGFR signaling pathways will also be covered. Finally,
we focus on recent examples from the literature demonstrating direct oxidation and
regulation of EGFR by H2O2 and how these discoveries may form the basis for de-




































Figure 1.2: Oxidative modification of cysteine residues by hydrogen peroxide (H2O2). (A)
The initial reaction product of a thiolate with H2O2 yields sulfenic acid (RSOH). This modification,
also known as sulfenylation, is reversible and can be directly reduced back to the thiol form or
indirectly through disulfide bond formation. (B) Sulfenic acids can be stabilized by the protein
microenvironment and/or undergo subsequent modification. For example, they can condense with a
second cysteine in the same or different protein to generate a disulfide bond. Alternatively, reaction
with the low molecular weight thiol glutathione (GSH, red circle) affords a mixed disulfide through
a process known as S -glutathionylation. In a few proteins, such as PTP1B, nucleophilic attack of a
backbone amide on RSOH results in sulfenamide formation. Sulfenyl groups can also oxidize further
to the sulfinic (RSO2H) and/or sulfonic (RSO3H) acid form under conditions of high oxidative stress.
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1.3 Early Evidence for EGF-Mediated H2O2 Production and
Redox Regulation of EGFR Signaling
In 1995, Gamou and Shimizu published the first report to suggest a connection be-
tween H2O2 and EGFR. In this study, the authors examined the effect of exogenously
added H2O2 on EGFR phosphorylation (30). EGFR- hyper producing human squa-
mous carcinoma NA cells treated with H2O2 (0 - 1 mM) exhibited an increase in the
incorporation of [32P]-phosphate, albeit at half the signal observed for EGF-stimulated
cells. On the basis of data obtained from tryptic phosphopeptide mapping, this dis-
crepancy was attributed to the fact that H2O2 might preferentially enhance EGFR
Tyr phosphorylation, whereas EGF stimulation would trigger both serine/threonine
(Ser/Thr) as well as Tyr receptor phosphorylation.
During this same time frame (i.e. the mid-90s), the role of H2O2 expanded beyond
the traditional view as "toxic byproducts of aerobic metabolism" and began to emerge
as secondary messengers in physiological cell signaling. In order for H2O2 to serve as
a signaling molecule, its concentration must increase rapidly above the steady-state
threshold (i.e., high nanomolar to low millimolar) and remain elevated long enough
for it to oxidize protein effectors (31). In one of the earliest examples, platelet-derived
growth factor (PDGF) was shown to induce endogenous H2O2 generation, which is
correlated with enhanced Tyr phosphorylation, activation of MAPK pathways, DNA
synthesis, and chemotaxis (13). These results suggested that H2O2 might act as a
signaling molecule generated in response to growth factor stimulation. Soon there-
after, Rhee and colleagues reported that addition of EGF to EGFR-overexpressing
human epidermoid carcinoma A431 cells significantly elevated levels of intracellular
reactive oxygen species (ROS) (10) as measured by 2,7-dichlorofluorescein diacetate
(DCFH-DA) (32). Enzymes such as catalase, peroxiredoxins (Prxs), and glutathione
peroxidases (Gpxs) scavenge endogenous H2O2 by catalyzing the dismutation (cata-
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lase) or reduction (Prxs, Gpxs) of H2O2 (33, 34). Introduction of exogenous catalase
in EGF-stimulated A431 cells by electroporation attenuated the intracellular build-
up of ROS, suggesting that H2O2 was the major ROS involved in EGF-dependent
signal transduction (10). EGF-induced increases in Tyr phosphorylation levels of
PLC-γ1, a well-characterized physiological substrate of EGFR, were also blunted by
catalase incorporation. Although the precise role and/or target(s) of H2O2 generated
for EGFR signaling were not directly addressed in this study, the authors proposed
that inhibition of cysteine-dependent PTPs by H2O2 may be required to increase
the steady-state level of protein Tyr phosphorylation. This landmark contribution
by Rhee and coworkers set the stage for delineating the molecular details underlying
redox regulation of EGFR signaling.
In a separate study, Goldkorn et al. reported that exogenous H2O2 stimulated
EGFR tyrosine kinase activity and increased receptor half-life (35). Experiments per-
formed in A549 human lung adenocarcinoma epithelial cells and isolated membrane
fractions showed an increase in EGFR Tyr autophosphorylation levels when treated
with H2O2 (0-200 µM), and also markedly enhanced receptor activation in conjunction
with the native EGF ligand. Pulse-chase experiments with [35S]-methionine revealed
that EGFR half-life was 8 h when treated with EGF, whereas H2O2 treatment ex-
tended receptor half-life to 18 h (combined treatment with EGF and H2O2 yielded
a half-life of 12 h). Additionally, two-dimensional phosphoamino acid analysis cor-
roborated earlier findings (30) that the phosphorylation site distribution was shifted
predominantly towards Tyr after exposure to H2O2. On the basis of these data, the
authors of this study postulated that EGF- and H2O2-induced receptor activation
may have separate functions and represent an alternate mechanism by which EGFR
signaling can be tuned in parallel to treatment with its native ligand.
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1.4 Effect of H2O2 on Signaling Networks Downstream of EGFR
After ligand binding, EGFR transmits activation signals to prominent downstream
cascades, including the Ras/MAPK and PI3K/Akt pathways (Figure 1.3A). In ad-
dition to the overall increase in Tyr autophosphorylation of EGFR, the endogenous
generation of H2O2 also appears to modulate the activity of these two signaling routes.
Receptor activation initiates the Ras-Raf-MEK-Erk1/2 signaling module through re-
cruitment of Src homology 2 domain-containing (SHC) adaptor protein, growth factor
receptor-bound protein 2 (Grb2), and a guanine nucleotide exchange protein (SOS)
to form the SHC-Grb2-SOS complex, a process stimulated by elevated intracellular
H2O2 (36). Once associated with the receptor, SOS facilitates guanine nucleotide
exchange to activate Ras, which subsequently activates a kinase cascade including
Raf (MAP3K), MEK (MAP2K), and Erk1/2 (MAPK). Oxidative stress is known
to influence the MAPK signaling pathways, but little is known about the molecular
mechanisms responsible for such effects (37). For example, Erk1/2 is activated in
response to exogenous H2O2, which enhances cell survival after oxidant injury (38,
39). On the other hand, it is not known whether the activity of Erk1/2 kinase is
directly modulated by ROS.
EGFR also transmits signals through the PI3K/Akt pathway (40). In response to
EGF stimulation, PI3K increases the levels of phosphatidylinositol 3,4,5-trisphosphate
(PIP3), which leads to recruitment and activation of serine/threonine kinase, Akt at
the plasma membrane (41, 42). Activity of the PI3K/Akt pathway is balanced by ac-
tion of the opposing lipid phosphatase, PTEN, which will be discussed in later sections
of this review. In cells overexpressing the NADPH oxidase isoform Nox1, increased
endogenous H2O2 production elevates intracellular PIP3 levels and consequently abro-
gates the ability of PTEN to promote downstream signaling (43). EGFR-dependent
activation of Akt has also been shown to enhance cell survival during oxidative stress-
induced apoptosis, analogous to Erk1/2 (44). Interestingly, structural analysis by
8












































Figure 1.3: EGFR signaling pathways and general mechanisms for thiol-based redox mod-
ulation of signaling proteins. (A) Binding of EGF to EGFR induces receptor dimerization, fol-
lowed by autophosphorylation of tyrosine (Tyr) residues (red circles) within its cytoplasmic domain.
In turn, these phosphorylated Tyr residues serve as docking sites for associating proteins to activate
a number of downstream signaling cascades. Two such pathways, Ras/ERK and PI3K/AKT, are
shown here for simplicity. The EGF-EGFR interaction also triggers the assembly and activation of
NADPH oxidase (Nox) complexes, followed by subsequent production of H2O2 through spontaneous
dismutation or action of SOD. Once formed, endogenous H2O2 may pass through specific aquaporin
(AQP) channels and/or diffuse across the membrane to reach the intracellular cytosol. Transient
increases in H2O2 leads to the oxidation of local redox targets. (B) Model for redox-dependent signal
transduction. Protein tyrosine kinases (PTKs) catalyze the transfer of γ-phosphoryl groups from
ATP to tyrosine hydroxyls of proteins, whereas protein tyrosine phosphatases (PTPs) remove phos-
phate groups from phosphorylated tyrosine residues. PTPs function in a coordinated manner with
PTKs to control signaling pathways to regulate a diverse array of cellular processes. (C) Regulatory
cysteines in protein kinases can undergo oxidation/reduction to modulate their function. Depending
on the kinase, redox modifications can stimulate or inhibit function. (D) Oxidation of the conserved
active site cysteine residue in PTPs inactivates these enzymes, and can be restored by reducing the
oxidized residue to its thiol form. SOx: oxidized cysteine.
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x-ray crystallography has revealed that Akt2 can form an intramolecular disulfide
bond between two cysteines in the activation loop, which inhibits the kinase (45).
Overexpression of glutaredoxin (Grx) has been shown to protect Akt against H2O2-
induced oxidation, resulting in sustained phosphorylation of Akt and inhibition of
apoptosis (46). A more recent study is indicative of isoform-specific regulation of
Akt by PDGF-induced H2O2 (47). In particular, the authors demonstrate that Akt2
Cys124 undergoes sulfenic acid modification during growth factor signaling, which
inactivates the kinase.
EGFR activation can also occur through a process known as trans-activation. In
this scenario, ligand-inaccessible RTKs may still initiate downstream signaling in lieu
of ligand-receptor induced activation. Production of H2O2 induced by other ligands
such as angiotensin II activates c-Src, a redox-regulated kinase (48). In turn, EGFR
undergoes activation through c-Src initiated receptor Tyr phosphorylation to prop-
agate downstream signaling (48–50). Neighboring EGFR kinases may then undergo
activation in a lateral-based mechanism. Trans-activation represents another level by
which EGFR activity can be modulated by H2O2. In addition, other studies have
implicated oxidative inactivation of PTPs in promoting EGFR trans-activation (51).
1.5 Interplay of Reversible Tyrosine Phosphorylation and Re-
dox-Dependent Signaling
Regulation of tyrosine phosphorylation depends on the delicate balance between
the action of protein kinases and phosphatase (Figure 1.3B, and C). In EGFR sig-
naling, the coordinated regulation of this equilibrium allows for rapid response to
changing growth factor levels, whereas dysregulated kinase and phosphatase activity
can have severe pathological consequences such as cancer, diabetes, and inflamma-
tion (52, 53). Because the balance of these two opposing forces is a central event
10
in cell signaling, it is not surprising that phosphatase as well as kinase activities are
tightly regulated at several levels, including cysteine-based redox modulation. In large
part, owing to early studies carried out by Denu and Tanner (54), attention rapidly
focused on PTPs as the direct targets of H2O2 (Figure 1.3D). The PTP superfam-
ily contains a signature motif, (I/V)HCXXGXXR(S/T), which includes an invariant
cysteine residue that functions as a nucleophile in catalysis. The catalytic cysteine of
PTPs is characterized by a low pKa value ranging from 4.6 - 5.5 due to the unique
electrostatic environment of the active site, which also renders the enzyme susceptible
to inactivation by reversible oxidation (55, 56). Second-order rate constants for oxi-
dation of the PTP cysteine thiolate by H2O2 have been measured in vitro and range
from 10 to 160 M−1 s−1 (54, 57, 58).
Protein tyrosine phosphatase 1B (PTP1B) functions as a negative regulator of the
EGFR signaling pathway by directly targeting phosphorylated tyrosine residues that
control signaling output (59–62). Given that PTP1B is localized exclusively to the
cytoplasmic face of the endoplasmic reticulum (ER), it has been proposed to dephos-
phorylate activated EGFR at sites of contact between the ER and plasma membranes
or upon trafficking of internalized EGFR in close proximity to the ER (63, 64). Stud-
ies reported in 1998 provided the first indication that EGF-mediated H2O2 production
is correlated with oxidation and inactivation of PTP1B (65). Incorporation of radio-
labeled iodoacetic acid (IAA) a sulfhydryl-modifying reagent that reacts with active
site Cys215 of PTP1B (54) was decreased in PTP1B after EGF stimulation of A431
cells, consistent with oxidation of this essential residue. Conversely, treatment with
dithiothreitol (DTT), thioredoxin (Trx), or glutaredoxin (Grx) as reductants readily
reversed PTP1B inhibition. Interestingly, assays with recombinant protein indicated
that the Trx system functioned more efficiently as an electron donor for PTP1B reac-
tivation, as compared to Grx or glutathione (GSH), suggesting that Trx may function
as the physiological reductant (65).
11
The phosphatase and tensin homologue (PTEN) is another PTP known to main-
tain a closely intertwined relationship with EGFR. PTEN exhibits dual protein and
lipid phosphatase activity and functions as a negative regulator of the PI3K/Akt sig-
naling pathway (66), one of the two major signaling routes downstream of EGFR.
PTEN contains five cysteine residues in its catalytic domain and undergoes reversible
inactivation by H2O2 (67). Site-directed mutagenesis and mass spectrometry indi-
cated that Cys124 was the primary target of H2O2, yielding a sulfenic acid intermedi-
ate that condenses with Cys71 to form an intramolecular disulfide bond (68). Cellular
studies also point to a connection between growth factor-induced generation of H2O2
and reversible inactivation of PTEN. For example, EGF stimulation of cells results
in elevated levels of oxidized PTEN in lysates, as indicated by an electrophoretic mo-
bility shift assay that reports on disulfide formation (69). In an alternative approach,
protein thiols are alkylated by N -ethylmaleimide (NEM) in lysates generated from
growth factor stimulated cells. Reversibly oxidized protein thiols are then reduced
with DTT and alkylated with biotin-conjugated maleimide. This method was used
to examine reversible oxidation of PTEN in response to EGFR activation (69). To-
gether, these studies indicate that EGF-induced activation of PI3K correlates with
inactivation of the opposing phosphatase, PTEN. In this way, PTEN inactivation
by endogenous H2O2 serves as a positive feedback loop to enhance PIP3 accumula-
tion/Akt activation during EGFR signaling.
SHP2 and DEP-1 represent two additional phosphatases that have been shown to
interact with EGFR. SHP2 directly associates with EGFR through its SH2 domains
and regulates receptor interactions with downstream signaling components such as
Ras (70). Co-localization of SHP2 with EGFR occurs at low nanomolar concentra-
tions (4 ng/ml) of EGF, and was identified as the most sensitive PTP in response to
signal-derived H2O2 (71). It is unknown if DEP-1 co-localizes with EGFR intracellu-
larly, albeit evidence implicates in vitro oxidation of DEP-1 (72).
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1.6 Generation and Metabolism of H2O2 During EGFR Sig-
naling
The family of NADPH oxidase (Nox) enzymes and their dual oxidase counterparts
(Duox) generate superoxide by transferring electrons from cytosolic nicotinamide ade-
nine dinucleotide phosphate (NADPH) to molecular oxygen (73). Once it is generated,
superoxide is dismutated spontaneously ( 105 M−1 s−1 at pH 7) or enzymatically by
superoxide dismutase (SOD; 109 M−1 s−1) to H2O2 and molecular O2 (74, 75). The
prototypical Nox isoform, Nox2 (also known as gp91phox) was originally identified
and characterized in macrophages and neutrophils, where it functions as an integral
part of the innate immune system (76). The active form of Nox2 exists as a multi-
subunit complex, consisting of the membrane-bound cytochrome b558 (gp91phox and
p22phox), several cytosolic proteins (p47phox, p40phox, p67phox), and the small GT-
Pase Rac1. Since the initial discovery of Nox2, other Nox homologues (Nox 1-5 and
Duox 1-2) have been identified in almost every cell type, localized both to the plasma
membrane (where they produce superoxide extracellularly) as well as intracellular
organelles, and serve as major sources of H2O2 for signaling (77–79).
Several Nox isoforms play a critical role in EGFR-mediated signaling cascades.
For example, Park et al. demonstrated that the PI3K pathway constitutes a posi-
tive feedback loop for Nox1 activation in growth factor-stimulated cells (43). This
study demonstrated that the Rac-guanine nucleotide exchange factor (GEF) β-Pix is
required for and also augments EGF-induced generation of H2O2. In this loop, β-Pix
and activated Rac1 bind to the C-terminal region of Nox1, relieving auto-inhibitory
constraints. Independent studies have also shown that phosphorylation of Nox acti-
vator 1 (NOXA1) on Ser282 by Erk1/2 kinases and on Ser172 by protein kinases C
and A decreases Rac1 binding to down-regulate Nox1 (80, 81).
Nox4 is an isoform that regulates the activity of internalized EGFR. Keaney and
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colleagues report that Nox4 is localized to the ER in vascular endothelial cells where
it appears to regulate the activity of PTP1B in a spatially dependent manner (82).
Nox4-dependent oxidation of PTP1B required co-localization of both proteins in the
ER, as shown by targeting PTP1B to the cytoplasm. Importantly, the study also
demonstrated that Nox4-dependent oxidation and inactivation of PTP1B is correlated
with reduced phosphorylation of EGFR in proximity to the ER. The significance of
co-localization was also verified by ER-targeting of the antioxidant enzyme, catalase.
Lastly, EGF-stimulation of A431 cells leads to specific complex formation between
Nox2 and EGFR, as demonstrated by co-immunoprecipitation experiments (71).
Superoxide dismutase 1 (SOD1) is another enzyme involved in redox mediation
of growth factor signaling. SOD1 is an abundant copper/zinc enzyme located in the
cytoplasm and belongs to the SOD family of enzymes. Other members of this fam-
ily include mitochondrial SOD2 (manganese) and extracellular SOD3 (copper/zinc).
Although superoxide can spontaneously dismutate to form H2O2, the second-order
rate constant of the reaction is enhanced over 10,000-fold by SOD (74, 75). Indeed,
SODs catalyze the conversion of superoxide into H2O2 and molecular O2 to maintain
superoxide at low steady-state concentration ( 10−10 M) (83, 84). Inhibition of SOD1
by the tetrathiomolybdate inhibitor, ATN-224, increases the intracellular concentra-
tion of superoxide at the expense of H2O2 production, thereby attenuating EGFR
and Erk1/2 phosphorylation (85).
Membrane transport represents another important mechanism to modulate en-
dogenous H2O2 produced during EGFR signaling. Early studies demonstrated that
EGF stimulation of cells leads to a rapid increase in the concentration of extracellular
H2O2 and that the addition of catalase to culture medium was sufficient to inhibit
EGFR autophosphorylation (86, 87). These findings raise the question of how extra-
cellularly generated H2O2 could mediate intracellular signaling pathways. Although
it had been largely assumed that H2O2 could diffuse across cellular membranes, more
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recent evidence indicates that H2O2 may preferentially enter the cell through specific
plasma membrane aquaporin channels (88–90). Collectively, these studies suggest
that the number or type of aquaporins expressed on the cell surface might modulate
the level of intracellular H2O2 available for signaling.
Efforts have also focused on delineating mechanisms to regulate intracellular H2O2
levels during EGF-mediated signaling. In this regard, superoxide dismutases, cata-
lase, and other peroxidases all function to protect cells against undue oxidative stress.
Prxs are a family of thiol-based peroxidases that catalyze the dismutation of H2O2
into water and molecular oxygen (91). Prx possesses two cysteines that transiently
oxidize to form a disulfide as it metabolizes H2O2. The disulfide in Prx is subse-
quently reduced by the protein disulfide reductase, Trx, to complete the catalytic
cycle. Overexpression of the PrxII isoform reduces EGF-induced intracellular H2O2
levels (92). Another study demonstrated that PrxII overexpression is associated
with a decrease in EGF-induced cellular PIP3, whereas a dominant negative (DN)
form of PrxII increased PIP3 levels, presumably by H2O2 modulation of PTEN re-
dox state (69). Similarly, overexpression of another antioxidant enzyme, glutathione
peroxidase-1 (Gpx1), decreased Tyr phosphorylation of EGFR, activation of Akt,
and cellular proliferation (93). In addition to SODs and peroxidases, cells rely
on the glutaredoxin/glutathione (Grx/GSH), Trx/thioredoxin reductase (Trx/TrxR),
and glutathione/glutathione reductase (GSH/GSR) buffering systems. For exam-
ple, EGFR signaling is associated with subcellular compartmental oxidation of Trx1.
Jones and colleagues have measured the redox states of cytosolic and nuclear Trx1 and
mitochondrial Trx2 using redox Western blot methods during endogenous H2O2 pro-
duction induced by EGF signaling (94). Interestingly, results from this study showed
that only the cytoplasmic Trx1 pool undergoes significant oxidation in response to
growth factor treatment. Furthermore, the GSH/GSSG redox couple, which was
also examined in this study, did not undergo oxidation. This work suggests that
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physiological H2O2 generation in response to EGF signaling is specifically associated
with oxidation of the Trx1 system and not the GSH system. However, whether Trx1
oxidation is part of the signaling mechanism itself or simply results from peroxidase-
dependent termination of the redox signal remains an active area of investigation.
The estimated intracellular steady-state concentration of H2O2 hovers in the low-
nanomolar to low-micromolar range (31). Then again, these estimates assume that
H2O2 is uniformly distributed throughout the cell. Given that the source of H2O2
produced for EGF signaling (e.g. Nox enzymes) are localized to specific regions of
the cell, it stands to reason that signal mediated changes in H2O2 concentration may
not be homogenous throughout the cell. Rather, the oxidant concentration near a
source of generation must achieve high local concentrations to function effectively
as a second messenger. A growing body of research has focused on delineating the
mechanisms that facilitate localized rises in intracellular H2O2 during growth factor
signaling. Although the cell contains millimolar concentrations of GSH, it reacts
too slowly with H2O2 to provide much buffering capacity (95). By contrast, Prxs
are extremely efficient at H2O2 elimination, reducing H2O2 at second-order rate con-
stants of 105-108 M−1s−1 (96, 97). Recent work reported by the Rhee laboratory has
shown that membrane localized PrxI can be deactivated by phosphorylation in EGF-
stimulated cells and in mice during wound healing (98). Knockdown experiments
suggested that c-Src kinase is at least partially responsible for PrxI phosphorylation.
RTK activation (e.g. PDGFR) can also lead to overoxidation of the PrxII isoform
catalytic cysteine to sulfinic acid, resulting in a transiently inactivated protein (98).
Collectively, these studies demonstrate that selective inactivation of PrxI and PrxII
allows for transient H2O2 accumulation around plasma membranes where signaling
components are concentrated, while simultaneously preventing toxic accumulation of
ROS elsewhere in the cell during EGF signaling (Figure 1.4). Other mechanisms to
modulate localized redox buffering capacity surely await discovery.
16




















Figure 1.4: Redox regulation of peroxiredoxins (Prxs) during EGFR signaling. Receptor
activation results in localized phosphorylation and inactivation of peroxiredoxin I (PrxI) by PTKs,
such as the redox-regulated cytoplasmic Src (c-Src). Deactivation of PrxI diminishes the redox-
buffering capacity adjacent to the cell membrane, allowing for a transient and localized increase in
H2O2 levels for signal transduction. Additionally, elevated H2O2 concentrations can inactivate Prx2
by oxidation of its catalytic cysteine to sulfinic acid.
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1.7 Regulation of Intrinsic EGFR Tyrosine Kinase Activity
Through Cysteine Oxidation
As outlined above, a growing body of evidence demonstrates that EGFR activity
and downstream signaling pathways are regulated by redox-based mechanisms. Up
until this point we have only considered downstream events that enhance the overall
extent of EGFR activation, such as PTP inactivation. We have also highlighted key
regulatory themes in redox signaling, including co-localization of sources/targets of
H2O2 and modulation of local redox buffering capacity. Until recently, there was scant
evidence to indicate that the intrinsic tyrosine kinase activity of EGFR itself might be
regulated by endogenous H2O2 produced during cell signaling (99–101). In the section
below, we recount recent work from our own laboratory, which has demonstrated that
EGFR is directly modulated by endogenous H2O2, as well as studies from other groups
that hint at the possibility of modification by reactive nitrogen species (RNS).
Previous data from our group demonstrated that breast cancer cells associated
with increased expression of EGFR is correlated with a substantial increase in pro-
tein sulfenylation (102). Prompted by this observation, we conducted a more detailed
investigation of EGF-induced protein sulfenylation in A431 cells (71). Facilitating
these studies, we have recently described a new technology that allows for the detec-
tion and visualization of sulfenylation proteins within intact cells (103–106), thereby
circumventing concerns associated with the analysis of lysates/homogenates includ-
ing limited spatial-temporal resolution and oxidation artifacts inherent to the lysis
procedure (107). Inspired by earlier work demonstrating the selective reaction of
5,5-dimethyl-1,3,-cyclohexanedione (commercially known as dimedone) with protein
sulfenic acids (108) (Figure 1.5A), we developed a suite of bi-functional probes that
contain a membrane-permeable analog of dimedone coupled to an azide or alkyne
chemical handle (Figure 1.5B). An orthogonally functionalized biotin or fluorescent
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tag can be appended post-cell labeling for detection via the Staudinger ligation (109)
or Huisgen [3+2] cycloaddition also known as click chemistry (110). Overall, this gen-
eral approach provides a facile method for monitoring protein sulfenylation directly
in living cells (Figure 1.5C).

































Figure 1.5: General strategy for detecting protein cysteine sulfenylation (RSOH) in
cells. (A) Chemoselective reaction between sulfenic acid and 5,5-dimethyl-1,3-cyclohexanedione
(dimedone, 1). (B) Azide and alkyne-functionalized small-molecule probes for trapping and tagging
protein sulfenic acids include DAz-2 (2) and DYn-2 (3). (C) Detection of protein sulfenic acids in
living cells. Target cells are incubated with cell-permeable probes to trap and tag protein sulfenic
acids in situ. In subsequent steps, lysates are prepared and tagged proteins are further elaborated by
attachment of biotin or fluorescence labels via click chemistry and enables detection by Western blot
or in-gel fluorescence. Alternatively, biotinylated proteins may be enriched for proteomic analysis.
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Employing this method, we demonstrated that EGFR undergoes sulfenylation in
response to EGF addition, even at low-nanomolar concentrations of growth factor (71)
(Figure 1.6A). Reciprocal immunoprecipitation analysis also showed that EGFR and
Nox2 became associated in an EGF-dependent fashion (71). The intracellular kinase
domain of EGFR contains six cysteine residues, one of which (Cys797) is located in the
ATP-binding pocket (Figure 1.6B) and is conserved among nine additional receptor
and non-receptor tyrosine kinases (Figure 1.6C) (111). Given its active site location
and conservation, we hypothesized that Cys797 might be preferentially targeted by
endogenous H2O2. Of particular relevance, this residue is selectively targeted by ir-
reversible EGFR inhibitors, such as afatinib, extensively used in basic research and
clinical trials for breast and non-small cell lung cancers (112, 113). Consistent with
this proposal, pre-treatment of cells with inhibitors that irreversibly modify Cys797
prevented sulfenylation of EGFR. Mass spectrometry was subsequently used to ver-
ify Cys797 as the specific site of oxidation. Finally, oxidation of Cys797 increased
EGFR kinase activity by approximately five-fold. To put these findings into con-
text, a comparable degree of stimulation is observed for L858R and T790M oncogenic
EGFR mutations (114–116). Beyond the A431 cell line model, recent studies in our
group also indicate that wild type and several activated mutant EGFR kinases un-
dergo sulfenylation in both lung and breast tumors (T.H.T. and K.S.C., unpublished
data). Hence, it appears that oxidation of specific residues in PTPs (catalytic Cys)
and EGFR (Cys797) both contribute to an increase in downstream signaling (Fig-
ure 1.6A). Current work is directed toward understanding the molecular mechanism
by which sulfenylation of EGFR Cys797 enhances kinase activity. The proximity of
Cys797 to the ATP ligand as well as the C-helix and activation segment raises the














































































































































Figure 1.6: Model for H2O2-dependent regulation of EGFR tyrosine kinase activity. (A)
Binding of EGF induces production of H2O2 through Nox2. Nox-derived H2O2 directly modifies
EGFR cysteine (Cys797) to sulfenic acid in the active site, which enhances its tyrosine kinase activity.
Endogenous H2O2 can also oxidize and deactivate localized PTPs, leading to a net increase in EGFR
phosphorylation. (B) Crystal structure of the EGFR kinase domain (PDB 3GT8) bound to AMP-
PNP, a hydrolysis resistant ATP analog, and Mg2+. Dashed yellow lines and accompanying numbers
indicate the distance (Å) between the γ-sulfur atom of Cys797 and key substrate functional groups.
Note also that Cys797 can adopt different rotamers and sulfenylation of this residue may enhance
its ability to participate in electrostatic and hydrogen-bonding interactions with its substrate. (C)
Abbreviated sequence alignment of EGFR and nine other kinases that harbor a cysteine at the
structural position that corresponds to Cys797 (adapted from ref. (113)).
We have also applied our chemical biology approach to monitor global changes in
EGF-dependent protein sulfenylation (71). Interestingly, growth factor addition led
to widespread changes in protein sulfenylation within cells. EGF induced cysteine ox-
idation in a dose- and time-dependent manner and was accompanied by concomitant
fluxes in intracellular H2O2. Additional experiments showed that treatment with
cell-permeable PEGylated catalase attenuated EGF associated changes in protein
sulfenylation, underscoring the importance of endogenous H2O2. Although sulfenyla-
tion of EGFR (and several PTPs) were the focus our recent study (71), many protein
targets of EGF-induced endogenous H2O2 remain to be identified and will necessitate
large-scale proteomic analysis.
Remarkably, a number of studies indicate that EGFR may also undergo modula-
tion by RNS at cysteine residues distinct from Cys797. Reaction of cysteine thiols
with RNS, such as nitric oxide (NO), generates nitrosothiols (S-NO). This process,
known as S-nitrosylation, is a well-established reversible post-translational cysteine
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modification and has been implicated in proliferative and anti-proliferative cellular ef-
fects (117). The approach most often used to identify protein nitrosothiols is known as
the biotin switch technique (BST) (118). The BST is an indirect method whose suc-
cess relies heavily on the alkylation of free thiols and the selectivity/efficiency of the
ascorbate reducing agent towards nitrosothiols (119, 120). Nonetheless, this method
was utilized in two separate studies reporting S-nitrosylation of EGFR. Treatment
of several cell types with one millimolar of an exogenous nitric oxide (NO) donor
1,1-diethyl-2-hydroxy-2-nitrosohydrazine (DEA-NO) inhibited EGFR autophospho-
rylation (121, 122). Serine mutation of EGFR Cys166, located in the extracellular
domain, rendered the receptor resistant to NO-induced inhibition. Alternatively, an-
other cysteine residue located at the extracellular EGFR ligand-binding interface
undergoes nitrosylation after exposure to one millimolar of exogenous NO donor
S-nitroso-L-cysteine (Cys-NO) (123). S-nitrosylation of these residues may inhibit
EGFR-mediated signaling by interfering with the ligand interaction site, although
this proposal awaits evaluation. By contrast, a more recent study demonstrates
that S-nitrosylation induced by the chemical NO donor (Z)-1-[N-(2-aminoethyl)-N-(2-
ammonioethyl)amino] diazen-1-ium-1,2-diolate known as DETA-NO can upregulate
EGFR signaling and correlates with a transformed breast cancer phenotype (124,
125). An important area for future research is to determine whether EGFR under-
goes direct S-nitrosylation in response to physiological stimuli.
1.8 Future Perspectives
Of the 95 receptor and non-receptor PTKs in the human genome, nine additional
members harbor a cysteine residue that is structurally homologous to EGFR Cys797
(Figure 1.6C), including two EGFR subfamily members, HER2 and HER4. Although
speculative at this time, it is possible that this group of kinases is regulated by
oxidation of this residue. EGFR Cys797 and its structural analogues are located at
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the N-terminal end of an alpha helix, also known as the Ncap position. Interestingly,
cysteine is the most sparsely occurring Ncap residue in natural proteins, comprising
less than 1% of all these positions (126). Interaction of a cysteine located at the
Ncap position with the helix dipole can drastically lower thiol pKa and increases its
reactivity (127, 128). Of note, the Ncap effect has also been attributed to the reactivity
of the human PrxI catalytic cysteine (98). Another subfamily of PTKs, which includes
cytoplasmic Src and FGFR1, contains a cysteine located within a glycine rich loop
that interacts with the γ-phosphate of ATP (129). Oxidation of this residue inhibits
the kinase activity of c-Src and FGFR1 in vitro; however neither kinase has been
confirmed as a direct target of endogenous H2O2 in cells. Over 150 kinases have a
cysteine in or around the nucleotide-binding site, some of which may play similar
regulatory roles. However, much more work will be required to define the scope and
molecular details underlying the redox-regulated kinome.
EGFR is mutated or amplified in a number of human carcinomas including breast
and lung cancers, which has motivated the development of selective kinase inhibitors,
including analogs that covalently modify Cys797 and are currently in Phase II and III
clinical trials (130). The recent finding that EGFR Cys797 undergoes sulfenic acid
modification (71) and that elevated EGFR and HER2 in cancer cells correlates with
a substantial increase in global protein sulfenylation (102), raises several fundamental
questions vis-à-vis cysteine oxidation and thiol-targeted irreversible inhibitors. For
example, the acrylamide moiety of irreversible EGFR inhibitors undergoes Michael
addition with Cys797 in its thiol form, but these inhibitors would not react with the
sulfenic acid or other cysteine chemotypes (Figure 1.7A). Thus, oxidation of Cys797
could affect the potency of these inhibitors, particularly under conditions of oxida-
tive stress often associated with cancer. On the other hand, the sulfenic acid moi-
ety represents an entirely new opportunity in covalent inhibitor design whereby the
electrophilic S-atom is targeted using a nucleophilic warhead (Figure 1.7B). In this
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approach, the propensity for specific cysteine residues in kinases, and other thera-
peutically important proteins, to undergo sulfenylation could be exploited for the
development of inhibitors that target this unique modification, similar to the proof-
of-concept compounds we have recently reported to target oxidized PTPs (131).
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Figure 1.7: Covalent cysteine-based protein targeting strategies. (A) Conventional covalent
inhibitors of kinases inactivate their target through covalent attachment to the cysteine thiol func-
tional group. However, the electrophilic center (e.g., acrylamide, haloacetamide, vinyl sulfonamide)
that reacts with the cysteine can exhibit nonspecific reactivity toward other cellular thiols, includ-
ing glutathione present at millimolar concentrations inside mammalian cells. The electrophile may
also react with other nucleophilic functionalities present in biological systems (amino and imidazole
groups of amino acids, various reactive sites in nucleic acid bases, water). (B) Orthogonal strategy
as one potential mechanism to address issues associated with employing an electrophilic functional
group to target one cysteine among a sea of biological nucleophiles. According to this approach,
active site-directed small-molecule inhibitors containing a reactive nucleophilic substituent form a
covalent bond with a sulfenic acid-modified cysteine side chain. Such modifications form transiently
in specific proteins during H2O2-mediated signal transduction in normal cells, but form constitu-
tively in diseases associated with chronically elevated levels of H2O2, including cancer. In the sulfenic
acid oxidation state, the electron-deficient sulfur exhibits enhanced electrophilic character that can
be selectively targeted by certain nucleophilic compounds. Because sulfenic acid is a unique chem-
ical moiety in biochemistry, this strategy might decrease the potential for off-target activity while
retaining the advantages gained by covalent targeting.
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1.9 Conclusions
The perspectives presented here highlight the emerging and rapidly expanding role
of redox regulation during EGFR signaling. These studies point to the unique chem-
istry of reactive cysteine residues within specific target proteins, including EGFR.
These redox reactions enable covalent regulation of protein function, much like phos-
phorylation. The expanding array of modifications that target cysteine suggests that
we are just beginning to understand the molecular basis for specificity of redox sig-
naling. One theme that has consistently emerged in numerous studies is the co-
localization of the oxidant sources with the redox-regulated target protein. As case
in point, ligand activation triggers the association of EGFR and the NADPH oxi-
dase, Nox2. We have also tried to emphasize the value of selective and cell-permeable
chemical approaches to elucidate regulatory mechanisms that govern H2O2-mediated
sulfenylation of proteins. In addition, we are just beginning to appreciate that dif-
ferent biological oxidants may target distinct cysteine residues in the same protein
and thus lead to unique regulatory outcomes. Given that aberrant sulfenylation of
proteins is linked to aggressive cancer phenotypes and that genetic lesions in H2O2-
metabolizing enzymes can contribute to tumorigenesis, defining mechanisms that
control reversible protein sulfenylation will be vital to understanding both human
physiology and disease. Finally, it is hoped that the discovery of EGFR as a direct
target of H2O2 will lead to a broader examination of the redox-regulated kinome




1. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103 (2),
211–25.
2. Schlessinger, J. (2002). Ligand-induced, receptor-mediated dimerization and ac-
tivation of egf receptor. Cell, 110 (6), 669–72.
3. Cohen, S. (1962). Isolation of a mouse submaxillary gland protein accelerating
incisor eruption and eyelid opening in the new-born animal. J Biol Chem, 237,
1555–62.
4. Cohen, S., Carpenter, G., & King, J., L. (1980). Epidermal growth factor-
receptor-protein kinase interactions. co-purification of receptor and epidermal
growth factor-enhanced phosphorylation activity. J Biol Chem, 255 (10), 4834–
42.
5. Carpenter, G., King, J., L., & Cohen, S. (1978). Epidermal growth factor stim-
ulates phosphorylation in membrane preparations in vitro. Nature, 276 (5686),
409–10.
6. Cohen, S. (2008). Origins of growth factors: ngf and egf. J Biol Chem, 283 (49),
33793–7.
7. Macias, A., Azavedo, E., Hagerstrom, T., Klintenberg, C., Perez, R., & Skoog,
L. (1987). Prognostic significance of the receptor for epidermal growth factor in
human mammary carcinomas. Anticancer Res, 7 (3 Pt B), 459–64.
8. Yarden, Y. & Sliwkowski, M. X. (2001). Untangling the erbb signalling network.
Nat Rev Mol Cell Biol, 2 (2), 127–37.
9. Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. Int J
Radiat Oncol Biol Phys, 59 (2 Suppl), 21–6.
10. Bae, Y. S., Kang, S. W., Seo, M. S., Baines, I. C., Tekle, E., Chock, P. B.,
& Rhee, S. G. (1997). Epidermal growth factor (egf)-induced generation of
hydrogen peroxide. role in egf receptor-mediated tyrosine phosphorylation. J
Biol Chem, 272 (1), 217–21.
11. Miller, E. W., Tulyathan, O., Isacoff, E. Y., & Chang, C. J. (2007). Molecular
imaging of hydrogen peroxide produced for cell signaling. Nat Chem Biol, 3 (5),
263–7.
12. Lo, Y. Y. & Cruz, T. F. (1995). Involvement of reactive oxygen species in
cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol
Chem, 270 (20), 11727–30.
13. Sundaresan, M., Yu, Z. X., Ferrans, V. J., Irani, K., & Finkel, T. (1995). Re-
quirement for generation of h2o2 for platelet-derived growth factor signal trans-
duction. Science, 270 (5234), 296–9.
26
14. Colavitti, R., Pani, G., Bedogni, B., Anzevino, R., Borrello, S., Waltenberger,
J., & Galeotti, T. (2002). Reactive oxygen species as downstream mediators
of angiogenic signaling by vascular endothelial growth factor receptor-2/kdr. J
Biol Chem, 277 (5), 3101–8.
15. May, J. M. & de Haen, C. (1979). Insulin-stimulated intracellular hydrogen
peroxide production in rat epididymal fat cells. J Biol Chem, 254 (7), 2214–20.
16. Meier, B., Radeke, H. H., Selle, S., Younes, M., Sies, H., Resch, K., & Haber-
mehl, G. G. (1989). Human fibroblasts release reactive oxygen species in re-
sponse to interleukin-1 or tumour necrosis factor-alpha. Biochem J, 263 (2),
539–45.
17. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W.
(1994). Angiotensin ii stimulates nadh and nadph oxidase activity in cultured
vascular smooth muscle cells. Circ Res, 74 (6), 1141–8.
18. Rhee, S. G. (2006). Cell signaling. h2o2, a necessary evil for cell signaling. Sci-
ence, 312 (5782), 1882–3.
19. D’Autreaux, B. & Toledano, M. B. (2007). Ros as signalling molecules: mecha-
nisms that generate specificity in ros homeostasis. Nat Rev Mol Cell Biol, 8 (10),
813–24.
20. Dickinson, B. C. & Chang, C. J. (2011). Chemistry and biology of reactive
oxygen species in signaling or stress responses. Nat Chem Biol, 7 (8), 504–11.
21. Finkel, T. (2011). Signal transduction by reactive oxygen species. J Cell Biol,
194 (1), 7–15.
22. Reddie, K. G. & Carroll, K. S. (2008). Expanding the functional diversity of
proteins through cysteine oxidation. Curr Opin Chem Biol, 12 (6), 746–54.
23. Paulsen, C. E. & Carroll, K. S. (2010). Orchestrating redox signaling networks
through regulatory cysteine switches. ACS Chem Biol, 5 (1), 47–62.
24. Jacob, C., Battaglia, E., Burkholz, T., Peng, D., Bagrel, D., & Montenarh,
M. (2012). Control of oxidative posttranslational cysteine modifications: from
intricate chemistry to widespread biological and medical applications. Chem
Res Toxicol, 25 (3), 588–604.
25. Zheng, M., Aslund, F., & Storz, G. (1998). Activation of the oxyr transcription
factor by reversible disulfide bond formation. Science, 279 (5357), 1718–21.
26. Chen, C. Y., Willard, D., & Rudolph, J. (2009). Redox regulation of sh2-domain-
containing protein tyrosine phosphatases by two backdoor cysteines. Biochem-
istry, 48 (6), 1399–409.
27
27. Aslan, M. & Ozben, T. (2003). Oxidants in receptor tyrosine kinase signal trans-
duction pathways. Antioxid Redox Signal, 5 (6), 781–8.
28. Tonks, N. K. (2005). Redox redux: revisiting ptps and the control of cell signal-
ing. Cell, 121 (5), 667–70.
29. Finkel, T. (2012). From sulfenylation to sulfhydration: what a thiolate needs to
tolerate. Sci Signal, 5 (215), pe10.
30. Gamou, S. & Shimizu, N. (1995). Hydrogen peroxide preferentially enhances
the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett,
357 (2), 161–4.
31. Stone, J. R. & Yang, S. (2006). Hydrogen peroxide: a signaling messenger.
Antioxid Redox Signal, 8 (3-4), 243–70.
32. Bass, D. A., Parce, J. W., Dechatelet, L. R., Szejda, P., Seeds, M. C., & Thomas,
M. (1983). Flow cytometric studies of oxidative product formation by neu-
trophils: a graded response to membrane stimulation. J Immunol, 130 (4), 1910–
7.
33. Giorgio, M., Trinei, M., Migliaccio, E., & Pelicci, P. G. (2007). Hydrogen perox-
ide: a metabolic by-product or a common mediator of ageing signals? Nat Rev
Mol Cell Biol, 8 (9), 722–8.
34. Halliwell, B. & Gutteridge, J. M. C. (1999). Free radicals in biology and medicine.
Oxford: Oxford University Press.
35. Goldkorn, T., Balaban, N., Matsukuma, K., Chea, V., Gould, R., Last, J., . . .
Chavez, C. (1998). Egf-receptor phosphorylation and signaling are targeted by
h2o2 redox stress. Am J Respir Cell Mol Biol, 19 (5), 786–98.
36. Rao, G. N. (1996). Hydrogen peroxide induces complex formation of shc-grb2-
sos with receptor tyrosine kinase and activates ras and extracellular signal-
regulated protein kinases group of mitogen-activated protein kinases. Oncogene,
13 (4), 713–9.
37. McCubrey, J. A., Lahair, M. M., & Franklin, R. A. (2006). Reactive oxygen
species-induced activation of the map kinase signaling pathways. Antioxid Redox
Signal, 8 (9-10), 1775–89.
38. Guyton, K. Z., Liu, Y., Gorospe, M., Xu, Q., & Holbrook, N. J. (1996). Activa-
tion of mitogen-activated protein kinase by h2o2. role in cell survival following
oxidant injury. J Biol Chem, 271 (8), 4138–42.
39. Wang, X., Martindale, J. L., Liu, Y., & Holbrook, N. J. (1998). The cellular
response to oxidative stress: influences of mitogen-activated protein kinase sig-
nalling pathways on cell survival. Biochem J, 333 ( Pt 2), 291–300.
28
40. Leslie, N. R. (2006). The redox regulation of pi 3-kinase-dependent signaling.
Antioxid Redox Signal, 8 (9-10), 1765–74.
41. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter,
G. F., . . . Hawkins, P. T. (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate
in the activation of protein kinase b. Science, 277 (5325), 567–70.
42. Franke, T. F., Kaplan, D. R., Cantley, L. C., & Toker, A. (1997). Direct regula-
tion of the akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science, 275 (5300), 665–8.
43. Park, H. S., Lee, S. H., Park, D., Lee, J. S., Ryu, S. H., Lee, W. J., . . . Bae,
Y. S. (2004). Sequential activation of phosphatidylinositol 3-kinase, beta pix,
rac1, and nox1 in growth factor-induced production of h2o2. Mol Cell Biol,
24 (10), 4384–94.
44. Wang, X., McCullough, K. D., Franke, T. F., & Holbrook, N. J. (2000). Epi-
dermal growth factor receptor-dependent akt activation by oxidative stress en-
hances cell survival. J Biol Chem, 275 (19), 14624–31.
45. Huang, X., Begley, M., Morgenstern, K. A., Gu, Y., Rose, P., Zhao, H., & Zhu,
X. (2003). Crystal structure of an inactive akt2 kinase domain. Structure, 11 (1),
21–30.
46. Murata, H., Ihara, Y., Nakamura, H., Yodoi, J., Sumikawa, K., & Kondo, T.
(2003). Glutaredoxin exerts an antiapoptotic effect by regulating the redox state
of akt. J Biol Chem, 278 (50), 50226–33.
47. Wani, R., Qian, J., Yin, L., Bechtold, E., King, S. B., Poole, L. B., . . . Furdui,
C. M. (2011). Isoform-specific regulation of akt by pdgf-induced reactive oxygen
species. Proc Natl Acad Sci U S A, 108 (26), 10550–5.
48. Ushio-Fukai, M., Alexander, R. W., Akers, M., Yin, Q., Fujio, Y., Walsh, K.,
& Griendling, K. K. (1999). Reactive oxygen species mediate the activation of
akt/protein kinase b by angiotensin ii in vascular smooth muscle cells. J Biol
Chem, 274 (32), 22699–704.
49. Chen, K., Vita, J. A., Berk, B. C., & Keaney, J., J. F. (2001). C-jun n-terminal
kinase activation by hydrogen peroxide in endothelial cells involves src-dependent
epidermal growth factor receptor transactivation. J Biol Chem, 276 (19), 16045–
50.
50. Giannoni, E., Buricchi, F., Grimaldi, G., Parri, M., Cialdai, F., Taddei, M. L.,
. . . Chiarugi, P. (2008). Redox regulation of anoikis: reactive oxygen species as
essential mediators of cell survival. Cell Death Differ, 15 (5), 867–78.
51. Reynolds, A. R., Tischer, C., Verveer, P. J., Rocks, O., & Bastiaens, P. I. (2003).
Egfr activation coupled to inhibition of tyrosine phosphatases causes lateral
signal propagation. Nat Cell Biol, 5 (5), 447–53.
29
52. Tonks, N. K. (2006). Protein tyrosine phosphatases: from genes, to function, to
disease. Nat Rev Mol Cell Biol, 7 (11), 833–46.
53. Blume-Jensen, P. & Hunter, T. (2001). Oncogenic kinase signalling. Nature,
411 (6835), 355–65.
54. Denu, J. M. & Tanner, K. G. (1998). Specific and reversible inactivation of
protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic
acid intermediate and implications for redox regulation. Biochemistry, 37 (16),
5633–42.
55. Zhang, Z. Y. & Dixon, J. E. (1993). Active site labeling of the yersinia protein
tyrosine phosphatase: the determination of the pka of the active site cysteine
and the function of the conserved histidine 402. Biochemistry, 32 (36), 9340–5.
56. Lohse, D. L., Denu, J. M., Santoro, N., & Dixon, J. E. (1997). Roles of as-
partic acid-181 and serine-222 in intermediate formation and hydrolysis of the
mammalian protein-tyrosine-phosphatase ptp1. Biochemistry, 36 (15), 4568–75.
57. Winterbourn, C. C. & Metodiewa, D. (1999). Reactivity of biologically impor-
tant thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol
Med, 27 (3-4), 322–8.
58. Sohn, J. & Rudolph, J. (2003). Catalytic and chemical competence of regulation
of cdc25 phosphatase by oxidation/reduction. Biochemistry, 42 (34), 10060–70.
59. Flint, A. J., Tiganis, T., Barford, D., & Tonks, N. K. (1997). Development
of "substrate-trapping" mutants to identify physiological substrates of protein
tyrosine phosphatases. Proc Natl Acad Sci U S A, 94 (5), 1680–5.
60. Liu, F. & Chernoff, J. (1997). Protein tyrosine phosphatase 1b interacts with and
is tyrosine phosphorylated by the epidermal growth factor receptor. Biochem J,
327 ( Pt 1), 139–45.
61. Wu, Y., Kwon, K. S., & Rhee, S. G. (1998). Probing cellular protein targets of
h2o2 with fluorescein-conjugated iodoacetamide and antibodies to fluorescein.
FEBS Lett, 440 (1-2), 111–5.
62. Lou, Y. W., Chen, Y. Y., Hsu, S. F., Chen, R. K., Lee, C. L., Khoo, K. H.,
. . . Meng, T. C. (2008). Redox regulation of the protein tyrosine phosphatase
ptp1b in cancer cells. FEBS Journal, 275 (1), 69–88.
63. Haj, F. G., Markova, B., Klaman, L. D., Bohmer, F. D., & Neel, B. G. (2003).
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-
1b. J Biol Chem, 278 (2), 739–44.
64. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G., & Bastiaens, P. I. (2002).
Imaging sites of receptor dephosphorylation by ptp1b on the surface of the
endoplasmic reticulum. Science, 295 (5560), 1708–11.
30
65. Lee, S. R., Kwon, K. S., Kim, S. R., & Rhee, S. G. (1998). Reversible inactiva-
tion of protein-tyrosine phosphatase 1b in a431 cells stimulated with epidermal
growth factor. J Biol Chem, 273 (25), 15366–72.
66. Leslie, N. R., Bennett, D., Lindsay, Y. E., Stewart, H., Gray, A., & Downes,
C. P. (2003). Redox regulation of pi 3-kinase signalling via inactivation of pten.
EMBO J, 22 (20), 5501–10.
67. Maehama, T., Taylor, G. S., & Dixon, J. E. (2001). Pten and myotubularin:
novel phosphoinositide phosphatases. Annu Rev Biochem, 70, 247–79.
68. Lee, S. R., Yang, K. S., Kwon, J., Lee, C., Jeong, W., & Rhee, S. G. (2002).
Reversible inactivation of the tumor suppressor pten by h2o2. J Biol Chem,
277 (23), 20336–42.
69. Kwon, J., Lee, S. R., Yang, K. S., Ahn, Y., Kim, Y. J., Stadtman, E. R., & Rhee,
S. G. (2004). Reversible oxidation and inactivation of the tumor suppressor
pten in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S
A, 101 (47), 16419–24.
70. Agazie, Y. M. & Hayman, M. J. (2003). Molecular mechanism for a role of shp2
in epidermal growth factor receptor signaling. Mol Cell Biol, 23 (21), 7875–86.
71. Paulsen, C. E., Truong, T. H., Garcia, F. J., Homann, A., Gupta, V., Leonard,
S. E., & Carroll, K. S. (2012). Peroxide-dependent sulfenylation of the egfr
catalytic site enhances kinase activity. Nat Chem Biol, 8 (1), 57–64.
72. Persson, C., Kappert, K., Engstrom, U., Ostman, A., & Sjoblom, T. (2005).
An antibody-based method for monitoring in vivo oxidation of protein tyrosine
phosphatases. Methods, 35 (1), 37–43.
73. Lambeth, J. D. (2004). Nox enzymes and the biology of reactive oxygen. Nat
Rev Immunol, 4 (3), 181–9.
74. McCord, J. M. & Fridovich, I. (1969). Superoxide dismutase. an enzymic func-
tion for erythrocuprein (hemocuprein). J Biol Chem, 244 (22), 6049–55.
75. Hsu, J. L., Hsieh, Y., Tu, C., O’Connor, D., Nick, H. S., & Silverman, D. N.
(1996). Catalytic properties of human manganese superoxide dismutase. J Biol
Chem, 271 (30), 17687–91.
76. Babior, B. M., Lambeth, J. D., & Nauseef, W. (2002). The neutrophil nadph
oxidase. Archives of Biochemistry and Biophysics, 397 (2), 342–4.
77. Suh, Y. A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., . . . Lam-
beth, J. D. (1999). Cell transformation by the superoxide-generating oxidase
mox1. Nature, 401 (6748), 79–82.
31
78. Cheng, G., Cao, Z., Xu, X., van Meir, E. G., & Lambeth, J. D. (2001). Ho-
mologs of gp91phox: cloning and tissue expression of nox3, nox4, and nox5.
Gene, 269 (1-2), 131–40.
79. De Deken, X., Wang, D., Many, M. C., Costagliola, S., Libert, F., Vassart, G.,
. . . Miot, F. (2000). Cloning of two human thyroid cdnas encoding new members
of the nadph oxidase family. J Biol Chem, 275 (30), 23227–33.
80. Oh, H., Jung, H. Y., Kim, J., & Bae, Y. S. (2010). Phosphorylation of serine282
in nadph oxidase activator 1 by erk desensitizes egf-induced ros generation.
Biochem Biophys Res Commun, 394 (3), 691–6.
81. Kroviarski, Y., Debbabi, M., Bachoual, R., Perianin, A., Gougerot-Pocidalo,
M. A., El-Benna, J., & Dang, P. M. (2010). Phosphorylation of nadph oxidase
activator 1 (noxa1) on serine 282 by map kinases and on serine 172 by protein
kinase c and protein kinase a prevents nox1 hyperactivation. FASEB Journal,
24 (6), 2077–92.
82. Chen, K., Kirber, M. T., Xiao, H., Yang, Y., & Keaney, J., J. F. (2008). Reg-
ulation of ros signal transduction by nadph oxidase 4 localization. J Cell Biol,
181 (7), 1129–39.
83. Fridovich, I. (1995). Superoxide radical and superoxide dismutases. Annu Rev
Biochem, 64, 97–112.
84. Gardner, P. R., Raineri, I., Epstein, L. B., & White, C. W. (1995). Superoxide
radical and iron modulate aconitase activity in mammalian cells. J Biol Chem,
270 (22), 13399–405.
85. Juarez, J. C., Manuia, M., Burnett, M. E., Betancourt, O., Boivin, B., Shaw,
D. E., . . . Donate, F. (2008). Superoxide dismutase 1 (sod1) is essential for h2o2-
mediated oxidation and inactivation of phosphatases in growth factor signaling.
Proc Natl Acad Sci U S A, 105 (20), 7147–52.
86. DeYulia, J., G. J., Carcamo, J. M., Borquez-Ojeda, O., Shelton, C. C., & Golde,
D. W. (2005). Hydrogen peroxide generated extracellularly by receptor-ligand
interaction facilitates cell signaling. Proc Natl Acad Sci U S A, 102 (14), 5044–9.
87. DeYulia, J., G. J. & Carcamo, J. M. (2005). Egf receptor-ligand interaction
generates extracellular hydrogen peroxide that inhibits egfr-associated protein
tyrosine phosphatases. Biochem Biophys Res Commun, 334 (1), 38–42.
88. Bienert, G. P., Schjoerring, J. K., & Jahn, T. P. (2006). Membrane transport
of hydrogen peroxide. Biochim Biophys Acta, 1758 (8), 994–1003.
89. Bienert, G. P., Moller, A. L., Kristiansen, K. A., Schulz, A., Moller, I. M., Schjo-
erring, J. K., & Jahn, T. P. (2007). Specific aquaporins facilitate the diffusion
of hydrogen peroxide across membranes. J Biol Chem, 282 (2), 1183–92.
32
90. Miller, E. W., Dickinson, B. C., & Chang, C. J. (2010). Aquaporin-3 mediates
hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc
Natl Acad Sci U S A, 107 (36), 15681–6.
91. Wood, Z. A., Schroder, E., Robin Harris, J., & Poole, L. B. (2003). Structure,
mechanism and regulation of peroxiredoxins. Trends Biochem Sci, 28 (1), 32–40.
92. Kang, S. W., Chae, H. Z., Seo, M. S., Kim, K., Baines, I. C., & Rhee, S. G.
(1998). Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide gen-
erated in response to growth factors and tumor necrosis factor-alpha. J Biol
Chem, 273 (11), 6297–302.
93. Handy, D. E., Lubos, E., Yang, Y., Galbraith, J. D., Kelly, N., Zhang, Y. Y., . . .
Loscalzo, J. (2009). Glutathione peroxidase-1 regulates mitochondrial function
to modulate redox-dependent cellular responses. J Biol Chem, 284 (18), 11913–
21.
94. Halvey, P. J., Watson, W. H., Hansen, J. M., Go, Y. M., Samali, A., & Jones,
D. P. (2005). Compartmental oxidation of thiol-disulphide redox couples during
epidermal growth factor signalling. Biochem J, 386 (Pt 2), 215–9.
95. Winterbourn, C. C. (2008). Reconciling the chemistry and biology of reactive
oxygen species. Nat Chem Biol, 4 (5), 278–86.
96. Parsonage, D., Karplus, P. A., & Poole, L. B. (2008). Substrate specificity and
redox potential of ahpc, a bacterial peroxiredoxin. Proc Natl Acad Sci U S A,
105 (24), 8209–14.
97. Peskin, A. V., Low, F. M., Paton, L. N., Maghzal, G. J., Hampton, M. B., &
Winterbourn, C. C. (2007). The high reactivity of peroxiredoxin 2 with h(2)o(2)
is not reflected in its reaction with other oxidants and thiol reagents. J Biol
Chem, 282 (16), 11885–92.
98. Woo, H. A., Yim, S. H., Shin, D. H., Kang, D., Yu, D. Y., & Rhee, S. G. (2010).
Inactivation of peroxiredoxin i by phosphorylation allows localized h(2)o(2) ac-
cumulation for cell signaling. Cell, 140 (4), 517–28.
99. Buhrow, S. A., Cohen, S., & Staros, J. V. (1982). Affinity labeling of the pro-
tein kinase associated with the epidermal growth factor receptor in membrane
vesicles from a431 cells. J Biol Chem, 257 (8), 4019–22.
100. Clark, S. & Konstantopoulos, N. (1993). Sulphydryl agents modulate insulin-
and epidermal growth factor (egf)-receptor kinase via reaction with intracel-
lular receptor domains: differential effects on basal versus activated receptors.
Biochem J, 292 ( Pt 1), 217–23.
101. Woltjer, R. L. & Staros, J. V. (1997). Effects of sulfhydryl modification reagents
on the kinase activity of the epidermal growth factor receptor. Biochemistry,
36 (32), 9911–6.
33
102. Seo, Y. H. & Carroll, K. S. (2009). Facile synthesis and biological evaluation
of a cell-permeable probe to detect redox-regulated proteins. Bioorg Med Chem
Lett, 19 (2), 356–9.
103. Reddie, K. G., Seo, Y. H., Muse Iii, W. B., Leonard, S. E., & Carroll, K. S.
(2008). A chemical approach for detecting sulfenic acid-modified proteins in
living cells. Mol Biosyst, 4 (6), 521–31.
104. Leonard, S. E., Reddie, K. G., & Carroll, K. S. (2009). Mining the thiol proteome
for sulfenic acid modifications reveals new targets for oxidation in cells. ACS
Chem Biol, 4 (9), 783–99.
105. Seo, Y. H. & Carroll, K. S. (2011). Quantification of protein sulfenic acid modi-
fications using isotope-coded dimedone and iododimedone. Angew Chem Int Ed
Engl, 50 (6), 1342–5.
106. Truong, T. H., Garcia, F. J., Seo, Y. H., & Carroll, K. S. (2011). Isotope-coded
chemical reporter and acid-cleavable affinity reagents for monitoring protein
sulfenic acids. Bioorg Med Chem Lett, 21 (17), 5015–20.
107. Leonard, S. E. & Carroll, K. S. (2011). Chemical ’omics’ approaches for under-
standing protein cysteine oxidation in biology. Curr Opin Chem Biol, 15 (1),
88–102.
108. Benitez, L. V. & Allison, W. S. (1974). The inactivation of the acyl phosphatase
activity catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate de-
hydrogenase by dimedone and olefins. J Biol Chem, 249 (19), 6234–43.
109. Saxon, E. & Bertozzi, C. R. (2000). Cell surface engineering by a modified
staudinger reaction. Science, 287 (5460), 2007–10.
110. Rostovtsev, V. V., Green, L. G., Fokin, V. V., & Sharpless, K. B. (2002). A step-
wise huisgen cycloaddition process: copper(i)-catalyzed regioselective "ligation"
of azides and terminal alkynes. Angew Chem Int Ed Engl, 41 (14), 2596–9.
111. Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small
molecule kinase inhibitors. Nature Reviews. Cancer, 9 (1), 28–39.
112. Singh, J., Petter, R. C., & Kluge, A. F. (2010). Targeted covalent drugs of the
kinase family. Curr Opin Chem Biol, 14 (4), 475–80.
113. Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011). The resurgence of
covalent drugs. Nat Rev Drug Discov, 10 (4), 307–17.
114. Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong,
K.-K., . . . Eck, M. J. (2008). The t790m mutation in egfr kinase causes drug
resistance by increasing the affinity for atp. Proc Natl Acad Sci U S A, 105 (6),
2070–2075.
34
115. Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., &
Eck, M. J. (2007). Structures of lung cancer-derived egfr mutants and inhibitor
complexes: mechanism of activation and insights into differential inhibitor sen-
sitivity. Cancer Cell, 11 (3), 217–227.
116. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An al-
losteric mechanism for activation of the kinase domain of epidermal growth
factor receptor. Cell, 125 (6), 1137–1149.
117. Jaffrey, S. R., Erdjument-Bromage, H., Ferris, C. D., Tempst, P., & Snyder,
S. H. (2001). Protein s-nitrosylation: a physiological signal for neuronal nitric
oxide. Nat Cell Biol, 3 (2), 193–7.
118. Jaffrey, S. R. & Snyder, S. H. (2001). The biotin switch method for the detection
of s-nitrosylated proteins. Sci STKE, 2001 (86), pl1.
119. Wang, H. & Xian, M. (2011). Chemical methods to detect s-nitrosation. Curr
Opin Chem Biol, 15 (1), 32–7.
120. Giustarini, D., Dalle-Donne, I., Colombo, R., Milzani, A., & Rossi, R. (2008).
Is ascorbate able to reduce disulfide bridges? a cautionary note. Nitric Oxide,
19 (3), 252–8.
121. Estrada, C., Gomez, C., Martin-Nieto, J., De Frutos, T., Jimenez, A., & Vil-
lalobo, A. (1997). Nitric oxide reversibly inhibits the epidermal growth factor
receptor tyrosine kinase. Biochem J, 326 ( Pt 2), 369–76.
122. Murillo-Carretero, M., Torroglosa, A., Castro, C., Villalobo, A., & Estrada, C.
(2009). S-nitrosylation of the epidermal growth factor receptor: a regulatory
mechanism of receptor tyrosine kinase activity. Free Radic Biol Med, 46 (4),
471–9.
123. Lam, Y. W., Yuan, Y., Isaac, J., Babu, C. V., Meller, J., & Ho, S. M. (2010).
Comprehensive identification and modified-site mapping of s-nitrosylated tar-
gets in prostate epithelial cells. PLoS One, 5 (2), e9075.
124. Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour,
L. A., . . . Ambs, S. (2010). Increased nos2 predicts poor survival in estrogen
receptor-negative breast cancer patients. J Clin Invest, 120 (11), 3843–54.
125. Switzer, C. H., Glynn, S. A., Cheng, R. Y., Ridnour, L. A., Green, J. E., Ambs,
S., & Wink, D. A. (2012). S-nitrosylation of egfr and src activates an oncogenic
signaling network in human basal-like breast cancer. Mol Cancer Res, 10 (9),
1203–15.
126. Penel, S., Hughes, E., & Doig, A. J. (1999). Side-chain structures in the first
turn of the alpha-helix. J Mol Biol, 287 (1), 127–43.
35
127. Anderson, T. A. & Sauer, R. T. (2003). Role of an n(cap) residue in determin-
ing the stability and operator-binding affinity of arc repressor. Biophys Chem,
100 (1-3), 341–50.
128. Miranda, J. J. (2003). Position-dependent interactions between cysteine residues
and the helix dipole. Protein Sci, 12 (1), 73–81.
129. Kemble, D. J. & Sun, G. (2009). Direct and specific inactivation of protein
tyrosine kinases in the src and fgfr families by reversible cysteine oxidation.
Proc Natl Acad Sci U S A, 106 (13), 5070–5.
130. Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara,
D. J. (1997). Structure-based design of a potent, selective, and irreversible in-
hibitor of the catalytic domain of the erbb receptor subfamily of protein tyrosine
kinases. J Med Chem, 40 (7), 1130–5.
131. Leonard, S. E., Garcia, F. J., Goodsell, D. S., & Carroll, K. S. (2011). Redox-




Isotope-Coded Chemical Reporter and
Acid-Cleavable Affinity Reagents for Monitoring
Protein Sulfenic Acids
2.1 Abstract
We have developed an approach that allows relative quantification of protein
sulfenic acids using a pair of light and heavy isotope labeled probes, DAz-2 and
d6-DAz-2. In conjunction with a new complementary acid-cleavable linker, Yn-ACL,
we demonstrate that tagged peptides are successfully labeled, enriched, and fully
characterized by LC-MS/MS analysis. Overall, this method can be applied to map
sites of cysteine oxidation and compare protein sulfenylation in normal and disease
states.
2.2 Introduction
Reactive oxygen species (ROS), such as hydrogen peroxide (H2O2), were once
viewed as the inevitable toxic byproducts of aerobic existence, but increasing evi-
dence indicates that ROS can act as secondary messengers in cellular signaling (1–3).
Physiological events mediated by redox-signaling include cellular proliferation, differ-
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entiation, and apoptosis, whereas uncontrolled ROS production can lead to patho-
logical events such as cancer and age-associated degenerative disorders (4). Cells can
detect changes in ROS homeostasis through selective oxidative modification of the
thiol side chain of cysteine residues. These modifications can drastically alter protein
structure and function. Of these, reversible modifications include disulfide bonds and
sulfenic acids (RSOH). Sulfenic acids are the first oxoform formed as a result of thio-
late oxidation. The sulfenic acid product can be stabilized by the protein environment,
condense with other protein thiols to form an intra- or intermolecular disulfide bond,
or become further oxidized to the sulfinic (RSO2H) or sulfonic (RSO3H) acids. Due to
their switch-like nature, reversible thiol modifications represent a central mechanism
to detect and regulate changes in the cellular redox balance (3, 5).
The discovery of regulatory cysteine switches, particularly sulfenic acids, has stim-
ulated efforts to develop chemical tools to detect these post-translational modifi-
cations (6, 7). In large part, current methods are based on the selective reaction
between 5,5-dimethyl-1,3-cyclohexanedione (dimedone) and sulfenic acids (8). To fa-
cilitate detection and isolation of sulfenylated proteins, we have recently developed
bifunctional dimedone-based probes attached to an azide chemical reporter, known
as DAz-1 and DAz-2 (1; Figure 2.1a) (9–12). After protein labeling, the reporter
group is coupled to a biotinylated reagent via bioorthogonal ligation methods, such
as the Staudinger ligation or Huisgen [3 + 2] cycloaddition (click chemistry) (13–
15). Subsequent selection and enrichment by avidin affinity chromatography followed
by streptavidin-HRP immunoblot or LC-MS/MS analysis permits visualization and
identification of sulfenylated proteins (10). However, the identification of precise sites
of cysteine oxidation and their quantification remains challenging, and is an active
area of research.
Current proteomic methods utilize various approaches to profile and quantify


































































Figure 2.1: General strategy for labeling and enrichment of sulfenic acid-modified pro-
teins and peptides. (a) Structures of DAz-2 (1) and d6-DAz-2 (2) azido-probes for detection
of protein sulfenylation. (b) Structure of Yn-ACL (3), a biotinylated acid-cleavable linker with an
alkyne handle. (c) Method for detection and enrichment. Proteins are labeled with either 1 or 2
and labeled proteins are coupled via click chemistry with 3. Biotinylated labeled samples are then
enriched for using either avidin affinity cartridges or streptavidin-coated magnetic beads. Peptides
are generated using in-gel or on-resin trypsin digestion. Enriched peptides are then eluted with 30%
ACN + 0.4% TFA or guanidine HCl and detected by MS2 analysis. Subsequently, enriched peptides
are subjected to TFA cleavage to release the biotin moiety and are detected by MS2 analysis.
reagents and differential thiol trapping, permits quantification of protein disulfide
bonds in cell lysates (16, 17). Weerapana et al. reported a method to detect low
pKa cysteines using alkyne-functionalized iodoacetamide that can be conjugated to
a TEV protease-cleavable affinity tag (18). Strategies based on d5-NEM have also
been devised to detect cysteine oxidation (19). Despite these advances, none of these
techniques are specifically suited to the investigation of sulfenic acid modifications.
To address this issue, we have recently reported the ICDID method, which enables
quantification of protein sulfenic acid modifications using isotope-labeled dimedone-
based probes (20). Herein, we present a complementary strategy for the detection
and relative quantification of protein sulfenic acid modifications that couples a new
isotope-coded version of DAz-2 (2; Figure 2.1a) with release of the adduct from
avidin using an acid-cleavable biotinylated tag (3; Figure 2.1b).
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2.3 Results and Discussion
Our general approach for ratiometric quantification of protein sulfenylation fol-
lows the strategy outlined in Figure 2.1c: 1) sulfenylated proteins are covalently
modified by DAz-2 (1) or d6-DAz-2 (2); 2) labeled proteins are then conjugated via
click chemistry to Yn-ACL (3), a cleavable biotin conjugate with an alkyne handle;
3) biotinylated proteins or peptides generated via protease cleavage are enriched by
avidin affinity cartridge or streptavidin-coated magnetic beads. Both methods yield
biotinylated products that can be detected and characterized further by mass spec-
trometry (MS); 4) The biotin moiety can be cleaved with 95% trifluoroacetic acid
(TFA), and the resulting peptides are detected by tandem mass spectrometry (MS2).
Overall, this approach allows us to perform quantitative analysis of relative changes
in protein sulfenic acid modifications.
The ratiometric method outlined above incorporates a set of isotope-coded ("light
and heavy") sulfenic acid-specific probes. DAz-2 was prepared as previously reported
(10). d6-DAz-2 was generated by coupling deuterated linker 4 (Scheme 2.1) with pro-
tected 1,3-cyclohexanedione (10). Compound 4 was synthesized according to known
reactions, except that deuterated 3-bromopropanol (6) was utilized as the starting
material (21). Selective protection of the primary alcohol with TBDPS increased the
boiling point of compound 6, facilitating purification in subsequent steps. Current
methods to enrich and identify sulfenylated proteins rely heavily on biotinylated tags
in order to enrich for proteins of interest. However, the biotin functional group can
complicate the MS2 analysis and subsequent database searching, especially for smaller
peptides (22, 23). In some cases, particularly in complex peptide mixtures, it is ideal
to remove the biotin tag after enrichment of labeled proteins or peptides, prior to MS
analysis.
To facilitate large-scale proteomic analysis, a wide variety of cleavable linkers have
been reported (24–27). Inspired by these approaches, we designed a cleavable biotiny-
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Scheme 2.1: Synthesis of deuterated fragment for d6-DAz-2 (2)
Scheme 2.2: Synthesis of alkyne acid-cleavable linker (Yn-ACL) (3).
lated linker (Scheme 2.2) to use in conjunction with sulfenic acid probes 1 and 2. The
new reagent, termed Yn-ACL (3), is composed of three parts: 1) a biotin moiety, 2) a
Boc-derivative cleavable by TFA, and 3) an alkyne group for bioorthogonal ligation.
Borane reduction of 3-hydroxy-3-methyl butanenitrile (12) afforded amine (11) in
high yield. To prevent undesirable side reactions in future steps, 11 was treated with
Fmoc-Cl to give the protected amine (10). The hydroxy group in 10 was activated
using base-mediated conditions with 1-chloroethyl chloroformate to give activated
compound 9. Subsequently, compound 9 was coupled to propargylamine in DMF to
give the resulting carbamate (8). Deprotection of the carbamate (8) under mild basic
conditions gave compound 7. The final step of the synthesis was achieved by coupling
NHS-activated biotin to compound 7 with TEA in DMF to give Yn-ACL (3) in 37%
yield over 6 steps. Although a biotinylated linker incorporating the Boc group has
been previously reported (24), it is important to note that Yn-ACL (3) represents
an advance in several respects. In particular, the design of Yn-ACL (3) allows for a
more straightforward synthesis and the spacer between the carbamate cleavage site
and alkyne handle of Yn-ACL is minimal, which ensures a small mass tag (249 Da)
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post-TFA cleavage to facilitate MS analysis.
C64S C82S Gpx3 (hereafter referred to as Gpx3), a double mutant of recombinant
glutathione peroxidase Gpx3 from yeast (28), was selected as the model protein for
subsequent studies. Gpx3 contains a catalytic cysteine at Cys36, which is oxidized to
a sulfenic acid in the presence of H2O2. MS confirmed the intact mass of unmodified
mutant Gpx3 as 22738.91 Da (Figure 2.2a). Next, we confirmed the mass of DAz-2-
labeled Gpx3. The mutant protein was reacted with H2O2 and the oxidized cysteine
labeled with DAz-2. Thereafter, azide-tagged protein was coupled to Yn-ACL via
click chemistry. Intact MS analysis confirmed that oxidized Gpx3 was successfully
labeled by DAz-2 and conjugated to Yn-ACL, corresponding to a molecular weight of
23352.65 Da (Figure 2.2b). Oxidation of Cys36 to sulfinic acid was also observed, as
previously reported (20). Next, we evaluated the properties of the cleavable site on
Yn-ACL (Figure 2.2c). Mutant Gpx3 was labeled employing the same conditions for
intact mass analysis and then subjected to 95% TFA cleavage for 0 - 6 h at 25 ◦C or 37
◦C. Streptavidin-HRP immunoblot analysis of the products showed a robust, DAz-2-
dependent signal originating from Yn-ACL-tagged Gpx3. On the other hand, samples
that were subjected to 95% TFA exhibited a reduction in signal over time, indicating
successful cleavage of the biotin moiety. Complete loss of signal was observed at 4 h
for samples subjected to cleavage at 25 ◦C, compared to 1 h for samples cleaved at
37 ◦C, demonstrating that cleavage is most efficient at 37 ◦C.
Having established the orthogonality of the cleavable biotinylation reagent, Yn-
ACL, we next evaluated two methods of sample enrichment: 1) avidin affinity car-
tridge, and 2) streptavidin-coated magnetic beads. For the first approach, Gpx3
was biotinylated as illustrated in Figure 2.1c, subjected to in-gel trypsin digestion,
and purified by avidin affinity cartridge. The MS spectrum corresponding to the
input peptide sample is complex (Figure 2.3a) and indicates that trypsin digestion














































































































Figure 2.2: Sulfenic acid modification is detected in model protein C64S C82S Gpx3 using
DAz-2 and Yn-ACL. (a) MS intact mass analysis shows that unmodified Gpx3 (•) corresponds to
a molecular weight of 22738.91 Da. Gpx3 dimers (■) are also present. (b) MS intact mass analysis
shows that DAz-2 and Yn-ACL labeled Gpx3 ( ■) corresponds to a molecular weight of 23352.65
Da. 25 µM Gpx3 was treated with 37.5 µM H2O2 and labeled with 10 mM DAz-2 for 2 h at 37 ◦C.
Afterwards, labeled protein was coupled via click chemistry with 3. Over-oxidation of the catalytic
cysteine to sulfinic acid (⋆) is also observed at 22776.79 Da. (c) Comparative analysis of TFA cleavage
conditions of Gpx3 labeled protein. Labeled protein was subjected to 95% TFA cleavage for 0 - 6
h at 25 ◦C or 37 ◦C. Samples were resolved by SDS-PAGE and visualized by streptavidin-HRP
Western blot. Equal protein loading was verified by re-probing with anti His-HRP.
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(C*GFTPQYK) was eluted from the avidin column using 30% ACN/0.4% TFA in
water (note that the Boc group is stable under these conditions) and analyzed by
LC-MS/MS (Figure 2.3b). The molecular ion peak at m/z = 765.16 corresponds
to peptide labeled by DAz-2 and conjugated to Yn-ACL, with the loss of one water
molecule [M + 2H - H2O]+2; other charge states of the tagged peptide were also
observed (Table 2.S1, Figure 2.S2a). After treatment of the biotinylated peptide
with 95% TFA, the signal at m/z = 765.16 disappeared. Instead, a new signal at
m/z = 587.58 was observed corresponding to the TFA-cleaved peptide, [M + 2H
- H2O]+2 (Figure 2.S2b). Collision-induced dissociation (CID) tandem mass spec-
tra of the aforementioned precursor ion confirmed the identity of the tagged peptide
(Figure 2.3c, Table 2.S2).
Attempts to cleave biotinylated peptides directly from the avidin affinity cartridge
(or streptavidin-coated magnetic beads) using 95% TFA resulted in leaching of avidin
subunits into the sample, significantly complicating MS analysis (data not shown).
For the second enrichment method, biotinylated protein was captured on strept-
avidin-coated magnetic beads, submitted to on-resin trypsin digestion, and biotiny-
lated peptide retained on the beads was eluted. To determine the best conditions for
elution from the resin, we first evaluated recovery of biotinylated intact Gpx3 under
various conditions via streptavidin-HRP immunoblot analysis (Figure 2.4a). Treat-
ment with 30% ACN/0.4% TFA in water (v/v) at 25 ◦C or 37 ◦C afforded moderate
recovery of the tagged protein; other temperatures were also explored (Figure 2.S3a),
but did not provide satisfactory MS results due to the lack of efficient sample recovery
(data not shown). Applied at a concentration of 8 M, guanidine HCl in water showed
the best recovery of tagged protein, based on comparison of the input and eluent im-
munoblot signals. Additional experiments to evaluate the concentration-dependence
of guanidine HCl elution show that 8 M affords maximal recovery (Figure 2.S3b).
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Figure 2.3: Enrichment and ESI-LC/MS/MS analysis of sulfenic acid-modified
C*GFTPQYK peptide from Gpx3 using avidin affinity cartridges. Samples were gen-
erated as in Figure 2.2. After trypsin digestion, biotinylated peptides were enriched for using avidin
affinity cartridges. (a) MS scan of input peptides. (b) MS scan of enriched sulfenic acid-modified
peptides. m/z 765.16 corresponds to intact sulfenic acid-modified peptides with the loss of water,
[M + 2H - H2O]+2. (c) MS2 spectra of TFA cleaved sulfenic acid-modified peptides after CID of
the precursor ion m/z 587.36 [M + 2H - H2O]+2.
and that the biotin moiety was effectively cleaved by ≥10% (v/v) TFA (Figure 2.4a),
as indicated by the absence of immunoblot signal. In subsequent experiments, biotin-
tagged Gpx3 was enriched on streptavidin-coated magnetic beads and digested on-
resin with trypsin. The MS scan of supernatant from the trypsin reaction is complex
and demonstrates complete sample digestion (Figure 2.4b). The resin was washed ex-
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tensively to remove unbiotinylated products; retained peptides were then eluted with
8 M guanidine HCl and analyzed by MS2 (Figure 2.4c). The molecular ion peak at
m/z = 765.11 corresponds to peptide labeled by DAz-2 and conjugated to Yn-ACL,
with the loss of one water molecule [M + 2H - H2O]+2; other charge states of the
tagged peptide were also observed (Figure 2.S4a, Table 2.S1). After TFA cleavage,
the emergence of a new signal at m/z = 587.61 indicates successful cleavage of the
biotin moiety (Figure 2.S4b). The MS2 spectra of TFA-cleaved peptide after CID
shows complete mapping of the expected product (Figure 2.4d, Table 2.S2). Collec-
tively, our characterization of both enrichment methods by LC-MS/MS demonstrates
that the biotin-tagged Gpx3 peptide is successfully enriched, eluted, and that the
biotin moiety can be separated by TFA treatment. The flexibility of our method
provides options for other model systems that may be more ideally suited for one
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Figure 2.4: Enrichment and ESI-LC/MS/MS analysis of sulfenic acid-modified
C*GFTPQYK peptide from Gpx3 using streptavidin-coated magnetic beads. Samples
were generated as in Figure 2.2. Biotinylated proteins were enriched for using streptavidin-coated
magnetic beads and peptides were generated by on-resin trypsin digestion. (a) Comparison of
streptavidin-coated magnetic bead elution conditions. Enriched Gpx3 labeled protein was eluted
using either 30% ACN + 0.4% TFA at 25 ◦C or 37 ◦C, boiling with guanidine HCl (8 M) pH 1.2,
or boiling with 30% ACN + 10% TFA for 15 min. I = input, S = supernatant, and E = eluent. (b)
MS scan of on-resin trypsin digested supernatant. (c) MS scan of enriched sulfenic acid-modified
peptides. m/z 765.11 corresponds to the intact sulfenic acid-modified peptide with the loss of water,
[M + 2H - H2O]+2 and m/z 531.38 (•) corresponds to TBTA, [M + H]+. (d) MS2 spectra of TFA
cleaved sulfenic acid-modified peptides after CID of the precursor ion m/z 587.32 [M + 2H - H2O]+2.
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Finally, we applied the strategy outlined in Figure 2.5a to quantify the relative
amounts of oxidized Gpx3 in two different samples. In the first sample, Gpx3 was
oxidized with 0.1 eq. H2O2 and labeled with d0-DAz-2 or treated with 1.5 eq. H2O2
and labeled with d6-DAz-2. In subsequent steps, heavy and light DAz-2 probes
were removed with gel filtration spin columns, and the protein samples were com-
bined. Tagged Gpx3 was ligated to Yn-ACL, enriched by avidin affinity cartridge
or streptavidin-coated magnetic beads, and peptides were analyzed by LC-MS/MS.
Based on our experimental design, we anticipated that the ratio and intensity of
d6-DAz-2-labeled peptide would be higher relative to the d0-DAz-2-treated sample.
The resulting data from each enrichment method, represented as extracted ion chro-
matograms (Figure 2.5b and Figure 2.5d) and single MS scans (Figure 2.5c and Fig-
ure 2.5e), are consistent with this expectation and indicate that the ratio of d0-DAz-2:
d6-DAz-2-tagged peptide is 1:2. The molecular ion peak at m/z = 765 and 768 cor-
respond to peptides labeled with d0 or d6-DAz-2 and conjugated to Yn-ACL, with
the loss of one water molecule [M + 2H - H2O]+2. The observed difference of 3 Da
between these ions represents the expected mass change for the +2 charge state and
further MS2 analysis was carried out to confirm the identity of these substituents (Fig-
ure 2.S5a and Figure 2.S5b). The inset of Figure 2.5e shows the expected decrease in























































































































































Figure 2.5: Relative quantification of Gpx3 sulfenic acid modification. (a) General scheme
for labeling strategy. Parallel samples of 25 µM Gpx3 were treated with low or high concentrations
of H2O2 and labeled with 10 mM d0 or d6-DAz-2 for 2 h at 37 ◦C. Samples were combined and
ligated via click chemistry with 3 and enriched with avidin affinity cartridges or streptavidin-coated
magnetic beads. The enriched peptides were then subjected to LC-MS/MS analysis. (b) Extracted
ion chromatogram and (c) MS scan of avidin affinity cartridge-enriched peptides. (d) Extracted ion
chromatogram and (e) MS scan of bead-enriched peptides. The extracted ion chromatograms of m/z
765 and 768 [M + 2H - H2O]+2 correspond to peptides tagged with d0 or d6-DAz-2 and conjugated
to Yn-ACL. The observed difference of 3 Da between these ions represents the expected mass change
for the +2 charge state. The d0-DAz-2: d6-DAz-2 ratios, determined by taking the areas under
the curves, are 1:2 for avidin affinity cartridge enriched peptides and 1:1.6 for streptavidin-coated
magnetic bead enriched peptides. The bar graph inset shows d6/d0 ratios for modified peptides




To summarize, we have presented a new approach that allows relative quantifi-
cation of protein sulfenic acid modifications. This method utilizes a set of light and
heavy sulfenic acid-specific probes and a complementary acid-cleavable linker to label
and enrich tagged peptides. Using the prototype thiol peroxidase, Gpx3, we demon-
strate that the biotinylation reagent, Yn-ACL is orthogonal to DAz-2. Biotin-tagged
peptides can be enriched via avidin affinity cartridge or streptavidin-coated magnetic
beads, cleaved with TFA to remove the biotin moiety, and subjected to LC-MS/MS
analysis. A key feature of this approach is that it facilitates mapping the specific
site of cysteine oxidation. Additionally, we show that the isotope probe pair, d0-
DAz-2 and d6-DAz-2, can be used to monitor relative changes in protein oxidation.
Together, these studies set the stage for global profiling of sulfenic acid formation
in H2O2-mediated signaling pathways and disease states associated with oxidative
stress.
2.5 Contributions
T.H.T. and Y.H.S. performed synthetic experiments. T.H.T. performed biological
experiments. F.J.G. performed mass spectrometry experiments. K.S.C., T.H.T.,
F.J.G., and Y.H.S. designed experimental strategies.
2.6 Supplementary Methods
General Experimental. All reactions were performed under an argon atmo-
sphere in oven-dried glassware. Methylene chloride was distilled over calcium hydride
and tetrahydrofuran was distilled over sodium hydride prior to use. Reagents and
solvents were purchased from Sigma or other commercial sources and were used with-
out further purification. Analytical thin layer chromatography (TLC) was carried
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out using Analtech Uniplate silica gel plates and visualized using a combination of
UV, ceric ammonium molybdate, ninhydrin, and potassium permanganate staining.
Flash chromatography was performed using silica gel (32-63 µM, 60 Å pore size) from
Sorbent Technologies Incorporated. NMR spectra were obtained on a Bruker Avance
400 (400 MHz for 1H; 100 MHz for 13C). 1H and 13C NMR chemical shifts are reported
in parts per million (ppm) referenced to the residual solvent peak. Low-resolution
electrospray ionization (ESI) mass spectra were obtained with an Agilent 6120 Single
Quadrupole LC/MS.
Experimental Procedures and Spectroscopic Data
Synthesis of Deuterated Fragment for d 6-DAz-2. Compound 4 was synthe-
sized according to established literature procedures, except deuterated 3-bromopropanol
was used; physical properties were consistent with previously reported values (21).
Synthesis of Alkyne Acid-Cleavable Linker (Yn-ACL). Compound 11. In
an oven-dried round bottom flask purged with argon, 3-hydroxy-3-methyl-butanenitrile
(1.24 mL, 12.00 mmol) was dissolved in THF (30 mL). 1M BH3-THF complex (36.00
mL, 36.00 mmol) was added to the reaction at 0 ◦C. The resulting solution was heated
to reflux for 1 h, cooled to 0 ◦C, and quenched with MeOH. 1M HCl (36 mL) was
added to the reaction mixture, refluxed for 1 h, and the solution was concentrated in
vacuo to provide compound 11 (1660 mg, 11.89 mmol) in 99% yield as a white solid.
1H NMR (MeOD, 400 MHz): δ 3.06 (t, J = 7.2 Hz, 2H), 1.77 (t, J = 7.2 Hz, 2H),
1.25 (s, 6H). 13C NMR (MeOD, 100 MHz): δ 70.66, 40.63, 37.45, 29.45.
Compound 10. Compound 11 (1700 mg, 12.2 mmol) was added to a solution of
Na2CO3 (3879 mg, 36.6 mmol) dissolved in H2O (40 mL) and 1,4-dioxane (30 mL)
and cooled to 0 ◦C with an ice bath. To the resulting solution, Fmoc-Cl (3492 mg,
13.5 mmol) in 1,4-dioxane (10 mL) was added dropwise. The temperature was slowly
brought up to rt and the reaction was allowed to stir for 4 h. After completion of the
reaction, the reaction mixture was extracted with DCM (3 x 50 mL), washed with
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brine (50 mL), dried over MgSO4, and concentrated in vacuo. The crude residue was
purified by silica gel chromatography, eluting with 1:9 ethyl acetate: dichloromethane
to yield compound 10 (3569 mg, 11.0 mmol) in 90% yield as a white solid. Rf : 0.13
(1:9 ethyl acetate: dichloromethane). 1H NMR (CDCl3, 400 MHz): δ 7.77 (d, J =
7.6 Hz, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.31 (td, J = 7.6 Hz,
1.2 Hz, 2H), 4.40 (d, J = 4.4 Hz, 2H), 4.22 (t, J = 6.8 Hz, 1H), 3.36 (t, J = 6.0 Hz,
2H), 1.69 (t, J = 6.8 Hz, 2H), 1.26 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 156.56,
144.06, 141.32, 127.65, 127.04, 125.08, 119.96, 70.87, 66.59, 47.34, 42.18, 37.43, 29.71.
ESI-LRMS calcd. for C20H23NO3 (M+H) 326.4, found 326.2.
Compound 9. In an oven dried round bottom flask, compound 10 (1000 mg,
3.08 mmol) was dissolved in DCM (40 mL). 1-chloroethyl chloroformate (0.43 mL,
4.00 mmol) was added dropwise and the reaction mixture was cooled to 0 ◦C. To the
resulting solution, dry pyridine (0.37 mL, 4.63 mmol) was added dropwise slowly and
the reaction was allowed to stir at 0 ◦C for 4 h. After completion of the reaction,
0.5M HCl (50 mL) was added and the reaction mixture was extracted with DCM
(3 x 30 mL). The organic layers were combined, washed with brine (30 mL), dried
over MgSO4, and concentrated in vacuo. The crude residue was purified by silica gel
chromatography, eluting with 1:2 ethyl acetate: hexane to yield compound 9 (968
mg, 2.24 mmol) in 73% yield as a white solid. Rf : 0.43 (1:2 ethyl acetate: hexane).
1H NMR (CDCl3, 400 MHz): δ 7.77 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 7.6 Hz, 2H),
7.40 (t, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 6.39 (q, J = 5.6 Hz, 1H), 4.41
(d, J = 6.8 Hz, 2H), 4.21 (t, J = 6.8 Hz, 1H), 3.32 (q, J = 6.8 Hz, 2H), 2.03 (t, J
= 7.2 Hz, 2H), 1.81 (d, J = 6.0 Hz, 2H), 1.54 (s, 6H). 13C NMR (CDCl3, 100 MHz):
δ 156.32, 150.82, 143.95, 141.33, 127.69, 127.05, 125.04, 119.99, 84.88, 84.14, 66.65,
47.29, 40.32, 36.60, 25.67, 25.17. ESI-LRMS calcd. for C23H26ClNO5 (M+Na+) 454.9,
found 454.1.
Compound 8. In a round bottom flask, compound 9 (500 mg, 1.16 mmol) was
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dissolved in dry DMF (19 mL). In a separate flask, propargyl amine (0.15 mL, 2.32
mmol) was dissolved in dry DMF (1 mL) and then added dropwise to the reaction
mixture. The resulting solution was allowed to stir at rt for 12 h. After completion
of the reaction, EtOAc (50 mL) was added and the reaction mixture was extracted
with H2O (5 x 20 mL). The organic layer was washed with brine (20 mL), dried with
MgSO4, filtered, and concentrated in vacuo to yield a clear orange oil. The crude
residue was purified by silica gel chromatography, eluting with 1:3 ethyl acetate:
hexane to yield compound 8 (277 mg, 0.68 mmol) in 59% yield as a pale yellow solid.
Rf : 0.10 (1:3 ethyl acetate: hexane). 1H NMR (CDCl3, 400 MHz): δ 7.77 (d, J =
7.6 Hz, 2H), 7.60 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6
Hz, 2H), 4.41 (d, J = 6.8 Hz, 2H), 4.21 (t, J = 6.8 Hz, 1H), 3.89 (s, 2H), 3.31-3.29
(m, 2H), 2.20 (t, J = 2.4 Hz, 1H), 2.01 (t, J = 6.4 Hz, 2H), 1.48 (s, 6H). 13C NMR
(CDCl3, 100 MHz): δ 156.35, 155.10, 143.98, 141.34, 127.68, 127.04, 125.02, 119.98,
80.98, 79.89, 71.44, 66.56, 47.31, 40.64, 36.78, 30.43, 26.53. ESI-LRMS calcd. for
C24H26N2O4 (M+Na+) 429.4, found 429.2.
Compound 7. In a round bottom flask, compound 8 (200 mg, 0.49 mmol) was
dissolved in dry DMF (2 mL) and cooled to 0 ◦C. Piperidine (0.5 mL) was added to
the reaction and the resulting solution was brought up to rt and allowed to stir for
30 min. After completion of the reaction, the reaction mixture was concentrated in
vacuo to yield compound 7 (90 mg, 0.49 mmol) in 99% yield. ESI-LRMS calcd. for
C9H16N2O2 (M+Na+) 207.4, found 207.1.
Alkyne Acid-Cleavable Linker (Yn-ACL) 3. In a round bottom flask, a mixture of
compound 7 (90 mg, 0.49 mmol) and NHS biotin (201 mg, 0.59 mmol) was dissolved
in DMF (5 mL). TEA (0.20 mL, 1.47 mmol) was added to the reaction and the
resulting solution was stirred at rt for 4 h. After completion of the reaction, the
reaction mixture was concentrated in vacuo. The crude residue was purified by silica
gel chromatography, eluting with 1:9 methanol: ethyl acetate to yield compound 3
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(200 mg, 0.49 mmol) in 99% yield as a golden brown solid. Rf : 0.09 (1:9 methanol:
ethyl acetate). 1H NMR (CDCl3, 400 MHz): δ 4.49-4.46 (m, 1H), 4.29-4.26 (m, 1H),
3.85 (s, 2H), 3.49 (dt, J = 53.2 Hz, 5.2 Hz, 1H), 3.29-3.27 (m, 2H), 3.13-3.08 (m,
1H), 2.85 (dd, J = 12.8 Hz, 4.8 Hz, 1H), 2.72 (d, J = 9.2 Hz, 1H), 2.15 (dt, J = 64.4
Hz, 7.6 Hz, 2H), 1.95-1.92 (m, 2H), 1.72-1.67 (m, 2H), 1.65-1.57 (m, 2H), 1.53-1.48
(m, 2H), 1.39 (s, 6H). 13C NMR (CDCl3, 100 MHz): δ 171.38, 164.46, 155.54, 81.01,
80.24, 71.28, 62.10, 60.25, 55.59, 40.58, 36.30, 35.99, 32.90, 28.50, 28.07, 26.70, 25.69,
24.50. ESI-LRMS calcd. for C19H30N4O4S (M+Na+) 433.5, found 433.3.
Stock Solutions. DAz-2 and d6-DAz-2 stocks were made up to a final concen-
tration of 250 mM in a 70:30 mixture of DMSO and 500 mM Bis-Tris HCl pH 7.4.
Yn-ACL stock was made up to a final concentration of 5 mM in DMSO. All reagents
were added directly to purified protein samples.
Cloning, Expression, and Purification of Recombinant Gpx3. Recombi-
nant C64S C82S Gpx3 protein was expressed and purified as described previously (28).
DAz-2 Labeling of C64S C82S Gpx3. C64S C82S Gpx3 (hereafter referred
to as Gpx3) was previously stored in 50 mM Tris HCl pH 7.4, 300 mM NaCl, 10%
glycerol, and 5 mM DTT. DTT was removed from Gpx3 via spin filtration using P-30
micro BioSpin columns (BioRad) buffer exchanged into Gpx3 buffer (50 mM Tris HCl
pH 7.4, 300 mM NaCl). 25 µM Gpx3 was labeled with 10 mM DAz-2 and treated
with 37.5 µM H2O2 for 2 h at 37 ◦C while rocking. Small molecules were removed by
passing the reactions through two consecutive P-30 columns.
Detection of DAz-2 Labeled Proteins Using Click Chemistry. Probe
modified proteins were detected via bioorthogonal Huisgen [3 + 2] cycloaddition (click
chemistry). The protein samples were buffer exchanged into click labeling buffer (50
mM triethanolamine pH 7.4, 1% SDS). The samples were incubated with Yn-ACL
(100 µM), TCEP (1 mM), TBTA (100 µM), and CuSO4 (1 mM) and allowed to
react for 1 h at rt while rocking. Click chemistry reactions were passed through two
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consecutive P-30 columns to remove small molecules.
ESI-LC/MS Analysis of Intact Gpx3 Labeled with DAz-2 and Yn-ACL.
Gpx3 was labeled with DAz-2 and Yn-ACL as previously described above. The intact
protein sample was analyzed on an electrospray linear ion trap mass spectrometer
(LTQ-XL, Thermo Scientific) after separation on an Agilent Eclipse XDB-C8 2.1 mm
x 15 mm trap with mobile phases A (0.1% formic acid in water) and B (0.1% formic
acid in acetonitrile) which was used to trap, desalt, and elute proteins onto a Varian
2.1 mm x 50 mm 5 µm PLRP-S C18 column with a gradient of 5% to 100% B in 14
min at a flow rate of 200 µL/min.
TFA Cleavage Conditions of Yn-ACL Labeled Proteins. The biotin moiety
of Yn-ACL was cleaved from biotinylated protein samples using a cleavage cocktail
(95% TFA, 2% TIS). The samples were subjected to cleavage conditions for 0 - 6 h at
rt or 37 ◦C while rocking. Afterwards, the cleavage cocktail was removed via vacuum
centrifugation. The samples were analyzed by immunoblot as described below.
Immunoblot. Protein samples were resuspended in SDS protein loading buffer
containing 10% 2-βME. The samples were separated by SDS-PAGE using Mini-
Protean TGX 4-15% Tris-Glycine gels (BioRad) and transferred to a polyvinylidene
difluoride (PVDF) membrane (BioRad). After transfer, the PVDF membrane was
blocked with 3% BSA for 1 h at rt. The membrane was washed with TBST (2 x 10
min) and then incubated with 1:80,000 streptavidin-HRP (GE Healthcare). PVDF
membrane was washed with TBST (2 x 10 min) and then developed with chemilu-
minescence (GE Healthcare ECL Plus Western Blot Detection System) and imaged
by film. To verify equal protein loading, His-tag of Gpx3 protein was probed with
1:100,000 His-HRP (Thermo Scientific). Membranes were routinely stained with Pon-
ceau S to assess quality of protein transfer and loading.
In-Gel Trypsin Digestion of Biotinylated Labeled Proteins. Gpx3 was
labeled with DAz-2 and Yn-ACL as described above and exchanged into 25 mM
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ammonium bicarbonate, pH 8.3 (Ambic). The samples were concentrated via vacuum
centrifugation and separated by SDS-PAGE. The SDS-PAGE gel was rinsed with H2O
and then stained with SimplyBlue SafeStain (Invitrogen). After staining, the gels
were washed with H2O and bands of interest were excised. The excised bands were
dehydrated in 2:1 ACN: 25 mM Ambic, and subsequently rehydrated with 25 mM
Ambic twice prior to reducing with 10 mM DTT for 1 h at 56 ◦C. DTT was removed,
and the samples were alkylated with 55 mM iodoacetamide for 45 min at rt in the
dark. Iodoacetamide was removed, and the excised bands were washed with 25 mM
Ambic and then dehydrated and rehydrated two additional times. Sequencing grade
modified trypsin (Promega), at a ratio of 1: 25 (w/w), was added to the excised
bands and incubated overnight at 37 ◦C. Peptides were extracted from the gel by
collecting the supernatant and by dehydrating and rehydrating the excised bands.
Peptide samples were concentrated via vacuum centrifugation.
Avidin Affinity Cartridge Enrichment of Biotinylated Labeled Peptides.
Biotinylated labeled peptides generated from the in-gel trypsin digestion described
above were enriched for using the Cleavable ICAT Reagent Kit for Protein Labeling
(Applied Biosystems) according to the manufacturer’s instructions.
ESI-LC/MS/MS Analysis of Gpx3 Peptides Labeled with DAz-2 and
Yn-ACL. Gpx3 peptides were labeled with DAz-2 and Yn-ACL, and enriched for us-
ing avidin affinity cartridges as previously described or streptavidin-coated magnetic
beads as described below. The peptide samples were analyzed on an electrospray
linear ion trap mass spectrometer (LTQ-XL, Thermo Scientific) after separation on
an Agilent Eclipse XDB-C8 2.1 mm x 15 mm trap with mobile phases A (0.1% formic
acid in water) and B (0.1% formic acid in acetonitrile) which was used to trap, desalt,
and elute proteins onto a Vydac Everest reverse-phase C18 monomeric column (2.1
mm x 150 mm, 300 Å, 5 µm) with a gradient of 5% to 60% B in 60 min at a flow
rate of 200 µL/min.
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TFA Cleavage of Biotinylated Peptide Samples for MS Analysis. The
biotin moiety of Yn-ACL was cleaved from biotinylated peptide samples using a cleav-
age cocktail (95% TFA, 2% TIS). The samples were subjected to cleavage conditions
for 1 h at 37 ◦C while rocking. Afterwards, the cleavage cocktail was removed via
vacuum centrifugation. Cleaved peptide samples were resuspended in 0.1% formic
acid and subjected to MS analysis.
Streptavidin-Coated Magnetic Bead Enrichment of Biotinylated La-
beled Proteins. Gpx3 was labeled with DAz-2 and Yn-ACL as described above
and exchanged into phosphate buffered saline (PBS). Protein samples were enriched
for using MagnaBind Streptavidin (Thermo Scientific) magnetic beads. Samples were
incubated with the beads for 1 h at rt with rocking. After enrichment, the beads were
washed three times with PBS (500 µl, 5 min)
Elution Conditions for Streptavidin-Coated Magnetic Beads Elution
Comparison. Biotinylated labeled Gpx3 was enriched using streptavidin-coated
magnetic beads as described above. Enriched protein was eluted with 30% ACN/0.4%
TFA in water for 15 min at 25 ◦C or 37 ◦C, boiling with 30% ACN/10% TFA in water,
or boiling with 8M guanidine HCl in water. Samples were analyzed by immunoblot
as described above.
Elution Conditions for Temperature-Dependent Study of 30% ACN
Elution for Streptavidin-Coated Magnetic Beads. Biotinylated labeled Gpx3
was enriched using streptavidin-coated magnetic beads as described above. Enriched
protein was eluted with 30% ACN/0.4% TFA in water for 15 min at 37 ◦C, 60 ◦C, or
boiling. Samples were analyzed by immunoblot as described above.
Elution Conditions for Concentration-Dependent Study of Guanidine
HCl Elution for Streptavidin-Coated Magnetic Beads. Biotinylated labeled
Gpx3 was enriched using streptavidin-coated magnetic beads as described above.
Enriched protein was eluted by boiling with 1, 4, or 8M guanidine HCl. Samples
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were analyzed by immunoblot as described above.
On-Resin Trypsin Digestion of Enriched Biotinylated Labeled Proteins.
Biotinylated Gpx3 was enriched using streptavidin-coated magnetic beads as de-
scribed above. After enrichment, the beads were washed three times with PBS (500
µl, 5 min) and resuspended in 2M urea in 25 mM Ambic pH 8.3. Sequencing grade
modified trypsin (Promega), at a ratio of 1: 25 (w/w), was added to the beads and
incubated overnight at 37 ◦C. The next day, the beads were washed three times with
2M urea in 25 mM Ambic pH 8.3 and three times with 25 mM Ambic pH 8.3 (500
µl, 5 min). The enriched peptides were eluted by boiling with 8M guanidine HCl for
15 min. The peptide samples were de-salted by passing through a MacroSpin C18
column (Nest Group), concentrated via vacuum centrifugation, resuspended in 0.1%
formic acid, and subjected to MS analysis.
Ratiometric Quantification of Sulfenic Acid Modifications Using DAz-2
and d 6-DAz-2. Parallel samples of Gpx3 were subjected to two labeling conditions:
(1) 25 µM Gpx3 treated with 10 mM d6-DAz-2 and 37.5 µM H2O2 or (2) 25 µM
Gpx3 treated with 10 mM d0-DAz-2 and 2.5 µM H2O2 for 2 h at 37 ◦C. The samples
were passed through two consecutive P-30 columns to remove excess small molecules.
The d0-DAz-2 and d6-DAz-2 labeled samples were combined and then subjected to
click chemistry with Yn-ACL as described above. The biotinylated labeled samples
were enriched using either the avidin affinity cartridge or the streptavidin-coated




Figure 2.S1: Sequence coverage obtained from C64S C82S Gpx3 trypsin digestion. Underlined
sequence corresponds to the additional sequence from the vector.
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Figure 2.S2: ESI-LC/MS/MS analysis of avidin affinity cartridge enrichment. (a) MS2 of m/z
765.16 produces the biotinylated fragment m/z 312.18 [M + H]+, fragmented enriched sulfenic acid-
modified peptide with loss of water, m/z 587.26 [M + 2H - H2O]+2, and m/z 1173.54 [M + H -
H2O]+. (b) Extracted ion chromatogram of TFA cleaved peptide m/z 587.58 [M + 2H - H2O]+2.
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Figure 2.S3: Comparison of streptavidin-coated magnetic bead elution conditions 30% ACN + 0.4%
TFA or guanidine HCl. Samples were generated as in Figure 2.2. I = input, S = supernatant,
and E = eluent. (a) Temperature-dependent study of 30% ACN + 0.4% TFA elution conditions.
Enriched Gpx3 labeled protein was eluted using 30% ACN + 0.4% TFA at 37 ◦C, 60 ◦C, or boiling
for 15 min. (b) Concentration-dependent study of guanidine HCl elution conditions. Enriched Gpx3
labeled protein was eluted using guanidine HCl (1, 4, or 8 M) pH 1.2 for 15 min.
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Figure 2.S4: ESI-LC/MS/MS analysis of streptavidin-coated magnetic bead enrichment. (a) MS2 of
m/z 765.11 [M + 2H - H2O]+2 produces fragmentation of the intact sulfenic acid-modified peptide
to give the biotinylated fragment m/z 312.22 [M + H]+, fragmented sulfenic acid-modified peptide
m/z 587.63 [M + 2H - H2O]+2, and m/z 1173.54 [M + H - H2O]+. (b) Extracted ion chromatogram
of TFA cleaved peptide m/z 587.61 [M +2H - H2O]+2.
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Figure 2.S5: ESI-LC/MS/MS analysis of enriched intact sulfenic acid-modified C*GFTPQYK pep-
tides from ratiometric quantification studies. (a) Avidin affinity cartridge enriched peptides. (b)
Streptavidin-coated magnetic beads enriched peptides. MS2 spectra shows the biotin fragment m/z
312 [M + H]+, fragmented sulfenic acid-modified peptides m/z 587 (d0) and 590 (d6) [M + 2H -
H2O]+2, and m/z 1173 (d0) and 1179 (d6) [M + H - H2O]+.
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2.8 Supplementary Tables
Table 2.S1: Expected and observed m/z of C*GFTPQYK peptide from Gpx3
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CHAPTER III
Peroxide-dependent sulfenylation of the EGFR
catalytic site enhances kinase activity
3.1 Abstract
Protein sulfenylation (SOH) is a post-translational modification of emerging im-
portance in higher eukaryotes. However, investigation of its diverse roles remains
challenging, particularly within a native cellular environment. Herein we report the
development and application of DYn-2, a new chemoselective probe for detecting
sulfenylated proteins in cells. These studies show that epidermal growth factor recep-
tor (EGFR)-mediated signaling results in hydrogen peroxide (H2O2) production and
oxidation of downstream proteins. In addition, we demonstrate that DYn-2 has the
ability to detect differences in sulfenylation rates within the cell, which are associated
with differences in target protein localization. Finally, we show that EGFR is di-
rectly modified by H2O2 at a critical active site cysteine (Cys797), which enhances its
tyrosine kinase activity. Collectively, our findings highlight sulfenylation as a global
signaling mechanism akin to phosphorylation, with regulatory implications for other




Hydrogen peroxide (H2O2) is a source of oxidative stress, but also acts as an
essential second messenger in signal transduction networks of normal healthy cells,
wherein growth factors, cytokines and a variety of other ligands trigger its produc-
tion through activation of their corresponding receptors (1, 2). Indeed, H2O2 has
been demonstrated to regulate many basic cellular processes including proliferation,
differentiation, growth, migration, and survival. For example, binding of epidermal
growth factor (EGF) to the extracellular domain of the EGF receptor (EGFR) results
in the assembly and activation of NADPH oxidase (Nox) complexes, which generate
H2O2 (3, 4) (Figure 3.1a). Once formed, H2O2 modulates signaling cascades by reac-
tion with specific biomolecular targets.
There is now a wealth of evidence indicating that protein cysteine residues are
sensitive targets of H2O2, both by direct oxidation and vis-à-vis thiol peroxidases (5,
6). The product of the reaction between H2O2 and a thiolate is sulfenic acid (SOH).
Also known as sulfenylation, this modification is reversible (either directly or indi-
rectly by disulfide formation) and provides a mechanism by which changes in cellular
redox state can be exploited to regulate protein function, analogous to phosphoryla-
tion (7, 8). Recent studies shed new light on the role of sulfenic acid and expand the
repertoire of proteins that can undergo sulfenylation (9–13), hinting at the regulatory
potential and significance of these modifications. Nonetheless, the scope of sulfeny-
lation in biological processes, particularly in eukaryotic signal transduction, remains
virtually unknown.
Investigating the role of sulfenylation remains challenging, particularly in the con-
text of the native cellular environment (14). We now present the development and
application of DYn-2, a chemoselective probe for detecting sulfenylated proteins di-
rectly in cells with improved sensitivity. These studies show that DYn-2 is capable of
monitoring global changes in protein sulfenylation generated by Nox-mediated growth
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factor signaling. In addition, we demonstrate that DYn-2 has the ability to detect
differences in sulfenylation rates within the cell, due to differences in target protein
localization. Finally, we show that EGFR is modified by H2O2 at a critical cysteine
(Cys797) in its catalytic site that stimulates its kinase activity, thereby demonstrating
that sulfenylation, as well as phosphorylation, can regulate receptor tyrosine kinase
(RTK) function.
3.3 Results
EGF modulates cell morphology and EGFR trafficking. To investigate
events after the interaction of EGF with its receptor we used the human epider-
moid carcinoma A431 cell line, which naturally expresses high levels of EGFR. As
shown by phase contrast microscopy, EGF stimulation induced rapid changes in cell
shape (Supplementary Results, Supplementary Figure 3.S1). Additionally, we used
immunofluorescence to determine whether EGF-dependent changes in morphology
coincided with receptor mobilization (Figure 3.S1b). EGFR localized to the plasma
membrane without EGF stimulation and concentrated at sites of membrane ruffling
within two minutes of mitogen treatment. At 30 minutes, the majority of EGFR
had accumulated in punctate foci throughout the peripheral cytoplasm, and after one
hour, internalized receptors had recycled back to the cell surface. These data show
that EGF stimulation dramatically changes cell morphology and receptor localization,
setting the stage to probe oxidant-mediated signal transduction.
Cellular redox balance affects EGF-mediated signaling. Next, we exam-
ined the relationship between EGFR signaling and reactive oxygen species (ROS)
in A431 cells. Intracellular generation of ROS was measured via the conversion of
2,7-dihydro-dichlorofluorescein diacetate (H2DCF-DA) to fluorescent product dichlo-
rofluorescein (DCF). Coincident with membrane ruffling, EGF-stimulated cells ex-
hibited an increase in DCF fluorescence intensity (Figure 3.1c). Moreover, reversible
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Figure 3.1: Cellular redox status affects EGF-mediated signaling. (a) EGF binding to EGFR
and subsequent dimerization induces receptor auto- phosphorylation on specific tyrosine residues
within the cytoplasmic domain. The newly phosphorylated sites serve as interaction platforms for
proteins involved in key prosurvival pathways, such as PI3K/ AKT and Ras/ERK. Receptor-ligand
interaction also stimulates the production of ROS and oxidation of intracellular biomolecules, leading
to modulation of the signaling cascade. (b) Confocal fluorescence images of EGFR localization
in A431 cells before (T0) and after 100 ng/ml EGF stimulation for 2, 15, 30, and 60 min (T1,
T2, T3, and T4, respectively). Cells were stained with rabbit anti-EGFR followed by Alexa594-
conjugated goat anti-rabbit (red). White arrows highlight changes in receptor localization (T0,
plasma membrane; T1, membrane ruffles; T2, cell stretching and migration; T3, perinuclear and
endosomal membranes; T4, cell surface and ruffles). Nuclei were counterstained with DAPI (blue).
Scale bar, 10 µm. (c) EGF-induced ROS generation in A431 cells as revealed by DCF fluorescence.
Data are representative of three independent readings, were normalized to the vehicle control and
error bars show ± s.e.m. ∗∗indicates that P <0.001, ∗indicates that P <0.05 when compared against
EGF-only treated cells. (d-f) Western blots showing phosphorylated (p) and total EGFR, AKT,
and/or ERK. A431 cells were stimulated with the indicated concentrations of EGF, H2O2 or vehicle
for 5 min (d), or with 100 ng/ml EGF or vehicle for 5 min (e,f). Where specified, cells were treated
with the indicated concentrations of PEG-catalase (e), apocynin (f), or gefitinib (g), prior to EGF
stimulation.
and irreversible inhibitors of EGFR (gefitinib and afatinib, respectively), Nox (apoc-
ynin), phosphatidylinositol-3-OH kinase (PI3K, wortmannin), and the antioxidant,
N-acetyl cysteine (NAC) attenuated EGF-dependent ROS generation. Control ex-
periments with an NO synthase inhibitor (L-NAME) had no significant impact on
ROS levels, as expected (Figure 3.1c). These experiments support and extend pre-
vious observations (3, 15) that EGF-mediated ROS production requires both EGFR
and Nox activation.
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We then investigated the effect of exogenous H2O2 on phosphorylation of EGFR
and downstream kinases, AKT and ERK. In the absence of EGF, treatment with
H2O2 was sufficient to trigger a dose-dependent increase in phosphorylation of each
kinase (Figure 3.1d and Supplementary Figure 3.S2 for all uncut gel images in this
study). Control experiments showed that each protein became phosphorylated in re-
sponse to EGF and that EGFR or PI3K inhibitors attenuated this effect, as expected
(Figure 3.1d and Supplementary Figure 3.S3a). Subsequently, we examined the role
of H2O2 produced by EGF stimulation (i.e., endogenous H2O2) on pathway activa-
tion. Scavenging of growth factor-induced H2O2 with PEG-catalase or NAC sup-
pressed EGFR phosphorylation (Figure 3.1e), global tyrosine phosphorylation, and
AKT/ERK activation (Supplementary Figure 3.S3b-e). Additionally, Nox inhibitors,
apocynin and diphenyleneiodium (DPI), blunted protein phosphorylation, whereas
L-NAME had no apparent effect (Figure 3.1f and Supplementary Figure 3.S3f,g).
Collectively, these data underscore the importance of endogenous H2O2 for EGFR
signaling as a result of Nox activation.
The requirement for protein sulfenylation in yeast H2O2 sensing (16) and T-cell ac-
tivation (17) has been shown through inhibition with 5,5-dimethyl-1,3-cyclohexadione
(dimedone), a small-molecule that reacts selectively with sulfenic acid under aqueous
conditions (18–20) (Figure 3.2a). Along these lines, treatment of cells with dimedone,
prior to EGF stimulation, inhibited EGFR, AKT, and ERK phosphorylation (Sup-
plementary Figure 3.S3h), consistent with an essential role for protein sulfenylation
in EGFR signaling.
Synthesis and evaluation of DYn-1 and DYn-2. Chemical probes directly
conjugated to biotin or a fluorophore often have limited cell permeability due to their
bulky detection tag. Accordingly, protocols involving such reagents typically involve
homogenization of cells prior to labeling, which disrupts the native environment,
including redox balance. To address this issue, we have developed a strategy for
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detecting protein sulfenic acids directly in cells (11, 20, 21), wherein the dimedone
warhead is functionalized with a small azide chemical handle that does not impede
membrane permeability (DAz-1 and DAz-2, Figure 3.2b). An alkyne-functionalized
detection tag is then appended post-homogenation using the Staudinger ligation or
click chemistry.
Recent studies demonstrate that alkynyl-chemical reporters, in combination with
azide-bearing detection tags, offer superior sensitivity relative to the reverse orien-
tation (22). In light of this observation, we designed and synthesized the alkyne-
modified analogs, DYn-1 (1) and DYn-2 (2) (Figure 3.2b,c and Supplementary Meth-
ods). The synthesis began with ethyl protection of the reactive diketone. Alkyla-
tion of 3-ethoxy-cyclohex-2-enone with 3-bromopropyne to afford DYn-1 proceeded
smoothly; however, low yields were obtained in analogous reactions for 5-iodopent-1-
yne. As a result, we examined monoalkylation of the dianion of 1,3-cyclohexadione.
Using this strategy, DYn-2 was prepared without protecting groups in a single step
from commercially available materials in 96% yield (Figure 3.2c).
With DYn-1 and DYn-2 in hand, we performed comparative studies to determine
their utility for detecting protein sulfenic acid modifications alongside DAz-2. To this
end, we used a recombinant thiol peroxidase from budding yeast, known as Gpx3,
with an active site cysteine (Cys36) that is readily oxidized to sulfenic acid (16).
Analysis of these reactions by Western blot revealed robust, H2O2-dependent labeling
of Gpx3 by DYn-2, with increased intensity relative to DAz-2 (Figure 3.2d). Control
reactions, performed in the absence of probe, showed no detectable signal by Western
blot (Figure 3.2d). Conversely, DYn-1 exhibited a marked reduction in sulfenic acid
labeling compared to DYn-2 (Supplementary Figure 3.S4a). Therefore, DYn-1 was
not pursued further.
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Figure 3.2: Development and validation of probes for detecting sulfenic acid. (a) Selective
reaction between sulfenic acid and dimedone. (b) Chemical structures of chemical reporters for
sulfenic acid. (c) Design and synthesis of DYn-2 (2). LDA, lithium diisopropylamide; HMPA,
hexamethyl phosphoramide; 5-iodopent-1-yne. (d) Comparison of DAz-2 and DYn-2 detection of
sulfenic acid in recombinant Gpx3. 50 µM protein was untreated or exposed to 100 µM H2O2 and
incubated in presence or absence of 1 mM probe for 15 min at 37 ◦C. Labeled proteins were detected
by streptavidin-HRP Western blot. Comparable protein loading was confirmed by reprobing the
blot with anti-His tag antibody. (e) Western blots showing DAz-2 and DYn-2 detection of protein
sulfenic acids and total GAPDH in A431 cells. Cells were stimulated with 100 ng/ml EGF or vehicle
for 5 min, washed, collected as described in Methods, and then incubated with 5 mM probe or
vehicle for 1 h at 37 ◦C.
Next, we verified the nature of the covalent adduct formed between oxidized
Gpx3 and DYn-2 by electrospray ionization mass spectrometry (ESI-MS) (Supple-
mentary Figure 3.S4b,c). Analysis of the intact protein afforded a single major species
with a molecular weight of 22916.39 Da, consistent with a single DYn-2 adduct. De-
tailed examination of trypsin cleavage products confirmed Cys36 as the site of mod-
ification from the doubly-charged peptide ion at m/z 551.52 corresponding to H2N-
C-(2)GFTPQYK-OH and the series of b and y-type ions observed in the MS/MS
spectrum. Overall, Western blot and MS analyses establish that DYn-2 selectively
targets protein sulfenic acid modifications.
We then evaluated DYn-2 for detecting sulfenic acids in cells using the strategy
outlined in Supplementary Figure 3.S5a. Analysis of probe labeling by Western blot
revealed sulfenylated proteins in both A431 and HeLa cells (Figure 3.2e and Sup-
plementary Figure 3.S5b,c). The qualitative profile of DYn-2 labeling was similar to
DAz-2, suggesting that the probes reacted with the same protein targets. Notably, the
total signal from DYn-2 labeling was greater than DAz-2 under identical conditions,
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and the signal ratio of EGF-stimulated and unstimulated A431 cells was almost 40%
greater for DYn-2. Detection of sulfenylated proteins by DYn-2 was also dependent
on probe dose and time of incubation (Supplementary Figure 3.S5d,e). Controls per-
formed with or without catalase in lysis buffer further confirmed that DYn-2 labeling
did not occur after cell homogenization (Supplementary Figure 3.S5f). Addition of
DYn-2, before or after EGF treatment, did not affect phosphorylation of EGFR or
downstream targets (Supplementary Figure 3.S3h and Supplementary Figure 3.S5g),
likely due to the decrease in reactivity inherent to many dimedone analogs. Lastly,
probe-treated cells showed no loss of viability and maintained redox balance (Supple-
mentary Figure 3.S6). Collectively, these results validate DYn-2 as a robust chemical
reporter for protein sulfenylation in cells and our general approach of tagging oxidized
proteins in situ.
Dynamic, global protein sulfenylation in response to EGF. The preceding
studies reveal EGF-dependent changes in protein sulfenylation. This observation
is the first of its kind and, thus we investigated this discovery in greater detail.
Addition of EGF to A431 cells increased intracellular ROS (Figure 3.3a) and protein
sulfenylation (Figure 3.3b,c) in a dose-dependent manner. The maximal increase in
sulfenic acid modification was apparent at 100 ng/ml EGF, which fell to the basal level
at 500 ng/ml. ROS generation (Figure 3.3d) and protein sulfenylation (Figure 3.3e,f)
were also dynamic temporal events, peaking 5 min after EGF stimulation (100 ng/ml)
and declining thereafter. Furthermore, pharmacological studies indicated that EGF-
dependent changes in protein sulfenylation required EGFR, PI3K, and Nox activation,
as well as intracellular H2O2 (Supplementary Figure 3.S7).
Fluorescence microscopy with antibodies against the protein-dimedone adduct (21)
further highlighted the dynamic nature of EGF-mediated protein sulfenylation (Fig-
ure 3.3g). Relative to unstimulated cells, EGF treatment markedly increased signal
intensity with a peak at 6 min, whereas control samples omitting primary antibody
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Figure 3.3: Profiling EGF-mediated ROS production and protein sulfenylation. A431 cells
were incubated with EGF at the indicated concentrations (a, b) or the indicated times (d,e). In
(a), A431 cells were stimulated with EGF or vehicle for 5 min, and ROS was measured by DCF
fluorescence. In (b), A431 cells were stimulated with EGF or vehicle for 2 min and sulfenic acids
were detected by Western blot as in Figure 3.2e. (c) Densitometric quantification of each lane in b.
In (d), A431 cells were stimulated with 500 ng/ml EGF or vehicle and ROS was measured by DCF
fluorescence. In (e), A431 cells were stimulated with 100 ng/ml EGF or vehicle and sulfenic acids
detected as in b. (f) Densitometric quantification of each lane in f. Western blots were reprobed
for GAPDH as a loading control. Data are representative of four independent experiments for
Western blots and three independent readings for ROS measurements and represent the mean ±
s.e.m. ∗∗indicates that P <0.001, ∗∗indicates that P <0.01, and ∗indicates that P <0.05 compared
to vehicle control. (g) Fluorescence images of sulfenylation (red) in A431 cells before (T0) and after
stimulation with 100 ng/mL EGF for 0.5, 1, 1.5, or 2 min, then treated with 5 mM dimedone for
5 min at 37 ◦C in EGF-containing media; total EGF exposure was 5.5, 6, 6.5 and 7 min (T1, T2,
T3, and T4, respectively). Nuclei were counterstained with DAPI (blue). Scale bar, 10 µm. In (h),
A431 cells were stimulated with 100 ng/mL EGF or vehicle for 0.5 min and treated with dimedone
as in g. Cells were stained for the dimedone-protein adduct (red) and Nox2 (green). The merged
image reveals partial co-localization (yellow). Scale bar, 10 µm.
showed no signal (Supplementary Figure 3.S8). The slight difference in sulfenylation
peak times observed by Western blot (and ROS levels by DCF) and immunofluores-
cence analyses is most likely due to variations in sample handling inherent to each
procedure.
There are seven isoforms of nonphagocytic NADPH oxidase (Nox1-5 and Duox1
and 2) that exhibit unique activation mechanisms and tissue-specific expression (23).
Western blot and immunofluorescence analyses revealed that Nox2 is a major iso-
form in A431 cells (Supplementary Figure 3.S9a,b). Because proteins in the vicinity
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of Nox are prime targets for oxidation, we wondered whether Nox2 might colocalize
with sites of protein sulfenylation. Immunofluorescence analysis indicated the dis-
tribution of Nox2 at the plasma membrane and perinuclear area (Figure 3.3h and
Supplementary Figure 3.S9c). Remarkably, the merged image of Nox2 and protein
sulfenylation revealed a significant degree of colocalization (Figure 3.3h). Together,
these data show that EGF-stimulation results in dynamic changes of protein sulfeny-
lation, whose distribution in cells overlaps with Nox2.
Differential oxidation of phosphatases. We next sought to identify targets
of H2O2 within the EGFR pathway. Growth factor-induced ROS generation is com-
monly attributed to oxidation and inactivation of an essential active site cysteine
residue in protein tyrosine phosphatases (PTPs). While the analysis of cysteine ox-
idation in cell extracts indicates that PTP inhibition promotes kinase signaling (17,
24, 25), rates of these reactions are orders of magnitude slower relative to H2O2-
metabolizing enzymes, raising the specter of physiological relevance (26). Because
direct evidence of PTP oxidation in cells has not yet been reported, we used DYn-2 to
investigate sulfenylation in three signaling phosphatases: PTEN, PTP1B and SHP2.
PTEN is predominantly cytoplasmic and functions reciprocal to PI3K, PTP1B down-
regulates endocytosed receptors within the endoplasmic reticulum (ER), while SHP2
interacts directly with EGFR at the plasma membrane through its SH2 domains
where it serves to mediate interactions with downstream components.
Western blot analysis of immunoprecipitated PTPs showed that each protein un-
derwent EGF-dependent sulfenylation in A431 cells (Figure 3.4a-c). Moreover, each
PTP displayed a distinct oxidation profile with respect to growth factor concentra-
tion (Figure 3.4a-c): SHP2 sulfenylation peaked at a relatively low level of EGF (20
ng/ml), followed by PTEN (500 ng/ml), and finally PTP1B (750 ng/ml). Subse-
quently, we investigated PTP localization in cells before and after EGF treatment.
Immunofluorescence staining showed that SHP2 underwent a dramatic change in lo-
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Figure 3.4: Differential sulfenylation of PTPs in EGF-treated cells. (a-c) Western blots
showing sulfenylated and total immunoprecipitated PTEN, PTP1B, and SHP2. A431 cells were
stimulated with EGF or vehicle for 2 min at the indicated concentrations, washed, collected, and
then incubated with 5 mM DYn-2 or vehicle for 1 h at 37 ◦C. Following treatment, lysates were
immunoprecipitated with mouse anti-PTEN (a), mouse anti-PTP1B (b), or rabbit anti-SHP2 (c) and
recovered with protein A or G coated beads. Sulfenylation of PTPs was detected by streptavidin-
HRP Western blot. To verify equivalent recovery of immunoprecipitated protein, Western blots were
reprobed for total PTP as indicated. (d-f) Confocal fluorescence images of A431 cells stimulated
with vehicle or 100 ng/ml EGF for 5 min. Cells were fixed and stained with anti-PTEN (d), anti-
PTP1B (e), or anti-SHP2 (f), followed by Alexa488-conjugated goat anti-mouse (green, d,e) or
Alexa594-conjugated goat anti-rabbit (red, f). Nuclei were counterstained with DAPI (blue). Scale
bar, 10 µm. The white arrows in (f) highlight the change in subcellular localization of SHP2 after
stimulation with EGF.
calization, concentrating at sites of plasma membrane ruffling, whereas EGF had no
apparent effect on PTEN or PTP1B (Figure 3.4d-f). Overall, these data demon-
strate that PTPs undergo EGF-dependent oxidation and suggest that the extent of
sulfenylation in the cell may be related to differences in target protein localization.
Identification of EGFR as a sensitive target of H2O2. The overall level
of EGFR autophosphorylation reflects the balance between kinase and phosphatase
activities. H2O2-induced PTP inhibition would shift the balance toward phosphoryla-
tion; however, the increase in EGFR phosphorylation could similarly be accounted for
by H2O2-mediated enhancement of intrinsic kinase activity. To examine this possibil-
ity, we first tested whether EGFR was a target of H2O2 in cells. Strikingly, these stud-
ies revealed that EGF stimulation led to robust sulfenic acid modification of EGFR
(Figure 3.5a), a finding that was recapitulated with exogenous H2O2 (Figure 3.5b).
EGFR sulfenylation peaked at the lowest concentration of EGF employed in this study
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Figure 3.5: EGF-mediated sulfenylation of EGFR Cys797 in cells. (a,b) Western blots
showing sulfenylated and total EGFR. A431 cells were stimulated with EGF at the indicated con-
centrations or vehicle for 2 min (a) or H2O2 for 10 min (b) and sulfenic acids were detected by
streptavidin-HRP Western blot as in Figure 3.4a-c, except that rabbit anti-EGFR was used for im-
munoprecipitation. (c,d) Western blots showing coimmunprecipitation of Nox2 and EGFR. A431
cells were stimulated with 100 ng/ml EGF or vehicle for the indicated times, harvested in native
lysis buffer to preserve protein-protein interactions, and immunoprecipitated using goat anti-EGFR
(c) or rabbit anti-Nox2 (d). (c) The presence of Nox2 was evaluated using goat anti-Nox2 and
comparable recovery of immunoprecipitated EGFR was confirmed by probing the blot with rabbit
anti-EGFR. IC, isotype control. (d) The presence of EGFR was evaluated using rabbit anti-EGFR
and comparable recovery of immunoprecipitated Nox2 was confirmed by probing the blot with goat
anti-Nox2. (e) Western blot showing sulfenylated and total EGFR. A431 cells were incubated with
1 or 5 µM afatinib (+ and ++, respectively), 10 µM canertinib, 1 µM pelitinib or vehicle before
treatment with H2O2 and sulfenylation was detected as in b. (f) Measurement of EGFR tyrosine
kinase activity in vitro. Recombinant EGFR kinase was untreated or exposed to H2O2 at the in-
dicated concentrations and then assayed for activity. Data are representative of three independent
readings and represent the mean ± s.e.m. ∗∗∗indicates that P <0.001, ∗∗indicates that P <0.01, and
∗indicates that P < 0.05 compared to vehicle control.
(4 ng/ml) and at ∼10 µM exogenous H2O2 (Supplementary Figure 3.S9d). Given the
marked increase in EGFR oxidation at low EGF concentrations, we wondered whether
the receptor might form a complex with Nox2. This proposal was confirmed by co-
immunoprecipitation, which demonstrated EGF- and time-dependent association of
Nox2 with EGFR and visa versa (Figure 3.5c,d). In addition, we found that the
EGFR/Nox complex co-immunoprecipitated SHP2, consistent with its propensity for
oxidation in cells (Supplementary Figure 3.S9e).
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Oxidation of EGFR active site modulates kinase activity. The kinase do-
main of EGFR contains six cysteine residues. Of these, a conserved cysteine within
the ATP binding site (Cys797, Supplementary Figure 3.S9f) is a major target for
irreversible inhibitors in cancer clinical trials (27, 28). On this basis, we hypothesized
that Cys797 might be the site of oxidation. This proposal was supported by studies
with irreversible inhibitors, which blocked exogenous H2O2-mediated EGFR sulfeny-
lation (Figure 3.5e). Next, we mapped the site of EGF-induced oxidation in cells using
dimedone. ESI-LC/MS/MS analysis of pepsin-digested EGFR confirmed Cys797 as
the site of covalent modification from the doubly-charged peptide ion at m/z 402.80
corresponding to H2N-MPFGC∗L-OH and the series of b- and y-type ions observed
in the MS/MS spectrum (Supplementary Figure 3.S9g). The reduced EGFR pep-
tide was also detected and the ratio of peak areas of the dimedone-modified peptide
ion relative to the unmodified version was approximately 6:1 (Supplementary Fig-
ure 3.S9h).
Given the proximity of Cys797 to the ATP binding site (Supplementary Fig-
ure 3.S9f) it is plausible that oxidation of this residue modulates enzymatic activity.
To test this hypothesis, we performed activity assays using the recombinant EGFR
kinase domain. First, we verified that enzyme activity increased as a function of
EGFR concentration and decreased with inhibitor treatment (Supplementary Fig-
ure 3.S9i-k). Subsequent studies revealed that tyrosine kinase activity was enhanced,
relative to the untreated control, by moderate H2O2 concentrations (0.05-10 µM),
followed by a decline at levels greater than 50 µM (Figure 3.5f). Incubation with
the reducing agent, dithiothreitol (DTT) mitigated inhibition by H2O2 (Supplemen-
tary Figure 3.S9l), indicating that the decline in EGFR activity at high oxidant
concentrations involves reversible thiol oxidation. Control experiments also showed
that H2O2 had no significant effect on other components of the assay system (Sup-
plementary Figure 3.S9m). Collectively, these data demonstrate that EGFR Cys797
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is a direct target of endogenous H2O2, ostensibly through its association with Nox2,
and that signaling levels of this oxidant enhance EGFR kinase activity.
3.4 Discussion
Historically, protein cysteine oxidative has been investigated using indirect meth-
ods of detection (14) (Supplementary Figure 3.S10a,b). As these approaches require
comprehensive blocking of free thiols at the outset of the procedure, their application
is restricted to the analysis of oxidation within purified proteins or cell lysates. Al-
ternatively, oxidative cysteine modifications can be detected on the basis of their dis-
tinct chemical attributes using selective probes (Supplementary Figure 3.S10c), which
enable cysteine oxidation to be detected directly in cells. This is not a trivial consid-
eration since redox potentials differ markedly among subcellular compartments (29)
and, when the redox balance of the cell is disrupted during lysis, proteins undergo a
massive amount of artifactual oxidation. This fundamental, but often ignored issue,
increases the challenge involved in detecting modifications in low-abundance proteins
and for interpreting biological significance.
With the development of DYn-2, we have expanded the chemical toolbox with
which to probe protein sulfenic acid formation in cells. The discovery that pro-
tein sulfenylation is a dynamic process during EGFR-mediated signaling likely has
broader implications for other receptor-mediated processes. Consistent with this pro-
posal, alterations in protein sulfenic acid modifications have been observed in lysates
generated from HEK293 cells treated with the cytokine TNFα (30) and CD8+ T
cells stimulated with CD3/CD28 antibodies (17). While the changes in global pro-
tein sulfenylation observed in our study generally showed a strong positive correlation
with ROS levels, cells treated with 500 ng/ml EGF were an exception to this rule. In-
terestingly, the apparent lack of sulfenylation is consistent with the absence of global
disulfide bond formation in A431 cells under these conditions (31), and may reflect ox-
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idation of sulfenic to sulfinic acid, upregulation of efflux transporters, dissociation of
EGFR clusters from lipid rafts, and/or activation of alternate pathways that function
independent of cysteine oxidation.
Each protein analyzed in this study exhibited a unique sulfenylation profile in
cells (Figure 3.6a,b). For PTPs, differential susceptibility to oxidation is particularly
notable because their active site cysteines are deprotonated at physiological pH and
their reaction rates with H2O2 are almost identical in biochemical studies (32, 33).
One possible explanation for this apparent paradox is that the proximity of target
proteins to the source of ROS (e.g., Nox) has a significant influence on rates of oxida-
tion within the cell. Consistent with this model, we observed that EGFR and SHP2
form a complex with Nox2. On the other hand, oxidation of PTP1B, an ER-resident
phosphatase, was not observed until much higher EGF levels. Along these lines, a
recent study in aortic endothelial cells showed that PTP1B oxidation by Nox4 re-
quires ER localization of both proteins (34). Alternatively, the absence of PTP1B
oxidation at lower EGF concentrations might result from sulfenyl amide formation
outcompeting the DYn-2 trap (Supplementary Figure 3.S10d). However, this scenario
seems unlikely as sulfenyl amide condensation in PTP1B is expected to be at least
100-fold slower than intramolecular disulfide formation in PTEN and SHP2 (35, 36).
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Figure 3.6: Model for redox regulation of EGFR signaling. (a) Densitometric quantification
of EGFR and PTP sulfenylation from blots in Figure 3.4a-c and Figure 3.5a. Data are representative
of four independent experiments and represent the mean ± s.e.m. for each protein. ∗∗∗indicates that
P < 0.001, ∗∗indicates that P <0.01 and ∗indicates that P < 0.05 when compared against vehicle
control. (b) The mitogen EGF binds to EGFR and induces the production of ROS in A431 cells via
Nox2. The proximity of target proteins to Nox2 impacts the rate of cysteine oxidation within the
cell. Dashed lines are relevant to EGFR internalization. (c) Model for H2O2-mediated increase in
EGFR kinase activity. Nox-generated H2O2 directly modifies EGFR at a critical cysteine (Cys797)
in the active site, which enhances its tyrosine kinase activity. Endogenous H2O2 also oxidizes
and deactivates PTPs, which serves to maintain EGFR phosphorylation. Collectively, these events
lead to an increase in receptor autophosphorylation, which promotes signaling through downstream
pathways.
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Another central finding of this study is that EGFR becomes sulfenylated at Cys797
in EGF-stimulated cells and this modification enhances its intrinsic tyrosine kinase
activity (Figure 3.6c). Interestingly, the decline in EGFR activity at higher H2O2
concentrations may reflect disulfide bond formation with another cysteine in the ki-
nase domain, however future studies will be required to fully address this possibility.
The biphasic response of recombinant EGFR kinase activity with H2O2 paralleled
that of receptor sulfenic acid modification in cells; however, the peroxide concentra-
tion required for maximal rate enhancement was approximately 20-fold lower relative
to sulfenylation in cells. One likely explanation for this difference is that antiox-
idant enzymes and other biomolecular targets consume the H2O2 applied to cells.
Another noteworthy aspect of this behavior is that cellular sulfenylation and kinase
activity decreased above 50 µM H2O2, whereas EGFR phosphorylation continued to
increase at peroxide levels above 500 µM. These findings suggest a complex inter-
play between EGFR kinase activity and PTP inhibition at different concentrations
of H2O2, wherein low levels stimulate catalysis, an effect that may be lost at higher
doses, but is compensated for by PTP inactivation. Additionally, oxidation of Cys797
could positively regulate other aspects of EGFR function, including protein-protein
interactions.
It is intriguing to consider the possibility that cysteine oxidation may serve as a
general mechanism to regulate RTK activity. Of the 95 receptor and non-receptor
protein tyrosine kinases (PTKs) in the human genome, nine additional members har-
bor a cysteine residue at the structural position that corresponds to Cys797, including
two additional EGFR family members, Her2 and Her4 (28). Another subfamily of
PTKs, which includes cytoplasmic Src as well as FGFR1, have a cysteine residue
within a conserved glycine rich loop that interacts with the γ-phosphate of ATP.
Interestingly, cellular studies implicate cysteine oxidation in Src regulation (37–39),
albeit with apparently contradictory results. Furthermore, biochemical analysis of
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Src shows that the glycine loop cysteine is reactive and that addition of DTT to re-
combinant FGFR1 stimulates kinase activity (40). To date, however, it has not been
ascertained whether Src is a direct target of signaling-mediated H2O2 in cells; nor has
the reaction of peroxide with FGFR1 been reported.
EGFR is mutated or amplified in a number of human carcinomas including breast
and lung cancers, which has motivated the development of inhibitors, including
analogs that covalently modify Cys797, which are currently under evaluation in clini-
cal trials (27, 28). Recently, we have reported that overexpression of EGFR and Her2
in breast cancer cell lines correlates with elevated H2O2 and global protein sulfeny-
lation (21). Coupled with the discovery that EGFR Cys797 undergoes sulfenic acid
modification, these findings raise several fundamental questions vis-à-vis cysteine ox-
idation and thiol-targeted irreversible inhibitors. For example, the acrylamide moiety
of the aforementioned EGFR inhibitors undergoes Michael addition with Cys797 in
its thiol form, but does not undergo facile reaction with the sulfenic acid or disul-
fide states, which could influence the potency of these drugs. In addition, can the
propensity for a particular cysteine residue to undergo oxidation be exploited in the
design of irreversible inhibitors with a nucleophilic warhead targeting the sulfenylated
protein, as has recently been reported for PTPs (41)? Taking this one step further,
could this strategy be exploited to selectively target proteins in cells under oxidative
stress, a condition that is associated with cancer, diabetes, and neurodegeneration?
These topics represent new and exciting avenues for future research.
In summary, we have developed the new chemoselective probe, DYn-2, for detect-
ing sulfenylated proteins in cells. Using this reagent, we have shown that growth
factor-mediated signal transduction leads to oxidation of key signaling proteins, in-
cluding EGFR. From a broader perspective, our findings highlight sulfenylation as
a signaling mechanism analogous to phosphorylation and allude to new redox-based
strategies for therapy development. In conjunction with new tools for ROS detec-
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tion (2, 42, 43) and quantitative proteomic analysis (41, 44–46), these results presage
a bright future ahead in the dissection of the regulatory mechanisms that underlie
redox-regulation of cell signaling.
3.5 Methods
DYn-2 (2). Lithium diisopropylamide (LDA) was prepared by the dropwise addi-
tion of 2.5 M solution of n-BuLi (15.7 ml, 39.2 mmol) to a solution of diisopropylamine
(3.97 g, 39.2 mmol) in THF (40 ml) and the resulting pale yellow mixture was stirred
at -78 ◦C for 30 min in a 250 ml flask equipped with a magnetic stir bar under N2
pressure. A solution of 1,3-cyclohexadione (2.0 g, 17.8 mmol) in THF (20 ml) and
HMPA (10 ml) was added dropwise to the LDA solution at -78 ◦C. The resulting
mixture was allowed to stir at -78 ◦C for 1.5 h. The temperature was increased to 0
◦C briefly to facilitate the stirring, and then cooled again to -78 ◦C. To this dianion
slurry, a solution of 5-iodopent-1-yne (3.81 g, 19.6 mmol) in THF (20 ml) was added
dropwise at -78 ◦C. The reaction was stirred and allowed to warm to 25 ◦C over
2 h. The mixture was then neutralized with 1.0 M HCl (22 ml) and concentrated
under reduced pressure. The residue was diluted with H2O and extracted with ethyl
acetate (3 x 50 ml). The organic phase was then washed with brine, dried over anhy-
drous MgSO4, and concentrated. Purification by column chromatography (gradient:
dichloromethane/methanol from 100:0 to 98:2) afforded compound 2 as a mixture
of the keto and enol forms (3.0 g, 96% yield). The product was further purified by
reversed-phase preparative HPLC (Varian Polaris 5 C18-A 150 × 21.2 mm column)
using a gradient of water/acetonitrile from 95:5 to 5:95 over 30 min. 1H-NMR (400
MHz, CDCl3): δ 5.42 (s, 1H), 3.41 (d, J = 4.0 Hz, 2H), 2.75 - 1.72 (m, 16H), 1.68 -
1.45 (m, 6H). 13C-NMR (100 MHz, CDCl3): δ 204.9, 204.4, 197.0, 189.2, 104.2, 84.4,
84.1, 69.1, 68.9, 58.5, 49.1, 41.8, 39.9, 30.1, 29.6, 28.5, 26.4, 26.2, 26.1, 24.7, 18.8,
18.7. ESI-MS: m/z for C11H14O2 calculated: 178.23; observed: 179.1 [M+H]+.
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Cell culture. HeLa cells were cultured as previously described (11). A431 cells
(American Type Culture Collection) were maintained at 37 ◦C in a 5% CO2 humidified
atmosphere. Unless indicated otherwise, cells were cultured in high-glucose DMEM
medium (Invitrogen) containing 10% FBS (Invitrogen), 1% GlutaMax (Invitrogen),
1% MEM nonessential amino acids (Invitrogen), and 1% penicillin-streptomycin (In-
vitrogen). For EGF treatment, cells were cultured until 80-90% confluent, rinsed
with PBS, and placed in high-glucose DMEM medium without serum for 16-18 h.
Following serum-deprivation, cells were treated with the indicated concentration of
EGF for the indicated time period. EGF treatment was stopped by the removal of
the medium and washing with PBS.
Sulfenic acid labeling in cells. HeLa cells were labeled as previously de-
scribed (11). A431 cells were lifted with 0.25% trypsin-EDTA, harvested by cen-
trifugation at 1500g for 2 min, washed, and resuspended in serum-free DMEM at a
density of 3-4 × 106 cells/ml. Intact cells in suspension were incubated with DMSO
vehicle (2% v/v) or the indicated concentration of sulfenic acid probe (DYn-2, DAz-2,
or dimedone) at 37 ◦C in a 5% CO2 humidified atmosphere with periodic gentle agi-
tation. Following treatment for the indicated time, cells were collected, and washed
with PBS. The resulting cells were routinely counted using a hemocytometer and
uniformly displayed greater than 90% viability by trypan blue exclusion.
Click chemistry. Cell lysate (200 µg, 1 mg/ml) was pretreated with 75 µl
NeutrAvidin-agarose (Pierce) to remove endogenously biotinylated proteins. The pre-
cleared lysate was incubated with 100 µM azide- or alkyne-biotin, 1 mM TCEP-HCl,
100 µM TBTA ligand, and 1 mM CuSO4 for 1 h at 25 ◦C with gentle rocking (final
reaction volume of 200 µl). The reaction was quenched by 40 mM EDTA, followed
by methanol precipitation of the proteins. The resulting protein precipitate was then
resolubilized in Laemmli sample buffer containing 5% of SDS in PBS. To analyze
immunoprecipitated proteins, the resin was treated with 20 µl click chemistry mix
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(100 µM azide-biotin, 1 mM TCEP, 100 µM TBTA, 1 mM CuSO4 in PBS) as above;
reactions were quenched by boiling with 20 µl Laemmli sample buffer for 10 min.
Immunostaining and fluorescence imaging. A431 cells were seeded on collagen-
coated coverslips (BD Biosciences) and cultured as described above. The cells were
then fixed with 4% paraformaldehyde in PBS for 15 min, washed three times with
PBS, followed by blocking in 5% horse serum, 0.1% Triton X-100 in PBS for 30 min at
25 ◦C (blocking solution). The cells were then treated with rabbit anti-EGFR (1005,
Santa Cruz Biotechnology), mouse anti-PTEN (A2B1, Santa Cruz Biotechnology),
mouse anti-PTP1B (FG6, Calbiochem), or rabbit anti-SHP2 (Santa Cruz Biotechnol-
ogy), at 2 µg/ml in blocking solution for 1 h at 25 ◦C. Control cells were treated with
PBS only. The cells were washed three times in PBS and incubated with Alexa594-
conjugated goat anti-rabbit (Invitrogen), Alexa488-conjugated goat anti-rabbit (In-
vitrogen), or Alexa488-conjugated goat anti-mouse (Invitrogen) secondary antibodies
diluted to 1:1000 in blocking solution for 1 h at 25 ◦C in the dark. For experiments
involving dimedone, cells were fixed in cold methanol:acetone (1:1), blocked, and
treated with rabbit anti-2-thiodimedone (1:3000) as previously described. The cells
were then washed three times with PBS and stained by Alexa594-conjugated goat
anti-rabbit secondary antibody (1:1000) for 1 h at 25 ◦C in the dark. To visualize
Nox2, cells were double stained with rabbit anti-2-thiodimedone antibody (1:3000)
and PE-conjugated mouse anti-Nox2 antibody (7D5, MBL International, 1:1000), fol-
lowed by Alexa488-conjugated goat anti-rabbit secondary antibody (1:1000). Cells
were then washed three times with blocking solution, counterstained with 0.1 mg/ml
DAPI, washed with PBS, and mounted with Fluoromount G (Southern Biotech).
Confocal fluorescence imaging studies on A431 cells were performed with an Olym-
pus FV1000 microscope and an x100 oil-immersion objective lens. Excitation of
Alexa488-conjugate was carried out with an argon laser and emission was collected
using a 488-nm to 515-nm filter set. Excitation of Alexa594- or PE-conjugate was
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carried out with a HeNe laser, and emission was collected using a 548-nm to 644-nm
filter set.
3.6 Contributions
C.E.P., T.H.T. and A.H. performed cell culture and immunostaining experiments.
F.J.G. performed mass spectrometry experiments. V.G. and S.E.L. performed syn-
thetic experiments. K.S.C. designed experimental strategies with help from C.E.P.
and V.G.
3.7 Supplementary Methods
Synthetic Materials and Methods. All reactions were performed under a ni-
trogen atmosphere in oven-dried glassware. Tetrahydrofuran was distilled over sodium
hydride prior to use. All other reagents and solvents were purchased from Sigma in
the highest available purity and were used without further purification. Analytical
thin layer chromatography (TLC) was carried out using Analtech Uniplate silica gel
plates and visualized using a combination of UV and potassium permanganate stain-
ing. Flash chromatography was performed using silica gel (32-63 µM, 60 Å pore size)
from Sorbent Technologies Incorporated. NMR spectra were obtained on a Bruker
Avance 400 (400 MHz for 1H; 100 MHz for 13C) in CDCl3 (Cambridge Isotope Lab-
oratories). 1H and 13C NMR chemical shifts are reported in parts per million (ppm)
referenced to the residual CHCl3. Low-resolution electrospray ionization (ESI) mass
spectra were obtained with an Agilent 6120 Single Quadrupole LC/MS.
3-ethoxy-6-(prop-2-yn-1-yl)cyclohex-2-enone. To a lithium diisopropylamide
(LDA) solution, prepared from diisopropylamine (1.66 ml, 12 mmol) and n-BuLi (4.8
ml of a 2.5 M solution in hexanes, 12 mmol) in anhydrous THF (45 ml) at -78 ◦C
under argon, was added 3-ethoxycyclohex-2-enone (1.4 g, 10 mmol) in THF (20 ml),
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dropwise over 0.5 h. The reaction was stirred for an additional 2 h at -78 ◦C. Stirring
was followed by the dropwise addition of propargyl bromide (1.3 ml, 12 mmol). The
reaction was allowed to warm to rt and stirred for 8 h. The reaction was quenched
with water (20 ml) and sat. NH4Cl (20 ml). The aqueous phase was extracted with
DCM (3x50 ml), and the organic phases were combined, washed with brine (20 ml),
dried over Na2SO4, and concentrated. The resulting syrup was purified with silica gel
column chromatography using 6:4 Hexanes: ethyl acetate resulting in a yellow oil 3
(1.6 g, 8.99 mmol) in 89% yield. Rf : 0.6 (1:1 hexanes: ethyl acetate). 1H NMR (400
MHz, CDCl3) 5.31 (s, 1H), 3.98 - 3.78 (m, 2H), 2.76 (dt, J = 16.6, 3.2 Hz, 1H), 2.59
- 2.41 (m, 2H), 2.41 - 2.20 (m, 4H), 1.95 (q, J = 2.3 Hz, 1H), 1.82 (dtd, J = 16.8,
11.5, 5.1 Hz, 1H), 1.45 - 1.27 (m, 3H). ESI-MS: m/z for C11H14O2 calculated 178.10;
observed 179.1 [M+H]+.
4-(prop-2-yn-1-yl)cyclohexane-1,3-dione (1). To a solution of 3-ethoxy-6-
(prop-2-yn-1-yl)cyclohex-2-enone (0.05 g, 0.29 mmol) in acetonitrile (2 ml) and water
(2 ml) was added CAN (0.015 g, 0.028 mmol). The solution was heated to reflux for
2 hr. The reaction mixture was then diluted with brine (20 ml), and extracted with
EtOAc (3x20 ml). The organic phases were combined, washed with brine (30 ml),
dried over Na2SO4, and concentrated in vacuo. The resulting orange solid was purified
by silica gel column chromatography using 1:1 Hexanes:EtOAc to give compound 1 as
a pale yellow solid (0.042 g, 0.28 mmol) in 96% yield. Rf : 0.3 (1:1 Hexanes:EtOAc).
1H NMR (400 MHz, dmso-d6) δ 11.05 (s, 1H), 5.25 (s, 1H), 3.43 - 3.14 (m, 1H), 2.76
(d, J = 24.8 Hz, 1H), 2.37 - 2.16 (m, 4H), 2.04 (dt, J = 28.7, 11.9 Hz, 1H), 1.81 -
1.57 (m, 1H). 13C NMR (100 MHz, dmso-d6) δ 103.4, 82.7, 72.2, 25.7, 18.9. ESI-MS:
m/z for C9H10O2 calculated: 150.07; observed: 151.1 [M+H]+.
Synthesis of 5-iodopent-1-yne, alkyne-biotin and azide-biotin. 5-iodopent-
1-yne was synthesized according established literature procedures (47). Alkyne-biotin
was synthesized according to established literature procedures (48). Azide-biotin was
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synthesized according to established literature procedures (49). In all cases, ESI-MS,
1H and 13C NMR NMR spectra matched literature values (47–49).
Reagent Source, Purity and Stock Solutions. All stocks were stored at -20
◦C, unless otherwise indicated. The EGF (BD Biosciences) solution was prepared at
30 µg/ml in ddH2O. H2O2 was purchased from Sigma and lower concentrations were
made by dilution of the stock solution with ddH2O. Gefitinib (1 mM, Santa Cruz
Biotechnology, >99% purity), Afatinib (100 µM and 500 µM, Chemietek, >99% pu-
rity), Canertinib (1 mM, Chemietek, >99% purity), Pelitinib (100 µM, Santa Cruz
Biotechnology, 98% purity), Apocynin (10 mM, Calbiochem, ≥98% purity), and
Wortmannin (10 mM, Cayman Chemicals, ≥98% purity) stocks were prepared in
DMSO at the indicated concentrations. DAz-2 was synthesized and purified (≥99%
purity) as previously described (11). DAz-2, DYn-1 (≥98% purity) and DYn-2 (≥99%
purity) were prepared in DMSO at 250 mM. Dimedone (Sigma, ≥99% purity) was
prepared as a 50:50 mixture of DMSO and 0.5 M Bis-Tris HCl (pH 7.0) at 250 mM.
Catalase (20,000 U/ml, Sigma) included in lysis buffers and PEG-catalase (100,000
U/ml, Sigma) were prepared in 50 mM Tris-HCl (pH 7.4) and stored at -80 ◦C or made
up fresh, respectively. L-NAME (10 mM, Calbiochem, ≥98% purity) and NAC (1 M,
Research Products International, >99% purity) were freshly prepared in serum-free
DMEM at the indicated concentrations. DPI (2.5 mM, 5 mM, and 10 mM, Sigma,
≥98% purity) stocks were made in DMSO. Azide- or alkyne-biotin were prepared at 5
mM in DMSO, TBTA ligand was prepared at 2 mM stock in 4:1 DMSO:tBuOH, and
TCEP-HCl (Sigma) and CuSO4 (Sigma) were freshly prepared at 50 mM in ddH2O.
Expression, purification, and labeling of sulfenylated Gpx3. Recombinant
Cys82Ser Gpx3 and Cys64Ser Cys82Ser Gpx3 were expressed and purified as previ-
ously described (16). Cys82Ser Gpx3 and Cys64Ser Cys82Ser Gpx3 were previously
stored in 50 mM Tris HCl pH 7.4, 300 mM NaCl, 10% glycerol, and 5 mM DTT.
DTT was removed from Gpx3 mutants via spin filtration using P-30 micro BioSpin
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columns (BioRad) pre-equilibrated with Gpx3 buffer (50 mM Tris HCl pH 7.4, 300
mM NaCl). 50 µM Cys82Ser Gpx3 was treated with 1 mM DAz-2, 1 mM DYn-1,
1 mM DYn-2 or vehicle in the presence or absence of 100 µM H2O2 for 15 min at
37 ◦C. Excess probe was removed by spin filtration, and azide- or alkyne-modified
Cys82Ser Gpx3 was biotinylated and analyzed as described in Methods. After click
chemistry, the reactions were quenched by addition of an equal volume of Laemmli
sample buffer. To verify the DYn-2 adduct by mass spectrometry, Cys64Ser Cys82Ser
Gpx3 was incubated with H2O2 and 10 mM DYn-2 for 1 h at 37 ◦C with gentle rock-
ing. The concentrations of Cys64Ser Cys82Ser Gpx3 and H2O2 used are indicated in
the figure legends. Excess reagent was removed by spin filtration as described above.
Lysate preparation. Cells were harvested in modified RIPA lysis buffer [50 mM
triethanolamine, pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1%
SDS, 1x EDTA-free complete mini protease inhibitors (Roche), 200 U/ml catalase
(Sigma)]. After 20 min incubation on ice with frequent mixing, unlysed cell fragments
were removed by centrifugation at 14000g for 15 min at 4 ◦C, and protein concen-
tration was determined by BCA assay (Pierce). For analysis of protein phosphoryla-
tion, cells were harvested in phosphorylation lysis buffer [50 mM triethanolamine, pH
7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 5 mM sodium
pyrophosphate, 50 mM sodium fluoride, 10 µM β-glycerophosphate, 1 mM sodium
orthovanadate, 0.5 mM DTT, and 1x complete mini protease inhibitors (Roche)]. For
co-immunoprecipitation of Nox2 with EGFR, cells were harvested by gentle scraping
with a rubber policeman in native lysis buffer A (50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.1% Triton X-100, 0.1% NP-40, 4 mM EDTA, 1 mM sodium orthovanadate,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate and 1x complete mini
protease inhibitors) and lysed with gentle rotation at 4 ◦C for 1 h. Coimmunopre-
cipitation of EGFR with Nox2 was performed as described above, except in native
lysis buffer B (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.5% NP-40,
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20 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1x complete mini protease
inhibitors).
Western blot. Protein samples were separated by SDS-PAGE using Mini-
Protean TGX 4-15% Tris-Glycine gels (BioRad) and transferred to a polyvinylidene
difluoride (PVDF) membrane (BioRad). After transfer, the membrane was blocked
with 3% BSA or 5% milk (pAKT/AKT blotting) in TBST for 1 h at 25 ◦C. The
membrane was washed with TBST and immunoblotting was performed with the fol-
lowing primary and secondary antibodies at the indicated dilutions in TBST, un-
less otherwise noted: phospho-EGFR (pY1068, Abcam, 1:1000), EGFR (1005, Santa
Cruz Biotechnology, 1:200), phospho-AKT (pS473 XP, Cell Signaling Technology,
1:2000 or pT308, Cell Signaling Technology, 1:1000), AKT (Cell Signaling Tech-
nology, 1:2000), phospho-ERK (pT185/pY187, Invitrogen, 1:1000), ERK (Invitro-
gen, 1:1000), streptavidin-HRP (GE Healthcare, 1:8000 - 1:80000), His-HRP (Pierce,
1:50000), GAPDH (Santa Cruz Biotechnology, 1:200), PTEN (A2B1, Santa Cruz
Biotechnology, 1:200), PTP1B (Calbiochem, 1:1000), SHP2 (Santa Cruz Biotechnol-
ogy, 1:200), Nox2 (ab31092, Abcam, or Santa Cruz Biotechnology, 1:500 - 1:1000
in PBST), Nox1 (ab55831, Abcam, 1:500 in PBST), phospho-Tyrosine (Millipore,
1:1000), goat anti-rabbit IgG-HRP (Calbiochem, 1:2000 - 1:50000), rabbit anti-mouse
IgG-HRP (Invitrogen, 1:30000), and donkey anti-goat IgG-HRP (Santa Cruz Biotech-
nology, 1:30000 in PBST). PVDF membrane was developed with chemiluminescence
(GE Healthcare ECL Plus Western Blot Detection System) and imaged by film. Data
was quantified by densitometry with ImageJ (Wayne Rasband, US National Institutes
of Health, http://rsbweb.nih.gov/ij/). PVDF membranes were stripped using mild
stripping buffer (200 mM glycine pH 2.2, 0.1% SDS, 1% Tween-20) according to
established protocol (www.abcam.com) before reprobing.
Immunoprecipitation. EGFR was immunoprecipitated from 500 µg cell lysate
(1 mg/ml) with 1 µg of anti-EGFR antibody. PTPs were immunoprecipitated from
94
1 mg lysate prepared from A431 cells cultured in low-glucose DMEM with 1 µg
anti-PTEN antibody, anti-PTP1B antibody (BD Transduction Laboratories), or anti-
SHP2 antibody overnight at 4 ◦C with gentle rocking. The immunocomplexes were
isolated by incubating 20 µl protein A sepharose (EGFR and SHP2; GE Healthcare)
or protein G agarose (PTEN and PTP1B; Roche) for an additional 2 h at 4 ◦C
with rocking. The resin was collected by centrifugation at 100g for 2 min at 25
◦C, washed three times with cold RIPA buffer (Boston BioProducts), subjected to
click chemistry as described in Methods, and proteins were eluted by boiling with
Laemmli sample buffer for 10 min. Nox2 and SHP2 were co-immunoprecipitated
with EGFR from 500 µg of lysate with 20 µl goat anti-EGFR antibody-conjugated
agarose (Santa Cruz Biotechnology) or isotype control (normal goat IgG) in a total
volume of 500 µl for 4 h at 4 ◦C with gentle rocking. The resin was collected as above
and washed three times with cold native lysis buffer, and eluted as above. EGFR
was coimmunoprecipated with Nox2 as above, except using 20 µl rabbit anti-Nox2
antibody-conjugated agarose (Santa Cruz Biotechnology) or normal rabbit IgG as an
isotype control. For ESI-MS analysis in Supplementary Figure 3.S4c, A431 cells were
stimulated with 4 ng/ml EGF for 2 min, harvested by trypsinization, and treated
with dimedone as in Methods. Following treatment, EGFR was immunoprecipitated
from 6 mg cell lysate as described above. The EGFR was eluted by boiling for 10
min in 10% SDS in ddH2O and then precipitated by acetone. The resulting protein
precipitate was resuspended in Laemmli sample buffer, and resolved by SDS-PAGE.
Intracellular ROS detection. Intracellular ROS were measured in a 96-well
plate using the fluorescent probe DCF (the intracellular product of H2-DCF diac-
etate that fluoresces in the presence of ROS, including H2O2). A431 cells were seeded
at 1.5 × 104 per well, grown and stimulated with EGF as described in Methods.
Inhibitors/scavengers were added to culture medium prior to treatment for the pe-
riod of time indicated in figure legends. Following stimulation, cells were washed
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twice with PBS, and incubated in the dark for 30 min at 25 ◦C with 10 µM 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCF-DA, Sigma) in PBS. H2DCF-DA is a
cell permeable indicator for ROS that is a nonfluorescent compound that can enter
cells and is trapped by intracellular esterase cleavage of the diacetate group. H2DCF
is converted into a fluorescent product upon interaction with intracellular ROS. After
incubation, the intensity of fluorescence was measured at 488 nm (excitation) and
525 nm (emission) using a SpectraMax M5 microplate reader (Molecular Devices).
To examine the effect of DYn-2 on intracellular ROS, serum-deprived A431 cells were
washed three times with PBS and then harvested by 0.25 % trypsin/EDTA. The
trypsin was neutralized with DMEM and cells were collected by centrifugation at
1500g for 2 min. Cells were aliquoted at 6 × 105 cells per microcentrifuge tube and
treated with 5 mM DYn-2 or DMSO vehicle (2% v/v) for 1 h at 37 ◦C. Following
treatment, the cells were washed three times with PBS, seeded into 96-well plates at 1
× 105 cells/well in triplicate, and analyzed for DCF fluorescence as described above.
Cell viability. Serum-deprived A431 cells were labeled with 5 mM DYn-2 or
DMSO vehicle (2% v/v) as described in Methods. After labeling, the cells were
washed three times with PBS and resuspended in 500 µl PBS with an equal volume
of trypan blue solution (0.4 % w/v). The mixture was incubated at 25 ◦C for 3 min,
and 10 µl of the cell suspension was loaded onto a hemocytometer and counted under
a microscope.
Quantification of glutathione in A431 Cells. Serum-deprived A431 cells
were treated with 5 mM DYn-2 or DMSO vehicle (2% v/v) as described in Methods.
After labeling, the cells were washed three times with PBS and lysed in 1x GSH
MES buffer (Cayman Chemicals). Levels of total, reduced, and oxidized glutathione
were measured using the Glutathione Assay kit (Cayman Chemicals) according to
the manufacturers instructions.
Quantification of peroxiredoxin SO3 in A431 Cells. Serum-deprived A431
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cells were treated with 5 mM DYn-2 or 2% (v/v) DMSO as described in Methods.
After labeling, cells were lysed in modified RIPA lysis buffer, resolved by SDS-PAGE,
and analyzed by anti-Peroxiredoxin-SO3 (Abcam, 1:1000) Western blot.
In-gel trypsin digestion of Gpx3. DYn-2 labeled Gpx3 was resolved by SDS-
PAGE and stained with SimplyBlue SafeStain (Invitrogen). After staining, the gels
were washed with H2O and bands of interest were excised. The excised bands were
dehydrated in 2:1 ACN: 25 mM ammonium bicarbonate (Ambic), pH 8.0 and subse-
quently rehydrated with 25 mM Ambic pH 8.0 twice prior to reducing with 10 mM
DTT for 1 h at 56 ◦C. DTT was removed and the samples were alkylated with 55
mM iodoacetamide for 45 minutes at 25 ◦C in the dark. Iodoacetamide was removed
and the excised bands were washed with 25 mM Ambic pH 8.0 then dehydrated and
rehydrated two additional times. Sequencing grade modified trypsin (Promega) was
added to the excised bands at a ratio of 1:25 (w/w), and the samples were incubated
overnight at 37 ◦C. Peptides were extracted from the gel by collecting the super-
natant and by dehydrating and rehydrating the excised bands. Peptide samples were
concentrated via vacuum centrifugation and analyzed by ESI-LC-MS/MS.
In-gel pepsin digestion of immunoprecipitated EGFR. The band corre-
sponding to EGFR was excised and the gel slice was processed as above with the
following modifications. After iodoacetamide removal, the excised bands were washed
with 75 mM K2HPO4/75 mM KH2PO4 pH 2.5 then dehydrated and rehydrated two
additional times with 2:1 ACN: 75 mM K2HPO4/75 mM KH2PO4 pH 2.5 and 75 mM
K2HPO4/75 mM KH2PO4 pH 2.5, respectively. Sequencing grade pepsin (Princeton
Separations) was added to excised bands at 20 ng/µL and incubated overnight at 37
◦C.
ESI-LC/MS/MS Analysis. Protein and peptides were analyzed on an electro-
spray linear ion trap mass spectrometer (LTQ-XL, Thermo Scientific) after separation
on an Agilent Eclipse XDB-C8 2.1 mm x 15 mm trap with mobile phases A (0.1%
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formic acid in water) and B (0.1% formic acid in acetonitrile) which was used to
trap, desalt, and elute peptides onto a Vydac Everest reverse-phase C18 monomeric
column (2.1 mm x 150 mm, 300 Å, 5 µm) with a gradient of 5% to 60% B in 60
min at a flow rate of 200 µL/min. Peptide and protein identification were performed
using Mascot (http://www.matrixscience.com). Mass lists, in the form of Mascot
generic files, were created automatically and used as the input for Mascot MS/MS
Ion searches against a database containing the full sequence of EGFR. The search
parameters were as follows: The enzyme specificity was Pepsin A with one missed
cleavage permitted. The variable modifications included Carbamidomethyl (C-SH),
Dimedone (C-SOH), and Oxidation (M). The mass tolerance for the precursor ions
obtained from the ESI-TRAP was set to ± 2 Da and the fragment mass tolerance was
set to ± 2 Da. The maximum expectation value (p) for accepting individual MS/MS
spectra was set at 0.05.
In vitro EGFR kinase assay. The tyrosine kinase activity of recombinant hu-
man EGFR kinase domain (Promega) was assayed using the ADP-Glo™Kinase Assay
(Promega) according to the manufacturers protocol (www.promega.com), except that
DTT was not included in the reaction buffer. In brief, the ADP-Glo™Kinase Assay
is a luminescent assay that measures ADP formed from the EGFR kinase reaction;
ADP is converted into ATP, which is a substrate in a reaction catalyzed by Ultra-
Glo™Luciferase that produces light. The luminescent signal positively correlates with
ADP amount and kinase activity. Poly (4:1 Glu, Tyr) (Promega) was used as a pep-
tide substrate. When present, EGFR inhibitors, H2O2 or DTT were added to the
reaction mixture for the period of time indicated in figure legends.
Statistical analysis. Each graph represents the mean values for the correspond-
ing experiment ± s.e.m. Where appropriate, statistical significances were determined
from unnormalized data using the two-tailed Student’s t-test, which is a variation of
the ANOVA test appropriate for small sample sizes. Each statistically-characterized
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Western blot experiment is representative of four independent trials and each ROS,
glutathione, or recombinant EGFR experiment is representative of three independent
readings. p-values smaller than 0.05 were deemed statistically significant and ranges
are provided in the figure legends. The full p-values for each experiment in order
from left to right are: Figure 3.1c, calculated with respect to the EGF-only sample:
7.30 × 10−8, 1.73 × 10−6, 2.38 × 10−8, 0.02, 0.003, 0.0016; Figure 3.3a, calculated
with respect to the vehicle only control: 3.83 × 10−7, 1.02 × 10−7; Figure 3.3c: 0.02,
0.0016, 4.00 × 10−3; Figure 3.3d, calculated with respect to the vehicle only control:
0.003, 0.04, 0.005; Figure 3.3f, calculated with respect to the vehicle only control:
0.0012, 0.018; 0.025; Figure 3.5h, calculated with respect to the 0 µM H2O2 control:
0.00014, 0.003, 3.00 × 10−5, 0.002, 0.002, 0.008; Figure 3.6a, calculated with respect
to the corresponding vehicle only control for each protein: EGFR, 0.002, 0.007; SHP2,




Figure 3.S1: EGF-dependent morphological changes in A431 cells. Top images: Bright-field
images of A431 cells before (T0) and after 100 ng/ml EGF stimulation for 2, 15, 30, and 60 min
(labeled as T1, T2, T3, and T4, respectively). Bottom images: Combined bright-field and confocal
fluorescence image of A431 cells (Figure 3.1b depicts the confocal fluorescence image alone). Cells
were fixed and stained as described in Methods with rabbit anti-EGFR antibody (2 µg/ml) followed
by Alexa594-conjugated (red) goat anti-rabbit secondary antibody (1:1000). White arrows highlight
changes in receptor localization (T0, plasma membrane; T1, membrane ruffles; T2, regions of cell
stretching and migration; T3, perinuclear and endosomal membranes; T4, plasma membrane and
ruffles). Nuclei were counterstained with DAPI (blue). Scale bar, 10 µm.
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Figure 3.S2: Uncut full Western blots shown (part 1) in Figure 3.1d-f, Figure 3.2c,d, Fig-
ure 3.3b,e, Figure 3.4a-c, and Figure 3.5a-e. The regions surrounded by dashed lines represent
the panels in the respective figures. IG, immunoglobulin; IB, nonspecific immunoreactive band
non-specific band; D, degradation; P, phosphorylated; DM, dimer.
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Uncut full Western blots shown (part 2) in Figure 3.1d-f, Figure 3.2c,d, Figure 3.3b,e, Figure 3.4a-c,
and Figure 3.5a-e. The regions surrounded by dashed lines represent the panels in the respective fig-
ures. IG, immunoglobulin; IB, nonspecific immunoreactive band non-specific band; D, degradation;
P, phosphorylated; DM, dimer.
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Figure 3.S3: Effect of inhibitors, antioxidants, and sulfenic acid probes on EGF-mediated
signaling. (a-h) Western blots showing global tyrosine phosphorylation (pTyr) or phosphorylated
(p) EGFR, AKT and/or ERK and total EGFR, AKT, and/or ERK as loading controls. (a) A431
cells were stimulated with 100 ng/ml EGF or vehicle for 5 min. Where indicated, A431 cells were
pretreated with 10 µM gefitinib, 100 µM afatinib or 100 µM wortmannin for 25 min. (b,c) A431
cells were treated with the indicated concentrations of PEG-catalase for 5 min (b) or 30 min (c)
and then stimulated with 100 ng/ml EGF or vehicle for 5 min. Gefitinib treatment was as in a.
(d,e) A431 cells were stimulated with 100 ng/ml EGF or vehicle for 5 min in the presence of the
indicated concentrations of NAC. Gefitinib treatment was as in a. (f) A431 cells were stimulated
with 100 ng/ml EGF or vehicle for 5 min. Where indicated, A431 cells were pretreated with the
indicated concentrations of apocynin for 25 min before stimulation. (g) A431 cells were stimulated
with 100 ng/ml EGF or vehicle for 5 min. Where indicated, A431 cells were pretreated with the
indicated concentrations of DPI for 5 min before stimulation. (h) A431 cells were stimulated with
100 ng/ml EGF or vehicle for 5 min. Where indicated, A431 cells were pretreated with the indicated
concentrations of DYn-2 or dimedone for 25 min before stimulation.
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Figure 3.S4: DYn-2 detection of Gpx3 sulfenic acid by Western blot and mass spec-
trometric analysis. (a) Comparison of DAz-2, DYn-1 and DYn-2 detection of sulfenic acid in
recombinant Gpx3. 50 µM protein was untreated or exposed to 100 µM H2O2 and incubated in
presence or absence of 1 mM probe for 15 min at 37 ◦C. Labeled proteins were then conjugated to
azide-biotin (Az-Biotin) or alkyne-biotin (Alk-biotin) via copper(I)-catalyzed azide-alkyne [3+2] cy-
cloaddition (click chemistry), separated by SDS-PAGE, and detected by streptavidin-HRP Western
blot, as described in Methods. Comparable protein loading was confirmed by Ponceau stain. (b)
ESI-LC/MS intact mass analysis shows the covalent attachment of a single DYn-2 molecule to Gpx3
(, 22916.39 Da). The inset shows the deconvoluted mass spectrum. The observed mass shift is
177.48 Da, whereas the expected mass shift for a single DYn-2 adduct is 176.08 Da. The slight dis-
crepancy is well within range of the mass accuracy for the LTQ-XL instrument (100 ppm or ± 2.29
Da at 22916.39). Over-oxidation of the catalytic cysteine to sulfinic acid (SO2H) is also observed
(, 22776.36 Da). 25 µM Gpx3 was treated with 37.5 µM H2O2 and labeled with 10 mM DAz-2 for
1 h at 37 ◦C. (c) ESI-LC/MS/MS analysis of the reaction from a using collision-induced dissociation
(CID) of the precursor ion m/z 551.52 [M + 2H - H2O]+2 corresponding to DYn-2-tagged peptide
(C(2)GFTPQYK-OH) derived from trypsin digest of Gpx3.
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Figure 3.S5: DYn-2 labeling of protein sulfenic acids in A431 cells. (a) Bioorthogonal
chemical reporter strategy to label sulfenylated proteins in cells and their subsequent detection using
click chemistry and streptavidin-HRP Western blot. (c) Western blot showing DAz-2 and DYn-2
detection of protein sulfenic acids and total GAPDH in HeLa cells incubated with 5 mM probe or
vehicle for 2 h at 37 ◦C. (right panel b,c) Densitometric quantification of electrophoretic lanes from
c and Figure 3.2d. (c) The numbers situated above indicate the fold-increase in sulfenylation signal
between unstimulated and EGF-treated cells. (d,e) Western blot showing dose- and time-dependent
detection of protein sulfenic acids in A431 cells and total GAPDH as loading controls. A431 cells
were stimulated with 100 ng/ml EGF for 5 min, washed, lifted as described in Methods and then
treated with vehicle or the indicated concentrations of DYn-2 for 1 h at 37 ◦C (d), or with 5 mM
DYn-2 for the indicated times (e), and protein sulfenic acids were detected by streptavidin-HRP
Western blot as in Figure 3.2e. Densitometric quantification of each electrophoretic lane from dose
(d) and time (e) dependencies are shown at the right of their respective Western blots and data were
normalized to the maximal signal observed in each case. (f) A431 cells were treated with 5 mM
DYn-2 or vehicle for 1 h at 37 ◦C, washed, harvested in the presence or absence of 200 U/ml catalase,
and protein sulfenic acids were detected by streptavidin-HRP Western blot as in Figure 3.2d. Data
for all graphs are representative of four independent experiments and represent the mean ± s.e.m.
(g) A431 cells were stimulated with 100 ng/ml EGF or vehicle for the indicated times, washed,
harvested, resuspended in serum-free DMEM, and incubated with 5 mM DYn-2 or DMSO vehicle
(2% v/v) for 15 min at 37 ◦C as described in Methods.
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Figure 3.S6: DYn-2 treatment of A431 cells does not trigger cell death or oxidative stress.
A431 cells were stimulated with 100 ng/ml EGF for 5 min, washed, and incubated with 5 mM DYn-2
or vehicle for 1 h at 37 ◦C as described in Methods. Following treatment: (a) A431 cell viability was
evaluated by cell counting using trypan blue exclusion after DYn-2 or vehicle treatment and results
were expressed as the percentage of viable cells. (b,c) Production of intracellular ROS was measured
by DCF fluorescence as described in Supplementary Methods. Where indicated, H2O2 was added
at a final concentration of 400 µM. In (c), data were normalized to vehicle control as 100% DCF
fluorescence. (d) Reduced glutathione (GSH) and oxidized glutathione (GSSG) levels were measured
in DYn-2 and vehicle-treated samples as described in Supplementary Methods. (e) GSH represented
as a percentage of total glutathione pool. (f) Samples were resolved by SDS-PAGE and analyzed
by anti-Prx-SO3 Western blot (left). Comparable protein loading was confirmed by anti-GAPDH
Western blot. Prx-SO3 signal was quantified by densitometry, and normalized to the vehicle control
(right). Data for all graphs are representative of three independent readings and represent mean ±
s.e.m.
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Figure 3.S7: EGF-mediated sulfenylation requires EGFR activity and is modulated by
cellular redox status in A431 cells. Western blots showing protein sulfenic acids in A431 cells
and total GAPDH. (a) A431 cells were stimulated with 100 ng/ml EGF for 2 min after pretreatment
with 10 µM gefitinib, 1 µM afatinib, 10 µM canertinib, 1 µM pelitinib, 100 µM apocynin, 100 µM
wortmannin, 100 µM L-NAME or vehicle for 25 min. In (b), A431 cells were stimulated with 100
ng/ml EGF for 2 min after pretreatment with PEG-catalase at the indicated concentration for 5 min.
In (c), A431 cells were stimulated with 100 ng/ml EGF for 5 min after pretreatment with NAC at the
indicated concentration for 5 min. In (d), A431 cells were stimulated with 100 ng/ml EGF for 2 min
after pretreatment with apocynin at the indicated concentration for 5 min (d). In (e) A431 cells were
stimulated with 100 ng/ml EGF for 5 min after pretreatment with DPI at the indicated concentration
for 5 min. Following treatment, cells were incubated with DYn-2 or vehicle for 1 h (a) or 15 min
(b-e) at 37 ◦C and sulfenic acids were detected by streptavidin-HRP Western blot as in Figure 3.2e.
When applied at 25 µM, DPI decreased sulfenic acid modification of proteins; however, higher doses
were associated with an increase in sulfenylation relative to control samples. This observation is
most likely due to DPI-mediated inhibition of the thioredoxin-thioredoxin reductase system that
reduces oxidized cysteines to their reduced state.
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Figure 3.S8: Secondary antibody only control in A431 cells. Confocal fluorescence images
of A431 cells labeled with secondary antibody only. Cells were fixed and stained as described in
Methods with Alexa488-conjugated (green) goat anti-rabbit secondary or Alexa594-conjugated (red)
goat anti-rabbit secondary antibodies (1:1000). Nuclei were counterstained with DAPI (blue). Scale
bar, 10 µm.
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Figure 3.S9: Nox2 expression, H2O2-mediated Cys797 oxidation and modulation of recombinant
EGFR tyrosine kinase activity. (a, b) Expression of Nox1 and Nox2 in A431 cells was analyzed by Western
blot with rabbit anti-Nox1 and rabbit anti-Nox2, with GAPDH as a loading control (a) or immunofluorescence mi-
croscopy (b). In (b), cells were fixed and stained with rabbit anti-Nox1 or rabbit anti-Nox2 antibodies at 2 µg/ml,
followed by Alexa594-conjugated goat anti-rabbit (red) secondary antibodies (1:1000). Nuclei were counterstained
with DAPI (blue). Scale bar, 10 µm. (c) A431 cells were fixed but not permeabilized and stained with PE-conjugated
(red) mouse anti-Nox2 antibody. Nuclei were counterstained with DAPI (blue). Scale bar, 10 µm. (d) Western blot
showing sulfenylated and total EGFR. A431 cells were stimulated with H2O2 at the indicated concentrations for 10
min and sulfenic acids were detected by streptavidin-HRP Western blot as in Figure 3.5b. (e) Western blot showing
coimmunoprecipitation of SHP2, EGFR, and Nox2. A431 cells were stimulated with 100 ng/ml EGF or vehicle for
the indicated times and samples were processed as in Figure 3.5c. The presence of SHP2 was evaluated using a
rabbit anti-SHP2 antibody and comparable recovery of immunoprecipitated EGFR was confirmed by probing the
Western blot with rabbit anti-EGFR antibody. IC, isotype control. (f) Crystal structure of EGFR kinase domain
with irreversible inhibitor, 13-JAB bound covalently to Cys797 (top panel; PDB 2J5E) or non-covalently associated
with the ATP analog, AMPNP and Mg2+ (bottom panel; PDB 3GT8). Molecular images were generated with Pymol
(http://pymol.sourceforge.net). (g) Extracted ion (ion current at m/z 402.8) chromatogram (left) and MS/MS spec-
trum (right) of the precursor ion m/z of 402.80 [M + 2H]+2 corresponding to dimedone-tagged peptide (MPFGC*L)
from native EGFR. A431 cells were stimulated with 4 ng/ml EGF for 2 min, washed, incubated with 5 mM dimedone
for 1 h at 37 ◦C, immunoprecipitated with anti-EGFR antibody as in Figure 3.5a, and resolved by SDS-PAGE. The
band corresponding to EGFR (∼170 kDa) was excised, digested with pepsin, and analyzed by ESI-LC/MS/MS as
described in Supplementary Methods. (h) Top spectrum: Extracted ion (ion current at m/z 333.48 [M+2H]+2) chro-
matogram corresponding to the unmodified peptide (MPFGCL) from native EGFR. Bottom spectrum: The extracted
ion (ion current at m/z 402.80 [M+2H]+2) chromatogram corresponding to the dimedone-tagged peptide (MPFGC*L)
from native EGFR. The ratio of dimedone-modified to unmodified peptide was determined by taking the areas under
the curves and was determined to be approximately 6:1. Samples were generated as in g. (i-k) Measurement of EGFR
tyrosine kinase activity in vitro as described in Supplementary Methods. (i) Recombinant EGFR (rEGFR) kinase
activity titration. (j,k) rEGFR was incubated with gefitinib (j) or afatinib (k) at the indicated concentrations and
assayed for kinase activity. (l) rEGFR was incubated with H2O2 or vehicle for 15 min, and then 1 mM DTT or
vehicle was added for an additional 10 min and assayed for kinase activity. (m) The ATP-regenerating system from
the EGFR kinase activity assay was untreated or co-incubated with the indicated concentrations of H2O2 and assayed
for kinase activity. Data for all graphs are representative of three independent readings and represent the mean ±
s.e.m.
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Figure 3.S10: Indirect and direct chemical techniques to monitor cysteine oxidation and
PTP oxidation/trapping scheme. (a) Loss of reactivity with thiol-modifying reagents indirectly
monitors cysteine oxidation. ROS and RNS oxidize reactive protein thiols (red protein). Addition of
a thiol-specific alkylating agent such as NEM or IAM derivatized with a detection handle covalently
modifies free thiols. Increased cysteine oxidation exhibits a decrease in probe signal. (b) Restoration
of thiol-labeling by reducing agents indirectly monitors cysteine oxidation. Initially samples are
incubated with NEM or IAM to irreversibly alkylate free thiols. Next a reducing agent returns
oxidized cysteines to free thiols. Addition of NEM or IAM derivatized with a detection handle
covalently modifies nascent thiols. Increased cysteine oxidation exhibits an increase in probe signal.
(c) Direct detection of specific cysteine oxoforms. Samples are incubated with a chemoselective
alkylating agent for a specific cysteine oxoform (i.e. nitrosothiols and sulfenic acids) derivatized with
a detection handle. Visualization of probe incorporation results in an increase in signal with increased
oxidation. (d) Reaction of H2O2 with the catalytic cysteine thiolate of PTPs generates sulfenic acid
(second order reaction). Once formed, the sulfenic acid can condense with a backbone amide to form
a sulfenamide in PTP1B, or with a second cysteine residue to form an intramolecular disulfide in
PTEN and SHP2 (first order reaction). Alternatively, the sulfenic acid intermediate can be trapped
by dimedone or DYn-2 (second order reaction). The amount of sulfenic acid detected is a function
of the: (i) rate of oxidation (∼2-10 M−1s−1) (32, 33), (ii) rate of dimedone/DYn-2 trap (∼103
M−1s−1) (19, 50), and (iii) rate of intramolecular condensation (∼10−3 s−1 for sulfenamide (36) and
∼10 s−1 for intramolecular disulfide) (35). Note: the aforementioned rates were measured in vitro
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Characterizing the Role of Cys797 in Redox-Based
Regulation of EGFR
4.1 Abstract
EGF-mediated signaling results in H2O2 production and sulfenylation of down-
stream target proteins. EGFR has been identified as a target of signal-derived H2O2
and is directly modified at its critical active site cysteine (Cys797), resulting in en-
hanced tyrosine kinase activity. To further characterize the importance of this residue
in physiologic signaling events, we generated cysteine mutants (C797S and C797A) to
dissect the effect of Cys797 sulfenylation on EGFR kinase activity. In vitro and cellu-
lar studies demonstrate mutation of Cys797 decreases affinity for ATP and abrogates
kinase activation and sulfenylation levels. Additionally, we examine the impact of
common oncogenic EGFR mutations on the ability of Cys797 to undergo redox-based
modification. We demonstrate Cys797 oxidation reduces potency of thiol-targeted
EGFR inhibitors, suggesting alternative approaches for inhibitor development should
be explored. Finally, we demonstrate cysteine oxidation may serve as a general mech-
anism to regulate kinase activity in two structural homologues of EGFR. Taken to-
gether, our results demonstrate the role of Cys797 in redox-based EGFR regulation
and highlight the importance of defining the mechanisms that control reversible pro-
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tein sulfenylation to understand human physiology and pathology.
4.2 Introduction
Epidermal growth factor receptor (EGFR) is one of the most studied receptor
tyrosine kinases (RTK) and serves as a quintessential model for understanding the
biological function of RTKs in physiological signaling and disease states (1). Activa-
tion of RTKs by their respective extracellular ligands (i.e. growth factors) initiates
downstream signaling networks to regulate a number of processes which include cellu-
lar proliferation, differentiation, metabolism, and survival. Growth factor-dependent
stimulation can also mediate localized production of hydrogen peroxide (H2O2) (2, 3),
which serves as a second messenger in signal transduction cascades (4–6). In partic-
ular, binding of epidermal growth factor (EGF) to EGFR triggers the assembly and
activation of NADPH oxidase (Nox) complexes to generate H2O2 (7, 8), which reacts
with redox-sensitive protein targets largely through modification of specific cysteine
residues. The direct product of the reaction between H2O2 and a protein thiolate
(RS-) is sulfenic acid (RSOH), also referred to as sulfenylation. Cysteine oxidation
represents a biologically important mechanism for regulation of protein activity and
to detect changes in the cellular redox balance (9, 10).
Utilizing chemical probes selective for sulfenic acid (DYn-2), we recently demon-
strated EGF-mediated signaling induces dynamic changes in global protein sulfenyla-
tion in downstream pathways (11). EGFR and Nox2 become associated in an EGF-
dependent fashion to induce endogenous production of H2O2, which subsequently
modulates target proteins (Figure 4.1A). Three protein tyrosine phosphatases (PTPs)
(SHP2, PTEN, PTP1B) were found to undergo ligand-dependent oxidation and ex-
hibit a unique sulfenylation profile in cells due to differences in their subcellular
location. A central finding of this study demonstrates EGFR undergoes sulfenylation
at its active site cysteine Cys797 in response to EGF and enhances its tyrosine ki-
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nase activity. The EGFR intracellular kinase domain contains six cysteine residues,
only one of which (Cys797) is located in the ATP-binding pocket. Given its active
site location and proximity to the ATP ligand, sulfenylation of Cys797 may enhance
kinase ability to participate in electrostatic and hydrogen-bonding interactions with
its substrate (Figure 4.1B). Furthermore, the location of this residue with respect
to the C-helix and activation segment also raises the possibility of transition-state
stabilization and/or destabilization of its auto-inhibitory conformation (12). EGFR
Cys797 is located at the N-terminal end of an α-helix, also referred to as the Ncap
position. Cysteine residues are the most sparsely occurring Ncap residue in native
proteins, and comprises <1% of all these positions (13). The interaction of cysteines
located at the Ncap position with the helix dipole can drastically lower the thiol pKa
and increase its susceptibility to oxidation (14, 15). To note, the Ncap effect has been
attributed to the reactivity of the catalytic cysteine in human peroxiredoxin I (8).
Interestingly, Cys797 is conserved among nine additional receptor and non-receptor
kinases (Supplementary Figure 4.S1) and it is possible that activity of these structural





















Figure 4.1: Signal-derived H2O2 directly targets EGFR and enhances its tyrosine kinase
activity upon oxidation. (A) Binding of EGF induces production of H2O2 through Nox2. Nox-
derived H2O2 directly modifies EGFR cysteine (Cys797) to sulfenic acid in the active site, which
enhances its tyrosine kinase activity. Endogenous H2O2 can also oxidize and deactivate localized
PTPs, leading to a net increase in EGFR phosphorylation. (B) Crystal structure of the EGFR
kinase domain (PDB 3GT8) bound to AMP-PNP, a hydrolysis resistant ATP analog, and Mg2+.
Dashed yellow lines and accompanying numbers indicate the distance (Å) between the γ-sulfur
atom of Cys797 and key substrate functional groups. Note also that Cys797 can adopt different
rotamers and sulfenylation of this residue may enhance its ability to participate in electrostatic and
hydrogen-bonding interactions with its substrate.
Perturbation of physiologic kinase signaling due to mutations and other genetic
alterations is a hallmark of many disease states and can result in aberrant kinase ac-
tivity and malignant transformation (16). EGFR is mutated or amplified in a number
of human carcinomas (i.e. breast and lung cancers), which has motivated the devel-
opment of reversible ATP-competitive inhibitors (17). This class of inhibitors, which
include gefitinib (18) and erlotinib (19), achieve selectivity by recognizing unique fea-
tures of the EGFR ATP-binding domain and have proven successful in clinical trials.
Somatic mutations in the EGFR kinase domain have been identified as a cause of non-
small cell lung cancer (NSCLC) (20, 21), and the two most frequent mutations are the
exon 19 point mutation (L858R) and exon 19 deletion (∆746-750) (22, 23). L858R
is the single most common mutation (approximately 40%) and lies within the kinase
activation loop. This point mutation is 50-fold more active than wild-type EGFR and
constitutively activates the kinase by destabilizing its auto-inhibitory conformation,
which is normally maintained in the absence of ligand stimulation (12, 24). Cells bear-
ing these oncogenic EGFR mutations exhibit decreased affinity for ATP and are, in
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general, more sensitive to reversible ATP-competitive inhibitors than cells expressing
wild-type kinase (25–27).
Lung cancer patients expressing these common mutations (L858R and ∆746-750)
eventually relapse after 12-18 months of treatment (28). In approximately 50% of
cases, drug resistance to ATP-competitive inhibitors is due to a second site mutation
(T790M) of the gatekeeper residue (29). This residue is located at the entrance of
the hydrophobic pocket in the back of the ATP binding pocket, and makes it an
important determinant of inhibitor specificity. Studies provided evidence that the
T790M mutation induces drug resistance by restoring ATP affinity to comparable
levels as wild-type EGFR, thereby increasing the concentration of ATP-competitive
inhibitor required to maintain efficacy (30). Moreover, L858R/T790M mutants re-
main sensitive to covalent irreversible inhibitors which can be utilized to overcome
clinical resistance to reversible ATP-competitive treatments (31–33).
In physiologic signaling, H2O2 levels are maintained through pro- and anti-oxidant
enzymes and buffering systems to promote cellular growth and survival. On the con-
trary, chronic H2O2 levels can ultimately result in cell death and are prevalent in
pathologic conditions (34, 35). Oxidation of H2O2-sensitive cysteine residues form
transiently in specific proteins to mediate redox-based signal transduction, but can
undergo malignant transformation in disease states associated with high oxidative
stress. Previous data from our group demonstrates that elevated expression levels of
EGFR and HER2 (member of EGFR subfamily) are correlated to increased protein
oxidation and global sulfenylation in breast cancer cells (36). When coupled to the
recent discovery that EGFR Cys797 undergoes sulfenic acid modification, these find-
ings raise several fundamental questions regarding the function of cysteine oxidation
with respect to EGFR signaling in normal and disease states. For example, what
are the molecular mechanisms underlying the role of Cys797 oxidation? How, and
to what extent, does oxidation of EGFR Cys797 ultimately affect kinase activity?
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Additionally, can cysteine oxidation serve as a general mechanism to regulate kinase
activity, specifically in structural homologues of EGFR?
In order to gain a better understanding of physiologic EGFR signaling, the scope
and molecular details by which Cys797 affects redox-based regulation of EGFR must
be delineated. Interestingly, EGFR Cys797 is also the target residue of a number of
covalent irreversible inhibitors currently under evaluation in clinical trials: EKB-569
(pelitinib), HKI-272 (neratinib), and BIBW 2992 (afatinib) (31, 32, 37). These com-
pounds contain an electrophilic acrylamide moiety that reacts with the EGFR Cys797
thiolate through Michael addition to achieve irreversible binding. Pre-treatment of
A431 cells with these covalent inhibitors prevents formation of sulfenyl EGFR and
highlights the dual role of this kinase regarding its importance in kinase signaling and
as a direct drug target (11). Given the proximity of EGFR Cys797 to the ATP-binding
pocket and because thiol (RSH)-targeted acrylamide inhibitors do not recognize the
kinase in its sulfenic acid form, we postulate that Cys797 oxidation can alter the po-
tency of irreversible EGFR inhibitors. Chronically high levels of H2O2 affiliated with
cancers can lead to aberrant levels of oxidized EGFR Cys797 and decrease the thiol
form available for covalent modification by RSH-targeted inhibitors, thereby reducing
drug efficacy. Additionally, the location of oncogenic EGFR mutations with respect
to Cys797 may induce conformational changes and/or alter its sensitivity to H2O2.
To address these questions, we generated cysteine mutants (C797S and C797A)
to probe the effect of this mutation with respect to EGFR kinase activity. We char-
acterized the kinetic parameters of wild-type (WT) and mutant kinases in vitro. We
demonstrate that cysteine mutants are less active than wild-type EGFR and have de-
creased affinity for ATP, suggesting Cys797 may play a role in substrate interaction.
Full-length EGFR kinase isolated from cells and activity assays revealed moderate
H2O2 treatment enhanced tyrosine kinase activity for wild-type, but not for cys-
teine mutants. Additionally, EGFR autophosphorylation and sulfenylation levels for
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cysteine mutants are abrogated in response to H2O2 stimulation in situ. Using thiol-
targeted inhibitors, we examine the effect of EGFR Cys797 oxidation with respect
to compound potency. EGFR undergoes sulfenylation in two common oncogenic mu-
tants (L858R/T790M and ∆746-750) in response to EGF and provides some insight
regarding the effect of oxidation in disease states. EGF-mediated ErbB2 sulfenyla-
tion was also explored, and indicates EGFR family members are subject to growth
factor-induced oxidation. Finally, we demonstrate cysteine oxidation may serve as a
general mechanism to modulate kinase activity in a structural homologue of EGFR.
Collectively, these studies highlight the importance of EGFR Cys797 oxidation in
physiologic kinase signaling and have broad implications for the development of new
redox-based strategies to target H2O2 cysteines in therapeutically important proteins.
4.3 Results
Mutation of EGFR Cys797 affects kinase activity in vitro
To investigate the role of EGFR Cys797, we generated two cysteine mutants:
C797S and C797A. Serine and alanine are both used as replacements for cysteine
in the literature. Although serine can make it a closer match to cysteine due to
its size, alanine substitutions can remove the effect of side chains and help deduce
the involvement of side chain interactions. Therefore, we chose to characterize the
behavior of both substitutions in order to evaluate the full extent of the mutation.
Due to its active site location and proximity to the ATP ligand, we characterized
the catalytic activity of wild-type and mutant enzymes. Kinetic characterization was
performed with recombinant protein expressing the kinase domain (696-1022). The
kinetic parameters for ATP and peptide substrate poly [Glu4:Tyr1] were determined
using a continuous, colorimetric in vitro kinase assay (adapted from (24, 30)) and
are summarized in Table 4.1. Fold activity (kcat) and rate plots of wild-type and
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mutant kinases for ATP (Figure 4.2A, B) and peptide (Figure 4.2C, D) are shown
as well. On average, C797S and C797A mutants are 2-fold less active than wild-type
as determined from their calculated kcat values. Decreased catalytic activity of these
mutants, as compared to wild-type, is likely due to disruption of substrate binding
interactions although structural data would be needed to support this. Affinity for
ATP (Km values) is decreased by 2.6- and 3-fold for mutants, respectively. Addi-
tionally, affinity for peptide substrate is decreased 2-fold for both C797S and C797A.
The increases in Km values for the C797S and C797A are modest, but suggest this
mutation induces structural changes in the ATP-binding pocket. The kinetic param-
eters we determined for wild-type EGFR are comparable to those previously reported
using similar and different assay systems (24, 30, 38). Covalent EGFR irreversible
inhibitors afatinib and PD168393 (Supplementary Figure 4.S2) were used to validate
the fraction of catalytically competent EGFR. MS/MS analyses of wild-type EGFR
confirmed labeling with these ATP-competitive compounds and ensure our kinetic
parameters are based on competent enzyme (Supplementary Figure 4.S3A, B).
Table 4.1: Kinetic Parameters of Wild-Type, C797S, and C797A EGFR
ATPa Peptideb
Km (µM) kcat (s−1) kcat/Km Km (µM) kcat (s−1) kcat/Km
WT 7.45 ± 0.36 0.00542 ±
3.40 E-4
7.28 E-4 906 ± 48 0.0175 ±
3.46 E-4
1.93 E-5
C797S 19.62 ± 0.84 0.00320 ±
1.36 E-4
1.63 E-4 1911 ± 119 0.00845 ±
7.00 E-4
4.42 E-6
C797A 21.72 ± 1.12 0.00281 ±
9.77 E-4
1.29 E-4 2134 ± 129 0.00637 ±
2.19 E-4
2.99 E-6
a Parameters for ATP were determined using a consensus peptide with the sequence RAHEEIYHFFFAKKK.










































































Figure 4.2: Mutation of Cys797 decreases EGFR tyrosine kinase activity. (A) Fold activity
of WT, C797S, and C797A kinases with respect to ATP. The fold activity of WT and mutant enzymes
was calculated by determining the kcat for each protein with ATP and saturating peptide substrate
(RAHEEIYHFFFAKKK) and dividing by the kcat for WT enzyme. (B) Rate plot of WT and C797
mutant kinases with respect to ATP. (C) Fold activity of WT, C797S, and C797A kinases with
respect to substrate. The fold activity of WT and mutant enzymes was calculated by determining
the kcat for each protein with saturating ATP and poly [Glu4Tyr1] as peptide substrate and dividing
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Figure 4.3: EGF and H2O2 treatment induces autophosphorylation of WT EGFR isolated
from immunoprecipitates. (A) Full length native WT EGFR was immunoprecipitated from A431
cell lysate, assayed for tyrosine kinase activity with ATP, and stimulated with EGF (3.3 ng/µl)
or H2O2 (0-100 µM). Western blot shows phosphorylated (p) and total EGFR. (B) Densitometric
quantification of A. EGF and H2O2 treatment increases kinase activity in EGFR immunoprecipitates.
(C) DTT reverses EGF and H2O2-mediated EGFR autophosphorylation. To assess the reversibility
of H2O2-induced kinase activation, immunoprecipitated EGFR was pre-incubated with H2O2 (5
µM) followed by addition of DTT simultaneous with ATP. (D) Afatinib blocks inherent EGFR
kinase activity. To verify that EGFR autophosphorylation was due to enhanced kinase activity,
immunoprecipitated EGFR was pre-incubated with afatinib (1 µM). Data are representative of
three independent readings and represent the mean ± s.e.m. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001
compared to untreated control.
We also investigated the in vitro effect of EGFR Cys797 mutation on kinase ac-
tivity using full-length receptor. Although we have previously demonstrated H2O2
treatment enhances tyrosine kinase activity of wild-type EGFR, these results were
generated with recombinant protein expressing the kinase domain. Therefore, this
approach allows us to investigate the behavior of wild-type and mutant EGFR in
its complete form. For our studies, we used the human epidermoid carcinoma A431
cell line naturally expresses high concentrations of EGFR and serves as an effective
model to study the wild-type kinase (39). Full-length native WT EGFR was iso-
lated from A431 cell lysate and assayed for tyrosine kinase activity with ATP. Upon
EGF or dose-dependent H2O2 treatment, autophosphorylation levels are increased
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by up to 3-fold compared to the unstimulated control (Figure 4.3A, B). To assess
the reversibility of H2O2-induced kinase activation, immunoprecipitated EGFR was
pre-incubated with H2O2 followed by addition of DTT simultaneous with ATP. DTT
blocks EGF and H2O2-mediated increases in EGFR autophosphorylation, and con-
firms H2O2-dependent activation occurs through a reversible mechanism (Figure 4.3A,
C). In addition, pre-incubation with afatinib completely abolishes EGFR autophos-
phorylation (Figure 4.3D) and verifies that the observed changes (Figure 4.3B) are
due to enhanced kinase activity. These results demonstrate H2O2 treatment enhances
wild-type EGFR activity in vitro using full-length receptor, and confirm our earlier
findings observed with the kinase domain.
Using the above approach, we transiently transfected C797S and C797A into HeLa
cells to evaluate the effect of this mutation in its fully-expressed form in vitro. Wild-
type EGFR was also transfected and served as a control to adjust for any potential
changes occurring from the transfection process. Wild-type EGFR autophosphoryla-
tion was increased 8-fold and 12-fold upon EGF and H2O2 treatment, respectively in
immunoprecipitates isolated from HeLa-transfected cell lysate (Supplementary Fig-
ure 4.S4A, B). On the contrary, C797s and C797A did not exhibit drastic changes in
autophosphorylation levels upon EGF and H2O2 treatment. On average, C797S was
determined to exhibit a 2-fold increase in phosphorylation but these changes may be
a result of the serine side-chain interaction or reversion of the serine mutation back to
its original residue. The fold change for C797A could not be calculated because de-
tection of autophosphorylation was completely abrogated. Collectively these results
highlight the functional role of EGFR Cys797 with respect to kinase activity in its
kinase domain and its full-length form in vitro.
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Mutation of EGFR Cys797 affects autophosphorylation and sulfenylation
level in situ
To place our findings in a more relevant signaling context, we explored the behav-
ior of wild-type and EGFR cysteine mutants in situ in response to EGF and H2O2
treatment. Wild-type, C797S, and C797A were transiently transfected into HeLa
cells, stimulated with EGF or H2O2, and analyzed for changes in autophosphoryla-
tion levels. EGF treatment induces a strong dose-dependent increase in wild-type
phosphorylation (Figure 4.4A, B), and is decreased in both cysteine mutants (Fig-
ure 4.4A, B). This decrease is more pronounced in the C797A mutant, which agrees
with our earlier in vitro kinase assays. Similarly, H2O2-mediated activation of EGFR
is reduced in C797 mutants compared to wild-type kinase (Figure 4.5A, B). Phos-
phorylation levels are completely abrogated in the C797A mutant, whereas C797S
mutant still exhibits a detectable amount of activity equivalent to its corresponding
untreated control. At higher H2O2 concentrations (500 µM), activation of C797S
increases to comparable levels to wild-type EGFR and may be due to concomitant
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Figure 4.4: EGF-mediated activation of EGFR is affected in C797 mutants in situ. (A)
WT, C797S, and C797A EGFR were transfected into HeLa cells and stimulated with EGF at the
indicated concentrations for 5 min. Western blot shows phosphorylated (p) and total EGFR. Both
mutants exhibit decreased autophosphorylation levels when compared to WT enzyme. (B) Densito-
metric quantification of A. Data are representative of three independent readings and represent the
mean ± s.e.m.
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Figure 4.5: H2O2-mediated activation of EGFR is affected in C797 mutants in situ. (A)
WT, C797S, and C797A EGFR were transfected into HeLa cells and stimulated with H2O2 at
the indicated concentrations for 5 min. Western blot shows phosphorylated (p) and total EGFR.
Both mutants exhibit decreased autophosphorylation levels when compared to WT enzyme. (B)
Densitometric quantification of A. At higher H2O2 concentrations (500 µM), C797S phosphorylation
levels increase and may be due to inhibition of protein tyrosine phosphatases (PTPs). Data are
representative of three independent readings and represent the mean ± s.e.m.
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Next, we investigated the effect of H2O2-mediated sulfenylation in wild-type,
C797S, and C797A. Dimedone and its derivatives are the prototypical sulfenic acid
probes and have been shown extensively to specifically react with sulfenyl groups
in vitro and in situ (40). These small molecules are used to trap and tag sulfenic
acids, and labeled proteins can subsequently be detected by specific antibodies (36)
or through attachment of biotin or fluorescent reporter (11, 41–43). HeLa cells were
transfected with wild-type or cysteine mutants and labeled with DYn-2 following
H2O2 stimulation. Upon treatment, EGFR sulfenylation is decreased in both cys-
teine mutants compared to sulfenyl wild-type levels (Figure 4.6A, B). In particular,
sulfenylation levels of C797A are completely abolished whereas the C797S mutant
does not exhibit as drastic of an effect. The behavioral differences of these mutants
is similar to those observed with in situ phosphorylation experiments (Figure 4.5),
and may be due to structural changes induced by these substitutions. We also at-
tempted to investigate the effect of EGF-mediated sulfenylation in wild-type and
mutant kinases, but did not obtain successful results. We suspect this is because
Nox2 is not expressed at high levels in HeLa cells (data not shown), and therefore
do not contain the cellular components necessary to generate endogenous H2O2 in re-
sponse to growth factor stimulation. MS/MS analysis of dimedone-labeled wild-type
EGFR confirms Cys797 as the site of modification in response to H2O2 treatment
(Supplementary Figure 4.S5). This was the only dimedone-labeled cysteine identi-
fied in our MS studies. Collectively these results demonstrate mutation of Cys797
decreases EGFR autophosphorylation and sulfenylation, and confirm H2O2-mediated
sulfenylation occurs at the EGFR active site residue Cys797.
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Figure 4.6: H2O2-mediated sulfenylation is decreased in EGFR Cys797 mutants in situ.
(A) WT, C797S, and C797A EGFR were transfected into HeLa cells and stimulated with H2O2 (25
µM) for 5 min. Sulfenic acids were detected by Strep-HRP western blot. Both mutants exhibit
decreased EGFR sulfenylation when compared to WT enzyme. (B) Densitometric quantification of
A. Data are representative of three independent readings and represent the mean ± s.e.m.
EGFR is sulfenylated in common oncogenic kinase mutations
As discussed earlier in the introduction, somatic mutations in the EGFR kinase
domain have been identified as a cause of NSCLC. In particular, two of the most
frequently occurring mutations (L858R and ∆746-750) confer increased sensitivity to
ATP-competitive inhibitors (i.e. gefitinib and erlotinib) by decreasing kinase affinity
for ATP (25–27). T790M is a second site mutation that accounts for half of the
cases wherein lung cancer patients undergoing treatment eventually relapse (28, 29).
Given the proximity of EGFR Cys797 to the substrate binding pocket, we speculate
oxidation of Cys797 may be affected in these oncogenic mutants. To investigate this,
we used two lung cancer cell lines harboring these somatic mutations: NCI-H1875
(L858R, T790M) and HCC827 (∆746-750) (44). Cells were stimulated with growth
factor in a dose-dependent manner, and labeled with DYn-2 to detect formation of
sulfenic acids. EGF-mediated sulfenylation of EGFR was detected in both onco-
genic mutants (Figure 4.7A, B). The fold-change of sulfenylation is higher in the
130
L858R/T790M mutant compared to ∆746-750, and suggests that the propensity of
the cysteine to undergo oxidative modification may be increased with respect to this
mutant (Figure 4.7C). Increased H2O2 sensitivity of Cys797 may be due to structural
changes induced by the L858R/T790M mutant, but further studies would be neces-
sary to dissect the separate contributions of each mutation. Moreover, chronic levels
of H2O2 associated with cancers expressing these mutations may provide an oxidiz-
ing environment that favors the sulfenyl EGFR form. Therefore, understanding the
role of EGFR sulfenylation in pathologic states may provide a platform to develop
effective treatments targeting this kinase.
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Figure 4.7: EGF mediates sulfenylation of EGFR in common oncogenic mutations. (A,
B) Western blots showing sulfenylated and total EGFR. Lung cancer cell lines expressing common
EGFR mutations, (A) NCI-H1975 (L858R, T790M) and (B) HCC827 (∆ E746-A750), were stimu-
lated with EGF at the indicated concentrations or vehicle for 2 min and sulfenic acids were detected
by Strep-HRP western blot. (C) Densitometric quantification of A and B. Data are representative
of three independent readings and represent the mean ± s.e.m.
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Figure 4.8: EGF mediates sulfenylation ErbB2 in breast cancer cells. (A) Western blot
showing sulfenylated and total ErbB2. MDA-MB-453 cells were stimulated with EGF at the indi-
cated concentrations or vehicle for 2 min and sulfenic acids were detected by Strep-HRP western
blot. (B) Densitometric quantification of A. Data are representative of three independent readings
and represent the mean ± s.e.m.
EGFR is part of a subfamily that consists of three additional closely related recep-
tors: HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Two of these receptors,
HER2 and HER4, contain a structurally homologous residue to EGFR Cys797. In
particular, overexpression of HER2 has been shown to play an important role in the
development and progression of breast cancer. Additionally, increased protein oxida-
tion and global sulfenylation has been observed in breast cancer cells with high HER2
expression levels (36). We sought to investigate if HER2 undergoes EGF-mediated
sulfenylation similar to EGFR. For these studies, we used the metastatic breast car-
cinoma MDA-MB-453, which expresses high levels of HER2. EGF treatment of these
cells induces oxidation of HER2 in a dose-dependent manner and peaks at 4 ng/ml
(Figure 4.8A, B). These results demonstrate EGFR subfamily members exhibit de-
tectable trends in sulfenylation similar to EGFR and its oncogenic mutations, and
highlight the importance of understanding the mechanisms underlying kinase redox-
regulation.
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Chronic H2O2 treatment reduces potency of irreversible thiol (RSH)-targeted
EGFR inhibitors
A number of covalent EGFR inhibitors achieve irreversible binding with an elec-
trophilic acrylamide moiety that reacts with the EGFR Cys797 thiolate through
Michael addition (45, 46). These compounds also utilize the 4-anilinoquinazoline
scaffold, identified by structure-based design, to direct them to the ATP-binding do-
main and facilitate reaction with Cys797 (47). Oxidation of Cys797 to its sulfenyl
form prevents recognition of EGFR by these targeted covalent inhibitors, and can
potentially affect compound potency given its active site location. Furthermore, el-
evated H2O2 levels affiliated with cancers can generate increased levels of sulfenyl
EGFR and simultaneously lower the available amount of reduced kinase.
To investigate the effect of EGFR oxidation on inhibitor potency, we used two
4-anilinoquinazoline inhibitors: afatinib (32) and PD168393 (45). Afatinib is a suc-
cessful irreversible inhibitor currently undergoing clinical trials. PD168393 is also
a potent compound, but did not make it to clinical trials due to low bioavailability
stemming from solubility issues. A431 cells were subjected to chronic H2O2 conditions
using glucose oxidase (GO) prior to inhibitor incubation. GO is an oxidoreductase
that catalyzes the oxidation of glucose to steadily produce H2O2 (48). This enzyme
can be used to mimic the chronic H2O2 levels typically associated with disease states
through H2O2 production over prolonged treatment. Following H2O2 and compound
treatment, cells were stimulated with EGF and analyzed for changes in autophos-
phorylation levels. As a technical issue, we point out that treating cells with H2O2
or other biological oxidants increases the fraction of sulfenyl EGFR but also results
in kinase activation and PTP inhibition. Therefore, the EGF-stimulation step was
included as a control to reflect the net increase mediated by EGF and H2O2 in these
phosphorylation assays.
EGFR phosphorylation levels were increased (up to 40%) under chronic H2O2
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conditions at higher concentrations of inhibitor compared to their respective EGF-
control for both compounds (Figure 4.9A, C). Afatinib and PD169383 achieve nearly
complete covalent inhibition of wild-type EGFR at 0.1 µM and higher in the EGF-
control, but the potency of these compounds are reversed at these concentrations when
cells are subjected to conditions of oxidative stress (Figure 4.9B, D). These results
demonstrate oxidizing conditions (chronic H2O2) reduces the potency of RSH-targeted
EGFR inhibitors by modifying the kinase into a different form. Additionally, we also
probed the effect of oxidation on inhibitor potency in oncogenic EGFR mutations
(L858R/T790M and ∆746-750) to determine if these mutant kinases exhibited results
to wild-type kinase. For L858R/T790M, chronic oxidizing conditions induce slight
increases in EGFR autophosphorylation levels, but the effect is not as pronounced
as we observed in wild-type EGFR (Supplementary Figure 4.S6A, Figure 4.S7A).
Therefore, sulfenylation does decrease the potency of afatinib and PD168393 in the
L858R/T790M mutation, but to a smaller degree when compared to wild-type ki-
nase (Supplementary Figure 4.S6B, Figure 4.S7B). In the ∆746-750 deletion mutant,
EGFR autophosphorylation levels are increased significantly under chronic H2O2 con-
ditions (Supplementary Figure 4.S6C, Figure 4.S7C). The potency of both inhibitors
is reversed at concentrations of 0.01 µM and higher under oxidizing conditions when
compared to its EGF control (Supplementary Figure 4.S6D, Figure 4.S7D). However,
it is important to note that afatinib and PD168393 are unable to achieve complete
irreversible inhibition in the ∆746-750 deletion mutant. This may indicate that this
mutant has inherent resistance to these compounds, which is further enhanced by
Cys797 sulfenylation. Taken together, these data confirm EGFR Cys797 sulfenyla-





























































































































Figure 4.9: Chronic H2O2 treatment reduces potency of RSH-targeted irreversible EGFR
inhibitors. A431 cells were incubated with glucose oxidase (2 u/ml) for 3 h to induce chronic H2O2
conditions, treated with the indicated concentrations of (A) afatinib or (C) PD168393 for 1 h, and
subsequently stimulated with EGF (100 ng/ml) for 5 min. Western blots show phosphorylated (p)
and total EGFR. The potency of both inhibitors was reduced in the presence of chronic H2O2.
(B, D) Densitometric quantification of A (afatinib) and C (PD168393), respectively. At higher
inhibitor concentrations, phosphorylation levels (%) for chronic H2O2-treated samples are higher
when compared to their EGF-treated counterpart. Data are representative of two independent
readings and represent the mean ± s.e.m.
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Structural homologue BTK may contain a redox-sensitive cysteine
There are nine other kinases that harbor a cysteine residue that is structurally
homologous to EGFR Cys797 as mentioned previously (Supplementary Figure 4.S1).
We postulate that this group of kinases could potentially be regulated by oxidation of
this residue, which may serve as a general mechanism for redox-based kinase signaling.
To investigate this, we decided to begin with Bruton’s tyrosine kinase (BTK), a non-
receptor kinase that plays an essential role in regulation calcium signaling during
B-cell receptor (BCR) activation (49). We chose BTK as our starting point because
it is the only other kinase besides EGFR (and HER2) that currently has inhibitors
undergoing clinical trials (46). BTK Cys481 is located in the kinase active site near the
beginning of an alpha helix similar to EGFR Cys797 (Figure 4.10A). In addition, BTK
contains a second cysteine residue (Cys527) that is approximately 8.1 Å from Cys481
which could possibly undergo redox-mediated disulfide bond formation. Cys481 is
also near the ATP binding site adjacent to the activation loop containing Tyr551,










Figure 4.10: Bruton’s Tyrosine Kinase (BTK) contains a cysteine residue (Cys481) that
is structurally homologous to EGFR Cys797. (A) BTK Cys481 is located in the enzyme
active site near the beginning of an alpha helix similar to EGFR Cys797. In addition, BTK contains
a second cysteine residue (Cys527) that is 8.1 Å from Cys481 which could undergo redox-mediated
disulfide bond formation. (B) BTK Cys481 is located near the substrate binding site, which is
adjacent to the activation loop containing Tyr551.
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To explore redox-based modulation of BTK activity in situ, we used the human
B-cell lymphoma Ramos cells. First, we investigated the effect of exogenous H2O2
on phosphorylation of BTK. H2O2 treatment triggers a dose- and time-dependent
increase in kinase phosphorylation levels (Supplementary Figure 4.S8C, D), and re-
capitulates IgM-induced activation of BTK (Supplementary Figure 4.S8A, B). These
results suggest H2O2 mediates changes in BTK phosphorylation levels, similar to
what we have observed for EGFR. To place these findings into context, we then
examined if IgM treatment was capable of inducing sulfenic acid formation. Upon
IgM stimulation, Ramos cells exhibited increased intracellular reactive oxygen species
(ROS) levels and global protein sulfenylation in a dose-dependent manner (Supple-
mentary Figure 4.S9A, B). The maximal increase in sulfenylation was apparently at
2.5 µg/ml IgM, and gradually fell to basal levels at higher ligand concentrations. ROS
generation and protein sulfenylation were also dynamic temporal events peaking at
2 min after IgM stimulation, and decreased thereafter (Supplementary Figure 4.S9C,
D). Together, these data demonstrate H2O2 mimics the effects of IgM stimulation
and provide the foundation to probe redox-based modulation of BTK.
We next sought to determine if BTK is a direct target of H2O2 in cells. Following
IgM stimulation and DYn-2 labeling, BTK was immunoprecipitated and analyzed
for changes in protein sulfenylation. These studies revealed that IgM stimulation
leads to sulfenic acid modification of BTK, peaking at 2.5 µg/ml IgM (Figure 4.11A).
Interestingly, this is the same concentration that induces maximal protein sulfenyla-
tion levels in our global studies (Supplementary Figure 4.S9B). BTK sulfenylation is
also a temporal event, peaking at 2 min following IgM stimulation (Figure 4.11B).
Given these findings, we hypothesized that BTK Cys481 is the site of oxidation due
to its structural homology to EGFR Cys797. To test this, we pre-incubated Ramos
cells with PCI-32765 to evaluate its effect on BTK sulfenylation. PCI-32765 is an
irreversible and potent inhibitor of BTK (Supplementary Figure 4.S2), and utilizes
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the same electrophilic acrylamide moiety as EGFR inhibitors to covalently modify
its target residue Cys481 (50, 51). Pre-treatment with PCI-32765 induced decreased
IgM-mediated sulfenylation of BTK (Figure 4.11C). The sulfenyl signal was not com-
pletely abolished, suggesting additional mechanisms may be involved in modulating
the oxidation status of Cys481. It is possible that the second cysteine residue (Cys527)
located in the kinase active site may participate in redox-mediated disulfide bond for-
mation with Cys481 (Figure 4.10A). Additional mass spectrometry and mutational
studies would be necessary to test these propositions and are currently underway.
Collectively, these results present strong evidence to indicate BTK is a direct target
of H2O2 and undergoes sulfenic acid modification at Cys481.
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Figure 4.11: IgM-mediated sulfenylation of BTK in cells. (A) Dose and (B) time-dependence
of BTK sulfenylation in Ramos cells. Cells were stimulated with IgM at the indicated concentrations
(A) or times (B), and sulfenic acids were detected by in-gel fluorescence. (C) PCI-32765 (irreversible
BTK inhibitor) treatment decreases BTK sulfenylation. Ramos cells were incubated with PCI-32765




Sulfenic acid modifications have proven to have significant impacts on kinase ac-
tivity during cellular signaling events (52, 53). In particular, recent studies have
demonstrated EGFR undergoes sulfenylation at its active site cysteine in response to
EGF and enhances its tyrosine kinase activity (11). Given its location and proximity
to the ATP ligand, structural changes induced by Cys797 sulfenylation may enhance
kinase ability to participate in electrostatic and hydrogen-bonding interactions with
its substrate. Therefore, delineating the molecular mechanisms and function of cys-
teine oxidation in EGFR signaling may lead to a better understanding of the role of
sulfenic acid during physiologic kinase-mediated events.
We generated two cysteine mutants (C797S and C797A) expressing the kinase do-
main and also its full-length receptor form to investigate the role of EGFR Cys797 in
vitro. We first performed kinetic characterization to look for any changes stemming
from residue mutation. Kinase activity assays revealed that these cysteine mutants
exhibited decreased catalytic activity and lowered affinity for ATP when compared
to wild-type enzyme (Table 4.1, Figure 4.2). Autophosphorylation assays with full-
length receptor corroborated these findings and provided strong evidence that Cys797
mutation has a detrimental effect with respect to kinase activity in vitro (Figure 4.3,
Supplementary Figure 4.S4). Additionally, EGFR autophosphorylation and sulfeny-
lation levels are completely abrogated in response to EGF or H2O2 stimulation in
cells (Figure 4.4, Figure 4.5, Figure 4.6). The behavior of these cysteine mutants in
vitro and in situ suggest Cys797 participates in binding interactions with the sub-
strate, which are dissolved upon residue mutation (Figure 4.1B). This series of studies
collectively demonstrate EGFR Cys797 plays an important role in EGF-mediated ac-
tivation, and occur through redox-based modification of this residue during normal
cell signaling.
A number of EGFR mutations have been identified as a cause of human carcino-
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mas. Commonly occurring oncogenic mutations (L858R/T790M and ∆746-750) have
been of particular interest because these mutations induce changes in the kinetic pa-
rameters of EGFR (24, 30), which subsequently affects sensitivity of the kinase in
response to reversible and irreversible inhibitor treatment. These mutations are lo-
cated in the activation loop near the ATP-binding pocket. Coupled with the active
site location of Cys797, we speculated that these mutations may affect oxidation of
Cys797. Analysis of EGFR Cys797 sulfenylation in these mutants revealed discernible
trends and suggest the L858R/T790M mutation increases the propensity of Cys797 to
undergo oxidation modification compared to the ∆746-750 mutant (Figure 4.7). This
has huge implications because deregulation of EGFR signaling in human cancers has
motivated the development of inhibitors to specifically target EGFR Cys797 in its
thiol form (46, 54–56). Disease states such as cancer are often correlated with chronic
levels of H2O2 and can lead to enhanced levels of protein sulfenylation (36). These
conditions favor oxidation and can shift the fraction of EGFR towards its sulfenyl
form. Interestingly, the potency of afatinib and PD168393 (irreversible thiol-targeted
inhibitors) was decreased under chronic H2O2 in wild-type and oncogenic mutant
EGFR (Figure 4.9, Supplementary Figure 4.S6, Figure 4.S7). These results suggest
alternate mechanisms to target sulfenyl EGFR must be developed to overcome the
potential shortcomings of thiol-targeted inhibitors introduced upon oxidation and
may afford additional means of achieve selectivity. The sulfenic acid modification
is a unique chemical moiety and therefore represents a new opportunity in covalent
inhibitor design. Nucleophilic warheads (i.e. dimedone-based derivatives) can be
utilized to target the electrophilic sulfur in sulfenyl proteins. In this approach, the
propensity of H2O2-sensitive cysteines in kinases and other therapeutically relevant
proteins (i.e. phosphatases) can be exploited to develop a new class of inhibitors sim-
ilar to the proof-of-concept compounds recently reported by our group to target PTP
oxidation (57). Following this study, we have developed a panel of first-generation
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RSOH-targeted inhibitors and evaluated compound selectivity towards EGFR Cys797
in response to concomitant kinase oxidation. To date, our compounds induce inhi-
bition towards EGFR under oxidizing conditions and demonstrate proof of principle
for our nucleophilic approach (T. Truong, V. Gupta, and K. Carroll, unpublished
results).
Protein kinases containing structurally homologous cysteine to EGFR Cys797
represent another exciting area of research (Supplementary Figure 4.1). This group
contains receptor and non-receptor kinases, including two EGFR subfamily members
HER2 and HER4. We speculated that oxidation of this residue may act as a general
mechanism to regulate this group of kinases. In particular, we explored the possibility
of two of these structural homologues to undergo sulfenylation in our studies, HER2
and BTK. Both kinases have irreversible inhibitors currently in clinical trials and
represent therapeutically important targets (56). Not surprisingly, HER2 was shown
to undergo EGF-mediated sulfenylation (Figure 4.8). HER2 can form a heterodimer
with EGFR upon stimulation, and oxidation of HER2 may be facilitated by receptor
dimerization (58). Our preliminary work with BTK demonstrates that it is a direct
target of H2O2 and undergoes sulfenic acid modification at Cys481 (Figure 4.11).
The enzyme active site contains a second cysteine residue (Cys527) that can poten-
tially undergo redox-mediated disulfide bond formation with Cys481 (Figure 4.10).
Recent studies have demonstrated ROS production is induced in response to BCR
activation in human B-cells (59), and is mediated in part by sulfenic acid formation
(60). Moreover, BTK has been shown to negatively regulate ROS production in hu-
man neutrophils (61). Further work is need to define the scope of BTK oxidation,
and represents an intriguing area of research. Another subfamily of protein tyrosine
kinases, which includes cytoplasmic Src and FGFR1, contains a cysteine residue lo-
cated within its glycine rich loop and interacts with the γ-phosphate of ATP (62).
Oxidation of this residue inhibits kinase activity of c-Src and FGFR1 in vitro, but
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neither of these kinases has been confirmed as a direct target of H2O2 in situ. In
the physiologic context, more than 150 kinases contain a cysteine in or around the
nucleotide-binding site and may play similar regulatory roles. However, a broader
examination will be required to define the scope and molecular details underlying the
redox-regulated kinome.
4.5 Conclusion
EGFR Cys797 sulfenylation plays a significant role in EGF-mediated cellular
events, and the continued effort to define these redox-based mechanisms may pro-
vide a better general understanding of kinase signal transduction and in pathologic
states associated with increased oxidative stress. Our efforts have demonstrated the
physiologic importance of Cys797, and have huge implications for the development of
new therapeutics whereby the sulfenic acid moiety can be exploited as an alternate
target by covalent inhibitors.
4.6 Methods
Cloning of EGFR C797 mutants. EGFR in pCMV6-XL4 was obtained from
Origene. EGFR C797S was generated by site-directed PCR mutagenesis with the
following primers: 5-CATGCCCTTCGGCTCGCTCCTGGACTATG-3 and 3-CAT-
AGTCCAGGAGCGAGCCGAAGGGCATG-5. EGFR C797A was generated with
the following primers: 5-CATGCCCTTCGGCGCCCTCCTGGACTATG-3 and 3-
CATAGTCCAGGAGGGCGCCGAAGGGCATG-5.
Cloning, expression, and purification of EGFR kinase domain (696-
1022). EGFR (696-1022) in pFastBac was obtained from Blue Sky BioServices.
EGFR C797S (696-1022) was generated by site-directed PCR mutagenesis with the
following primers: 5- CATGCCGTTCGGTTCGTTGTTGGACTACG-3 and 3- CGT-
142
AGTCCAACAACGAACCGAACGGCATG-5. EGFR C797A (696-1022) was gener-
ated with the following primers: 5- CATGCCGTTCGGTGCCTTGTTGGACTA-
CG-3 and 3- CGTAGTCCAACAAGGCACCGAACGGCATG-5. The three EGFR
kinase domain constructs (WT, C797S, and C797A) were expressed and purified using
a baculovirus/insect cell system by Blue Sky BioServices. The protein was concen-
trated to 5 mg/ml and stored in 50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 mM DTT,
and 20% glycerol.
Reagent source, purity, and stock solutions. All stocks were stored at -20 ◦C,
unless otherwise indicated. EGF (30 µg/ml, BD Biosciences) was prepared in ddH2O.
Serial dilutions of H2O2 (Sigma) were prepared in ddH2O. DYn-2 (≥ 99% purity) was
synthesized and purified as previously described (11). DYn-2 (250 mM) was prepared
in DMSO. Dimedone (250 mM, Sigma) was prepared in 70% DMSO/30% Bis-Tris (500
mM, pH 7.4). Catalase (20,000 U/ml, Sigma) included in lysis buffers was prepared in
50 mM Tris-HCl pH 7.4 and stored at -80 ◦C or made up fresh, respectively. Glucose
oxidase (500 U/ml, Sigma) was prepared fresh in 50 mM Tris-HCl pH 7.4. Azide
biotin (5 mM, Invitrogen) and TAMRA azide (5 mM, Invitrogen) were prepared in
DMSO. BTTP (100 mM, Peng Wu) was prepared in DMSO, and lower concentrations
were made by dilution of stock solution with ddH2O. Sodium L-ascorbate (Sigma) and
CuSO4 (Sigma) were prepared fresh in ddH2O. Afatinib (10 mM, ChemieTek, ≥ 99%
purity), PD168393 (10 mM, Santa Cruz Biotechnology, ≥ 95% purity), LFM-A13 (10
mM, Cayman Chemicals, ≥ 99% purity), and PCI-32765 (10 mM, Selleckchem, ≥
98% purity) stocks were prepared in DMSO at the indicated concentrations.
Enzyme kinetic assays and data analysis. Steady-state EGFR kinetic param-
eters were determined in triplicate by using the ATP/NADH coupled enzyme assay
system in a 384-well format (63). The reaction mixture contained 0.5 mg/ml BSA, 2
mM MnCl2, 1 mM phospho(enol) pyruvic acid (PEP; Sigma Aldrich, # P7002), 1 mM
TCEP (Sigma Aldrich), 0.1 M MOPS pH 7.5, 1⁄50 of the final reaction mixture vol-
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ume of pyruvate kinase/lactic dehydrogenase enzymes from rabbit muscle (PK/LDH;
Sigma Aldrich, # P-0294), 0.5 mM NADH (Sigma Aldrich), fixed (to determined ATP
kinetic parameters) or varied (to determine peptide kinetic parameters) concentra-
tions of peptide substrate, and 2.5 µM EGFR kinase. ATP was added last to initiate
the reaction. The two substrate kinase reaction was simplified to two one-substrate
reactions to determine ATP and peptide kinetic parameters separately. When deter-
mining ATP kinetic parameters, the peptide concentration was kept the same and
in excess (more than five times the Km value). When determining peptide kinetic
parameters, the ATP concentration was kept the same and in excess (more than five
times the Km value). Steady-state initial velocity data was drawn from the slopes
of the A340 curves and fit to the Michaelis-Menten equation to determine Vmax and
Km values. The peptide substrate was either a consensus peptide with the sequence
(RAHEEIYHFFFAKKK) (38, 64) or the widely used tyrosine kinase substrate poly
[Glu4Tyr1] (Sigma Aldrich, # P7244) as indicated in Table 4.1. Due to the limited
solubility of the consensus peptide in the ATP/NADH coupled enzyme assay sys-
tem, poly [Glu4Tyr1] was used as the peptide substrate to determine peptide kinetic
parameters. To verify that our derived kcat parameters reflected concentrations of
active enzyme, parallel aliquots of wild-type and mutant kinases were treated with
the EGFR-specific irreversible inhibitor afatinib to determine the fraction of catalyt-
ically active molecules. Mass spectrometry analysis demonstrated complete labeling
with this ATP-competitive compound, and assured that our values were based from
active enzyme.
Cell culture. Mammalian cell lines (American Type Culture Collection) were
maintained at 37 ◦C in a 5% CO2 humidified atmosphere. A431, HeLa, and MDA-
MB-453 cells were cultured in high glucose DMEM media (Invitrogen) containing 10%
FBS (Invitrogen), 1% GlutaMax (Invitrogen), 1% MEM nonessential amino acids
(Invitrogen), and 1% penicillin-streptomycin (Invitrogen). NCI-H1975, HCC827, and
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Ramos cells were cultured in RPMI 1640 media with glutamine (Invitrogen) contain-
ing 10% FBS (Invitrogen), 1% MEM nonessential amino acids (Invitrogen), and 1%
penicillin-streptomycin (Invitrogen). For EGF and H2O2 treatment, cells were cul-
tured until 80-85% confluency, washed with PBS, and placed in culture media without
serum (serum-starved) for 16 h. After serum deprivation, cells were treated with the
indicated concentration of EGF or H2O2 for the indicated time period. Treatment was
stopped by removing the media and washing with PBS. For glucose oxidase treatment,
cells were cultured until 80-85% confluency, washed with PBS, and serum-starved for
16 h. After serum deprivation, cells were treated with the indicated concentration
of glucose oxidase for the indicated time period to induce chronic H2O2. Cells were
then incubated with the indicated concentration of inhibitor for the indicated time
period, washed with PBS, and treated with the indicated concentration of EGF for
the indicated time period. Treatment was stopped by removing the media and wash-
ing with PBS. For goat anti-human IgM (Jackson ImmunoResearch) treatment, cells
were cultured until 80-85% confluency, washed with PBS, and placed in culture media
without serum (serum-starved) for 16 h. After serum deprivation, cells were treated
with the indicated concentration of IgM for the indicated time period. Treatment
was stopped by removing the media and washing with PBS.
Transfection of EGFR. HeLa cells were transfected at 80-85% confluency with
EGFR, EGFR C797S, EGFR C797A, or empty vector (pCMV6-XL4) using Lipofec-
tamine 2000 (Invitrogen) according to manufacturer guidelines for 24 h. For EGF and
H2O2 treatment, cells were washed with PBS after transfection and serum-starved for
2 h. After serum deprivation, cells were treated with the indicated concentration of
EGF or H2O2 for the indicated time period. Treatment was stopped by removing the
media and washing with PBS.
Sulfenic acid labeling in cells. Mammalian cells were lifted with 0.25% trypsin-
EDTA, harvested by centrifugation at 1000 rpm for 2 min, washed, and resuspended
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in serum-free media at a density of 3-4 × 106 cells/ml. Intact cells in suspension were
incubated with vehicle (DMSO, 2% v/v) or the indicated concentration of sulfenic
acid probe (DYn-2) at 37 ◦C in a 5% CO2 humidified atmosphere with periodic gentle
agitation for 15 min unless indicated otherwise. Following treatment for the indicated
time, cells were collected by centrifugation (1000 rpm) and washed with PBS. The
resulting cells were routinely counted using a hemocytometer and uniformly showed
greater than 90% viability by trypan blue exclusion.
Cell lysate preparation. Cells were harvested in HEPES lysis buffer [50 mM
HEPES pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 1× EDTA-free complete mini
protease inhibitors (Roche), and 200 U/ml catalase (Sigma)]. After 15 min incubation
on ice with frequent mixing, cell debris was removed by centrifugation at 14,000 rpm
for 15 min at 4 ◦C. Protein concentration was determined by BCA assay (Pierce).
For analysis of protein phosphorylation, cells were harvested in phosphorylation lysis
buffer [50 mM HEPES pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 5 mM sodium
pyrophosphate, 50 mM sodium fluoride, 10 µM β-glycerophosphate, 1 mM sodium
orthovanadate, 0.5 mM DTT, and 1× complete mini protease inhibitors (Roche)]. For
immunoprecipitated EGFR kinase assays, cells were harvested in RIPA B buffer [20
mM HEPES, pH 7.0, 150 mM NaCl, 0.2 mM MgCl2, 1% Triton X-100, 1× complete
mini protease inhibitors (Roche)].
Click chemistry. For global sulfenylation analyses, cell lysate (100 µg, 1 mg/ml)
was pre-incubated with NeutrAvidin agarose resin (50 µl, Pierce) to remove endoge-
nously biotinylated proteins. The pre-cleared lysate was incubated with azide biotin
(100 µM), CuSO4 (250 µM), BTTP (500 µM), and sodium L-ascorbate (2.5 mM)
for 1 h at rt with gentle rocking (final reaction volume, 100 µl). The reaction was
quenched with 1 mM EDTA, and the sample was subjected to methanol precipita-
tion. The resulting protein precipitate was then resolubilized in LDS sample buffer
(Invitrogen). For immunoprecipitated protein analyses, the resin was treated with 20
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µl click chemistry mix [azide biotin (100 µM), CuSO4 (250 µM), BTTP (500 µM),
and sodium L-ascorbate (2.5 mM) in PBS] for 1 h at rt with gentle rocking. The
reaction was quenched with 1 mM EDTA, and the samples were boiled with LDS
sample buffer. For in-gel fluorescence, TAMRA azide (100 µM) was used in place of
azide biotin.
Western blot. Protein samples were separated by SDS-PAGE using NuPAGE
Novex 4-12% Bis-Tris Midi gels (Invitrogen) and transferred to a polyvinylidene diflu-
oride (PVDF) membrane (BioRad). After transfer, the membrane was blocked with
3% BSA or 5% milk in TBST (ErbB2) for 1 h at rt. The membrane was washed with
TBST and immunoblotting was performed with the following primary and secondary
antibodies at the indicated dilutions in TBST, unless otherwise noted: phospho-
EGFR (pY1068, Abcam, 1:1000), EGFR (1005, Santa Cruz Biotechnology, 1:200),
ErbB2 (Neu C-18, Santa Cruz Biotechnology, 1:200), phospho-BTK (pY223, Ab-
cam, 1:1000), BTK (C-20, Santa Cruz Biotechnology, 1: 200), streptavidin-HRP (GE
Healthcare, 1:8000 - 1:80000), GAPDH (Santa Cruz Biotechnology, 1:200), goat anti-
rabbit IgG-HRP (Calbiochem, 1:30000 - 1:50000), and rabbit anti-mouse IgG-HRP
(Invitrogen, 1:30000 - 1:50000). PVDF membrane was developed with chemilumines-
cence (Pierce) and imaged by film. Data was quantified by densitometry with ImageJ
(Wayne Rasband, US National Institutes of Health, http://rsbweb.nih.gov/ij/).
In-gel fluorescence. Protein samples were separated by SDS-PAGE using Nu-
PAGE Novex 4-12% Bis-Tris Midi gels. The gel was destained 2X (40% methanol,
10% acetic acid, 50% H2O) and 1X with water for 10 min at rt to remove any back-
ground fluorescence from excess reagents. Afterwards, the gel was analyzed using a
Typhoon 9400 variable mode imager (Amersham Biosciences). The following wave-
lengths (excitation/emission) were used: 550/580 nm (TAMRA), and 280 or 450/610
nm (SYPRO ruby protein stain, Lonza).
Immunoprecipitation. EGFR was immunoprecipitated from 500 µg cell lysate
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(1 mg/ml) with goat anti-EGFR conjugated agarose (Santa Cruz Biotechnology) or
isotype control (normal goat IgG) overnight at 4 ◦C with gentle rocking. ErbB2
was immunoprecipitated from 500 µg cell lysate (1 mg/ml) with 1 µg of anti-ErbB2
antibody or isotype control for 2 h at 4 ◦C with gentle rocking. The immunocom-
plexes were isolated by incubating with Protein A/G Plus Agarose (20 µl, Santa Cruz
Biotechnology) overnight at 4 ◦C with rocking. BTK was immunoprecipitated from
750 µg cell lysate (1 mg/ml) with 2 µg of anti-BTK antibody or isotype control for
2 h at 4 ◦C with gentle rocking. The immunocomplexes were isolated by incubating
with Protein A/G Plus Agarose (20 µl, Santa Cruz Biotechnology) overnight at 4
◦C with rocking. The resin was collected by centrifugation at 100g for 2 min at rt,
and washed with cold RIPA buffer (1X) and cold PBS buffer (2X). The resin was
subjected to click chemistry as described earlier in Methods, and the bound proteins
were eluted by boiling with LDS sample buffer for 10 min, and resolved by SDS-PAGE
and analyzed by Western blot.
Immunoprecipitated EGFR kinase assays. To assess EGF and H2O2-induced
WT EGFR autophosphorylation activity, A431 cells were cultured until 80-85% con-
fluency, washed with PBS, and serum-starved for 2 h. After serum-deprivation, cells
were washed with cold PBS (2X) and lysed in RIPA B buffer as previously described.
EGFR was immunoprecipitated from 1000 µg (1 mg/ml) with goat anti-EGFR conju-
gated agarose (40 µl) for 30 min at 4 ◦C with gentle rocking. The resin was collected
by centrifugation at 100g for 2 min at rt, washed with cold RIPA B buffer (3X), and
resuspended in 40 mM HEPES, pH 7.4 (100 µl). EGFR kinase activity was assayed
with full-length native receptor immunoprecipitated from 30-50 µg lysate in 10 µl
reactions containing 20 mM HEPES pH 7.4, 6 mM MnCl2, 100 µM NaVO4 (New
England Biolabs), 1 µM ATP (Promega) and supplemented with EGF (3.3 ng/µl) or
H2O2 (0-100 µM). Control and EGF-treated reactions were initiated upon addition
of immunoprecipitated EGFR and incubated on ice for 5 min. For H2O2-treated re-
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actions, immunoprecipitated EGFR was pre-incubated with peroxide for 5 min on ice
prior to addition of ATP and an additional incubation on ice for 5 min. To assess the
reversibility of H2O2-induced EGFR kinase activation, immunoprecipitated EGFR
was pre-incubated +/- H2O2 as previously stated followed by addition of DTT (1
mM) simultaneous with ATP and EGF (as appropriate) for an additional 5 min on
ice. To verify that EGFR autophosphorylation was due to enhanced inherent kinase
activity, immunoprecipitated EGFR was pre-incubated with afatinib (0 or 1 µM) on
ice for 5 min prior to additional incubation with ATP and EGF for 5 min on ice. In
all cases, reactions were quenched upon addition of 5 µl LDS sample buffer and bound
proteins were eluted by boiling with LDS sample buffer for 10 min, and resolved by
SDS-PAGE and analyzed by Western blot.
To assess the role of Cys797 in H2O2-induced EGFR autophosphorylation activity,
HeLa cells were transfected with EGFR, C797S EGFR, C797A EGFR or empty vector
(mock) as previously described. After transfection (24 h), the cells were washed with
PBS and serum-starved for 4 h and lysates were generated as described above. WT
and C797 mutant EGFR kinase activity was assayed using identical conditions as
outlined above with the following modification. Immunoprecipitated WT and mutant
EGFR was pre-incubated with EGF (50 or 100 ng/µl) or H2O2 (0-10 µM) for 5 min
on ice. Kinase assays were initiated upon the addition of ATP (0.5 µM) and were
incubated for an additional 5 min on ice. Reactions were quenched and analyzed as
described above.
Sulfenic acid labeling of recombinant EGFR. WT EGFR was stored in 50
mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM DTT, and 20% glycerol. The protein
was reduced with 10 mM DTT for 30 min on ice. DTT was removed by passing
the protein through a NAP5 column (GE Healthcare) pre-equilibrated with 50 mM
HEPES pH 7.4, 100 mM NaCl. 10 µM protein was treated with H2O2 (5 eq.) for
5 min and labeled with dimedone (5 mM) for 1.5 h at rt with gentle rocking. For
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afatinib and PD168393, 10 µM protein was labeled with inhibitor (1 mM) for 1.5 h
at rt with gentle rocking. Following compound treatment, samples were boiled with
LDS sample buffer for 10 min, and resolved by SDS-PAGE.
In-gel pepsin digestion of recombinant EGFR. Labeled recombinant EGFR
was resolved by SDS-PAGE and stained with Coomassie. After destaining, the gel was
washed in H2O for 30 min. The bands of interest were excised, cut into small cubes,
and subjected to in-gel protein digestion. The gel pieces were washed with water
(2X), dehydrated with ACN (2X), and reduced with DTT (10 mM) in 25 mM Ambic
pH 7.8 for 30 min at 56 ◦C. Afterwards, DTT was removed and the gel pieces were
dehydrated with ACN (1X). The samples were then alkylated with 54 mM NEM in 25
mM Ambic pH 7.8 for 1 h at rt in darkness and agitation. NEM was removed and the
gel pieces were dehydrated with ACN (1X), rehydrated with 150 mM K2HPO4/150
mM KH2PO4 pH 2.5, and dehydrated with ACN (1X). The buffer/ACN solution
was removed, and the gel pieces were dried by vacuum centrifugation. Sequencing
grade pepsin (Princeton Separations) was resuspended in 75 mM K2HPO4/75 mM
KH2PO4 pH 2.5 at a concentration of 20 ng/µl. The pepsin (20 ng/µl) was added
to the dried gel pieces and incubated on ice for 1 h. Pepsin excess was removed
and 75 mM K2HPO4/75 mM KH2PO4 pH 2.5 was added until the gel pieces were
completely covered. The samples were incubated overnight at 37 ◦C. The following
day, the peptides were recovered by collecting the supernatant, desalted using a Zip-
Tip (Millipore), and concentrated by vacuum centrifugation. The resulting peptide
samples were resuspended in 0.1% formic acid and analyzed by LC-MS/MS.
LC-MS/MS Analysis. Peptides were analyzed on by liquid chromatography-
tandem MS (LC-MS/MS) using an EASY-nLC II system coupled to a linear ion trap
mass spectrometer (LTQ, Thermo Scientific). Peptides were concentrated and de-
salted on an RP pre-column (0.1 × 20 mm EASY column, Thermo Scientific) and
eluted onto an analytical RP column (0.075 × 100 mm EASY column, Thermo Scien-
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tific) at a flow rate of 400 nl/min using the following gradient: 5% to 15% B in 5 min,
15% to 55% B in 125 min, and 55% to 95% B in 5 min [solvent A: 0.1% formic acid
(v/v); solvent B: 0.1% formic acid (v/v), 80% CH3CN (v/v)]. For targeted exper-
iments, the LTQ was programmed in the ’selected MS/MS ion monitoring (SMIM)
mode (65). A survey scan (m/z 350-1600) was performed to check for the presence
of digested peptides, and for peptide separation along the gradient. This survey
scan was followed by a dependent MS/MS scan that fragments the most intense ions
to make a general identification of the peptides present. Subsequent MS/MS spec-
tra were programmed on +1 charged precursor ions of peptide MPFGCL modified by
dimedone (m/z 821.4), or +2 charged precursor ions of peptide MPFGCL modified by
afatinib (m/z 584.8) or PD168393 (m/z 526.2). Peptide identification was performed
using SEQUEST algorithm (BioWorks 3.2, Thermo Scientific) using the following
search parameters: enzyme specificity was pepsin with two missed cleavages permit-
ted, optional modifications (Met oxidation and Cys modification depending on the
reagent used), and mass tolerance of 2 and 1.2 amu for precursor and fragment ions,
respectively. MS/MS raw files were searched against the human Swiss-Prot database
containing porcine pepsin. SEQUEST results were analyzed using the probability
ratio method.
Intracellular ROS detection. Intracellular ROS was measured in a 96 well
plate format using the fluorescent probe DCF (the intracellular product of H2-DCF
diacetate that fluoresces in the presence of ROS, including H2O2). Ramos cells were
grown and stimulated with goat anti-human IgM as described in Methods. Following
stimulation, the cells were washed with PBS (3X) and seeded into 96-well plates at
1 × 105 cells/well in triplicate. The cells were incubated in the dark for 30 min at rt
with 2’,7’-dichlorodihydrofluorescein diacetate (H2DCF-DA; 10 µM, Sigma) in PBS.
H2-DCF-DA is a cell permeable indicator for ROS that is a non-fluorescent compound
that can enter cells, and trapped by intracellular esterase cleavage of the diacetate
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group. H2DCF is then converted into a fluorescent product upon interaction with in-
tracellular ROS. After incubation, the fluorescence intensity was measured at 488/525
nm (excitation/emission) using a SpectraMax M5 microplate reader (Molecular De-
vices).
4.7 Contributions
T.H.T. performed kinetic experiments. C.E.P. performed immunoprecipitated ki-
nase experiments. T.H.T. performed cell culture experiments. T.H.T. performed




























































































































Figure 4.S1: Sequence alignment of EGFR and nine additional kinases containing a
structurally homologous residue to EGFR Cys797. This group contains two ErbB2 family

































































































































































































Figure 4.S3: Identification of the MPFGC∗L peptide from EGFR labeled with RSH-
targeted inhibitors. (A) MS/MS spectrum of the precursor ion m/z 584.8 [M+2H]2+ correspond-
ing to afatinib labeled peptide (MPFGC*L) from recombinant WT EGFR. (B) MS/MS spectrum








































































Figure 4.S4: Cys797 mutants do not exhibit enhanced autophosphorylation levels in
response to EGF or H2O2 treatment. (A) Full length WT, C797S, and C797A EGFR was
immunoprecipitated from transiently transfected HeLa cells and assayed for tyrosine kinase activ-
ity with ATP and stimulated with EGF or H2O2 at the indicated concentrations. Western blot
shows phosphorylated (p) and total EGFR. (B) Densitometric quantification of A. EGF and H2O2
treatment increases autophosphorylation of WT EGFR, but not in C797 mutants. Data are rep-
resentative of three independent readings and represent the mean ± s.e.m. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 compared to untreated control.
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Figure 4.S5: MS/MS spectrum of the precursor ion m/z 821.4 [M+H]+ corresponding to dimedone










































































































































Figure 4.S6: Chronic H2O2 treatment reduces potency of PD168393 in common oncogenic
mutations. Lung cancer cell lines expressing common EGFR mutations, (A) NCI-H1975 (L858R,
T790M) and (C) HCC827 (∆ E746-A750), were incubated with glucose oxidase (2 u/ml) for 2 h
to induce chronic H2O2 conditions, treated with the indicated concentrations of PD168393 for 1 h,
and subsequently stimulated with EGF (100 ng/ml) for 5 min. Western blots show phosphorylated
(p) and total EGFR. The potency of PD168393 was reduced in the presence of chronic H2O2 in
both cases. (B, D) Densitometric quantification of A (NCI-H1975) and C (HCC827), respectively.
At higher inhibitor concentrations, phosphorylation levels (%) for chronic H2O2-treated samples are
higher when compared to their EGF-treated counterpart. Data are representative of two independent










































































































































Figure 4.S7: Chronic H2O2 treatment reduces potency of afatinib in common oncogenic
mutations. Lung cancer cell lines expressing common EGFR mutations, (A) NCI-H1975 (L858R,
T790M) and (C) HCC827 (∆ E746-A750), were incubated with glucose oxidase (2 u/ml) for 2 h to
induce chronic H2O2 conditions, treated with the indicated concentrations of afatinib for 1 h, and
subsequently stimulated with EGF (100 ng/ml) for 5 min. Western blots show phosphorylated (p)
and total EGFR. The potency of afatinib was reduced in the presence of chronic H2O2 in both cases.
(B, D) Densitometric quantification of A (NCI-H1975) and C (HCC827), respectively. At higher
inhibitor concentrations, phosphorylation levels (%) for chronic H2O2-treated samples are higher
when compared to their EGF-treated counterpart.
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Figure 4.S8: H2O2 treatment mimics IgM-induced activation of BTK. (A) Dose and (B)
time-dependent effect of IgM on BTK activation in Ramos cells. Cells were stimulated with IgM at
the indicated concentrations (A) or times (B). (C) Dose and (D) time-dependent effect of H2O2 on
BTK activation in Ramos cells. Cells were stimulated with H2O2 at the indicated concentrations
(C) or times (D). Western blot shows phosphorylated (p) and total BTK.
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Figure 4.S9: IgM-mediated ROS production and protein sulfenylation. (A) Dose and (C)
time-dependence of ROS production as indicated by DCF fluorescence in Ramos cells. Cells were
stimulated with IgM at the indicated concentrations (A) or times (C). (B) Dose and (D) time-
dependence of global protein sulfenylation in Ramos cells. Cells were stimulated with IgM at the
indicated concentrations (B) or times (D), and sulfenic acids were detected through western blot
with Strep-HRP. GAPDH was used as a loading control.
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CHAPTER V
Development and Characterization of Nucleophilic
RSOH-Targeted Inhibitors Towards EGFR Cys797
5.1 Abstract
Epidermal growth factor receptor (EGFR) plays a significant role in physiologic
signaling, and deregulation of its activity can lead to development of cancers. EGFR
has recently been identified as a direct target of signal-derived H2O2 through cysteine
oxidation. This modification occurs at EGFR Cys797, which is also targeted by irre-
versible inhibitors via an electrophilic acrylamide moiety. Oxidation of EGFR Cys797
can alter the potency of current EGFR inhibitors that cannot recognize the kinase in
its oxidized form. Therefore, we propose an alternate method whereby nucleophilic
warheads capable of recognizing sulfenic acid are employed to target oxidized EGFR.
Herein, we report the development of a panel of first-generation RSOH-targeted in-
hibitors and evaluate compound selectivity towards EGFR Cys797 in response to
concomitant kinase oxidation. Collectively, we demonstrate our compounds are ca-
pable of inducing potent inhibition towards EGFR under oxidizing conditions and
have broad implications for the continued development of irreversible inhibitors that
target H2O2-sensitive cysteines in therapeutically important proteins.
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5.2 Introduction
Epidermal growth factor receptor (EGFR) exemplifies the family of receptor ty-
rosine kinases (RTKs), which have been demonstrated to play pivotal roles in cellular
physiology and pathology (1). Upon ligand-dependent activation and concomitant
tyrosine phosphorylation, stimulation of RTKs such as EGFR results in localized
generation of hydrogen peroxide (H2O2) by NADPH-dependent oxidases (Nox) (2–4).
Although chronic exposure of H2O2 can result in cellular damage, tightly controlled
levels of H2O2 can act as secondary messengers to regulate signal transduction net-
works. H2O2 modulates biological processes largely through modification of specific
cysteine residues in redox-sensitive protein targets. The direct product of the reaction
between H2O2 and a protein thiolate (RS-) is sulfenic acid (RSOH), also known as
sulfenylation. This is modification is reversible, and serves as a central mechanism to
detect changes in redox homeostasis (5, 6). In a recent study, we utilized chemical
probes selective for sulfenic acid (DYn-2) to demonstrate epidermal growth factor
(EGF)-mediated signaling induces global and dynamic changes in protein sulfenyla-
tion (7). A central finding of this study provides evidence that EGFR is a directly
modified by signal-derived H2O2 and becomes sulfenylated at its active site cysteine
(Cys797). This modification enhances its intrinsic tyrosine kinase activity, and subse-
quent work has demonstrated mutation of this residue abrogates kinase activation and
sulfenylation, further highlighting the importance of Cys797 with respect to EGFR
function (Chapter 4).
Deregulation of physiologic kinase signaling due to mutations and other genetic
alterations is a hallmark of many pathologic conditions and can result in aberrant
kinase activity and malignant transformation (8, 9). EGFR is mutated or amplified
in a number of human carcinomas (i.e. breast and lung), which has motivated the
development of reversible ATP-competitive kinase inhibitors (10). These inhibitors,
including the 4-anilinoquinazolines gefitinib (11) and erlotinib (12), achieve target
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selectivity by recognizing unique features of the kinase ATP-binding pocket and have
proven successful in clinical trials. In particular, somatic mutations in the EGFR
kinase domain have been identified as a cause of non-small cell lung cancer (NSCLC)
(13, 14). The two most frequent mutations are the exon 19 point mutation (L858R)
and exon 19 deletion (∆746-750) (15, 16). L858 is the single most common mutation
(approximately 40%), and lies within the kinase activation loop. This point mutation
is 50-fold more active than wild-type EGFR and results in constitutive activation of
the kinase through destabilizing its auto-inhibitory conformation, which is normally
maintained in the absence of ligand stimulation (17, 18). Interestingly, these muta-
tions exhibit decreased affinity for ATP and confer increased sensitivity to gefitinib
and erlotinib through tighter binding compared to wild-type EGFR (19–22).
Unfortunately, lung cancer patients expressing these oncogenic mutations (L858R
and ∆746-750) eventually relapse after 12-18 months of treatment (23). Drug re-
sistance to ATP-competitive reversible inhibitors is due to a second site mutation
(T790M) of the gatekeeper residue. This residue is located at the entrance to the hy-
drophobic pocket in the back of the ATP binding pocket, making it an important de-
terminant of inhibitor specificity. T790M was originally believed to induce resistance
to gefitinib and erlotinib as a result of steric hindrance by the bulky methionine group
(24). However, this view conflicted with observations that reported T790M mutants
remained sensitive to structurally similar irreversible 4-anilinoquinazoline inhibitors
such as EKB-569 (25). A later study provided evidence that the T790M mutation
confers drug resistance by restoring ATP affinity to the same level as observed for
wild-type EGFR, therefore increasing the concentration of ATP-competitive reversible
inhibitor required to maintain efficacy (26). For this reason, covalent irreversible in-
hibitors remain effective and can be utilized to overcome clinical resistance of the
L858R/T790M mutation (27, 28).
The development of covalent irreversible inhibitors against EGFR represents an at-
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tractive area of research and has garnered great interest over the years (29–31). There
has been much controversy regarding covalent inhibitors since these compounds can
form reactive drug metabolites that can induce direct tissue damage or elicit immune
responses through haptenization of proteins (32). When used in conjunction, covalent
inhibitors provide an alternate approach to overcome the potency, selectivity, and effi-
cacy challenges faced by ATP-competitive reversible inhibitors (33). Development of
covalent EGFR inhibitors have been guided by structure-based design and primarily
target the nucleophilic thiol group of a cysteine (Cys797) located in the ATP-binding
site (34). These compounds utilize the 4-anilinoquinazoline scaffold and contain an
electrophilic acrylamide moiety installed at the 6-position that reacts with the EGFR
Cys797 thiolate through Michael addition to achieve irreversible binding. PD168393
was one of the first reported covalent inhibitors utilizing this approach, and is re-
garded as the prototype 4-anilinioquinazoline-based inhibitor (35). This compound
proved to be an effective inhibitor, but exhibited poor bioavailability due to low sol-
ubility under physiologic conditions and did not make it to clinical trials. Further
development of this scaffold (i.e. fine-tuned electrophilic warhead and orientation, in-
creased bioavailability) resulted in a number of new compounds that have advanced
to and shown promise in clinical trials: EKB-569 (pelitinib), HKI-272 (neratinib),
and BIBW 2992 (Tovok) (20, 27, 36). In addition, pre-treatment of cells with these
covalent inhibitors prevents formation of sulfenyl EGFR Cys797 and highlights the




































































Figure 5.1: Development of targeted covalent inhibitors for sulfenyl EGFR. (A) H2O2 levels
in normal cells are maintained through pro- and anti-oxidants to promote cellular proliferation and
survival. Chronically elevated levels of H2O2 are often associated with cancers and can ultimately
lead to cell death. (B) Oxidation of H2O2-sensitive cysteine residues form transiently in specific
proteins during H2O2-mediated signal transduction in normal cells, but form constitutively in dis-
eases (i.e. cancer) with high levels of oxidative stress. (C) Targeted approach to develop covalent
inhibitors for sulfenyl EGFR. Current irreversible EGFR inhibitors utilize an acrylamide moiety that
undergoes Michael addition with Cys797 in its thiol form, but these compounds do not react with
the sulfenic acid form. Oxidation of Cys797 can affect the potency of these inhibitors, particularly
under conditions of high oxidative stress often correlated with disease states. In an alternate ap-
proach, replacement of the acrylamide group with a nucleophilic warhead (i.e. 1,3-cyclohexanedione)
enables the sulfenyl form of the kinase to be targeted.
H2O2 levels in normal cells are maintained through pro- and anti-oxidants to pro-
mote cellular proliferation and survival (Figure 5.1A). On the contrary, chronically
elevated levels of H2O2 can ultimately lead to cell death and are prevalent in aging and
disease states (37, 38). Oxidation of H2O2-sensitive cysteine residues form transiently
in specific proteins during H2O2-mediated signaling under physiologic conditions, but
can undergo malignant transformation in disease states (i.e. cancer) associated with
high levels of oxidative stress (Figure 5.1B). In particular, overexpression of EGFR
and HER2 (member of EGFR subfamily) has been correlated to elevated H2O2 levels
and global protein sulfenylation in breast cancer cell lines (39). Coupled to the dis-
covery that EGFR Cys797 undergoes sulfenic acid modification, these findings raise
several fundamental questions with respect to cysteine oxidation and thiol-targeted
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irreversible inhibitors. The acrylamide moiety of covalent EGFR inhibitors under-
goes Michael addition with EGFR Cys797 in its reduced thiol form (Figure 5.1C),
but would not recognize this residue in its oxidized sulfenic acid form. Consequently,
chronically high levels of H2O2 affiliated with cancers can lead to aberrant levels of
oxidized EGFR Cys797 and alter the potency of these irreversible inhibitors. Alter-
nate mechanisms to target sulfenylated EGFR must be developed to overcome the
potential shortcomings of thiol-targeted irreversible inhibitors introduced upon kinase
oxidation and may afford further means of achieving selectivity.
Fortunately, sulfenic acid modification represents a new opportunity in covalent
inhibitor design whereby nucleophilic warheads (i.e. dimedone-based derivatives) can
be utilized to target the electrophilic sulfur in sulfenylated proteins. In this ap-
proach, the propensity for H2O2-sensitive cysteines in kinases and other therapeuti-
cally relevant proteins (i.e. phosphatases) to undergo sulfenylation can be exploited
for the development of inhibitors that target this unique chemical moiety (40). To
develop covalent inhibitors towards sulfenyl EGFR, we took a targeted approach
wherein we replaced the electrophilic acrylamide group on a common EGFR scaffold
(4-anilinoquinazoline) with a nucleophilic warhead (i.e. 1,3-cyclohexanedione) that
specifically reacts with sulfenic acids (Figure 5.1C). In particular, we chose PD168393
(Figure 5.2A) as the parent compound for the first generation of nucleophilic RSOH-
targeted EGFR inhibitors. Although other covalent EGFR inhibitors such as afatinib
or pelitinib have been identified that display more desirable clinical properties, we
elected to use PD168393 as a starting point due to synthetic simplicity purposes. We
rationalized that if our nucleophilic concept worked with the PD168393 scaffold, it
would warrant the development of future generations of RSOH-targeted EGFR in-
hibitors and justify the increase in synthetic complexity. Additionally, the PD168393
core is simpler and smaller than other EGFR inhibitor scaffolds and can potentially
mitigate issues with nucleophilic warhead orientation relative to Cys797 in the EGFR
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ATP-binding pocket.
We selected a panel of nucleophilic warheads (Figure 5.2B, 1a-5a) to derivatize
the 4-anilinoquinazoline core structure. Compound 1a is functionalized with the
prototypical sulfenic acid warhead 1,3-cyclohexanedione (dimedone-derivative) (Fig-
ure 5.2B, 1a), which has been shown extensively to specifically react with sulfenyl
groups in vitro and in situ (7, 41, 42). In addition, four other nucleophilic warheads
(Figure 5.2B, 2a-5a) were chosen based on their increased reactivity towards sulfenic
acid in comparison to dimedone (V. Gupta and K. Carroll, unpublished results).
Blunted control compounds (Figure 5.2B, 1b-5b) were also synthesized to compare
inherent differences in the binding affinities of compounds 1a-5a relative to PD168393,












































RSOH Compounds Blunted Controls
Core Structure
Figure 5.2: Structures of RSOH-targeted EGFR compounds and blunted controls. (A)
Structure of parent compound PD168393. (B) Structures of RSOH-targeted compounds (1a-5a)
and blunted controls (1b-5b). The 4-anilinoquinazoline core structure is shown at the top.
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With these tools in hand, we sought to determine if our nucleophilic RSOH-
targeted inhibitors were capable of effectively targeting the sulfenyl form of EGFR.
We compared the potency of RSH- and RSOH-targeted compounds under oxidiz-
ing conditions (acute and chronic H2O2) to determine if our compounds covalently
modified EGFR through redox-based inhibition. Next, we evaluated the effect of re-
ducing conditions (i.e. glutathione and antioxidants) on inhibitor potency. Washout
experiments were performed to determine whether these compounds inhibited EGFR
through reversible or irreversible mechanisms. Additionally, we screened the com-
pounds in lung cancer cell lines harboring common EGFR mutations (L858R/T790M
and ∆746-750) to evaluate their behavior in comparison to wild-type EGFR. Reac-
tivity towards HER2 was also evaluated in breast cancer cells. Finally, the most
promising inhibitors were tested in A431 xenograft nude mice models to explore their
anti-tumor properties in vivo. We observed that increased H2O2 levels in addition
to concomitant EGFR Cys797 oxidation enhance the extent of RSOH-targeted inhi-
bition in situ and in vivo. Notably, these studies demonstrate proof of principle of
our nucleophilic approach and form the basis for the development of new therapeutic
strategies to target H2O2-modulated pathways in disease states.
5.3 Results
Acute and chronic H2O2 affects potency of RSH- and RSOH-targeted
EGFR inhibitors
To investigate the potency of our nucleophilic inhibitors in situ, we used the human
epidermoid carcinoma A431 cell line, which naturally expresses high concentrations
of EGFR (43). We explored the dose-dependent effect of acute H2O2 treatment in
A431 cells to identify cellular conditions that would maximize the sulfenyl form of
EGFR for covalent modification by our nucleophilic inhibitors, while simultaneously
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decreasing the thiol form available for modification by RSH-targeted inhibitors (Sup-
plementary Figure 5.S1A-E). All compounds induced a dose-dependence decrease in
EGFR phosphorylation when treated with acute H2O2. IC50 values were calculated
for each compound from dose-response curves and, on average, determined to be 200
µM with respect to H2O2 (Supplementary Table 5.S1). For subsequent experiments,
cells were treated with 200 µM H2O2 to induce acute oxidizing conditions. As a tech-
nical issue, we point out that treating cells in culture with H2O2 or other biological
oxidants to increase the fraction of sulfenyl EGFR and augment the irreversible po-
tency of our nucleophilic inhibitors also activates EGFR kinase and inhibits tyrosine
protein phosphatases (PTPs). Therefore, we included an EGF-stimulation step as a
control to reflect the net increase mediated by EGF and H2O2 in EGFR autophos-
phorylation assays.
With these considerations in mind, we examined the potency of our nucleophilic
inhibitors under the acute H2O2 conditions previously identified. Cells were treated
with nucleophilic inhibitors (1a-5a) in a dose-dependent manner, and the extent of
inhibition was determined by EGFR autophosphorylation (Figure 5.3A, Supplemen-
tary Figure 5.S2 A-D). In all cases, the potency of RSOH-targeted inhibitors (1a-5a)
was increased under acute H2O2 and is reflected in their calculated IC50 values com-
pared to the respective EGF-stimulation control (Table 5.1). In particular, the IC50
value for compound 1a exhibited a 2-fold decrease in response to acute oxidation
(Figure 5.3D). To further demonstrate the importance of these results, we subjected
cells to chronic H2O2 conditions using glucose oxidase (GO). GO is an oxidoreductase
that catalyzes the oxidation of glucose to generate H2O2 (44). Using this enzyme,
we were able to mimic chronic H2O2 levels typically associated with disease states
through steady production of H2O2 over a prolonged period of treatment. Similar
to acute H2O2, chronic conditions induced by GO greatly increased the potency of
compound 1a (Figure 5.3B) and decreased the IC50 value by 20-fold (Figure 5.3D).
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Collectively, these results underscore the significant impact that these nucleophilic
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Figure 5.3: Acute and chronic H2O2 treatment increases potency of RSOH-targeted
compound 1a. Western blots show phosphorylated (p) and total EGFR. (A) Acute H2O2 treatment
increases potency of 1a. A431 cells were stimulated with H2O2 (200 µM) for 5 min to induce sulfenic
acid formation, treated with the indicated concentrations of 1a for 1 h, and subsequently stimulated
with EGF (100 ng/ml) for 5 min. (B) Chronic H2O2 treatment increases potency of 1a. A431 cells
were incubated glucose oxidase (2 u/ml) for 3 h to induce chronic H2O2 conditions, treated with the
indicated concentrations of 1a for 1 h, and subsequently stimulated with EGF (100 ng/ml) for 5 min.
(C) Blunted control 1b yields negligible change in potency. (D) Comparison of percent inhibition
of EGFR autophosphorylation from A (acute H2O2) and B (chronic H2O2). IC50 values exhibit a
2-fold change under acute H2O2, and 20-fold change under chronic H2O2. (E) Percent inhibition of


















































































































































































































































































































































































































To confirm that the potency of RSOH-targeted inhibitors (1a-5a) was correlated
to irreversible redox-modulated inhibition and not due to compound affinity to the
kinase ATP-binding pocket, we explored the potency of blunted controls 1b-5b un-
der the same acute H2O2 conditions. Although, compound 1b induced inhibition of
EGFR phosphorylation (Figure 5.3C), it yielded negligible change in potency (Fig-
ure 5.3C, E) when compared to its EGF-stimulated control. Other blunted controls
showed similar results (Supplementary Figure 5.S2E-H), and the calculated IC50 val-
ues did not exhibit significant fold changes as some of their nucleophilic RSOH coun-
terparts (Table 5.1). Some blunted controls (2b, 4b) were found to be slightly more
potent, but this may be due to differences in binding affinity in the ATP-binding
site. These results indicated that our compounds inhibit EGFR reversibly due to its
4-anilinoquinazoline core, and irreversibly when the compound is functionalized with
a nucleophilic warhead.
We also explored the effect of acute and chronic H2O2 treatment on potency of our
parent compound PD168393. Under acute H2O2, PD168393 inhibited EGFR phos-
phorylation to a similar extent in the EGF-stimulated control and oxidizing conditions
(Figure 5.4A, B). EGFR phosphorylation levels were increased under chronic H2O2
conditions, demonstrating that the potency of PD168393 was reduced at higher con-
centrations of inhibitor (Figure 5.4C, D). These data show that oxidizing conditions
(acute and chronic H2O2) affect the potency of RSH- and RSOH-targeted EGFR in-
hibitors, setting the stage for the development of nucleophilic compounds that target








































































































































Figure 5.4: Chronic H2O2 treatment reduces potency of RSH-targeted irreversible EGFR
inhibitors. A431 cells were incubated with (A) H2O2 (200 µM) for 5 min to induce acute conditions
or (C) glucose oxidase (2 u/ml) for 3 h to induce chronic H2O2 conditions, treated with the indicated
concentrations of PD168393 for 1 h, and subsequently stimulated with EGF (100 ng/ml) for 5 min.
Western blots show phosphorylated (p) and total EGFR. The potency of PD168393 was reduced
only in the presence of chronic H2O2, and not acute conditions. (B, D) Densitometric quantification
of A (acute H2O2) and C (chronic H2O2), respectively. At higher inhibitor concentrations, phospho-
rylation levels (%) of chronic H2O2-treated samples are higher when compared to their EGF-treated
counterpart. Data are representative of two independent readings and represent the mean ± s.e.m.
Reductive stress conditions affect potency of RSOH-targeted EGFR in-
hibitors
To further examine the mechanism by which our nucleophilic inhibitors induced
inhibition of EGFR, we subjected A431 cells to reductive stress conditions to deter-
mine the effect of biologically relevant thiols and anti-oxidants. Glutathione (GSH),
a tri-peptide containing thiol, is present at millimolar concentrations in the cell and a
component of the glutaredoxin/glutathione (Grx/GSH) and glutathione/glutathione
reductase (GSH/GSR) buffering systems which function to regulate and maintain in-
tracellular H2O2 levels. In cells treated with reduced GSH, compound 2a exhibited
decreased inhibition of EGFR phosphorylation (Figure 5.5C). When compared to the
potency observed in cells treated with acute H2O2 (Figure 5.5A), the IC50 value for
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compound 2a increased 3.5-fold (Figure 5.5D). In addition, the effect of N-acetyl-L-
cysteine (NAC), a widely used anti-oxidant, was also explored. Similar to reduced
GSH, NAC reduced the potency of compound 2a (Figure 5.5B) and resulted in a
12-fold increase in its IC50 value compared to acute H2O2 conditions (Figure 5.5D).
Therefore, reductive stress conditions reverse the potency of our nucleophilic RSOH
inhibitors by reducing the amount of sulfenyl EGFR available for covalent modifica-
tion.
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Figure 5.5: Reductive stress conditions decrease potency of RSOH-targeted EGFR com-
pounds. Western blots show phosphorylated (p) and total EGFR. (A) Acute H2O2 treatment
increases potency of 2a. A431 cells were stimulated with H2O2 (200 µM) for 5 min to induce
sulfenic acid formation, treated with the indicated concentrations of 2a for 1 h, and subsequently
stimulated with EGF (100 ng/ml) for 5 min. (B) N-acetyl cysteine (NAC) decreases potency of
2a. A431 cells were incubated with NAC (20 mM) for 1 h to induce reductive stress. (C) Reduced
glutathione (GSH) decreases potency of 2a. A431 cells were incubated with GSH (10 mM) for 1
h to induce reductive stress. (D) Comparison of percent inhibition of EGFR autophosphorylation
from A (acute H2O2), B (NAC), and C (GSH). IC50 values exhibit 3.5-fold increase under GSH, and
12-fold increase under NAC.
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Abundant protein thiols can interfere with potency of RSH- and RSOH-
targeted EGFR inhibitors
In order to evaluate the effectiveness of our compounds as a potential therapeu-
tic, it is important to consider potential interference from abundant protein thiols.
Human serum albumin (HSA) is the most abundant protein found in human plasma
and contains a redox-sensitive cysteine residue (Cys34) (45). This cysteine is prone
to oxidative modification because extracellular fluids contain very small amounts of
antioxidant defense enzymes. Although our nucleophilic compounds are expected to
target the EGFR kinase domain, non-specific inhibition of other proteins containing
H2O2 cysteines can potentially occur. To test this, we incubated A431 cells with
compound 1a in the presence of HSA (3% w/v). The potency of 1a is completely
reversed as indicated by the significant increase in EGFR autophosphorylation com-
pared to its EGF-stimulated control (Supplementary Figure 5.S3A, D). A similar
effect is observed with blunted control 1b (Supplementary Figure 5.S3B), demon-
strating that HSA interferes with the binding ability of our compounds to the ATP-
binding pocket. Most importantly, HSA reverses the potency of the parent compound
PD168393 (Supplementary Figure 5.S3C) and significantly increases its calculated
IC50 value (Supplementary Figure 5.S3E). The effect of HSA on inhibitor potency
is much more drastic for PD168393 than that observed for 2a with respect to fold
change under non-oxidizing conditions. Therefore, we would expect a similar effect
under oxidizing conditions with HSA with our compounds. Based on these results,
it appears that abundant proteins containing H2O2-sensitive residues (i.e. HSA) can
interfere with the effectiveness of both RSH- and RSOH-targeted EGFR inhibitors.
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Nucleophilic RSOH-targeted compounds demonstrate irreversible EGFR
adduct formation
The results from Figure 5.3 indicated that our compounds inhibit EGFR reversibly
due to its 4-anilinoquinazoline core (Figure 5.3C, E), and to some extent, irreversibly
under oxidizing conditions (acute and H2O2) when the compound contains a nu-
cleophilic warhead (Figure 5.3A, B, D). In order to determine the extent to which
irreversible inhibition occurs, we performed a washout experiment with compounds
2a and 3a. A431 cells were pre-incubate with fixed concentrations of inhibitor and
stimulated with H2O2 in a dose-dependent manner to induce sulfenic acid formation.
Following treatment, cells were subjected to a washout period and subsequently an-
alyzed for EGFR phosphorylation. Washout experiments revealed a dose-dependent
decrease in EGFR autophosphorylation with respect to increasing H2O2 concentra-
tion (Figure 5.6A, B). Although our compounds did not exhibit complete irreversible
inhibition after washout, these results indicate that covalent adduct formation does
occur with the kinase and confirm our findings from Figure 5.3. In addition, we also
explored the anti-proliferative activity of our nucleophilic RSOH-targeted inhibitors
(1a-5a) and their respective blunted controls (1b-5b) on A431 cells by standard MTT
assay. With the exception of 3a, our nucleophilic compounds exhibited a higher anti-
proliferative effect in A431 cells when compared to their blunted control counterpart
(Table 5.2). The IC50 value of 3a was comparable to its control 3b; however, this
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Figure 5.6: Washout effect of RSOH-targeted compounds. A431 cells were incubated with
(A) 2a or (B) 3a for 1 h, treated with H2O2 at the indicated concentrations for 1 h, and stimulated
with EGF (100 ng/ml) for 5 min proceeding a 2 h washout step. Western blots show phosphorylated
(p) and total EGFR. Dose-dependent H2O2 treatment reveals a correlation to increased inhibition of
EGFR autophosphorylation. The compounds tested do not exhibit complete irreversible inhibition
after washout, but do demonstrate some irreversible adduct formation with the kinase.
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Table 5.2: Anti-Proliferative Effects of RSOH-Targeted Compounds and Controls in A431 Cellsa

























0.96 ± 0.11 4b
O




0.91 ± 0.21 5b
O
3.22 ± 0.46
a Cellular proliferation was determined by standard MTT assay conditions.
b Cells were treated with compounds for 72 h prior to assay (0-1000 µM) and replenished every 24
h.
c IC50 values are representative of three independent trials and represent the mean ± s.e.m.
RSOH-targeted EGFR inhibitors are effective against common oncogenic
EGFR mutations
As discussed earlier in the introduction, somatic mutations in the EGFR kinase
domain have been identified as a cause of NSCLC. Interestingly, the two most fre-
quently occurring mutations (L858R and ∆746-750) have been shown to confer in-
creased sensitivity to ATP-competitive kinase inhibitors such as gefitinib and erlotinib
by decreasing the affinity for ATP (19–21). A second site mutation (T790M) accounts
for half of the cases wherein lung cancer patients undergoing treatment eventually re-
lapse (23, 24). Given the proximity of EGFR Cys797 to the inhibitor binding pocket,
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we speculate oxidation of Cys797 may be affected to some extent in these onco-
genic mutants. To investigate this, we used lung cancer cell lines harboring these
somatic mutations: NCI-H1975 (L858R, T790M) and HCC827 (∆746-750) (46). In-
cubation of NCI-H1975 (Figure 5.7A) and HCC827 (Figure 5.7B) with compound 1a
induced increased inhibition of EGFR phosphorylation under acute H2O2 treatment.
Interestingly, compound 1a had nearly no effect on EGFR autophosphorylation in
NCI-H1975 cells as shown by the EGF-stimulated control and an IC50 value could
not be calculated due to negligible change in phosphorylation levels as the concentra-
tion of inhibitor was increased (Figure 5.7C). IC50 dose-response curves for HCC827
demonstrated increased potency of compound 1a (Figure 5.7D). The effect of our
other nucleophilic inhibitors was also tested in both cell lines. IC50 values were eas-
ily calculated for 1a-5a in NCI-H1975 cells with respect to acute H2O2 conditions,
but could not be determined for the EGF-stimulated control due to insufficient data
sets for the dose-response curves (Supplementary Table 5.S2). For HCC827, IC50
dose-response curves demonstrated increased potency of compound 1a (Figure 5.7D).
In addition, compounds 2a-5a were also tested in HCC827 cells to evaluate potency
(Supplementary Table 5.S3). Trends in inhibitor potency were not as clear-cut in
these oncogenic mutants as they were with wild-type EGFR in A431 cells, and may
reflect differences in binding affinity of these compounds. Collectively, these results
indicate that our nucleophilic compounds are capable of inhibiting EGFR phosphory-














: - - --- -- + +++ ++
1a (µM): - 0 1010.1 1000.01 0 1010.1 1000.01

















: - - --- -- + +++ ++
1a (µM): - 0 1010.1 1000.01 0 1010.1 1000.01

















































































Figure 5.7: Acute H2O2 treatment increases potency of RSOH-targeted EGFR com-
pounds in lung cancer cells. (A, B) Western blots show phosphorylated (p) and total EGFR.
Lung cancer cell lines expressing common EGFR mutations, (A) NCI-H1975 (L858R, T790M) and
(B) HCC827 (∆ E746-A750), were stimulated with H2O2 (200 µM) for 5 min to induce sulfenic acid
formation, treated with the indicated concentrations of 1a for 1 h, and subsequently stimulated with
EGF (100 ng/ml) for 5 min. (C, D) IC50 values in NCI-H1975 and HCC827 cells were determined
by Western blot analysis of EGFR autophosphorylation from A and B, respectively.
ErbB2 (HER2) phosphorylation is affected by RSOH-targeted EGFR in-
hibitors
EGFR is grouped into a subfamily that consists of three additional closely re-
lated receptors: HER2 (erbB2), HER3 (erbB3), and HER4 (erbB4). In particular,
HER2 overexpression has been shown to play an important role in development and
progression in breast cancer. Many reversible and irreversible EGFR inhibitors also
target HER2. Therefore, we sought to determine the effect of our RSOH-targeted
EGFR inhibitors against HER2. We used the metastatic breast carcinoma MDA-
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MB-453, which expresses high levels of HER2, and induced acute H2O2 conditions
prior to treatment with our nucleophilic inhibitors. Inhibition of EGFR autophos-
phorylation levels was observed in cells treated with compound 3a (Figure 5.8A) and
IC50 dose-response curves reflected a significant increase under acute H2O2 treatment
(Figure 5.8). Other nucleophilic inhibitors were also screened against HER2 (Supple-
mentary Table 5.S4), but do not give clear trends with respect to inhibitor potency
as seen with EGFR in A431 cells. Although it appears that some of our compounds
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Figure 5.8: Acute H2O2 treatment slightly increases potency of RSOH-targeted EGFR
compounds towards ErbB2. (A) Western blots show phosphorylated (p) and total EGFR. Breast
cancer cells (MDA-MB-453) overexpressing ErbB2 were stimulated with H2O2 (200 µM) for 5 min
to induce sulfenic acid formation, treated with the indicated concentrations of 1a for 1 h, and
subsequently stimulated with EGF (100 ng/ml) for 5 min. (B) IC50 values in MDA-MB-453 cells
were determined by Western blot analysis of ErbB2 autophosphorylation from A.
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RSOH-targeted EGFR compounds decrease EGFR autophosphorylation
and sulfenylation in vivo
Collectively, our experimental efforts demonstrated that nucleophilic RSOH-targeted
EGFR inhibitors exhibit redox-modulated inhibition that is irreversible to an extent
in cell-based assays with wild-type and mutant EGFR. We wanted to explore the anti-
tumor properties of our compounds in vivo. For this, compounds were selected based
on their performance in DMPK studies (Scripps Florida) and subsequently tested in
an A431 xenograft nude mouse model (compounds 1a, 3a, 5a). Additionally, 5b and
PD168393 were included as controls in these studies. Mice were dosed with 20 or 50
mg/kg of the appropriate compound and the tumors were harvested and analyzed
for changes in EGFR phosphorylation and sulfenylation levels. Analysis of EGFR
phosphorylation levels revealed that higher dosage of compounds decreased kinase
autophosphorylation levels (Figure 5.9A). In particular, 3a seemed to exhibit the
most significant effect on inhibiting kinase activation regardless of compound dosage.
Blunted control 5b had comparable levels to its nucleophilic counterpart, which may
be due to binding affinity of these compounds to the ATP-binding pocket. PD168393
demonstrated nearly complete inhibition of EGFR phosphorylation levels compared
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Figure 5.9: RSOH-targeted EGFR compounds decrease EGFR autophosphorylation and
sulfenylation levels in xenograft mice models. Mice were dosed with 20 mg/kg (+) or 50 mg/kg
(++) of the indicated compound. (A) Increased compound dosage decreases EGFR phosphorylation
levels. Western blot shows phosphorylated (p) and total EGFR. (B, C) Increased compound dosage
decreases EGFR sulfenylation levels. Tissue samples were lysed in the presence of DYn-2 (10 mM)
and sulfenic acids were detected by Strep-HRP western blot. (D) PD168393 completely blocks
sulfenyl EGFR signal.
Sulfenylation levels of EGFR were also and demonstrated that higher dosage of
compounds decreased sulfenyl EGFR with respect to compounds 3a and 5a (Fig-
ure 5.9B, C). The result is more pronounced with 3a, and agrees with the observa-
tions from Figure 5.9A. Treatment with PD168393 blocked EGFR sulfenylation (Fig-
ure 5.9D), demonstrating that RSH-targeted inhibitors are successful with regards to
covalent inhibition before the sulfenyl form of EGFR could be generated. Collectively,
these data demonstrate that our nucleophilic RSOH-targeted compounds decrease
EGFR phosphorylation and sulfenylation levels in xenograft nude mice models and
show promise in vivo.
190
5.4 Discussion
Sulfenyl modification of EGFR at Cys797 has proven to have a significant impact
on kinase activation during EGF-mediated signaling (Chapter 3, 4). This modifica-
tion enhances its intrinsic tyrosine kinase activity, and mutation of this residue ab-
rogates EGFR autophosphorylation, sulfenylation, and decreases its affinity for ATP
(Chapter 4). Deregulation of EGFR signaling leads to the progression of a number of
human carcinomas (i.e. breast and lung cancers) and has motivated the development
of reversible and irreversible inhibitors to specifically target the kinase. Coinciden-
tally, EGFR Cys797 serves as a therapeutic target for covalent inhibitors which react
with the Cys797 thiolate through electrophilic Michael addition to achieve irreversible
adduct formation. These inhibitors recognize EGFR Cys797 in its reduced thiol form,
but are not able to recognize the residue upon oxidation.
The propensity for EGFR Cys797 to undergo sulfenylation highlights the impor-
tance of developing alternate redox-based therapeutic approaches to target this unique
modification. Therefore, we proposed a nucleophilic approach whereby sulfenic acid-
specific warheads replaced the electrophilic acrylamide group on a common EGFR
scaffold (4-anilinoquinazoline) (Figure 5.1C). We first explored the potency of these
compounds (Figure 5.2B) with respect to wild-type EGFR in A431 cells. Overall,
we observed that oxidizing conditions (acute and chronic H2O2) increase the potency
of our compounds with respect to their EGF-stimulated controls (Figure 5.3A, B).
Moreover, chronic H2O2 induced a more significant impact on nucleophilic inhibitor
potency because these conditions increased the sulfenyl form of EGFR for covalent
redox-based modification in a steady manner (Figure 5.3D). Although the thiolate
form of EGFR will always be targeted more effectively with electrophilic irreversible
inhibitors, we demonstrated chronic H2O2 affects the potency of this class of inhibitors
by reducing the amount of EGFR in the thiolate form. This is relevant because disease
states such as cancer are often associated with high levels of H2O2.
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Evaluation of blunted control compounds (Figure 5.3C, E) and washout experi-
ments (Figure 5.6A, B) revealed key aspects with respect to the mechanism of in-
hibition by our nucleophilic compounds. Overall, it is clear that our compounds
(1a-5a) bind reversibly to the ATP-binding pocket due to the results observed with
our blunted controls (1b-5b). However, oxidizing conditions demonstrate that our
compounds undergo irreversible redox-modulated inhibition as shown by fold change
in the calculated IC50 values from dose-response curves. Washout experiments fur-
ther confirmed our observations, but also indicated that our compounds are capable
of inducing partial, but not complete irreversible inhibition. This is most likely due to
slower reactivity rates of the nucleophilic warheads employed in this study compared
to the parent compound PD168393 (V. Gupta and K. Carroll, unpublished results).
Although a number of somatic mutations in the EGFR kinase domain have been
identified as a cause of NSCLC, we were particularly interested the most frequently
occurring ones: L858R/T790M and ∆746-750. These mutations have been shown to
reverse the effectiveness of ATP-competitive reversible inhibitors and have motivated
the development of covalent inhibitors to overcome acquired drug resistance. In ad-
dition to irreversibly targeting Cys797, researchers have also developed inhibitors to
directly target EGFR mutations (i.e. T790M) (47). We speculated that oxidation of
Cys797 may be affected to some extent in these oncogenic mutants due to its location
in the inhibitor binding pocket. Two different lung cancer cell lines were employed for
these studies: NCI-H1975 (L858R, T790M) and HCC827 (∆746-750). For the most
part, both cell lines exhibited increased compound potency (1a-5a) under acute H2O2
conditions. In particular, compound 1a had nearly no effect on EGFR autophospho-
rylation in the L858R/T790M cell line with respect to the EGF-stimulated control
but exhibited increase potency when subjected to oxidizing conditions. It is possi-
ble that EGFR Cys797 is rendered more sensitive to oxidation in the L858R/T790M
mutant, and explains why the phosphorylation levels were unaffected by 1a under
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non-oxidizing conditions. Molecular modeling and structural studies would be neces-
sary to confirm this observation, and would provide more insight as to how oxidation
of EGFR Cys797 may perturb potentially significant changes in the inhibitor binding
pocket.
In vivo studies conducted in A431 xenograft nude mouse models revealed our
compounds were able to induce observable decreases in EGFR phosphorylation and
sulfenylation. Complete inhibition was not observed for nucleophilic RSOH-targeted
inhibitors, confirming our cell-based washout experiments.
The first generation of RSOH-targeted EGFR inhibitors were successful, but also
revealed a number of issues that must to be addressed. First and foremost, we have
generated a panel of nucleophilic inhibitors that are capable of targeting and inhibiting
EGFR Cys797. Collectively, our results to date demonstrate that the propensity of
EGFR Cys797 to undergo sulfenylation can be exploited to develop a new class of
inhibitors based on a nucleophilic approach. The mode of inhibition occurs reversibly
due to its 4-anilinoquinolazine core, but also irreversibly in response to concomitant
EGFR oxidation. Unfortunately, washout experiments and in vivo studies indicate
that these compounds only induce partial covalent inhibition. To overcome this,
a second generation of RSOH-targeted EGFR inhibitors will incorporate some of
the following changes. The core structure will be modeled after afatinib, which has
proven successful in clinical trials and demonstrates more desirable properties such as
improved solubility and bioavailability in comparison to PD168393. We believe the
results of our current study warrant the change to a more clinically successful parent
compound. Originally, we chose the nucleophilic warheads used in this study based on
their improved reactivity rates in comparison to dimedone. These have since proven
to still react too slowly to effectively induce complete irreversible inhibition. We have
since identified a number of new nucleophilic warheads that exhibit reactivity rates
towards sulfenic acid that are several hundred-fold higher than the ones we selected
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for this study. Docking studies should be performed with the proposed compounds
for the second-generation panel of RSOH-targeted EGFR inhibitors to identify and
validate the success of potential compounds.
5.5 Conclusion
The importance of EGFR in physiologic signaling and as a therapeutic target in
cancer is clearly apparent and the continued effort to develop new approaches to target
EGFR remains an active area of research. The discovery of EGFR as a direct target
of H2O2 has fostered the development of a nucleophilic-based strategy to exploit the
sulfenyl form of the kinase. Most importantly, our efforts have demonstrated proof of
principle of this approach and have huge implications for the development of covalent
inhibition of other therapeutically relevant proteins.
5.6 Methods
Reagent source, purity, and stock solutions. All stocks were stored at -
20 ◦C, unless otherwise indicated. EGF (30 µg/ml, BD Biosciences) was prepared
in ddH2O. Serial dilutions of H2O2 (Sigma) were prepared in ddH2O. Compounds
1a-5a and 1b-5b (10 mM, ≥ 98% purity) were synthesized by V. Gupta (Carroll
lab) and stocks were prepared in DMSO at the indicated concentrations. PD168393
(10 mM, Santa Cruz Biotechnology, ≥ 95% purity) stocks were prepared in DMSO
at the indicated concentrations. DYn-2 (250 mM, ≥ 99% purity) was prepared in
DMSO and synthesized as previously described [7]. Catalase (20,000 U/ml, Sigma)
included in lysis buffers was prepared in 50 mM Tris-HCl pH 7.4 and stored at -80
◦C or made up fresh, respectively. Glucose oxidase (500 U/ml, Sigma), N-acetyl-L-
cysteine (NAC, Research Products International), and reduced L-glutathione (GSH,
Sigma) were prepared fresh in 50 mM Tris-HCl pH 7.4. Human serum albumin
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(HSA, fatty acid free, Sigma) was prepared directly in culture media at the indicated
concentrations. Azide biotin (5 mM, Invitrogen) was prepared in DMSO. BTTP
(100 mM, Peng Wu) was prepared in DMSO, and lower concentrations were made
by dilution of stock solution with ddH2O. Sodium L-ascorbate (Sigma) and CuSO4
(Sigma) were prepared fresh in ddH2O.
Cell culture. Mammalian cell lines (American Type Culture Collection) were
maintained at 37 ◦C in a 5% CO2 humidified atmosphere. A431 and MDA-MB-
453 cells were cultured in high glucose DMEM media (Invitrogen) containing 10%
FBS (Invitrogen), 1% GlutaMax (Invitrogen), 1% MEM nonessential amino acids
(Invitrogen), and 1% penicillin-streptomycin (Invitrogen). NCI-H1975 and HCC827
cells were cultured in RPMI 1640 media with glutamine (Invitrogen) containing 10%
FBS (Invitrogen), 1% MEM nonessential amino acids (Invitrogen), and 1% penicillin-
streptomycin (Invitrogen).
Cell lysate preparation. For analysis of protein phosphorylation, cells were
harvested in phosphorylation lysis buffer [50 mM HEPES pH 7.4, 150 mM NaCl,
1% NP-40, 0.1% SDS, 5 mM sodium pyrophosphate, 50 mM sodium fluoride, 10 µM
β-glycerophosphate, 1 mM sodium orthovanadate, 0.5 mM DTT, and 1x complete
mini protease inhibitors (Roche)]. After 15 min incubation on ice with frequent
mixing, cell debris was removed by centrifugation at 14,000 rpm for 15 min at 4
◦C. Protein concentration was determined by BCA assay (Pierce). For analysis of
protein phosphorylation in tissue lysate, samples were harvested in HEPES lysis buffer
[50 mM HEPES pH 7.4, 150 mM NaCl, 1% NP-40, 10% glycerol, 5 mM sodium
pyrophosphate, 50 mM sodium fluoride, 10 µM β-glycerophosphate, 1 mM sodium
orthovanadate, 0.5 mM DTT, and 1x complete mini protease inhibitors (Roche)]. For
analysis of protein sulfenylation in tissue lysate, samples were harvested in HEPES
lysis buffer [50 mM HEPES pH 7.4, 150 mM NaCl, 1% NP-40, 10% glycerol, 1x EDTA-
free complete mini protease inhibitors (Roche), and 200 U/ml catalase (Sigma)].
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EGFR autophosphorylation assays and data analysis. For autophospho-
rylation assays, cells were cultured until 80-85% confluency, washed with PBS, and
placed in culture media without serum (serum-starved) for 16 h. After serum de-
privation, cells were treated with the appropriate reagent (H2O2, glucose oxidase,
NAC, reduced GSH, or HSA) at the indicated concentration and time period. Cells
were then incubated with the indicated concentration of inhibitor for the indicated
time period, washed with PBS, and treated with the indicated concentration of EGF
for the indicated time period. Treatment was stopped by removing the media and
washing with PBS. Cell lysates were generated as described in Methods. Inhibi-
tion of EGFR autophosphorylation was determined by densitometric quantification
of Western blots. Percent inhibition was plotted against inhibitor concentration, and
IC50 values were calculated with a four parameter fit function using KaleidaGraph
software.
Washout effect of compounds. For washout assays, cells were cultured until
80-85% confluency, washed with PBS, and serum-starved for 16 h. After serum de-
privation, cells were incubated with compound at the indicated concentration for the
indicated time period. Cells were washed with PBS to remove excess compound, and
treated with H2O2 at the indicated concentration and time period to induce sulfenic
acid formation. Following H2O2 treatment, cells were washed with PBS, and placed
in serum-free media for the indicated washout time. After washout, cells were treated
with the indicated concentration of EGF for the indicated time period. Treatment was
stopped by removing the media and washing with PBS. Cell lysates were generated
as described in Methods.
Cell growth inhibition. A431 cells were seeded into 96-well format (2.0 × 104
cells/well) and cultured until 80-85% confluency. Cells were washed with PBS and
placed in complete culture media (phenol-free). Cells were incubated with compound
for 72 h (0-1000 µM) in triplicate, and media and compound was replenished every
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24 h. Cell viability was assessed by tetrazolium dye MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] (Life Technologies) according to manufacturer
guidelines. IC50 values were calculated using KaleidaGraph software and are repre-
sentative of three independent trials and represent the mean ± s.e.m.
Sulfenic acid labeling in tissue lysate. Tissue slices from xenograft mice
models were lysed and homogenized in HEPES lysis buffer in the presence of DYn-2
(10 mM). Tissue lysates were cleared of debris by centrifugation at 14,000 rpm for 15
min at 4 ◦C. The lysates were then passed through a p30 column (BioRad) to remove
excess probe and subjected to immunoprecipitation to analyze EGFR sulfenylation
levels.
Immunoprecipitation. EGFR was immunoprecipitated from 500 µg lysate (1
mg/ml) with goat anti-EGFR conjugated agarose (Santa Cruz Biotechnology) or
isotype control (normal goat IgG) overnight at 4 ◦C with gentle rocking. The resin
was collected by centrifugation at 100g for 2 min at rt, and washed with cold RIPA
buffer (1X) and cold PBS buffer (2X). The resin was subjected to click chemistry
as described in Methods, and the bound proteins were eluted by boiling with LDS
sample buffer for 10 min, and resolved by SDS-PAGE and analyzed by Western blot.
Click chemistry. For immunoprecipitated protein analyses, the resin was treated
with 20 µl click chemistry mix [azide biotin (100 µM), CuSO4 (250 µM), BTTP (500
µM), and sodium L-ascorbate (2.5 mM) in PBS] for 1 h at rt with gentle rocking.
The reaction was quenched with 1 mM EDTA, and the samples were boiled with LDS
sample buffer.
5.7 Contributions
T.H.T. performed cell culture experiments. V.G. performed synthetic experi-
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Figure 5.S1: Dose-dependence of acute H2O2 on EGFR phosphorylation levels. (A-E)
Western blots show phosphorylated (p) and total EGFR. A431 cells were stimulated with H2O2 at
the indicated concentrations for 5 min to induce sulfenic acid formation, treated with the indicated
concentrations of 1a-5a, and subsequently stimulated with EGF (100 ng/ml) for 5 min.
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Figure 5.S2: Acute H2O2 treatment increases potency of RSOH-targeted compounds.
Western blots show phosphorylated (p) and total EGFR. (A-D) Acute H2O2 treatment increases
potency of 2a-5a, respectively. (E-H) Acute H2O2 treatment of 2b-5b, respectively. A431 cells
were stimulated with H2O2 (200 µM) for 5 min to induce sulfenic acid formation, treated with the
indicated concentrations of 2a-5a or 2b-5b for 1 h, and subsequently stimulated with EGF (100
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Figure 5.S3: Human serum albumin (HSA) decreases potency of RSH- and RSOH-
targeted compounds. A431 cells were incubated with (A) 1a, (B) 1b, and (C) PD168393 in
the presence of HSA (3% w/v) for 1 h, and subsequently stimulated with EGF (100 ng/ml) for 5
min. All three compounds exhibited decreased potency in the presence of HSA. (D) IC50 values for
1a were determined by Western blot analysis of EGFR autophosphorylation from A. (E) IC50 values
for PD168393 were determined by Western blot analysis of EGFR autophosphorylation from C.
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5.9 Supplementary Tables
Table 5.S1: IC50 Values of H2O2 (Acute) in A431 Cells Treated with 1a-5a






a Compound was maintained at the listed concentration.
b IC50 values of H2O2 were determined by Western blot analysis of EGFR
autophosphorylation
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Table 5.S2: IC50 Values of RSOH-Targeted Compounds in NCI-H1975 Cells Treated with Acute
H2O2























a Cells were pre-treated with H2O2 (200 µM, 5 min), incubated with compound (1
h), and stimulated with EGF (100 ng/ml).
b IC50 values of EGF were determined by Western blot analysis of EGFR autophos-
phorylation.
c IC50 values of H2O2 were determined by Western blot analysis of EGFR autophos-
phorylation.
d ND, not determined. In some cases, the IC50 value could not be calculated because
no change in phosphorylation levels was observed.
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Table 5.S3: IC50 Values of RSOH-Targeted Compounds in HCC827 Cells Treated with Acute H2O2























a Cells were pre-treated with H2O2 (200 µM, 5 min), incubated with compound (1
h), and stimulated with EGF (100 ng/ml).
b IC50 values of EGF were determined by Western blot analysis of EGFR autophos-
phorylation.
c IC50 values of H2O2 were determined by Western blot analysis of EGFR autophos-
phorylation.
d ND, not determined. In some cases, the IC50 value could not be calculated because
no change in phosphorylation levels was observed.
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Table 5.S4: IC50 Values of RSOH-Targeted Compounds in MDA-MB-453 Cells Treated with Acute
H2O2























a Cells were pre-treated with H2O2 (200 µM, 5 min), incubated with compound (1
h), and stimulated with EGF (100 ng/ml).
b IC50 values of EGF were determined by Western blot analysis of EGFR autophos-
phorylation.
c IC50 values of H2O2 were determined by Western blot analysis of EGFR autophos-
phorylation.
d ND, not determined. In some cases, the IC50 value could not be calculated because
no change in phosphorylation levels was observed.
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The data presented in the previous chapters provides evidence that protein sulfeny-
lation directly modulates kinase activity during cellular signaling events and can be
exploited for the development of new therapeutics in disease states associated with
high levels of oxidative stress. In the present chapter, we summarize these findings
and the significance of this work. Moreover, we discuss future directions aimed at
the continued investigation of general mechanisms underlying redox regulation of pro-
tein kinases and the development of novel irreversible RSOH-targeted inhibitors for
epidermal growth factor receptor (EGFR).
6.2 Summary
Hydrogen peroxide (H2O2) acts as a second messenger to modulate signal trans-
duction networks through chemoselective oxidation of cysteine residues in protein
targets (1). Although the development of chemical probes to detect sulfenic acids
have greatly facilitated the detection of sulfenylated proteins (2), a large majority
of H2O2-modulated targets and the extent to which reversible oxidation influences
protein activity remains largely unknown. The overall goal of this thesis was to use
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sulfenic acid probes developed in our lab to elucidate the regulatory role of protein
sulfenylation within the context of kinase signaling, specifically EGFR. In Chapter
1, we presented an overview of the molecular mechanisms involved in redox-based
regulation of EGFR and its downstream signaling pathways (3).
In Chapter 2, we presented the development and application of a modified ap-
proach that allows relative quantification of sulfenic acids based on a pair of light
and heavy isotope labeled probes (DAz-2 and d6-DAz-2) in conjunction with a com-
plementary acid-cleavable linker (Yn-ACL) (4). This method can be used to directly
map sites of cysteine oxidation and compare sulfenic acid levels in normal and disease
states. One advantage of this method is that it utilizes an avidin enrichment step to
maximize identification of probe-labeled proteins.
In Chapter 3, we reported the development and application of a new alkyne-based
probe (DYn-2) for detection of sulfenic acids (5). These studies demonstrated epi-
dermal growth factor (EGF) signaling mediates endogenous H2O2 production and
induces dynamic changes in global protein sulfenylation in A431 cells. Three protein
tyrosine phosphatases (PTPs) were identified as direct targets of ligand-dependent
oxidation and exhibited a unique sulfenylation profile based on their subcellular lo-
cations. In addition, EGFR was identified as a direct target of signal-derived H2O2
at its active site cysteine (Cys797), which enhances its tyrosine kinase activity. The
results of this study revealed sulfenylation acts as a global signaling mechanism that
is akin to phosphorylation and has regulatory implications for other protein kinases
and have broad therapeutic implications for redox-sensitive cysteine residues.
In Chapter 4, we performed molecular characterization to delineate the role of
EGFR Cys797 sulfenylation and determine its effect on kinase activity. In vitro
and cell-based assays demonstrate that mutation of this residue abrogates EGFR
autophosphorylation, sulfenylation, and decreases its affinity for ATP. Moreover, oxi-
dation affects the propensity of Cys797 to undergo sulfenylation in common oncogenic
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EGFR mutants and the potency of inhibitors that target this residue in its reduced thi-
olate form. Additionally, we demonstrate HER2 and BTK undergo sulfenylation, pro-
viding evidence that kinases harboring a structurally homologous cysteine to Cys797
may be redox-regulated.
In Chapter 5, we reported the development of a panel of first generation nucle-
ophilic ROSH-targeted inhibitors and evaluated compound potency and selectivity to-
wards EGFR Cys797 in response to concomitant EGFR oxidation. We demonstrated
our nucleophilic compounds were capable of inhibiting EGFR autophosphorylation
under oxidizing conditions and occurred through partial irreversible mechanisms. Our
work provided proof of principle and indicates that the propensity of EGFR Cys797
to form sulfenic acid can be exploited to develop new classes of inhibitors.
6.3 Future Directions
Continued investigation of general mechanisms involved in redox regula-
tion of receptor and non-receptor kinases
Of the ∼95 receptor and non-receptor protein tyrosine kinases (PTKs) in the hu-
man genome, nine additional members contain a structurally homologous cysteine
residue to EGFR Cys797 (Figure 6.1) (6). This group contains two EGFR subfamily
members, HER2 and HER4. In Chapter 4, we demonstrated that HER2 undergoes
EGF-mediated sulfenylation. HER2 can form a heterodimer with EGFR upon stim-
ulation, and oxidation of HER2 may be facilitated by receptor dimerization. Overex-
pression of HER2 has been shown to play a role in the development and progression
of breast cancer. Additionally, increased protein oxidation and sulfenylation have
been observed in breast cancer cells with elevated EGFR and HER2 expression levels
(7). Coupled to previous literature work, our findings highlight the importance of
understanding the full extent of HER2 oxidation because of its close relationship as
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an EGFR subfamily member and its potential therapeutic implications (8).
We also explored the ability of Bruton’s tyrosine kinase (BTK) to undergo sulfenic
acid formation. Unlike receptor kinases EGFR and HER2, BTK is a non-receptor ki-
nase that plays an essential role in regulating calcium signaling during B-cell receptor
(BCR) activation. We chose BTK because it is the only other kinase in this group
(Figure 6.1) besides EGFR and HER2 that currently has inhibitors undergoing clin-
ical trials (8). Using sulfenic acid specific probes, we were able to demonstrate BTK
undergoes sulfenic acid modification at Cys481 upon IgM stimulation. Moreover,
pre-treatment with irreversible BTK inhibitor PCI-32765 decreased IgM-mediated
sulfenylation, albeit not completely. Therefore, we speculated that additional mech-
anisms may be involved in modulating the oxidation status of BTK Cys481. It is
possible that Cys481 undergoes redox-mediated disulfide bond formation with a sec-
ond cysteine residue (Cys527) located in the BTK kinase active site. Continued efforts
to delineate the effect and extent of oxidation on BTK activity will help determine
if this conserved residue (EGFR Cys797) acts as a general mechanism to regulate
kinase signaling. BTK is a member of the TEC family of kinases and include TEC,
ITK TXK, and BMX, all of whom are also structural homologues of EGFR (Fig-
ure 6.1). Findings demonstrating redox regulation of BTK may be applicable to the
TEC kinase family, as previously observed with the EGFR subfamily (i.e. EGFR and
HER2). Another subfamily of protein tyrosine kinases, which includes cytoplasmic
Src and FGFR1, contains a conserved cysteine residue located within its glycine rich
loop in the kinase active site. Oxidation of this residue has been shown to inhibit
kinase activity of c-Src and FGFR1 in vitro (9), but neither of these kinases has been
confirmed as an intracellular target of H2O2 to date. More than 150 kinases con-
tain a cysteine residue in or around the nucleotide-binding site and may have similar
regulatory roles, but a broader examination will be required to define the scope and


























































































































Figure 6.1: Sequence alignment of EGFR and nine additional kinases containing a structurally
homologous residue to EGFR Cys797.
Continued development of irreversible RSOH-targeted inhibitors of EGFR
EGFR is mutated or amplified in a number of human cancers (i.e. breast and
lung), which has motivated the development of reversible ATP-competitive and irre-
versible inhibitors (8, 10). Many covalent EGFR inhibitors contain an electrophilic
acrylamide moiety that reacts with the EGFR Cys797 thiolate through Michael ad-
dition to achieve irreversible binding. Our findings demonstrate oxidation of EGFR
Cys797 reduces potency of these RSH-targeted inhibitors and suggest alternate mech-
anisms to target the sulfenyl form of EGFR must be developed to overcome the po-
tential shortcomings of current inhibitors. To address this, we generated a panel of
nucleophilic RSOH-targeted inhibitors and evaluated their potency towards EGFR
Cys797. Our studies demonstrate that oxidizing conditions (acute and chronic H2O2)
increased the potency of our compounds. Subsequent washout experiments indicated
that our compounds were capable of inducing partial, but not complete irreversible
inhibition. We speculate that this is most likely due to the slower reactivity rates of
the nucleophilic warheads employed in our study with sulfenic acid (V. Gupta and












































Figure 6.2: Structures of 2nd generation RSOH-targeted EGFR compounds. (A) Structure
of parent compound afatinib. (B) Structures of 2nd generation RSOH-targeted compounds (6a-11a).
The core structure is shown at the top.
Although our first generation of RSOH-targeted EGFR inhibitors were successful
in demonstrating proof of principle of the nucleophilic warhead approach, our studies
revealed a number of issues that must be addressed. First and foremost, alternate
nucleophilic warheads must be identified in order to facilitate faster reactivity rates
with sulfenic acid. Additionally, solubility and bioavailability issues must be explored
as well. The parent compound, PD168393, was considered an effective inhibitor, but
did not make it to clinical trials due to poor bioavailability. We observed similar
solubility issues with our first generation compounds, indicating that an alternate
core structure must be considered for future inhibitor development. To address these
concerns, the synthesis of a second generation of RSOH-targeted EGFR inhibitors is
currently in progress and will incorporate some of the following changes. The core
structure will be modeled after afatinib (Figure 6.2A), which has proven successful
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in clinical trials. The afatinib core contains a water-solubilizing group (dialkylamine)
attached at the end of its Michael acceptor (acrylamide). This additional group
enhances the rate of the Michael addition reaction and increases solubility of the
compound. Second, we have since identified a number of new nucleophilic warheads
that exhibit reactivity rates towards sulfenic acid that are much faster than the ones
we selected for our original study (V. Gupta and K. Carroll, unpublished results).
These new nucleophiles will be used in place of our current ones, in order to enhance
reactivity rates with EGFR Cys797 (Figure 6.2B).
6.4 Concluding Remarks
This thesis presents key findings that demonstrate the important role of protein
sulfenylation during kinase-mediated signaling events. Continued work to understand
the scope of sulfenylation indicates that general mechanisms may have evolved to
regulate protein kinase function. Additionally, this modification can be exploited
for the development of new therapeutic approaches to treat pathologic conditions
characterized with high oxidative stress levels and presage an exciting future for
elucidating the role of sulfenic acids in normal and disease states.
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Bioorthogonal Chemical Reporters for Analyzing
Protein Sulfenylation in Cells
Abstract
Protein sulfenylation (RSOH), the redox-based modification of cysteine thiol side
chains by hydrogen peroxide (H2O2) is an important mechanism in signal transduc-
tion. Likewise, dysregulated protein sulfenylation contributes to a range of human
pathologies, including cancer. Efforts to elucidate the diverse roles of protein sulfeny-
lation in physiology and disease have been hampered by the lack of techniques to probe
these modifications in native environments. To address this problem, we have recently
introduced selective chemical reporters for the detection and identification of sulfeny-
lated proteins directly in cells. In this approach, a cyclic β-diketone warhead is func-
tionalized with an azide or alkyne chemical handle. An orthogonally functionalized
biotin or fluorescent reporter is then appended to the probe post-homogenization via
click chemistry for downstream analysis. These bi-functional probes are exquisitely
selective for protein sulfenyl modifications, non-toxic, and do not perturb intracellular
redox balance. Our laboratory has utilized these reagents to investigate sulfenylation
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in vitro and identify intracellular protein targets of H2O2 during cell signaling. These
methods are presented in this unit, and provide a facile way to detect protein sulfenic
acids. With the information gained from on-going studies, researchers can continue
to uncover the biological role of cysteine oxidation with regards to physiological and
pathological events.
Introduction
Although historically viewed as purely harmful, recent studies demonstrate that
hydrogen peroxide (H2O2) functions as an important physiological regulator of intra-
cellular signaling pathways, including cell growth and proliferation (1, 2). In this con-
text, H2O2 is produced by a family of membrane-bound NADPH-dependent oxidases
whose expression is tightly regulated, compartmentalized, and tissue-specific (3). The
downstream effects of H2O2 are mediated by covalent modification of cysteine residues
found within redox-sensitive target proteins (4, 5). Oxidation of these specific and
reactive cysteine residues in turn can lead to modulation of protein activity, much
like O-phosphorylation (6).
Sulfenic acid (RSOH), also known as sulfenylation, is the direct product of cysteine
modification by H2O2. The reactivity of a cysteine thiol toward H2O2 is profoundly
influenced by the protein environment. Important factors include accessibility and
proximity to side chains that may interact with the thiol, peroxide, or the oxidized
product. Most reactive are cysteine residues with low pKa values that exist as the nu-
cleophilic thiolate anion at physiological pH. However, other factors are undoubtedly
involved as the documented reactivity of protein thiolate anions with H2O2 ranges
across seven orders of magnitude (1-107 M−1s−1) (7). Some of these factors are com-
ing to light, but consensus motifs have not yet emerged and our understanding of
the molecular basis of sensitivity toward H2O2 for a given cysteine residue remains
largely ill-defined.
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Once formed, sulfenyl modifications can be stabilized by the microenvironment
or, in some cases, react with nearby protein or exogenous thiols to form disulfides
(Figure A.1a). Indirect evidence for the formation and stabilization of sulfenic acid
in proteins was first reported for the glycolytic enzyme GAPDH in the 1970’s (8), but
was not fully appreciated until detailed biochemical and structural analysis of NADH
peroxidase in the late 1990’s (9, 10). These landmark studies led to the discovery that
sulfenyl groups function as catalytic redox centers (11), alter enzyme chemistry (12),
and act as reversible sensors of H2O2 levels in microbial transcription factors (13).
Under conditions of oxidative stress, sulfenyl groups can also oxidize further to the
sulfinic (SO2H) or sulfonic acid (SO3H). On the other hand, mounting evidence also
points to the existence of specialized enzymes that mediate the direct reduction of
the sulfenyl modification back to the thiol state (14).
Historically, methods to detect reactive cysteines and H2O2-mediated oxidation
of protein thiols required the homogenization of cells, which disrupts the native en-
vironment (15). Under these crude conditions, cellular redox balance and protein
structure are compromised, leading to artifactual oxidation during sample processing.
The severity of this issue cannot be disregarded and greatly increases the challenges
associated with identifying sites of modification in low-abundance proteins, as well as
for interpreting the biological significance of the data.
To overcome this problem, we have developed small-molecule probes that enable
sulfenylated proteins to be trapped and tagged directly in cells (16–18). In this
approach, a cyclic β-diketone warhead (2; Figure A.1c) that is chemically selective for
sulfenic acids known as dimedone (8) (1; Figure A.1b) is functionalized with an azide
(3-5; Figure A.1c) or alkyne (6-8; Figure B.1c) reporter group. An orthogonally
functionalized biotin or fluorescent tag is then appended post-homogenization for
detection via the Staudinger ligation (19) or Huisgen [3+2] cycloaddition (i.e. click
chemistry) (20). In addition, we have developed two complementary isotope-coded
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probe pairs to quantify changes in protein sulfenylation (9, 10; Figure A.1c) (21, 22).
Most recently, we have reported tri-functional probes to monitor reversible oxidation
of protein tyrosine phosphatases (PTPs) comprised of a warhead bearing the cyclic
β-diketone group, a binding module that targets the probe to the PTP active site,
and an azide chemical reporter (11, 12; Figure A.1c) (15).
This collection of Basic Protocols presents a series of methods utilizing our probes
for in vitro detection of sulfenyl modifications within recombinant purified proteins
(Basic Protocol 1) and in situ detection in cultured mammalian cells (Basic Protocols
2 and 3). Labeled sulfenylated proteins can then be visualized by either Western blot
analysis (Basic Protocol 4) or in-gel fluorescence (Basic Protocol 5) after being coupled
to a biotin or fluorescent tag. Overall, our general approach provides a facile method
for profiling sulfenyl modifications in proteins.
On-going development of chemical tools for selective detection of protein sulfeny-
lation and other cysteine "oxoforms" are crucial for the progression of this rapidly
growing area of research. While it is known that cysteines residues are the primary
target of H2O2 (4), and that sulfenylation can lead to dramatic changes in protein
function, our knowledge regarding the individual sites, extent or dynamics of these
modifications in cells is still at an early phase. Acquiring such information is a key
step in delineating the molecular mechanisms that underlie redox-dependent con-
trol of intracellular signaling networks in physiology and disease. Furthermore, the
exploitation of redox-modulating strategies for cancer therapy requires a detailed un-
derstanding of the structure-activity relationships of sulfenyl modifications and their





























































































Figure A.1: Bioorthogonal detection of protein cysteine oxidation. (A) Oxidative modifi-
cations of protein cysteines. Low pKa thiols susceptible to oxidation can react with H2O2 to form
a sulfenic acid, also known as sulfenylation. This modification may be stabilized by the protein
microenvironment or condense with a second thiol to form an intra- or inter-molecular disulfide.
Alternatively, the sulfenic acid can undergo further oxidation to the sulfinic or sulfonic acid under
conditions of high oxidative stress, typically associated with disease states. (B) Chemoselective
reaction between sulfenic acid and 5,5-dimethyl-1,3-cyclohexanedione (dimedone, 1). (C) Selective
probes for detecting protein sulfenic acids based on the 1,3-cyclohexanedione scaffold (2). These
probes are functionalized with azide (3-5) or alkyne (6-8) chemical reporter groups, allow for rela-
tive quantification of sulfenic acids (9-10), and can target specific classes of redox-regulated proteins,
such as protein tyrosine phosphatases (PTPs) (11-12).
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Strategic Planning
Labeling Sulfenylated Proteins In Vitro.
In Basic Protocol 1, we demonstrate the application of our method in vitro for a
purified protein using the commercially available enzyme, glyceraldehyde 3-phosphate
dehydrogenase (GADPH). Upon exposure to H2O2, GAPDH becomes sulfenylated at
the active-site cysteine (C149) (8) and the modification is readily detected by our
probes (16, 23). Naturally, this method can be applied to investigate oxidation in
other proteins that harbor H2O2-sensitive cysteine residues. The experimental pa-
rameters for oxidation and protein labeling described in Basic Protocol 1 have been
optimized for GAPDH. Nevertheless, depending on the properties of the protein under
study, it may be necessary to adjust some of the conditions if the reported procedure
does not yield satisfactory results. For example, the H2O2 dose and exposure time can
be adjusted to modulate the extent of cysteine oxidation. Similarly, probe concentra-
tion or labeling time can be changed in order to optimize the signal: noise ratio. For
reference, the reaction rate of dimedone-based probes with protein sulfenic acids is on
the order of 103 M−1 min−1 (24). It is recommended that the user first attempt the
conditions outlined in Basic Protocol 1 with their protein of interest prior to adjusting
any experimental conditions. If the candidate protein demonstrates H2O2-sensitivity,
downstream experiments may involve site-directed mutagenesis of the target cysteine
and/or mass spectrometry (MS) analysis of intact and digested protein after probe la-
beling to map the site(s) of modification. In particular, our lab has demonstrated this
with respect to wild-type and C36S Gpx3 with DAz-1 (25) and with isotope-coded
probe pairs (21, 22).
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Labeling Sulfenylated Proteins in Living Cells.
We present an approach for detecting protein sulfenyl modifications in situ for
two human cell lines, A431 and HepG2 (Figure A.2a). A431 epithelial cells are a rich
model for studying the biology of epidermal growth factor receptor (EGFR) signaling
and for preclinical evaluation of EGFR therapeutics. The HepG2 epithelial cell line is
also a suitable model system for the study of receptor-mediated H2O2 production and
concomitant protein sulfenylation. In Basic Protocol 2, we demonstrate that EGF
stimulation of A431 cells leads to dynamic global changes in protein sulfenylation,
which may be important for growth factor signaling. Naturally, it is also possible
to adapt Basic Protocol 2 to monitor changes in sulfenylation with other cell lines
and stimulants. The dose- and time-dependent effects of a particular stimulant on
protein sulfenylation should be evaluated for each new cell line. Likewise, probe
concentration and labeling time may require some optimization. In addition, serum
starvation of cells may be required to reduce high basal levels of sulfenylation. The
procedure outlined in Basic Protocol 2 is somewhat involved and may prove difficult
for investigators new to mammalian cell culture. Consequently, in Basic Protocol 3,
we present a scaled-down method for detecting protein sulfenylation in HepG2 cells
exposed to exogenous H2O2. HeLa cells may also be used in Basic Protocol 3, as
they are another robust cell line that is easily propagated in the lab. We also note
that Basic Protocol 2 and 3 call for the preparation of a single cell suspension from
adherent culture for probe labeling. Therefore, it is prudent to work efficiently and
avoid significant time delay after stimulation. As labeling in suspension may not
prove ideal for some cell lines or stimulants, we also provide an alternative method







































































































Figure A.2: Cell-based detection of protein sulfenylation. (A) Strategy to detect protein
sulfenylation in living cells. Sulfenic acids are labeled in situ using selective, cell-permeable chemical
probes. Cells are then washed, homogenized, and probe-labeled proteins are conjugated to a biotin
or fluorescent tag via the bioorthogonal click chemistry reaction. This approach enables downstream
detection by immunoblot or in-gel fluorescence. Alternatively, biotinylated proteins may be enriched
for proteomic analysis. (B) Generic scheme for click chemistry bioconjugation. (C) Biotin tags
utilized in this study. (D) Fluorescent tags utilized in this study.
227
Choice of Chemical Reporter for Analyzing Protein Sulfenylation.
DAz-2 and DYn-2 (4 and 7; Figure A.1c) can both be used to detect protein
sulfenylation directly in cells. The major difference between these two probes is the
identity of the chemical reporter group (azide or alkyne), which dictates the orien-
tation of the triazole when "clicked" to the appropriate reporter tag (Figure A.2b).
The choice of probe depends on downstream analysis methods. If Western blot de-
tection is desired, either probe can be utilized with the corresponding biotin reporter
tag (13 or 14; Figure A.2). However, for in-gel fluorescent detection we recommend
the exclusive use of DYn-2 probe and azide-functionalized fluorescent tags (16 or 18;
Figure A.2d) owing to the lower background signal reported for this orientation (26).
Bioorthogonal Ligation of Reporter-Labeled Proteins.
Once proteins are labeled with DAz-2 or DYn-2, they can be detected via bioorthog-
onal ligation with a biotin or fluorescent tag (Figure A.2b). In our protocol, we de-
scribe click chemistry as the main method of bioorthogonal ligation. We and other
researchers have demonstrated the utility of click chemistry in vitro and in cells (17,
22, 27, 28). It is also possible to detect azide-tagged proteins through Staudinger
ligation with various phosphine-based reactive partners (16, 18). Although this ap-
proach is not included in this particular collection of protocols, the user is welcome
to explore this alternative bioorthogonal ligation method if they are interested.
Other Considerations.
For labeling sulfenylated proteins in vitro or in live cells, it is important to consider
factors that can influence basal levels of cysteine oxidation. For example, reactive
cysteines in recombinant proteins can undergo oxidation in the presence of oxygen
and trace amounts of transition metal ions in phosphate or Tris-based buffer solutions.
If this presents an issue for the user, buffer solutions can be made anaerobic by purging
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with nitrogen. In addition, cells should be cultured carefully (i.e., regular schedule
for splitting, appropriate plating density, no more than 20 passages, mycoplasma
testing) in high quality medium. Poor culturing conditions can lead to cell stress
and higher basal levels of cysteine oxidation. It is also recommended that the user
occasionally monitor cellular ROS levels by using carboxy-H2DCFDA (Invitrogen)
and/or a general protein marker for oxidative stress, such as an antibody against the
hyper-oxidized form of peroxiredoxin (Prx-SO3, Abcam). Furthermore, analogous to
phosphorylation studies, serum starvation may be required to reduce high basal levels
of protein sulfenylation. Lastly, control reactions should always be performed in the
absence of chemical probe, as indicated in each section below.
Basic Protocols
Basic Protocol 1
LABELING SULFENYLATED PROTEINS IN VITRO.
The following is a standard protocol for in vitro labeling of sulfenyl modifications
in purified proteins. We chose GAPDH as the model system here because it is well
known to undergo sulfenylation at its active-site cysteine (C149). This protocol can
be applied to investigate sulfenylation in any other protein of interest. Proteins can
be labeled with a number of biotin or fluorescent chemical reporters, allowing for
Western blot or in-gel fluorescent detection of labeled proteins.
Materials
• GAPDH, lyophilized powder (Sigma-Aldrich) or other purified protein of inter-
est
• Bio-Spin 6 Columns, pre-packed in Tris buffer (BioRad)
• Tris labeling buffer (see recipe)
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• Click labeling buffer (see recipe)
• PBS, 1X (Boston BioProducts)
• DMSO (vehicle; Sigma-Aldrich)
• 25 mM DAz-2 (Cayman Chemicals) or DYn-2 (Cayman Chemicals), prepared
in DMSO
• 1 mM H2O2 stock (Sigma-Aldrich), prepared fresh in H2O and maintained on
ice
• 5 mM biotin tag (biotin alkyne or azide; Invitrogen) in DMSO or 5 mM fluo-
rescent tag (TAMRA or AlexaFluor488 azide; Invitrogen) in DMSO
• 50 mM tris(2-carboxyethyl) phosphine hydrochloride (TCEP; Sigma-Aldrich),
prepared fresh in H2O
• 2 mM tris[(1-benzyl-1H -1,2,3-triazol-4-yl)methyl] amine (TBTA; Sigma Aldrich),
prepared in 4: 1 DMSO: t-butanol. TBTA can also be synthesized by published
methods (29).
• 50 mM CuSO4, prepared fresh in H2O
• Laemmli sample buffer, 2X with 10% β-mercaptoethanol (BioRad)
• Mini-Protean TGX 4-15% Tris-Glycine protein gels (BioRad)
1. Resuspend GAPDH in Tris labeling buffer (4 mg/ml).
We recommend using GAPDH at 4 mg/ml in order to obtain a starting con-
centration of ∼110 µM. If using a different protein, the protein of interest
should have a starting concentration of ∼100-110 µM. The relatively high pro-
tein concentration facilitates downstream gel-based MS analysis. However, if
this is not desired, lower initial protein concentrations can be used.
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2. Reduce GAPDH with 1 mM TCEP for 30 min at rt.
A freshly made stock solution of 50 mM TCEP should be used to obtain a
final concentration of 1 mM TCEP for reduction of protein thiols.
3. After protein reduction, remove excess TCEP with Bio-Spin 6 columns (pre-
equilibrated with Tris labeling buffer). Load 100 µl GAPDH protein per column.
To collect the reduced GAPDH protein, centrifuge the columns for 4 min at 1000
× g, rt.
The Bio-Spin 6 columns must be pre-equilibrated with the appropriate buffer
prior to use. To achieve this, centrifuge the columns for 2 min at 1000 × g to
remove packing buffer. Apply the new Tris labeling buffer in 500 µl aliquots.
After each application of new buffer, centrifuge the column for 1 min at 1000
× g. Repeat as required. We use four washes which results in >99.9% of
buffer exchanged.
4. Determine GAPDH protein concentration.
We determine the concentration of GAPDH using a NanoDrop2000c Spec-
trophotometer (Thermo Scientific) and a molar extinction coefficient of ϵ280
= 32890 M−1 cm−1.
5. Label 25 µM GAPDH with 1 mM DAz-2 or DYn-2 (from 25 mM probe stock).
Incubate GAPDH with 1.5 eq. H2O2 (37.5 µM from 1 mM H2O2 stock) or H2O
(mock treatment). Total volume of the labeling reactions should be 100 µl. In
addition, a no-probe control sample should always be prepared for comparison to




b. Tris labeling buffer (to make up remaining reaction volume)
c. 3.75 µl of 1 mM H2O2 (final concentration of 37.5 µM)
d. 4 µl of 25 mM DAz-2 or DYn-2 (final concentration of 1 mM)
6. Rock the labeling reactions for 1 h at 37 ◦C.
7. After protein labeling, remove excess probe with Bio-Spin 6 columns (pre-equilibrated
with click labeling buffer). Load 95 µl labeling reaction per column. To collect the
labeled GAPDH protein, centrifuge the columns for 4 min at 1000 × g, rt.
8. Detect probe-labeled proteins by orthogonal click chemistry. Total volume of the
click chemistry reaction should be 100 µl. Add the reaction components in the
following order to each sample and mix well:
a. 2 µl of 5 mM biotin or fluorescent reporter tag (final concentration of 100 µM)
b. 2 µl of 50 mM TCEP (final concentration of 1 mM)
c. 5 µl of 2 mM TBTA (final concentration of 100 µM)
d. 2 µl of 50 mM CuSO4 (final concentration of 1 mM)
9. Rock the click chemistry reactions for 1 h at rt.
If a fluorescent reporter tag is being used (i.e. TAMRA or AlexaFluor488
azide), perform the reactions in the dark. In addition, take all necessary
precautions to carry out remaining steps in the dark if a fluorescent tag is
used.
10. After click chemistry, remove excess reagents with Bio-Spin 6 columns (pre-equilibrated
with PBS). Load 95 µl labeling reaction per column. To collect the labeled GAPDH
protein, centrifuge the columns for 4 min at 1000 × g, rt.
11. Add 100 µl 2X Laemmli sample buffer (10% β-ME) to each column eluate.
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Note that the expected recovery of GADPH applied to a Bio-Spin 6 column
is ∼ 80%. This parameter must be empirically determined if a protein other
than GAPDH is used.
12. Boil the protein samples for 10 min at 95 ◦C, using a heating block.
13. Resolve samples by SDS-PAGE using Mini-Protean TGX 4-15% Tris-Glycine gels.
For GADPH, we typically load 200 ng protein per lane.
14. Analyze the results of the experiment with the detection method of choice.
a. Basic Protocol 4 Western blot
i. Figure A.3a DAz-2/Biotin Alkyne
ii. Figure A.3b DYn-2/Biotin Azide
b. Basic Protocol 5 In-gel fluorescence
i. Figure A.3c DYn-2/TAMRA Azide
ii. Figure A.3d DYn-2/AlexaFluor488 Azide
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Figure A.3: Detection of sulfenyl modifications with purified protein in vitro. GAPDH
was stimulated with H2O2 and labeled with DAz-2 or DYn-2 for 1 hr. Probe-labeled GAPDH
can be detected by streptavidin-HRP immunoblot (A-B) or ingel fluorescence (C-D). Equal protein
loading is demonstrated by reprobing the immunoblot with antibodies to GAPDH (immunoblot) or
by SYPRO red dye staining of the SDS-PAGE gel (fluorescence).
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Basic Protocol 2
LABELING ENDOGENOUS SULFENYLATED PROTEINS IN CELL
SUSPENSION.
The following is the standard protocol for labeling of intact A431 cells in suspen-
sion. We have recently demonstrated that A431 cells produce H2O2 upon stimulation
with EGF, which leads to dynamic global changes in protein sulfenylation (17). In
these experiments, the EGFR kinase is activated in A431 cells by stimulation with
EGF ligand. We encourage the user to examine other cell lines and stimulants as
appropriate in their experiments. Additionally, we recommend that the user consider
starting with Basic Protocol 3 in order to gain basic proficiency in these techniques
prior to attempting the more involved system described in Basic Protocol 2. Labeled
proteins can be detected by Western blot or in-gel fluorescence.
Materials
• A431 cells (ATCC)
• DMEM complete culture medium (high glucose DMEM supplemented with 10%
FBS, 1% GlutaMax, 1% MEM nonessential amino acids, and 1% penicillin-
streptomycin; Invitrogen)
• DMEM only (serum-free high glucose DMEM; Invitrogen)
• 0.25% trypsin (Invitrogen)
• 30 µg/ml EGF stock (BD Biosciences), prepared in H2O and kept on ice
• DMSO (vehicle; Sigma-Aldrich)
• 250 mM DAz-2 (Cayman Chemicals) or DYn-2 (Cayman Chemicals), prepared
in DMSO
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• Modified RIPA lysis buffer supplemented with EDTA-free protease inhibitors
and 200 U/ml catalase (see recipe)
• PBS, 1X (Boston BioProducts)
• BCA protein assay (Pierce)
• 5 mM biotin tag (biotin alkyne or azide; Invitrogen) in DMSO or 5 mM fluo-
rescent tag (TAMRA or AlexaFluor488 azide; Invitrogen) in DMSO
• 50 mM TCEP (Sigma-Aldrich), prepared fresh in H2O
• 2 mM TBTA (Sigma Aldrich), prepared in 4:1 DMSO: t-butanol. TBTA can
also be synthesized by published methods (29).
• 50 mM CuSO4, prepared fresh in H2O
• 0.5 M EDTA (Boston BioProducts)
• 10% SDS, prepared in H2O
• Laemmli sample buffer, 2X with 10% β-mercaptoethanol (BioRad)
• Mini-Protean TGX 4-15% Tris-Glycine protein gels (BioRad)
1. Grow A431 cells to 75-80% confluency in DMEM complete culture medium.
Our cells are grown in 100 mm tissue culture dishes. All volumes used in the
remainder of this protocol are reported with respect to 100 mm dishes.
2. Remove the DMEM complete culture medium, wash plates 3X with PBS, and
incubate cells in 10 ml serum-free DMEM for 16 h at 37 ◦C.
Culture medium and other cell culture reagents (e.g. 0.25% trypsin) should
always be pre-warmed to 37 ◦C prior to use in an experiment. Cells are very
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sensitive to changes in temperature and all precautions should be taken in
order to avoid sudden alterations in culture environment.
3. After serum-starvation, remove the serum-free DMEM and wash plates 3X with
PBS.
4. Add 5 ml of serum-free DMEM containing 100 ng/ml EGF to each plate of cells
and stimulate for 5 min at 37 ◦C.
A control should be performed in parallel using unstimulated cells in order to
assess EGF-dependent changes in protein sulfenylation.
5. At the end of the incubation period, remove the stimulation medium and wash
plates 3X with PBS.
6. Lift cells with 0.25% trypsin. Add 5 ml of serum-free DMEM to quench trypsin,
and collect cells by centrifugation for 2 min at 1500 × g at rt.
7. Remove medium and resuspend cells in serum-free DMEM at a density of 3-4 ×
106 cells/ml.
One 100 mm plate of A431 cells will typically yield ∼3 × 106 cells. Ac-
cordingly, we resuspend each plate in 800 µl serum-free DMEM and transfer
400 µl aliquots of cell suspension to 1.5 ml microcentrifuge tubes for labeling
experiments.
8. Label cells with 5 mM DAz-2 or DYn-2 (from 250 mM probe stock).
To 400 µl of cell suspension add 8.2 µl DAz-2 or DYn-2 to each sample and
gently mix. DMSO should be used as concurrent vehicle control for all probe-
labeling experiments.
9. Incubate cell labeling reactions for 1 h at 37 ◦C.
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After 30 min, gently mix cells. Labeling times may range from 15 min to 2
h. This variable is cell- and stimulant-type dependent.
10. After cell labeling, remove excess probe by washing cells 3X with PBS (500 µl, 2
min at 1500 × g) at rt.
At this point, washed cell pellets can be frozen in liquid N2 and stored at -80
◦C. Otherwise, we recommend continuing the experiment up to the precipita-
tion step.
11. Lyse cells in modified RIPA lysis buffer for 20 min on ice.
Cell lysis can be aided by vortexing or pipetting up and down.
12. Clear lysate of cell debris by centrifuging for 20 min at 16,000 × g, 4 ◦C.
13. Quantify protein content of cleared cell lysate using a standard BCA assay.
Protein concentrations typically range from 2-8 mg/ml, depending on the cell
type.
14. If a biotin tag is used to detect labeled proteins by Western blot, a pre-clear step
is recommend to remove endogenous biotinylated proteins prior to click chemistry.
If a fluorescent tag is used to detect labeled proteins by in-gel fluorescence, the
pre-clear step can be omitted and the user may continue to the next step of this
protocol.
Please refer to Support Protocol 1 for the pre-clear step.
15. Transfer 100 µg cell lysate to 1.5 microcentrifuge tubes for each sample.
16. Detect probe-labeled proteins via click chemistry. The total volume of the click
chemistry reaction should be 100 µl. Add the reaction components in the following
order to each sample and mix well:
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a. 89 µl cell lysate (100 µg)
Make up any remaining volume with the modified RIPA lysis buffer.
b. 2 µl of 5 mM biotin or fluorescent reporter tag (final concentration of 100 µM)
c. 2 µl of 50 mM TCEP (final concentration of 1 mM)
d. 5 µl of 2 mM TBTA (final concentration of 100 µM)
e. 2 µl of 50 mM CuSO4 (final concentration of 1 mM)
17. Rock click chemistry reactions for 1 h at rt.
If a fluorescent tag is used (i.e. TAMRA or AlexaFluor488 azide) perform
reactions in the dark. In addition, take all necessary precautions to carry out
the remaining steps of the experiment in the dark if a fluorescent reagent is
used.
18. Quench the click chemistry reactions with 40 mM EDTA (from 0.5 M stock). Rock
the reactions for 5 min at rt.
EDTA chelates any remaining copper, thereby quenching the click chemistry
reaction.
19. Perform a methanol or methanol/chloroform precipitation of the protein.
a. Support Protocol 2 Methanol precipitation
b. Support Protocol 3 Methanol/chloroform precipitation
Either precipitation method works well with our protocol and the choice is dic-
tated by user preference.
20. Add 20 µl 10% SDS to dissolve protein pellets.
A bath sonicator may be used at this step to help re-solubilize the protein
pellets.
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21. Add 20 µl Laemmli sample buffer, 2X (10% β-ME) to each sample and mix well.
22. Boil the protein samples for 10 min at 95 ◦C using a heating block.
23. Vortex the samples and centrifuge for 1 min at 16,000 × g, rt.
24. Resolve samples by SDS-PAGE using Mini-Protean TGX 4-15% Tris-Glycine gels.
Typically, 25 µg protein/lane is adequate to detect protein sulfenylation.
25. Analyze experimental results with the detection method of choice.
a. Basic Protocol 4 Western blot
i. Figure A.4a DAz-2/Biotin Alkyne
ii. Figure A.4b DYn-2/Biotin Azide
b. Basic Protocol 5 In-gel fluorescence
i. Figure A.4c DYn-2/TAMRA Azide
ii. Figure A.4d DYn-2/AlexaFluor488 Azide
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Figure A.4: Detection of EGF-mediated protein sulfenylation in A431 cells. A431 cells
were stimulated with 100 ng/ml EGF for 5 min. EGFR activation leads to the production of
endogenous H2O2 and concomitant changes in protein sulfenylation. Cells were labeled with DAz-2
or DYn-2 for 1 hr. Sulfenylated proteins can be detected by streptavidin-HRP immunoblot (A-B)
or in-gel fluorescence (C-D). Equal protein loading is demonstrated by reprobing the immunoblot




LABELING EXOGENOUS SULFENYLATED PROTEINS IN CELL SUS-
PENSION.
The following is a standard protocol for live cell labeling of sulfenyl modifications in
HepG2 cells, which are easy to subculture and manipulate. In this protocol, exogenous
H2O2 is applied directly to cells as opposed to ligand stimulation of endogenous H2O2
production. The user is also welcome to substitute HeLa cells for HepG2 cells in these
experiments (16).
Materials
• HepG2 cells (ATCC)
• MEM complete culture medium (MEM supplemented with 10% FBS, 1% Glu-
taMax, 1% MEM nonessential amino acids, and 1% penicillin-streptomycin;
Invitrogen)
• MEM with 0.5% FBS (MEM supplemented with 0.5% FBS; Invitrogen)
• 0.25% trypsin (Invitrogen)
• 100 mM H2O2 stock (Sigma-Aldrich), prepared fresh in H2O and maintained
on ice
• DMSO (vehicle; Sigma-Aldrich)
• 250 mM DAz-2 (Cayman Chemicals) or DYn-2 (Cayman Chemicals), prepared
in DMSO
• Modified RIPA lysis buffer supplemented with EDTA-free protease inhibitors
and 200 U/ml catalase (see recipe)
• PBS, 1X (Boston BioProducts)
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• BCA protein assay (Pierce)
• 5 mM biotin tag (biotin alkyne or azide; Invitrogen) in DMSO or 5 mM fluo-
rescent tag (TAMRA or AlexaFluor488 azide; Invitrogen) in DMSO
• 50 mM TCEP (Sigma-Aldrich), prepared fresh in H2O
• 2 mM TBTA (Sigma Aldrich), prepared in 4:1 DMSO: t-butanol
• 50 mM CuSO4, prepared fresh in H2O
• 0.5 M EDTA (Boston BioProducts)
• 10% SDS, prepared in H2O
• Laemmli sample buffer, 2X with 10% β-mercaptoethanol (BioRad)
• Mini-Protean TGX 4-15% Tris-Glycine protein gels (BioRad)
1. Grow HepG2 cells to 75-80% confluency in MEM complete culture medium.
Our cells are grown in 100 mm tissue culture dishes. All volumes used in
the remainder of this protocol are reported with respect to 100 mm dishes.
Culture medium and other cell culture reagents (e.g. 0.25% trypsin) should
always be pre-warmed to 37 ◦C prior to use in an experiment.
2. Remove MEM complete culture medium, and wash plates 3X with PBS. 3. Add
5 ml MEM (0.5% FBS) containing 500 µM H2O2 to each plate. Incubate cells
with H2O2 for 5 min at 37 ◦C.
A control should be performed in parallel using untreated cells in order to
assess H2O2 -dependent changes in protein sulfenylation.
3. Remove MEM (0.5% FBS) containing 500 µM H2O2. Wash plates 3X with
PBS.
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4. Continue the rest of the experiment as in Basic Protocol 2, steps 6 to 25.
For HepG2 cells, take care to use MEM (0.5% FBS) medium throughout
the rest of the experiment.
5. Expected results for HepG2 cells can be found in:
a. Figure A.5a DAz-2/Biotin Alkyne
b. Figure A.5b DYn-2/Biotin Azide





















Figure A.5: Global changes of protein sulfenylation in HepG2 cells exposed to exogenous
H2O2. HepG2 cells were treated with 500 µM H2O2 for 5 min. Cells were labeled with DAz-2 or
DYn-2 for 1 hr. Sulfenylated proteins can be detected by streptavidin-HRP immunoblot (A-B) or
in-gel fluorescence (not shown). Equal protein loading is demonstrated by reprobing the immunoblot
with antibodies to GAPDH (immunoblot).
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Basic Protocol 4
WESTERN BLOT DETECTION OF BIOTINYLATED PROTEINS
The following is a standard protocol for Western blot detection of biotinylated
proteins. After completing Basic Protocol 1, 2, or 3, the user should refer to this
section if a biotin tag (i.e. biotin alkyne or azide) was employed during the click
chemistry step.
Materials
• SDS-PAGE gel with resolved samples
• PVDF membrane, 0.2 µm (BioRad)
• TBST (Boston BioProducts)
• 3% BSA (Fisher), prepared in TBST
• Streptavidin-HRP antibody (GE-Healthcare)
• GAPDH antibody (Santa Cruz Biotechnology)
• Rabbit anti-mouse IgG-HRP (Invitrogen)
• ECL Plus Western Blot Detection System (GE Healthcare)
1. Transfer SDS-PAGE gel with samples of interest onto a PVDF membrane using
standard Western blot transfer techniques (30).
2. After transfer, block the PVDF membrane with 3% BSA for 1 h at rt.
3. Wash the membrane 2X with TBST for 10 min.
4. Incubate the membrane with streptavidin-HRP (1: 80,000) for 1 h at rt.
All antibodies in this protocol should be diluted in TBST.
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5. After antibody incubation, wash the membrane 2X with TBST for 10 min.
6. Develop the membrane with chemiluminescence using the ECL plus Western blot
detection system, as indicated by the manufacturer’s (GE Healthcare) instructions.
7. Image the results by film.
8. After imaging, re-block the membrane with 3% BSA for 1 h at rt.
9. Wash the membrane 2X with TBST for 10 min.
10. Incubate the membrane with GADPH primary antibody (1: 200) for 1 h at rt.
GAPDH serves as a loading control. Other protein standards may be used, as
necessary.
11. After primary antibody incubation, wash the membrane 2X with TBST for 10
min.
12. Incubate the membrane with rabbit anti-mouse HRP (1: 50,000) for 1 h at rt.
13. After secondary antibody incubation, wash the membrane 2X with TBST for 10
min.
14. Develop the membrane with chemiluminescence using the ECL plus Western blot
detection system, as indicated by the manufacturer’s instructions.
15. Image the results by film.
Basic Protocol 5
IN-GEL DETECTION OF FLUOROPHORE-TAGGED PROTEINS
The following is a standard protocol for in-gel detection of fluorophore-tagged
proteins. After completing Basic Protocol 1, 2, or 3, the user should refer to this
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section if a fluorescent tag (i.e. TAMRA or AlexaFluor488 azide) was used during
the click chemistry step.
Materials
• SDS-PAGE gel with resolved samples
• Destain solution (see recipe)
• Wash solution (see recipe)
• SYPRO Ruby Protein Stain (BioRad)
• Fluorescence gel scanner (e.g. Amersham Biosciences Typhoon 9400 variable
mode imager)
1. Destain SDS-PAGE gel with the samples of interest 2X with destain solution for
10 min.
The gel should be rocked during the destaining process. This step is necessary
to remove any background fluorescence from excess reagents. Gels should
be handled carefully during all destain and wash steps to avoid background
smudging.
2. Wash the gel with H2O for 10 min, while rocking.
3. Scan the gel using a fluorescence gel scanner.
We use a Typhoon 9400 variable mode imager (Amersham Biosciences) for
in-gel fluorescence analysis. The fluorescent reagents used in this protocol
have the following excitation and emission wavelengths:
a. TAMRA Azide 555/580 nm (ex/em)
b. AlexaFluor488 Azide 495/519 nm (ex/em)
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4. After visualizing results from the fluorescent reagent of choice, soak gel in destain
solution for 30 min.
5. Stain gel with SYPRO ruby protein stain to demonstrate equal protein loading,
as indicated by the manufacturers instructions.
The SYPRO ruby signal can typically be seen after 3 h incubation. After
staining, the gel can be washed 2X with wash solution for 10 min, and 1X with
H2O for 10 min prior to imaging. SYPRO ruby has the following excitation
and emission wavelengths: 280 or 450/610 nm (ex/em).
Support Protocols
Support Protocol 1
PRE-CLEARING CELL LYSATES OF ENDOGENOUS BIOTINYLATED
PROTEINS
The following is a standard protocol to pre-clear cell lysates of endogenous bi-
otinylated proteins prior to the click chemistry step.
Materials
• Cell lysates
• Modified RIPA buffer (see recipe)
• NeutrAvidin agarose resin (Pierce)
1. Aliquot NeutrAvidin resin into 1.5 ml microcentrifuge tubes for each sample.
To pre-clear 100 µg cell lysate, use 50 µl of NeutrAvidin resin.
2. Pre-equilibrate NeutrAvidin resin with modified RIPA buffer (3 × 500 µl) for 2
min at 2300 × g.
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After the last wash, take care to completely remove modified RIPA buffer to
maintain consistent protein concentration between each sample.
3. Load 100 µg cell lysate onto pre-equilibrated NeutrAvidin resin. Make up any
remaining volume with the modified RIPA lysis buffer.
The click chemistry reaction is the next step of the protocol, and these reac-
tions should have a total volume of 100 µl for 100 µg cell lysate (i.e. final
protein concentration = 1mg/ml). It is important to maintain this volume
during the pre-clear step and to consider the subsequent volume of added click
chemistry reagents. For example, the volume of the cell lysate loaded onto the
NeutrAvidin resin for the pre-clear step should not exceed 89 µl for 100 µg cell
lysate as the remaining volume (11 µl) will be the click chemistry reagents.
4. Rock pre-cleared samples for 30 min at 4 ◦C.
5. To collect pre-cleared cell lysate, centrifuge sample for 2 min at 2,300 × g, rt.
Transfer cell lysate to a clean 1.5 ml microcentrifuge tube. Discard NeutrAvidin
resin used for the pre-clear step.
The cell lysates are now free of endogenous biotinylated proteins. Continue




METHANOL PRECIPITATION OF PROTEINS.
The following is a standard protocol for methanol precipitation of proteins after
click chemistry. Alternatively, the user may choose to perform a methanol/chloroform
(Support Protocol 3) precipitation.
Materials
• Click chemistry reaction of cell lysate
• Methanol, ice-cold
1. Add 1 ml ice-cold methanol to each sample and vortex to mix.
2. Allow proteins to precipitate overnight at -80 ◦C.
3. Collect protein pellet by centrifuging the samples for 10 min at 16,000 × g, 4
◦C.
4. Carefully remove methanol, being careful not to disturb the protein pellet. Wash
the protein pellet with 1 ml ice-cold methanol.
The second methanol wash is necessary to remove any residual click chem-
istry reagents.
5. Centrifuge samples for 10 min at 16,000 × g, 4 ◦C.
6. Carefully remove the methanol, leaving the protein pellet behind. Continue
with the rest of the protocol.
Make sure to remove all traces of excess methanol prior to continuing to
the next step of the experiment.
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Support Protocol 3
METHANOL/CHLOROFORM PRECIPITATION OF PROTEINS
The following is a standard protocol for methanol/chloroform precipitation of
proteins after click chemistry.
Materials




1. To perform a methanol/chloroform precipitation, add the precipitation compo-
nents in the following order to each sample. Vortex the sample after the addition
of each component to mix.
a. 600 µl of methanol
b. 150 µl of chloroform
c. 400 µl of H2O
2. Centrifuge the samples for 10 min at 16,000 × g, 4 ◦C.
3. Carefully remove and discard as much of the upper aqueous layer as possible,
without disturbing the interface layer containing the protein precipitate.
• A thin interface layer containing the precipitated protein should form between
the upper aqueous layer and the lower organic layer.
4. Add 1 ml ice-cold methanol to each sample and vortex to mix.
5. Centrifuge the samples for 10 min at 16,000 × g, 4 ◦C.
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6. Carefully remove methanol, being careful not to disturb the protein pellet. Wash
the protein pellet with 1 ml ice-cold methanol.
• The second methanol wash is necessary to remove any residual click chemistry
reagents.
7. Centrifuge samples for 10 min at 16,000 × g, 4 ◦C.
8. Carefully remove methanol, leaving the protein pellet behind. Allow any remaining
methanol or chloroform to evaporate by leaving the sample tubes open on the
bench. Allow protein pellet to air-dry for 30 min to 1 h at rt. Continue with the
rest of the protocol.
• The dried protein pellet will be thin and have a translucent white color. It is
crucial to allow the protein pellet to completely dry prior to proceeding with




ON-PLATE LABELING OF ENDOGENOUS PROTEIN SULFENYLA-
TION IN CELLS.
The following is a standard protocol for labeling cells that remain attached to the
plate. Although we observe comparable results for suspension versus plate detection
of sulfenyl modifications (Figure A.4 a and Figure A.6 a), labeling cells in suspension
may not provide ideal for some cell lines or stimulants. The user should determine
which labeling method is best for their purposes.
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Materials
1. Follow steps 1-5 in Basic Protocol 2.
• For on-plate labeling, cells can be grown in 60 mm tissue culture dishes to
reduce probe consumption. Media volumes should be adjusted accordingly for
smaller culture plates. For example, EGF stimulation should be performed
with 2 ml for 60 mm plates, instead of 5 ml for 100 mm plates.
2. Add 2 ml serum-free DMEM containing 5 mM DAz-2 or DYn-2 (from 250 mM
probe stock) to each plate of cells.
• For 2 ml medium, 40.8 µl of 250 mM DAz-2 or DYn-2 is needed to achieve
a final concentration of 5 mM. In addition, a DMSO vehicle control should
always be included for unstimulated and EGF-stimulated cells.
3. Label cells for 1 h at 37 ◦C.
4. Remove serum-free DMEM containing 5 mM DAz-2 or DYn-2. Wash the plates
3X with PBS.
5. Lyse cells in modified RIPA lysis buffer using a rubber policeman. Transfer cell
lysates to a clean 1.5 ml microcentrifuge tube.
6. Follow steps 11-25 in Basic Protocol 2.
7. Expected results for on-plate labeling of protein sulfenyl modifications in A431
cells can be found in:
a. Figure A.6a DAz-2/Biotin Alkyne
Time-dependent labeling of A431 cells that remain attached to the plate indi-
cates that 1 h yields the best results.
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Alternatie Protocol 2
ON-PLATE LABELING OF EXOGENOUS PROTEIN SULFENYLATION
IN CELLS
The following is a standard protocol for on-plate labeling of sulfenylated proteins
in HepG2 cells.
Materials
See materials list for Basic Protocol 3
1. Follow steps 1-4 in Basic Protocol 3.
For on-plate labeling, cells can be grown in 60 mm tissue culture dishes to
reduce probe consumption. Media volumes should be adjusted accordingly for
smaller culture plates. For example, the H2O2 stimulation should be performed
with 2 ml for 60 mm plates, instead of 5 ml for 100 mm plates.
2. 2. Add 2 ml MEM (0.5% FBS) containing 5 mM DAz-2 or DYn-2 (from 250 mM
probe stock) to each plate of cells.
For 2 ml medium, 40.8 µl of 250 mM DAz-2 or DYn-2 is needed to achieve a
final concentration of 5 mM. In addition, a DMSO control should always be
included for untreated and H2O2-exposed cells.
3. Label cells for 1 h at 37 ◦C.
4. Remove MEM (0.5% FBS) containing 5 mM DAz-2 or DYn-2. Wash the plates
3× with PBS.
5. Lyse cells in modified RIPA lysis buffer using a rubber policeman. Transfer cell
lysate to a clean 1.5 ml microcentrifuge tube.
6. Follow steps 11-25 in Basic Protocol 2.
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7. Expected results for on-plate labeling of HepG2 cells can be found in:
a. Figure A.6b DAz-2/Biotin Alkyne
Time-dependent labeling of HepG2 cells that remain attached to the plate
indicates that 1 h yields the best results.



































Figure A.6: Labeling and detection of protein sulfenylation in adherent A431 and HepG2
cells. Cells were exposed to 100 ng/ml EGF (A431) or 500 µM H2O2 (HepG2) for 5 min. After
treatment, cells remained attached to the tissue culture plate and were labeled with DAz-2 for
the indicated times. Sulfenylated proteins were visualized by streptavidin-HRP immunoblot for (A)
A431 cells and (B) HepG2 cells. Equal protein loading is demonstrated by reprobing the immunoblot
with antibodies to GAPDH (immunoblot).
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Reagents And Solutions
Use Milli-Q purified water in all recipes and protocol steps.
Tris labeling buffer, pH 7.4
50 mM Tris-HCl, pH 7.4
150 mM NaCl
Sterilize by passing through a 0.2-ţm filter and store for up to 6 months at rt.
Click labeling buffer, pH 7.4
50 mM triethanolamine, pH 7.4
1% SDS
Sterilize by passing through a 0.2-ţm filter and store for up to 6 months at rt.
Modified RIPA lysis buffer, pH 7.4





Sterilize by passing through a 0.2-µm filter and store for up to 1 month at rt.
Shortly before use, add EDTA-free complete mini protease inhibitors (Roche)







Mix 400 ml methanol, 500 ml H2O, and 100 ml acetic acid to make 1 L destain





Mix 100 ml methanol, 700 ml H2O, and 100 ml acetic acid to make 1 L wash
solution. Store for up to 1 year at rt.
Commentary
Background Information
Historically, methods to detect reactive cysteines and H2O2-mediated oxidation
of protein thiols require the homogenization of cells, which disrupts the native en-
vironment. Under these conditions, cellular redox balance and protein structure are
compromised, leading to artifactual oxidation during sample processing. This core
issue is typically ignored in redox proteomic studies, but casts a pall on the biological
significance of such data. To address this problem, we have developed small-molecule
probes that enable sulfenylated proteins to be trapped and tagged directly in cells. Us-
ing this new approach, we have dissected the molecular mechanism of H2O2-sensing in
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yeast (25), reported the first in situ proteomic study of protein sulfenylation in mam-
malian cells (16), uncovered striking differences in sulfenylation profiles among breast
cancer subtypes (31), discovered a bacterial protein that functions in desulfenylation
(14), and demonstrated that sulfenylation functions a global signaling mechanism
akin to phosphorylation during EGFR signaling (17). Clearly, selective chemical re-
porters have opened the door to a better understanding of the important biological
role of protein cysteine sulfenylation.
Our first global analysis of sulfenylated proteins in HeLa cells revealed that poten-
tially modulatory cysteine residues exist in almost 200 individual proteins, including
kinases, phosphatases, transporters, GTPases, and transcription factors, thereby ex-
tending this form of redox regulation to a wide range of biological activities (16).
Nonetheless, the vast majority of H2O2-sensitive protein cysteine residues await iden-
tification. This is a vigorous area of research in our lab and, towards this end we
have developed two complementary isotope-coded probe pairs to quantify changes in
protein sulfenylation (9-10 and 4-5; Figure A.1 c) (21, 22). Most recently, we have
reported reagents to selectively monitor reversible oxidation of PTPs by adding an
active site-targeting module to the sulfenyl probes (10, 11; Figure A.1 c) (15).
Critical Parameters and Trouble Shooting
The order in which reagents are added during experiments to purified protein in
vitro or cells is an important consideration. In general, we add the ligand stimulant (or
H2O2) before the probe-labeling step. However, this parameter should be investigated
on a case-by-case basis, in addition to dose and time-dependent changes in labeling.
For cell labeling experiments, cells should be cultured carefully without sudden
changes in the culture environment. For example, culture reagents such as media
and trypsin should be pre-warmed to 37 ◦C prior to use. Depending on the cell
line, culture media should be replenished every 2-3 days. As with many biological
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processes studied in a cell culture model, the confluency at the time of stimulation
and labeling can impact the final results. If stimulant- or H2O2-dependent changes in
protein sulfenylation are difficult to discern, a number of factors should be checked.
All stocks (ligand stimulant and probes) should always be kept on ice during the
experiment and otherwise stored at -30 ◦C when not in use. In addition, lysis buffer
and cell lysates should be kept on ice at all times. Once cells have been stimulated,
downstream wash and lifting steps should be carried out in a timely manner. Any
unnecessary delays in sample handling prior to cell lysis should be avoided, as this
may also affect final results. Additionally, for maximum probe potency, culture media
used during cell labeling should not exceed 0.5% FBS.
Click chemistry reactions should always be performed with fresh TCEP and CuSO4
stocks. We typically make these stocks up fresh directly before setting up the reac-
tions. TCEP can oxidize over time, which would reduce the efficiency of the reaction
since it is required for reduction of CuSO4 to Cu(I). In addition, the second methanol
wash in both precipitation procedures is crucial in order to completely remove excess
click chemistry reagents. Failure to do so may result in higher background signals
during the visualization process. If equal loading is not observed, it is also important
to ensure that the protein pellets are completely re-solubilized. In some cases, this can
be a challenge, particularly for samples that have been methanol/chloroform precipi-
tated. Protein pellets must be completely free of chloroform prior to re-solubilization,
otherwise they will not fully return to solution.
For in-gel fluorescence experiments, special precautions should be taken once the
fluorescent tag is added to the sample. Steps such as the click chemistry reaction,
SDS-PAGE analysis, and destaining should be done in the dark to avoid sample
bleaching. During SDS-PAGE analysis, the dye front should be run completely off the
gel during electrophoresis to remove any unincorporated fluorescent tag and minimize
background fluorescence. Gels should also be thoroughly destained and washed prior
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to imaging. In addition, only clean gloves and containers should be used to handle
the gels. Because in-gel fluorescence is an extremely sensitive technique, faulty gel
handling can lead to fingerprints and smudges during the visualization process. Gels
should only be handled on the edges as carefully as possible, to avoid undesirable
blemishes on the scanned image.
Anticipated Results
Anticipated results for labeling of sulfenic acids in a purified protein (GAPDH)
can be found in Figure A.3 for both Western blot (Figure A.3 a and b) and in-
gel fluorescence detection (Figure A.3 c and d). It is expected that the active site
cysteine should exhibit a robust H2O2-dependent increase in probe labeling. If a
peroxide dependent effect is not observed in the protein of interest, it is possible
that the cysteine(s) are not H2O2-sensitive or that the basal level of oxidation is
high. Similarly, anticipated results for labeling of protein sulfenylation in cells (A431)
with a stimulant (EGF) that leads to endogenous production of H2O2 can be found
in Figure A.4 and Figure A.6 for Western blot (Figure A.4 a, b, and Figure A.6
a) and in-gel fluorescence detection (Figure A.4 c and d). If a stimulant induces
endogenous H2O2 production, an increase in sulfenylated proteins should be observed.
Finally, we provide a protocol for cells (HepG2) stimulated with H2O2 so that the user
may develop and hone their skills as necessary (Figure A.5 a, b, and Figure A.6 b).
DMSO vehicle control lanes should have negligible background signal. In cell lysate
samples that have been pre-cleared with NeutrAvidin agarose resin, signal may still
be evident at ∼66 and 97 kDa. In fact, these bands may be observed for unlabeled
and probe-labeled samples. This is not cause for major concern and indicates that
biotinylated proteins could not be completely depleted from samples. Results can
be considered successful if the signal from probe-labeled samples is higher than the
control lanes, and if a stimulant-dependent increase of signal is observed. If the user
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finds it difficult to observe the desired stimulant-dependent response, a number of
solutions can be explored. Simple adjustments such as changing the concentration
of the probe, stimulant, labeling times, and protein loading should be considered
(see Strategic Planning or Critical Parameters and Troubleshooting for more detailed
explanations). The sensitivity of the detection method can also be a factor and thus,
Western blot and in-gel fluorescence should both be explored.
Time Considerations
The experiments outlined in this protocol can typically be completed between
2-3 days from labeling to detection of sulfenylated proteins. Experiments with puri-
fied protein in vitro (Basic Protocol 1) can be paused after sample buffer has been
added to click chemistry reactions (6-8 h). Western blot or in-gel fluorescence de-
tection can be carried out on the same or following day, depending on the user.
Live cell experiments (Basic Protocol 2 and 3) can be paused at the methanol or
methanol/chloroform precipitation step (6-8 h). For live cell experiments, detection
of sulfenylated proteins should be performed the next day after samples have been
resuspended. Additionally, the user may pause the experiment directly after the cells
are labeled with DAz-2 or DYn-2. After washing cells to remove labeling media, cell
pellets can be harvested and stored at -80 ◦C (see Basic Protocol 2, step 10). However,
after cell lysis we recommend that the experiment be continued to the precipitation
step to avoid compromising the click chemistry reaction. We highly encourage the
user to explore Basic Protocol 2 with other cell types and stimulants relevant to their
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Redox Regulation of Protein Kinases
Abstract
Protein kinases represent one of the largest families of genes found in eukaryotes.
Kinases mediate distinct cellular processes ranging from proliferation, differentiation,
survival, and apoptosis. Ligand-mediated activation of receptor kinases can lead to
the production of endogenous H2O2 by membrane-bound NADPH oxidases. In turn,
H2O2 can be utilized as a secondary messenger in signal transduction pathways. This
review presents an overview of the molecular mechanisms involved in redox regulation
of protein kinases and its effects on signaling cascades. In the first half, we will focus
primarily on receptor tyrosine kinases (RTKs), whereas the latter will concentrate on
downstream non-receptor kinases involved in relaying stimulant response. Select ex-
amples from the literature are used to highlight the functional role of H2O2 regarding
kinase activity, as well as the components involved in H2O2 production and regula-
tion during cellular signaling. In addition, studies demonstrating direct modulation of
protein kinases by H2O2 through cysteine oxidation will be emphasized. Identification
of these redox-sensitive residues may help uncover signaling mechanisms conserved
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within kinase subfamilies. In some cases, these residues can even be exploited as
targets for the development of new therapeutics. Continued efforts in this field will
further basic understanding of kinase redox regulation, and delineate the mechanisms
involved in physiologic and pathological H2O2 responses.
Introduction
The response to extracellular stimuli relies on an integrated network of signal
transduction pathways that function in a highly coordinated manner. Crosstalk be-
tween these networks is modulated in part by phosphorylation of target proteins by
protein kinases and the complementary actions of protein phosphatases (1). Initiation
of signaling cascades occurs through the activation of receptor tyrosine kinases (RTKs)
upon stimulation with growth factors and other ligands. RTKs relay signals down-
stream through activation of effector proteins, such as non-receptor kinases. Protein
kinases (receptor and non-receptor) are among one of the largest families of genes
found within eukaryotes. For example, the human genome contains ∼ 518 kinase
genes, constituting about 1.7% of all human genes (2). Kinases are critical enzymes
involved in mediating a number of fundamental processes including the cell cycle,
proliferation, differentiation, metabolism, migration, and survival (3, 4). Perturba-
tion of physiologic kinase signaling due to mutations and other genetic alterations
can result in aberrant kinase activity and malignant transformation, as characterized
in a number of human disease states (5).
During cellular signaling, kinase activity can also be modulated by additional
mechanisms in conjunction with phosphorylation. A wealth of evidence now im-
plicates the regulatory role of reactive oxygen species (ROS) in signal transduction
networks (6–8). Controlled production of endogenous hydrogen peroxide (H2O2) can
be induced when stimulants bind to their respective receptors (i.e. RTKs) (9). In
turn, H2O2 modulates downstream pathways by reacting with specific protein targets
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through oxidative modification of key cysteine residues. Protein kinases represent
a large number of candidates that are regulated by and utilize H2O2 as secondary
messengers (10, 11). For more detailed discussion of general concepts underlying re-
dox signaling, the interested reader is referred to the following extensive reviews for
additional information on these topics (7, 8, 12–17). Abnormal H2O2 production can
result in promiscuous damage of biomolecules, and is prevalent in aging and disease
states such as human cancers, neurodegenerative disorders, and diabetes (18–20).
In this review, we provide an overview of the molecular mechanisms involved in
redox regulation of protein kinases and its effects on downstream signaling cascades.
We begin by highlighting key examples of receptor kinases characterized by stimulant-
induced H2O2 production as well as non-receptor kinases. Components involved in the
production and modulation of H2O2 levels during kinase signaling will be addressed.
In addition, we discuss the functional role of H2O2-mediated signaling with regards
to kinase activity. Finally, we shift our focus to examples from the literature that
demonstrates direct modulation of protein kinases by H2O2 occurs through cysteine
oxidation of key residues. Depending on the kinase, direct oxidation can result in
activation or deactivation. Continued efforts geared towards identifying protein tar-
gets of signal-derived H2O2 will further our mechanistic understanding of redox-based
kinase signaling, and may lead to the development of new therapeutic strategies.
Evidence for Redox Regulation of Receptor Tyrosine Kinases
RTKs play an important role in recognition and response to stimulant binding.
These enzymes are composed of an extracellular ligand binding domain, a transmem-
brane domain, and an intracellular domain containing a conserved tyrosine kinase
core and additional regulatory sequences. The RTKs covered in this review, with
the exception of the insulin receptor kinase (IRK), exist as monomers in the cellu-
lar membrane. In a simplified model (Figure B.1a), the receptor-ligand interaction
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induces receptor dimerization (homo- or hetero-), followed by autophosphorylation
of key residues located within the tyrosine kinase core to provide docking sites for
binding proteins. Once activated, the RTK relays the signal downstream through
non-receptor kinases to mediate a number of biological processes.
Beginning in the 1990s, several groups observed that growth factor stimulation re-
sulted in rapid bursts of intracellular H2O2. Contrary to the preconceived notion that
once considered ROS as toxic byproducts of aerobic respiration, ensuing efforts have
established that these species can act as secondary messengers. In a landmark study
by Finkel and colleagues, platelet-derived growth factor (PDGF)-induced H2O2 pro-
duction was shown to have downstream effects on global Tyr phosphorylation levels,
activation of MAPK pathways, DNA synthesis, and chemotaxis (21). Thereafter, epi-
dermal growth factor (EGF) was reported to induce increased endogenous ROS levels
upon receptor binding (22). Inhibition of ROS production by peroxide-detoxifying
enzymes and chemical inhibitors blocked normal Tyr signaling triggered by growth
factor stimulation. These observations, along with additional growth factors (Ta-
ble B.1), suggest that RTK stimulation may utilize redox-based mechanisms during
signal transduction in parallel to protein phosphorylation.
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Figure B.1: Activation of RTKs and downstream signaling cascades. (a) Growth factors
bind to RTKs to induce receptor dimerization, followed by autophosphorylation of key Tyr residues
(red circles) located within its cytoplasmic domain. In turn, these phosphorylated Tyr residues serve
as docking sites for associating proteins to activate a number of downstream signaling cascades. Two
such pathways, Ras/ ERK and PI3K/AKT, are shown here for simplicity. Ligand-receptor interac-
tions also trigger the assembly and activation of Nox complexes, followed by subsequent production
of H2O2 through spontaneous dismutation or action of SOD. Once formed, endogenous H2O2 may
pass through specific aquaporin (AQP) channels and/or diffuse across the membrane to reach the
intracellular cytosol. Transient increases in H2O2 lead to the oxidation of localized redox targets.
(b) Unlike other RTKs, IRK exists as a heterotetrameric receptor composed of two extracellular
α-subunits and two transmembrane β-subunits. Binding of insulin to IRK a subunits induces a
conformational change in its quaternary structure to enable ATP binding, receptor autophospho-
rylation, and production of Nox-derived H2O2. Once activated, IRK recruits members of the IRS
protein family to initiate glucose metabolism through the PI3K/AKT pathway. Insulin signaling
also has mitogenic effects that are mediated through Ras/ERK.
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Downstream Signaling Pathways Mediated by RTKs
Ligand stimulation of RTKs activates a number of signaling routes that include,
but are not limited to the following: 1) Ras/mitogen activated protein kinase (MAPK)
pathway, 2) phosphatidylinositol 3’ kinase (PI3K)/Akt pathway, or 3) phospholipase
C-γ (PLC-γ). RTKs essentially share similar transduction machinery to elicit, in
many cases, different cellular responses. In the Ras/MAPK pathway, signaling is
triggered in a sequential order (Ras-Raf-MEK-Erk1/2). This pathway is initiated by
receptor recruitment of adaptor protein SHC, growth factor receptor-bound protein 2
(Grb2), and a guanine nucleotide exchange protein (SOS) to form a tertiary complex.
SOS facilitates GDP exchange to activate the small GTPase Ras. Ras completes the
relay by stimulating a kinase cascade through activation of Raf (MAP3K), MEK,
and Erk1/2 (MAPK). Upon activation, Erk1/2 (extracellular regulated kinase 1/2)
translocates to the nucleus whereby it phosphorylates substrates (∼ 200 known tar-
gets to date) ranging from transcription factors, other kinases and phosphatases, and
cytoskeletal elements (23, 24). Small fractions of Erk1/2 may localize to other sub-
cellular compartments such as the mitochondria, Golgi apparatus, or cell membrane
to dictate signal specificity. Erk1/2 regulates cellular proliferation, differentiation,
and survival, whereas other MAPKs such as JNK (Jun N-terminal kinase) and p38
function mainly as stress-activated kinases involved in inflammatory response and
apoptosis (25, 26). MAPK pathways are known to be subject to redox regulation,
albeit mainly through indirect mechanisms occurring upstream (27).
The PI3K/Akt pathway represents a common route activated by RTKs susceptible
to redox-based modulation (28). Upon stimulation, PI3K increases the intracellular
levels of phosphatidylinositol (3,4,5) triphosphate (PIP3). PI3K phosphorylates phos-
phatidylinositol (4,5) bisphosphate (PIP2) at its 3-hydroxyl position to generate PIP3.
PIP3 acts as a lipid secondary messenger to activate Akt (also known as PKB, protein
kinase B) by binding to its pleckstrin homology (PH) domain (29, 30). This results
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in translocation of Akt to the membrane, wherein it undergoes phosphorylation by
PDK1 (phosphoinositide dependent kinase 1) and the mTOR (mammalian target of
rapamycin)-rictor kinase complex to enable full activation. Akt phosphorylates a
number of targets (∼ 100 known to date) to mediate a vast range of biological pro-
cesses involved in pro-survival events (31). PI3K/Akt activity is negatively regulated
by a dual protein and lipid phosphatase, PTEN (phosphatase and tensin homologue)
(32). PTEN modulates PI3K activity by hydrolyzing the 3-phosphate group from
PIP3, and thereby functions as a crucial tumor suppressor in this pathway (33, 34).
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Effect of stimulant Reference
PDGF M, R Nox Proliferation, migration Sundaresan et al., 1995
Sundaresan et al., 1996
EGF H Nox Proliferation Bae et al., 1997
Miller et al., 2002
VEGF H, P L, Nox Proliferation, migration, angiogenesis Colavitti et al., 2002
Ushio-Fukai et al., 2002
PGF B Nox Proliferation Lo & Cruz, 1995
Insulin M, R Nox Glucose, metabolism, glucose uptake/
transport
May & de Haen, 1979b
Mahadev et al., 2001b
∗ B, bovine; H, human; M, mouse; P, pig; R, rat. † L, lipoxygenase; ND, not determined.
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Sources of Reactive Oxygen Species
Biologically relevant ROS include superoxide (O2−), hydrogen peroxide (H2O2),
and the hydroxyl radical (OH). The half-lives of superoxide (t1/2 = 10−6 s) and hy-
droxyl radicals (t1/2 = 10−9 s) are considerably shorter when compared to hydrogen
peroxide (t1/2 = 10−5 s) (12). Superoxide can spontaneously dismutate to H2O2 (∼
105 M−1 s−1), a process greatly enhanced by superoxide dismutases (SODs) (35, 36).
SODs catalyze the conversion of superoxide into H2O2 and O2 (∼ 7 x 109 M−1 s−1)
to maintain steady-state levels of superoxide (∼ 10−10 M) (37, 38). Reaction of H2O2
with trace metal ions (Fe2+ or Cu2+) through Fenton or Haber-Weiss chemistry gen-
erates OH (in vivo concentration of 10−15 M) (39). H2O2 is the most abundant form
of ROS (in vivo concentration of 10−7 M), and considered to be the most stable
species generated in response to biological stimuli. Its rapid production is selectively
perceived by downstream targets, and subsequently undergoes controlled degradation
by antioxidant defense systems. The uncharged nature and relative stability of H2O2
permits it to freely diffuse across membranes to participate as a messenger in signal
transduction. More recently, evidence has demonstrated that aquaporin channels can
facilitate translocation of H2O2 across membranes (40–42).
Spatial and temporal production of H2O2 allows specificity during cellular sig-
naling. The NADPH oxidase (Nox) family of enzymes represents a major source of
endogenous ROS generated during redox-mediated kinase signaling. Nox enzymes
produce ROS by translocating an electron from reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) across the cell membrane (13). The prototypical Nox
enzyme, Nox2 (also known as gp91phox), was initially thought to be confined to phago-
cytes to protect against microbial invasion by generating millimolar quantities of
H2O2. Other Nox homologues (Nox1-5 and Duox1-2) have since been identified in
nonphagocytes and exhibit differential subcellular localization and cell- and tissue-
specific expression patterns (43–45). Activation of Nox complexes requires binding
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of flavin adenine dinucleotide (FAD) cofactors, association of cytoplasmic coactiva-
tor proteins (Nox1-4, Duox1-2), and/or calcium to its intracellular domain (Nox5,
Duox1-2).
Mitochondrial-derived oxidants represent another major source of intracellular
ROS. Formation of ROS occurs when electrons leak prematurely from the electron
transport chain (ETC) and result in the incomplete reduction of O2 and generation
of superoxide (46, 47). This process was believed to be an inevitable repercussion
of aerobic existence, but cellular stimuli have been shown to initiate controlled mi-
tochondrial ROS production (i.e. redox enzyme p66Shc) (48, 49). It is important to
note that other enzymes such as xanthine oxidase, cytochrome P-450, cyclooxyge-
nases, and lipoxygenases can also serve as critical sources of ROS within the cellular
context (9).
Reactive nitrogen species (RNS) may also act as biologically relevant signaling
molecules. Reaction of cysteine thiols with RNS, such as nitric oxide (NO), generates
nitrosothiols (SNO). This process, known as S-nitrosylation, is reversible and partic-
ipates in cellular signaling (50). Evidence supporting S-nitrosylation during kinase
signaling will be referenced appropriately within their respective sections.
Regulation of ROS Levels During Signal Transduction
The concentration of H2O2 must increase rapidly above a certain threshold, rang-
ing from low nanomolar to low micromolar levels, and remain elevated long enough
for it to oxidize its effectors in order to serve as an efficient signaling molecule (14).
Signal duration can be mediated through the collective efforts of antioxidant defense
systems. Enzymes such as catalase, peroxiredoxins (Prxs), and glutathione peroxi-
dases (Gpxs) contribute by catalyzing the dismutation (catalase) or reduction (Prxs,
Gpxs) of H2O2 (51, 52). Peroxiredoxins, namely 2-Cys Prxs, exist as homodimers
and contain a peroxidatic cysteine. This residue becomes oxidized upon reaction
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with H2O2 to a sulfenic acid, and condenses with a resolving cysteine in an adjoining
subunit to form an intermolecular disulfide. Glutathione peroxidases (i.e. in higher
eukaryotes) contain a selenocysteine that is oxidized by H2O2 to SeOH, and forms a
disulfide with glutathione. Disulfide bonds are reduced by buffering systems such as
thioredoxin/thioredoxin reductase (Trx/TrxR) (for Prxs) or glutathione/glutaredoxin
(GSH/Grx) (for Gpxs) with the aid of reducing equivalents provided by NADPH.
Completion of the catalytic cycle enables these enzymes to maintain intracellular
H2O2 levels as deemed necessary.



















Figure B.2: Model for redox-dependent signal transduction. (a) PTKs catalyze the transfer
of γ-phosphoryl groups from ATP to tyrosine hydroxyls of proteins, whereas PTPs remove phosphate
groups from phosphorylated Tyr residues. (b) Regulatory cysteines in protein kinases can undergo
oxidation/reduction to modulate their function. Depending on the kinase, redox modifications can
stimulate or inhibit enzymatic function. (c) PTPs function in a coordinated manner with PTKs
to control signaling pathways to regulate a diverse array of cellular processes. Oxidation of the
conserved active site cysteine residue in PTPs inactivates these enzymes, and can be restored by
reducing the oxidized residue back to its thiol form. SOx: oxidized cysteine.
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Coordination of Reversible Tyrosine Phosphorylation through Redox-Dependent
Signaling
The distinct but complementary function of kinases and phosphatases represents
a finely tuned process wherein crosstalk occurs between separate but interrelated
networks (Figure B.2a). Redox-based mechanisms coordinate enzymatic activity be-
tween the two groups (Figure B.2b, c). Localized changes in redox homeostasis can be
sensed through oxidative modification of cysteine residues within specific protein tar-
gets. The initial product of the reaction between H2O2 and a thiolate (SH) is sulfenic
acid (SOH) (Figure B.3). This reversible modification, also known as sulfenylation,
can be directly reduced back to the thiol or indirectly by disulfide bonds. Alterna-
tively, sulfenic acids can be stabilized by the protein microenvironment or undergo
additional modifications. Other relevant oxoforms include disulfides, sulfenamides,
nitrosothiols (SNO), sulfinic (SO2H), and sulfonic (SO3H) acids. The reversibility of
sulfenic acid represents a mechanism whereby redox-based signaling can be regulated,
akin to phosphorylation. In addition, disulfide exchange and bond formation can also
play an important role in maintaining specificity during redox signaling (15–17). The
utility and functional role of reversible cysteine oxidation has been evidenced by an
increasing number of studies (53–55). In particular, protein tyrosine phosphatases
(PTPs) were originally implicated as targets of signal-induced H2O2 production due
to early studies by Denu and Tanner (56). The PTP superfamily contains a sig-
nature motif, (I/V)-H-C-X-X-G-X-X-R-(S/T), which includes a conserved cysteine
that functions as a nucleophile during catalysis. The susceptibility of certain residues
to oxidation is inherently dependent on its nucleophilicity, and provides a basis for
specificity during redox-mediated signaling. Thiolate anions are intrinsically more
reactive than their protonated counterparts (57), exhibiting enhanced reactivity to-
wards H2O2 ranging across seven orders of magnitude (1-107 M−1 s−1) (58). Free
cysteines are typically protonated at physiological pH, and have a pKa of ∼ 8.5. Pro-
276
tein microenvironments can profoundly influence the pKa of cysteine thiols and in
some cases, decrease the pKa to as low as 3.5 (59, 60). These factors include metal
coordination, residue accessibility, proximity to the oxidant source, and stabilization
of the thiolate anion by electrostatic interactions from neighboring residues. The cat-
alytic cysteine of PTPs is characterized by a low pKa value ranging from 4.6 to 5.5
owing to the unique chemical environment of its active site, which renders it suscep-
tible to oxidative inactivation (61, 62). Although PTPs were initially suggested to be
the sole targets of ligand-induced ROS production, attention has also shifted towards
protein kinases. In the following sections, biochemical studies and evidence for redox
regulation will be presented for select kinase examples.






























Figure B.3: Oxidative modification of cysteine residues by H2O2. The initial reaction product
of a thiolate with H2O2 yields sulfenic acid (RSOH). This modification, also known as sulfenylation,
is reversible and can be directly reduced back to the thiol form or indirectly through disulfide
bond formation. Sulfenic acids can be stabilized by the protein microenvironment and/or undergo
subsequent modification. For example, sulfenic acids can condense with a second cysteine in the
same or different protein to generate disulfide bonds. Alternatively, reaction with the low molecular
weight thiol glutathione (GSH, red circle) affords a mixed disulfide through a process known as
S -glutathionylation. In some proteins, such as PTP1B, nucleophilic attack of a backbone amide
on RSOH results in sulfenamide formation. Sulfenyl groups can also oxidize further to the sulfinic
(RSO2H) and/or sulfonic (RSO3H) acid forms under conditions of high oxidative stress.
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Receptor Tyrosine Kinases
Platelet-Derived Growth Factor Receptor (PDGFR)
PDGF exists as a homo- or heterodimer connected by disulfide bonds, and is
composed from a combination of four isoforms (PDGF-A, PDGF-B, PDGF-C, and
PDGF-D). PDGF initiates signal transduction by binding to its receptor, PDGFR
(-α or -β forms). Activation of PDGFR engages signaling routes such as Ras/MAPK,
PI3K/Akt, or binding of PLC-γ to elicit mitogenic and anti-apoptotic effects. For
example, PDGF plays crucial roles in embryonic development, blood vessel forma-
tion, and wound response (63). PDGF-mediated signaling specificity in various cell
types (i.e. fibroblasts, smooth muscle cells) is achieved by different ligand-receptor
combinations (64). Therefore, discrepancies in the literature may actually reflect the
diverse signaling nature of these isoforms. For the purpose of this section, ligand and
receptor isoforms will be referenced when deemed necessary. In particular, the major-
ity of work discussed regarding PDGFR redox regulation is comprised of observations
obtained from PDGF-BB/ PDGFR-β interactions.
The biological relevance of growth factor-induced H2O2 production was first high-
lighted in vascular smooth muscle cells (VSMCs) (21). Endogenous ROS levels
peaked rapidly upon PDGF stimulation, and were inhibited by enzymatic and chem-
ical H2O2 scavengers. Transient H2O2 increases were also accompanied by elevated
Tyr phosphorylation levels and activation of the MAPK pathway. PDGF stimula-
tion of adipocytes has been shown to induce intracellular H2O2, originating from a
membrane-bound Nox complex (65). Signal-derived H2O2 subsequently participates
in facilitation and enhancement of adipose differentiation, albeit this observation is
isoform-specific (PDGF-AA) (66).
Many research efforts have been devoted to elucidating the molecular mechanisms
that produce and regulate endogenous H2O2 during cellular signaling. Activation
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of PI3K, a downstream effector of PDGFR, is required for growth factor-mediated
production of H2O2 (67). Mutation of PI3K binding sites (Tyr740 and Tyr751) or
exposure to PI3K inhibitors (LY294002 and wortmannin) failed to induce H2O2 pro-
duction upon ligand stimulation. These results and others (68) suggest that PIP3, the
product of activated PI3K, is essential for redox-based PDGF signaling. Additionally,
expression of a dominant negative (DN) mutant of the small GTPase Rac1 (Rac1N17)
blocks increases in H2O2 and corroborates earlier observations in fibroblasts (69).
Rac1 is one of several subunits comprising the Nox enzyme complex, and contains
an effector region (residues 124-135) required for Nox activation. Deletion of this
region does not interfere with its functional abilities, but abrogates Rac1-mediated
superoxide production through Nox (70). PIP3 stimulates Rac1 activation through
guanine nucleotide exchange factors (GEFs). Therefore, it appears that Rac1 activa-
tion of Nox is inherently dependent on PI3K production of PIP3, which has also been
demonstrated with regards to EGF-mediated signaling (71). Nox complexes serve as
the main oxidant source during PDGF signaling, as established by chemical inhibition
and enzyme overexpression studies (72, 73).
PDGFR activation can also occur through an alternate mechanism known as
trans-activation, and is specific to the β-receptor isoform (74, 75). In this scenario,
angiotensin II (AngII) binds to GPCRs (G protein-coupled receptors) to trigger H2O2
production and mobilization of Ca2+ from intracellular stores. In turn, H2O2 acti-
vates additional kinases such as c-Src and PKC (protein kinase C) to promote RTK
phosphorylation (76). The underlying mechanisms regarding H2O2 production during
these events remains unclear, although some evidence indicates that mitochondrial
function may play a role (77). Trans-activation represents an additional level whereby
alternate stimulants can initiate signaling of ligand-inaccessible RTKs in lieu of tra-
ditional ligand-receptor interactions (Figure B.4).
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Figure B.4: Trans-activation of PDGFR and EGFR. Alternative stimulants such as AngII can
initiate activation of ligand-inaccessible RTKs in lieu of traditional ligandreceptor interactions. In
this scenario, AngII binds to GPCRs to promote endogenous H2O2 production and activation of
redox regulated PTKs such as c-Src. Src promotes phosphorylation of PDGFR or EGFR, and
neighboring receptors can be activated in a lateral-based mechanism. Additionally, concurrent PTP
inactivation has also been suggested to promote RTK trans-activation.
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PDGFR activity is modulated by a number of PTPs, such as low molecular
weight PTP (LMW-PTP) (78) and SHP-2 (79). LMW-PTP is characterized by a
unique feature among the PTP family whereby it contains two cysteine residues,
Cys12 and Cys17, located in its catalytic pocket (80). Upon PDGF stimulation, en-
dogenous H2O2 inactivates LMW-PTP through disulfide bond formation to enable
increased receptor activity (73). GSH depletion by treatment with buthionine sul-
foxide (BSO), an inhibitor of γ-glutamylcysteine synthetase, severely impairs rescue
of oxidized LMW-PTP, and suggests phosphatase reactivation proceeds through a
GSH-dependent process. Glutaredoxin (Grx) was later identified as a component of
GSH-dependent modulation of LMW-PTP (81). LMW-PTP mutant C17A is unable
to recover from oxidative inactivation, and suggests Cys17 forms a disulfide bond with
Cys12 to protect the catalytic cysteine from hyperoxidation (i.e. sulfinic or sulfonic
acids). Follow-up studies imply PTPs may regulate the duration of PDGFR signal by
preferentially targeting membrane-exposed receptors, whereas the endosomal receptor
pool has been shown to remain phosphorylated for up to 2 h (82).
The extent of growth factor signaling can also be controlled by antioxidant de-
fense systems. In particular, PrxII functions as a negative regulator of PDGF sig-
naling (83). PrxII deficient mouse embryonic fibroblast (MEF) cells exhibit 2-fold
increases in H2O2 production and enhanced activation of PDGFR and PLC-γ1. Co-
immunoprecipitation demonstrates that active PrxII is recruited to the receptor upon
ligand stimulation. Translocated PrxII relieves oxidative inactivation of membrane-
associated PTPs by eliminating localized H2O2 production within the PDGFR mi-
croenvironment. These results demonstrate PrxII regulates site-selective amplifica-
tion of PDGFR phosphorylation through endogenous H2O2 (Figure B.5a). Alterna-
tively, mechanisms have evolved to allow localized H2O2 accumulation during sig-
naling. Prxs are extremely efficient at H2O2 elimination, and react with H2O2 at
second-order rate constants ranging from 105 - 108 M−1 s−1 (84, 85). Therefore, it is
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intriguing how H2O2 can accumulate within the cytosol long enough to modulate its
effectors. Recent studies have discovered phosphorylation of Tyr194 inactivates PrxI
(86). PrxI phosphorylation is induced in several cell types (NIH 3T3, A431, Ramos
B cells, Jurkat T cells) upon activation of various receptors (PDGFR, EGFR, BCR,
and TCR), and found to be localized to membrane microdomains. Nox1 deficient
mice exhibit a 60% reduction in PrxI phosphorylation, and suggests Nox1-derived
H2O2 induces inactivation of PrxI and PTPs to promote localized H2O2 accumula-
tion. Knockdown c-Src siRNA experiments decrease PrxI inactivation by 25-50%,
thereby identifying c-Src as the partially responsible kinase. This study provides
a key contribution that demonstrates localized PrxI inactivation enables transient
H2O2 accumulation near the membrane, while simultaneously preventing toxic ROS
increases elsewhere during signaling (Figure B.5b). Additionally, the two aforemen-
tioned studies highlight isoform-specific Prx responses involved in maintaining growth
factor-induced H2O2 production.
Until now, we have only discussed indirect mechanisms related to redox-based
modulation of PDGFR. Currently, there is little evidence to support direct modifi-
cation of PDGFR through cysteine oxidation. In an early study, PDGF stimulation
was reported to induce covalent receptor dimerization through disulfide bonds within
the extracellular domain (87). Unfortunately, the identification of residues responsi-
ble for PDGFR dimerization has not been reported. A separate study examined the
functional role of conserved cysteine residues located in the cytoplasmic domain of
PDGFR. Treatment with the sulfhydryl-specific alkylating agent, N -ethylmaleimide
(NEM), inhibits kinase activity and suggests the receptor contains critical cysteine
residues located within its kinase domain (88). MS analysis identified two residues,
Cys822 and Cys940, deemed necessary for receptor activity by in vitro assays us-
ing Ser mutants. Cys822 is located in the catalytic loop at the enzyme active site,
whereas Cys940 is located in the C-lobe of the kinase domain. These residues do not
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participate in disulfide bond formation, as determined by non-reducing gel analysis.
Additionally, they do not interfere with ATP substrate binding as is observed in other
RTKs (i.e. EGFR). Proteolytic cleavage assays demonstrate Cys940 affects receptor
activity by inducing a conformational change, but the mechanism by which this pro-
ceeds remains unclear. Although the preceding studies indicate PDGFR may require
specific cysteines for functional activity, it remains unknown whether the receptor






































Figure B.5: Isoform-specific roles of Prx during redox-based PDGFR signaling. (a) PrxII
functions as a negative regulator of PDGF signaling. Upon growth factor stimulation, active PrxII is
recruited to the membrane and serves to relieve oxidative inactivation of membraneassociated PTPs
by eliminating localized H2O2 production within the PDGFR microenvironment. (b) Receptor
activation can also induce localized phosphorylation and inactivation of PrxI by PTKs, such as the
redox-regulated c-Src. Deactivation of PrxI reduces the redox-buffering capacity adjacent to the
cellular membrane, allowing for transient and localized increases in H2O2 for signal transduction.
Additionally, increased H2O2 concentrations can also inactivate Prx2 by oxidation of its catalytic
cysteine to sulfinic acid
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Epidermal Growth Factor Receptor (EGFR)
Epidermal growth factor receptor (EGFR) was the first RTK to be identified, and
has since been widely characterized in physiologic and pathological settings (89–91).
EGFR, also known as erbB1 (or HER1), is grouped into a subfamily that consists
of three other closely related receptors: erbB2 (HER2), erbB3 (HER3), and erbB4
(HER4). EGFR forms a homo- or heterodimer followed by autophosphorylation of key
residues upon stimulation (92). Once activated, EGFR relays the signal through one
of its two major pro-survival signaling routes, Ras/MAPK or PI3K/Akt. The erbB
family of receptors is activated by various ligand-receptor combinations to achieve
signaling specificity in different cell types and signaling cascades (93). Therefore,
we will mainly focus on effects resulting from the EGF-EGFR interaction for the
purpose of this review. EGFR and other erbB family members have been found to
be mutated or amplified in human cancers such as breast and lung, making them
attractive targets for the development of therapeutic strategies (94, 95).
Culminating evidence has established that EGFR is modulated by and utilizes
H2O2 as a secondary messenger during cellular signaling (96, 97). Early reports
demonstrate exogenous H2O2 increases [32P] phosphate incorporation, albeit the sig-
nal is half of what is observed in EGF-stimulated cells (98). Tryptic phosphopeptide
mapping attributes this difference to preferential enhancement of EGFR Tyr phospho-
rylation by H2O2, whereas EGF triggers a combination of Ser/Thr and Tyr receptor
phosphorylation. In a landmark study, EGF was reported to increase endogenous
H2O2 levels upon receptor stimulation in cells overexpressing EGFR (A431) (22).
Catalase incorporation abolishes EGF-induced H2O2 production and blunts increased
Tyr phosphorylation of EGFR and PLC-γ1, a well-characterized target of EGFR. Ad-
ditionally, assays with mutated EGFR receptors demonstrate EGF-dependent H2O2
formation requires intrinsic kinase activity, but not necessarily its autophosphoryla-
tion sites. Subsequent reports have shown H2O2 activates EGFR kinase and markedly
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enhances receptor half-life in conjunction with the native ligand (99). From these re-
sults, it is apparent that H2O2 modulates EGFR activation and influences downstream
signaling. Other studies suggest S -nitrosylation may regulate EGFR activity, albeit
with contradictory results (100–102). Additionally, EGFR is the only other RTK
besides PDGFR known to undergo trans-activation by AngII, and proceeds through
H2O2-dependent c-Src activation (103–105). Neighboring EGFR kinases may be ac-
tivated in a lateral-based mechanism, and concurrent PTP inactivation has been
suggested to promote EGFR trans-activation (106). (Figure B.4)
PTPs were one of the first redox-based targets identified in EGF signaling. EGFR
was originally identified as an in vivo substrate of PTP1B using a substrate-trapping
mutant technique (107). These mutants retain their ability to bind substrates in a
cellular context, but lack catalytic functionality to enable stabilization of enzyme-
substrate complexes for isolation purposes. PTP1B is localized exclusively on the
cytoplasmic face of the endoplasmic reticulum (ER), and serves to dephosphorylate
activated EGFR that has been internalized and transported for endocytosis (108,
109). Signal-derived H2O2 inactivates PTP1B to enable equilibrium between EGFR
and PTP1B activity (110). PTP1B exhibits decreased time-dependent incorporation
of radiolabeled iodoacetic acid (IAA) in A431 cells when stimulated with EGF. IAA is
a sulfhydryl-modifying reagent known to react with the catalytic cysteine of PTP1B
(Cys215). PTEN is another PTP known to maintain a close relationship with EGFR,
and functions as a negative regulator of the PI3K/Akt pathway. Recent evidence im-
plicates PTEN regulates EGFR by targeting the receptor for degradation through
ubiquitylation (111). EGFR ubiquitylation is mediated by the Cbl family of E3 ubiq-
uitin ligases, which bind to the activated receptor to form a complex stabilized by
the phosphatase. PTEN contains five cysteine residues within its catalytic domain
and undergoes reversible inactivation by H2O2. Mutation of these residues reveals
Cys124 is oxidized upon exposure to exogenous H2O2, and forms an intramolecular
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disulfide with Cys71 that can be rescued by Trx (112). Subsequent work has shown
that EGF-induced H2O2 inactivates PTEN similarly to PTP1B (68). Collectively,
these studies provide evidence that growth factor activation of RTKs may not be suf-
ficient to increase the steady-state level of protein phosphorylation during signaling,
and that concomitant inactivation of PTPs is also required. Interestingly, Nox1 over-
expression induces increased PIP3 levels (68) and is a component involved in EGFR
activation of PI3K (71). PTEN inactivation represents a positive feedback loop that
promotes continued accumulation of intracellular PIP3 during EGF signaling.
EGF-induced H2O2 is produced and regulated by distinct components. Multiple
Nox isoforms mediate H2O2 production within EGF signaling cascades. For exam-
ple, a positive feedback loop due to sequential activation of PI3K-βPix-Rac1-Nox1 is
involved in endogenous H2O2 production (71). In this loop, EGF stimulation acti-
vates PI3K to elicit increased PIP3 production. These lipid products activate βPix
by interacting with its PH domain, which then catalyzes GDP exchange to activate
Rac1. Finally, Rac1 directly binds to Nox1 to promote NADPH electron transfer and
H2O2 generation. βPix siRNA-based knockdown experiments block EGF-induced
H2O2 production and Rac1 activation. A separate study reports Nox1 is negatively
modulated during EGF signaling by phosphorylation of Ser282 of Nox activator 1
(NOXA1, a Nox1 subunit) by Erk1/2 and Ser172 by PKC to prevent hyperactivation
(113, 114). Nox4 is another isoform that regulates EGFR in a spatially dependent
manner through PTP1B inactivation (115). Confocal microscopy and cellular frac-
tionation experiments with the ER marker protein GRP78 confirmed ER localization
of Nox4. Upon EGF stimulation, co-localization of Nox4 and PTP1B to the ER is
required for phosphatase inactivation in aortic endothelial cells. Nox4 siRNA knock-
down increases reduced PTP1B levels, indicating Nox4 serves as the primary oxidant
source for PTP1B oxidation within the ER and consequently allows Nox4 to spatially
modulate the duration of EGFR signaling. These results were validated by PTP1B
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substrate-trapping mutants, which were attenuated in their ability to effectively bind
EGFR due to Nox4 overexpression.
As described earlier, SODs catalyze the conversion of superoxide into H2O2 to
maintain steady-state levels. Treatment with SOD1 inhibitor ATN-224 decreases
intracellular H2O2 levels and attenuates EGFR activation and downstream targets
(116). Furthermore, SOD1 was shown to mediate transient oxidation of PTPs such
as PTP1B and PTEN. Separate studies demonstrate H2O2 utilized during EGF sig-
naling is generated extracellularly at the receptor-ligand interface, and permeates
across the membrane to facilitate kinase activation (117, 118). In vitro assays with
recombinant protein containing only the extracellular EGFR binding domain provides
evidence that this domain is sufficient to induce H2O2 production upon ligand bind-
ing. Once generated, H2O2 can freely diffuse across membranes or be transported
through aquaporin channels to elicit signaling events (42). Thereafter, buffering sys-
tems and peroxide-detoxifying enzymes such as Prx and Gpx mediate signal duration
by maintaining appropriate H2O2 levels (119–121).
287

































Figure B.6: General strategy for detecting protein sulfenic acids in cells. (a) Chemoselective
reaction between 5,5-dimethyl-1,3-cyclohexanedione (dimedone, 1) and sulfenic acid. (b) Azide and
alkyne-functionalized small-molecule probes for trapping and tagging protein sulfenic acids include
DAz-2 (2) and DYn-2 (3). (c) Detection of protein sulfenic acids in living cells. Target cells are
incubated with cell-permeable probes to trap and tag protein sulfenic acids in situ. After labeling, cell
lysates are prepared and tagged proteins are bioorthogonally ligated to biotin or fluorescent reporter
tags via click chemistry to enable detection by Western blot or in-gel fluorescence. Alternatively,
biotinylated proteins can be enriched for proteomic analysis.
Mounting evidence has established redox-based modulation of EGFR activity,
albeit mainly through indirect mechanisms. Although EGFR contains ∼ 50 cys-
teine residues, 9 of which are located within its intracellular domain, none of these
have been implicated to undergo oxidative modification until recently (122). Early
work demonstrates EGFR autophosphorylation is inactivated by NEM alkylation
(123, 124). NEM treatment blocks reaction of a nucleotide analog [(p-fluorosulfonyl)-
benzoyl]-5 adenosine (5-FSBA) with the kinase active site, suggesting alkylation may
exert an inhibitory effect by reacting with a cysteine residue located in the ATP
binding site (123). These observations were corroborated in separate studies whereby
co-incubation of EGFR with AMP-PNP, a hydrolysis-resistant ATP analog, blocks
receptor inactivation by NEM (125). Although these studies alluded that a cysteine
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residue may play a role in redox-based EGFR signaling, specific modification sites
were not identified. Sulfhydryl alkylating agents represent an indirect method to
detect cysteine modifications because they readily react with reduced thiols, but are
unable to modify other cysteine oxoforms important to signaling such as sulfenic acids.
Therefore, the detection of relevant cysteine modifications represents a tremendous
need for the development of tools geared towards this goal. Techniques based on chem-
ical probes (53, 126–130) and antibodies (131, 132) have recently been developed to
detect sulfenic acid formation. In particular, cell permeable probes enable direct trap-
ping of sulfenylated proteins within their native cellular environment. These probes
are functionalized with an azide or alkyne reporter group (53, 122, 128), and utilize a
cyclic β-diketone warhead chemically selective for sulfenic acids (133) (Figure B.6 a,
b). Bioorthogonal biotin or fluorescent reporter tags can be appended post-lysis for
detection via the Staudinger ligation (134) or Huisgen [3+2] cycloaddition (i.e. click
chemistry) (135). Overall, this general approach provides a facile method to profile
protein sulfenylation in a cellular context (Figure B.6 c).
Overexpression of EGFR and HER2 in breast cancer cell lines is correlated to high
H2O2 levels and increased global protein sulfenylation (131). In more recent work,
the functional role of protein sulfenylation during EGFR signaling was explored in
detail (Figure B.7a). Sulfenic acid formation was profiled in A431 cells upon ligand
stimulation, and captured with cell-permeable probe DYn-2 (122). Ensuing analysis
revealed EGF stimulation induces dynamic and global increases in protein sulfeny-
lation. This occurs in a dose- and time-dependent manner relative to EGF, and
is accompanied by Nox2-derived H2O2 production. DYn-2 was used in a targeted
approach to confirm sulfenylation of three phosphatases involved in EGFR signal-
ing: SHP2, PTEN, and PTP1B. Immunoprecipitation demonstrated each PTP was
sulfenylated in an EGF-dependent manner in cells. Moreover, individual PTPs dis-
played distinct oxidation profiles as a function of growth factor concentration. PTP
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sensitivity to EGF-mediated oxidation suggests this observation may be related to
subcellular protein localization, and is supported by previous work (115). Finally,
EGFR itself was shown to be activated and directly modified upon EGF stimulation,
peaking at low concentrations (4 ng/ml). The EGFR kinase domain contains six
cysteine residues, one of which is a conserved cysteine (Cys797) that resides in the
ATP binding site (Fig. 7b). This residue is selectively targeted by irreversible EGFR
inhibitors (i.e. afatinib) currently undergoing clinical trials for breast and non-small
cell lung cancers (136, 137). Treatment with irreversible EGFR inhibitors (afatinib,
canertinib, or pelitinib) abrogates the ability of DYn-2 to detect EGFR oxidation,
and suggests Cys797 may be susceptible to oxidation as evidenced by signal loss of
EGFR sulfenylation. Cys797 was identified as the site of EGFR modification by
MS analysis. These results demonstrate EGFR Cys797 is a direct target of growth
factor-induced H2O2, and that EGF signaling induces dynamic sulfenic acid formation
within EGFR signaling pathways (122). Phosphorylation and sulfenylation appear
to work in parallel with each other to regulate receptor kinase activity during EGF
signaling.
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Figure B.7: Model for H2O2-dependent regulation of EGFR activation. (a) Binding of EGF
to the receptor induces production of H2O2 through Nox2. Nox-derived H2O2 directly modifies
EGFR to sulfenic acid at a conserved cysteine residue (Cys797) located in its active site, which
enhances the receptor’s intrinsic tyrosine kinase activity. Endogenous H2O2 can also oxidize and
deactivate localized PTPs, leading to a net increase in EGFR phosphorylation and activation of
downstream signaling cascades. (b) Crystal structure of the EGFR kinase domain (PDB 3GT8)
bound to AMP-PNP, a hydrolysis-resistant ATP analog, and Mg2+. The yellow dashed lines and
accompanying numbers indicate the distance (Å) between the γ-sulfur atom of Cys797 and key
substrate functional groups. It is important to note that Cys797 can adopt different rotamers, and
sulfenylation of this residue may enhance its ability to participate in electrostatic and hydrogen
bonding interactions with its substrate.
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Vascular Endothelial Growth Factor Receptor (VEGFR)
Angiogenesis is the physiological process whereby new blood vessels are formed
from pre-existing vasculature. This is a vital process involved in embryonic develop-
ment, skeletal growth, wound repair, and reproductive functions (138). A wide range
of diseases including chronic inflammation, vascular ischemia, and atherosclerosis have
been linked to angiogenesis (139). Vascular endothelial growth factor (VEGF) is a key
angiogenic growth factor that stimulates cellular proliferation, migration, and tube
formation of endothelial cells (ECs). The biological effects of VEGF are mediated by
three RTKs, VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk1), and VEGFR-3, which differ
considerably in their signaling properties. VEGFR activation initiates downstream
signaling through Ras/MAPK, PI3K/Akt, PLC-γ, and Src family of kinases to induce
endothelial growth and mediate pro-survival effects. For the purpose of this section,
we will focus primarily on VEGFR-2 due to its involvement in VEGF-mediated redox
signaling (140).
Growth factor-induced H2O2 production modulates RTK activity, as discussed
in preceding sections. Interestingly, H2O2 treatment of ECs has been shown to up-
regulate gene expression of VEGF (141, 142). Further analysis with inhibitors of
protein (cycloheximide) and RNA synthesis (actinomycin D) demonstrate induction
of VEGF mRNA levels by H2O2 is inhibited by actinomycin D, indicating that de
novo RNA synthesis is required for this response. In a later study, H2O2 was also
found to elicit increased VEGFR-2 mRNA levels (143). The biological relevance of
these observations was explored in detail, and suggests upregulation of VEGF and
VEGFR-2 functions primarily to protect ECs against oxidative injury. Additionally,
VEGF-mediated signaling is also accompanied by bursts of intracellular ROS (144).
Akin to its RTK counterparts, VEGF-induced H2O2 production increases receptor
autophosphorylation and activation of downstream targets such as Erk1/2, Akt, and
PLC-γ1. Phosphatase inhibition with vanadate restores Tyr phosphorylation levels
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during VEGF stimulation, and reinforces the idea that oxidative inactivation of PTPs
such as PTP1B (145) and DEP-1 (146) promotes kinase activity. Similar to results
observed with PDGFR and EGFR, activation of PI3K was shown to be essential for
VEGF-derived H2O2 production using PI3K inhibitors (wortmannin) and Rac1N17.
Nox enzymes serve as the major source of endothelial H2O2, and are required for
EC proliferation and migration (147–149). Therefore, efforts quickly focused on eluci-
dating the potential role of Nox-derived H2O2 during VEGF-mediated signaling and
angiogenesis (150). Treatment of ECs with various Nox inhibitors (DPI, apocynin,
and AEBSF) and gp91phox antisense oligonucleotides attenuate receptor autophos-
phorylation, VEGF-stimulated proliferation and migration, and H2O2 production.
Rac1N17 overexpression results in similar decreases, indicating Nox2 activation is
Rac1-dependent. Evidence suggests that Nox-derived H2O2 during VEGF signaling
is spatially and temporally controlled by various components within discrete subcel-
lular compartments including caveolae/lipid rafts, focal adhesions/complexes, and at
the leading edge (151). Caveolae are flask-shaped membrane microdomains primarily
composed of protein caveolae (i.e. caveolin-1), and are subsets of lipid rafts that com-
partmentalize signaling components such as RTKs, GPCRs, and Rac1. Caveolin-1
negatively modulates VEGFR-2 by binding to the receptor (152). VEGF stimula-
tion promotes Tyr phosphorylation of caveolin-1, and triggers its dissociation from
VEGFR-2. Once released, activated VEGFR-2 localizes with p-caveolin-1 at focal
adhesions/complexes to initiate signaling. Focal adhesions are dynamic protein com-
plexes that mediate cell anchorage and motility with respect to the extracellular ma-
trix (ECM). A later study identified that co-localization of VEGFR-2 with Rac1 and
the small GTPase ARF6 (ADP-ribosylation factor 6) occurs in caveolae/lipid rafts
(153). Expression of DN ARF6 mutant (T27N) inhibits Rac1 activation, Tyr phos-
phorylation of caveolin-1, and translocation of VEGFR-2 from caveolae/lipid rafts.
Additionally, ARF6 (T27N) attenuates VEGF-induced H2O2 production and suggests
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ARF6 mediates recruitment of activated VEGFR-2 to focal adhesions/complexes
through Rac1-dependent Nox activation (Figure B.8a). Alternatively, Nox1 over-
expression has been shown to promote tumor angiogenesis through upregulation of
VEGF and VEGFR-2 (154).
VEGF signaling can also be modulated by extracellular SOD (ecSOD). ecSOD
is the major SOD found in the vascular extracellular space, and anchors to the EC
surface by binding to heparin sulfate proteoglycans (HSPGs) through its heparin-
binding domain (HBD). Extracellular H2O2 derived from ecSOD enhances VEGFR-2
autophosphorylation, and functions in a HBD-dependent manner (155). As discussed
earlier, VEGFR activation initially occurs in caveolin-enriched lipid rafts where Nox
complex subunits are localized within ECs. Sucrose gradient fractionation with ec-
SOD and ecSOD-∆HBD expressing cells demonstrate that the HBD is required for
ecSOD localization within caveolin-enriched lipid rafts. Additionally, PTPs involved
in regulating VEGFR-2 activity such as PTP-1B and DEP-1 were oxidatively inacti-
vated by ecSOD-derived H2O2. These PTPs were only inactivated in caveolae/lipid
rafts, thereby indicating ecSOD promotes VEGF-induced H2O2 production and re-
ceptor autophosphorylation in a localized manner.
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Figure B.8: Spatial and temporal modulation of VEGFR2 signaling occurs in discrete
subcellular compartments. (a) In the basal state, caveolin-1 (Cav1) negatively modulates
VEGFR2 by binding to the receptor in caveolae/lipid rafts. VEGF initiates activation of VEGFR2
by promoting dissociation of Cav1 from the receptor. Once released, activated VEGFR2 localizes
with phosphorylated Cav1 and paxillin (Pax) at focal adhesions/complexes to initiate downstream
signaling. Growth factor stimulation also recruits small GTPases, ARF6 and Rac1, to activate Nox
complexes located in caveolae/ lipid rafts. Localized production of H2O2 acts as a secondary mes-
senger during VEGF signaling to promote angiogenesis, proliferation, and migration in ECs. (b)
Endothelial migration is a key event that occurs during angiogenesis in ECs. Cell-cell adhesions
are mediated by interactions between VE-cadherin and IQGAP1, which are disrupted upon VEGF
stimulation to initiate the migration process. During active migration, IQGAP1 functions as a scaf-
folding protein to recruit signaling components such as activated VEGFR2, Nox, and Rac1 to the
leading edge. Additionally, Nox-derived H2O2 induces localized sulfenic acid formation in IQGAP1
to promote directional migration events. Adapted from Ushio-Fukai (2007).
Endothelial migration is essential for the formation of new blood vessels. Cell-
cell adhesion is mediated primarily by VE-cadherin, and requires co-localization of
IQGAP1 in quiescent ECs (156). VEGF initiates endothelial migration by reduc-
ing IQGAP1/VE-cadherin interactions to disengage cellular contacts. IQGAP1 is
a VEGFR-2 binding protein originally identified in a library screen, and preferen-
tially binds to the activated receptor at the leading edge in actively migrating cells
(157). IQGAP1 functions as a scaffolding protein that controls cellular motility and
morphogenesis by directly interacting with cytoskeletal and cell adhesion elements,
in addition to small GTPases such as Rac1. Co-immunoprecipitation demonstrates
VEGF stimulation rapidly promotes recruitment of Rac1 to IQGAP1, and initiates
complex formation with VEGFR-2. IQGAP1 siRNA knockdown inhibits VEGF-
induced H2O2 production and activation of downstream pathways such as PI3K/Akt.
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In a wound scratch assay, Nox2 translocates to the leading edge and co-localizes
with IQGAP1 upon VEGF stimulation (158). Collectively, these studies highlight
the crucial role of IQGAP1 in endothelial migration during redox-mediated VEGFR
signaling (Figure B.8b). A recent study using a dimedone-based trapping reagent
(DCP-Bio1) demonstrates IQGAP1 undergoes localized sulfenic acid formation at
the leading edge induced by VEGF-mediated H2O2 generation (159). Sulfenyl mod-
ification of IQGAP1 positively impacts its ability to promote directional migration
events, and was also observed in hindlimb ischemia models.
VEGFR-2 can also undergo direction modulation through cysteine oxidation. Dur-
ing VEGF signaling, Nox2-derived H2O2 selectively exerts its effects on the PI3K/Akt
pathway by inducing c-Src activation (160). A cysteinyl labeling strategy highly sen-
sitive to sulfenic acid detection (161) was used to examine potential oxidation of
VEGFR-2 and c-Src during VEGF signaling. Both kinases were identified to contain
redox-active cysteines, and require Nox-2 derived H2O2 to elicit downstream signaling.
This study does not identify the specific residues responsible for these observations, al-
though there have been numerous reports of redox-sensitive cysteines present in c-Src
(discussed later). Interestingly, a separate study reports VEGFR-2 activity is neg-
atively modulated by an intramolecular disulfide bond between Cys1209 (catalytic)
and Cys1199 (resolving) in its C-terminal tail (162). PrxII preserves VEGF signaling
in vascular ECs by rescuing VEGFR-2 from oxidative inactivation, as shown by PrxII
siRNA knockdown. Incorporation of cytosolic and membrane-targeted catalase effec-
tively abrogates VEGF-induced H2O2 production; however, VEGFR-2 phosphoryla-
tion is only restored in the presence of membrane-targeted catalase. This suggests that
PrxII, a cytosolic enzyme, must translocate to the cellular membrane to positively
modulate VEGFR-2 activity. PrxII has been previously identified to be distributed
within caveolae structures in vascular ECs, which coincides with known locations
of subcellular VEGFR-2 signaling (86). Sucrose gradient fractionation demonstrates
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co-localization of VEGFR-2 and PrxII occurs only within caveolae-enriched fractions.
Additionally, oxidatively inactivated VEGFR-2 was only found in caveolae fractions
in PrxII knockdown cells. These findings reinforce the idea that redox modulation
of VEGFR-2 signaling occurs in a highly localized manner in ECs and contrasting
effects of H2O2 on VEGFR-2 activity may be due to subcellular factors.
Insulin Receptor Kinase (IRK)
Insulin is the major hormone responsible for critical energy functions such as glu-
cose and lipid metabolism. Insulin activates insulin receptor kinase (IRK), which is
a heterotetrameric receptor composed of two extracellular α subunits and two trans-
membrane β subunits. Binding of insulin to the IRK extracellular domain induces
a conformational change in its quaternary structure that enables ATP binding and
leads to increased receptor autophosphorylation (163). Once activated, IRK elic-
its Tyr phosphorylation of various cytosolic docking proteins, most notably adaptor
protein SHC and members of the insulin receptor substrate (IRS) protein family
(164). Insulin signaling has mitogenic effects that are primarily associated with the
Ras/MAPK pathway through SHC (165). Unlike other RTKs previously discussed
in this review, IRK utilizes IRS docking proteins to initiate signal transduction (Fig-
ure B.1b). Activated IRS proteins recruit effectors to relay downstream signaling
through the PI3K/Akt pathway and GLUT4, which play major roles in insulin func-
tion. For example, Akt activation induces glycogen synthesis through inhibition of
GSK-3 (glycogen synthase kinase-3) (166). Additionally, the PI3K/Akt pathway me-
diates insulin-induced glucose uptake by translocation of GLUT4 vesicles to the cellu-
lar membrane (167, 168). Although RTKs mediate long-term events such as cellular
differentiation and mitogenesis, the primary function of IRK is the acute regulation
of glucose metabolism in muscle and adipose cells. Despite these differences, RTKs
and IRK essentially share the same transduction machinery to elicit their respective
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responses.
For many years, exogenous H2O2 has been recognized to mimic the effects of
insulin (i.e. glucose transport) in adipocytes (169). Insulin-induced production of
intracellular H2O2 was first observed in rat adipocytes (170). These observations
were coupled to increased glucose metabolism, and suggest H2O2 acts as a secondary
messenger to mediate the observed effects of insulin. H2O2 can enhance or reduce
insulin responsiveness, depending on the concentration and duration of the oxidant.
Prolonged exposure to H2O2 can impair insulin action and trigger insulin resistance, a
characteristic feature of type 2 diabetes (171–173). Under normal conditions, insulin-
induced H2O2 mediates early signaling events during the insulin action response. Akin
to previously discussed RTKs, endogenous H2O2 enhances activation of IRK and IRS
proteins through Tyr phosphorylation of key residues (174). Concomitant inactivation
of PTPs such as PTP1B and PTEN has similarly been shown to propagate kinase ac-
tivity during insulin signaling in hepatoma and adipose cells (175). Follow-up studies
have also demonstrated the role of insulin-dependent H2O2 generation with regards
to distal insulin response events (176). Signal-derived H2O2 blocked with chemical
inhibitors attenuated response events associated with the PI3K/Akt pathway, such as
glucose uptake and GLUT4 translocation. It is interesting to note that unlike PDGF
(67), insulin-induced H2O2 production is independent of PI3K activation. Treatment
of 3T3-L1 adipocytes with PI3K inhibitors (i.e. wortmannin or LY294002) does not
block H2O2 production upon insulin stimulation, and most likely proceeds through a
different mechanism than those identified in other RTKs.
Insulin-induced H2O2 production was originally linked to a membrane-bound com-
plex identified in adipocytes with enzymatic characteristics consistent with Nox ac-
tivity (65, 177). Northern blot analysis and reverse-transcriptase PCR (RT-PCR)
identified Nox4 as the isoform responsible for H2O2 production within the insulin
action pathway (178). Expression of Nox4 deletion constructs lacking NADPH or
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FAD/NADPH cofactor binding domains functioned in a dominant-negative manner
in differentiated adipocytes. These constructs attenuate insulin-derived H2O2 produc-
tion, Tyr phosphorylation of IRK and IRS proteins, PI3K/Akt pathway activation,
and subsequent insulin response events. Collectively, these results provide crucial
evidence linking H2O2 production to insulin-mediated signal transduction. Addition-
ally, co-expression of PTP1B and Nox4 reverses phosphatase activity and increases
Tyr phosphorylation. PTP1B plays an important role in downregulation of insulin
signaling and is an established therapeutic target for type 2 diabetes (179). PTP1B
knockout mice are healthy and exhibit heightened insulin sensitivity, enhanced glucose
and insulin tolerance, and are resistant to diet-induced obesity (180, 181). In partic-
ular, this has stimulated therapeutic-based approaches that target and recognize the
inactive form of PTPs (182, 183).
Accumulating evidence has speculated that direct modulation of IRK occurs upon
H2O2 exposure, but the functional details of this process are not fully character-
ized (184, 185). Iodoacetamide (IAM) treatment increases the catalytic activity of
the IRK cytoplasmic domain, whereas another alkylating agent, NEM, inhibits the
receptor (124). Regardless, both sulfhydryl agents strongly indicate that functional
activity of IRK can be mediated by oxidative modification of one or more cysteine
residues located within the IRK β chains. In a separate study, inhibitors of glu-
tathione synthetase (BSO) or glutathione reductase (BCNU, 1,3-bis-(2-chloroethyl)-
1-nitrosourea) were used to modulate intracellular GSH levels in IRK transfected
CHO cells (186). Both inhibitors increase the GSSG/GSH ratio to induce a moder-
ate shift to mildly oxidative conditions, and lead to structural and functional changes
in the IRK β-chain. Additionally, decreased sulfhydryl groups were observed in IRK
β-chains in the absence of detectable Tyr phosphorylation. These results suggest
IRK may proceed through a "redox-priming stage", wherein specific cysteine residues
undergo oxidative modification prior to full activation through receptor autophos-
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phorylation. Later studies with isolated IRK from transfected CHO cells provide a
functional role for redox-based receptor modulation (187). IRK autophosphorylation
is inhibited by binding of ADP within its catalytic active site, which serves to reg-
ulate kinase activity. Exposure to H2O2 induces oxidation of two residues (Cys1245
and Cys1308), nucleotide release, and reverses receptor inhibition. It is important
to note that direct redox modulation of IRK can promote insulin signaling, but may
also contribute to obesity. In muscle cells, cytoplasmic creatine kinase mediates the
rapid removal of ADP to promote IRK activation (188). This process does not oc-
cur in adipocytes, and represents a potentially advantageous mechanism to modulate
IRK activity in muscle cells. This advantage may be decreased if ADP conversion in
adipocytes is elevated due to increased H2O2 levels.
Fibroblast Growth Factor Receptor (FGFR)
Fibroblast growth factors (FGF) and their receptors (FGFRs) regulate devel-
opmental signaling pathways and are expressed in many different cell types (189).
The mammalian FGF family is composed of 18 distinct ligands, and exerts its ac-
tions through 4 highly conserved transmembrane RTKs (FGFR1, FGFR2, FGFR3,
and FGFR4). Upon stimulation, FGFR undergoes receptor dimerization and Tyr
autophosphorylation within its intracellular kinase domain. These residues act as
docking sites for adaptor proteins and lead the activation of four key downstream
pathways: 1) Ras/MAPK pathway, 2) PI3K/Akt pathway, 3) STAT (signal trans-
ducer and activator of transcription), and 4) PLC-γ.
The molecular mechanisms underlying redox regulation of FGFR remains the
least characterized amongst other RTKs. Initial studies demonstrate that basic FGF
(bFGF) induces H2O2 production upon stimulation in chondrocytes (190). FGF sig-
naling promotes early response genes such as c-fos and c-jun, which dimerize to form
the AP-1 transcription factor. Exposure to exogenous H2O2 recapitulates these ob-
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servations in chondrocytes and other cell types (191, 192). Additionally, cells treated
with DPI exhibit decreased H2O2 levels upon growth factor stimulation. These results
suggest that a Nox complex may serve as the oxidant source during FGF signaling, al-
beit further studies are necessary to confirm these observations. In an isoform-specific
study with PDGF and FGF, endogenous H2O2 facilitates adipose differentiation in
3T3-L1 adipocytes (66). Alternatively, FGF stimulation may generate H2O2 through
mechanisms independent of Nox complexes. In lung fibroblasts, Nox activity was
measured and remained unchanged during growth factor stimulation. Expression of a
dominant-negative Ras mutant (RasN17) diminishes signal-induced H2O2 production
and suggests it may proceed through a Ras-dependent mechanism (193).
A more recent study identifies direct oxidation of cysteine residues in FGFR. These
residues were first characterized in cytoplasmic Src (c-Src) using cysteine mutants to
distinguish decreased responses to H2O2 exposure (194). Mutation of c-Src Cys277
abolishes its sensitivity to H2O2 during in vitro assays, and maintains the kinase in a
constitutively active form. Gel analysis reveals oxidation of Cys277 inactivates c-Src
by forming homodimers connected by a disulfide bond. Cys277 is located within a
glycine rich loop (GQGCFG, Gly loop), which participates in catalysis by interacting
with the γ-phosphate of ATP. The Gly loop is a universally conserved signature motif
present among all protein kinases, but intervening residues can be variable (195).
Sequence analysis reveals that only a small subset of protein kinases (∼ 8) contains
a homologous residue at an equivalent position to c-Src Cys277. These include 3 of
10 Src family kinase members (Src, Yes, Fgr) and all 4 FGFR family members. To
confirm its significance, the equivalent residue in FGFR1 (Cys488) was mutated and
subjected to similar assays to assess its functional role. C488A attenuates the ability
of FGFR1 to respond to H2O2 and inactivates the kinase, as observed with c-Src.
This mutation does not completely abolish FGFR1 dimerization and suggests that
there may be other contributing factors. Although this study identifies a conserved
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redox active cysteine found in Src and FGFR family members, the cellular significance
of this modification currently remains unknown and presents a potential regulatory
mechanism unique to a small subset of kinases.
Non-Receptor Kinases
Akt (also named Protein Kinase B, PKB)
The serine/threonine kinase Akt is a central node downstream of growth factors,
cytokines, and other cellular stimuli (31). As described earlier, Akt can be acti-
vated by a wide range of stimulants, and is dependent on upstream production of
lipid products by PI3K. Negative regulation of Akt is maintained through direct de-
phosphorylation by protein phosphatase 2A (PP2A) (196), or phosphatase activity
of PTEN towards PIP3 (197). Akt has three isoforms (Akt1, Akt2, and Akt3), and
achieves signaling specificity through tissue-specific expression (198). Akt1 is the
predominantly expressed isoform in a majority of tissues, whereas Akt2 is found to
be highly enriched within insulin targeted-tissues (199, 200). In particular, Akt2-
deficient mice are insulin resistant and display a diabetic-like phenotype (201). Akt1-
null mice have normal glucose tolerance, but exhibit severe growth retardation (202,
203). These mice models demonstrate Akt isoforms are not functionally redundant
and are differentially expressed based on substrate preference and subcellular dis-
tribution. Aberrant gain or loss of Akt function underlies the pathological states
in a variety of diseases, and represents a prominent target for the development of
therapeutic strategies (204).
Signal-mediated production of endogenous H2O2 has been shown to increase Akt
activation in numerous cell types and is modulated by a various signaling components
(205). Exposure to PI3K inhibitors (wortmannin and LY294002) strongly attenuates
Akt phosphorylation levels and indicates upstream PI3K activation is required for
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redox-based modulation of Akt (206). Studies report that H2O2 can induce PIP3 lev-
els in cells overexpressing Nox1 (68), or accumulate PIP2 under conditions of oxidative
stress (207). These lipids bind to Akt to increase its activity and propagate down-
stream events. H2O2 activation of Akt is also mediated in part by Src kinase (208).
The detailed mechanism underlying this relationship has not been completely delin-
eated, but may be due to Src-mediated interference of PTEN phosphatase activity
(209). Additionally, EGFR-dependent activation of Akt enhances cell survival during
H2O2-induced apoptosis (210). Overexpression of constitutively active Akt in HeLa
and NIH 3T3 fibroblasts results in approximately 40% fewer apoptotic cells when
compared to control cells. These results indicate Akt activity may be elevated under
conditions of stress to promote cell survival, parallel to observations obtained with
Erk1/2 (211). Interestingly, Akt nitrosylation inactivates the kinase and is suggested
to contribute to redox-based insulin resistance as well (212, 213).
Redox modulation of multiple cysteine residues have been identified and shown
to regulate Akt kinase activity. Treatment with NEM blocks PDGF-induced Akt
activation without affecting PI3K function (214). Additionally, NEM inhibits phos-
phorylation of several Akt downstream effectors, which includes the p70S6K, 4E-BP1,
BAD, and FKHR family of transcription factors. These results suggest that sulfhydryl
alkylation interferes with the PI3K/Akt pathway at the Akt level. Crystal structures
reveal Akt2 forms an intramolecular disulfide bond (Cys297 and Cys311) within its
activation loop, which inactivates the kinase (215). These residues are conserved in
all three Akt isoforms, but do not significantly alter kinase activity in other isoforms.
Inactive Akt2 can be rescued by glutaredoxin (Grx) through reduction of this disulfide
to protect cells against apoptosis (216). Grx overexpression suppresses recruitment
of PP2A to Akt to sustain phosphatase activity and promote cell survival. A more
recent study identifies a third cysteine residue responsible for isoform-specific redox
regulation of Akt (217). Using DCP-Bio1, the authors observed that Akt2 forms
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a sulfenic acid in response to PDGF stimulation that inactivates the kinase. MS
analysis coupled with dimedone labeling and H2O2-treated Akt2 identified a sulfenyl
modification at Akt2 Cys124. This residue is located in the Akt2 linker region, is
not conserved in other isoforms, and is partially responsible for oxidative inactivation
of Akt2. Parallel H2O2 treatment of NIH 3T3 cells induces indiscriminate Tyr phos-
phorylation of Akt1 and Akt2, but eventually leads to oxidative inactivation of only
Akt2. Additionally, glucose uptake was decreased in WT Akt2, and was unperturbed
in an Akt2 C124S mutant. Although H2O2 induces Akt activation in many scenarios,
it appears that oxidative modification of these three cysteine residues may serve to
control the amplitude of Akt2 during signaling.
MAPK (Erk1/2, JNK, p38)
MAPKs are serine/threonine specific kinases that are modulated by a number
of receptor-ligand interactions (218–221). Although MAP kinases are composed of
five subfamilies, we will focus mainly on evidence implicating redox modulation of
Erk1/2, JNK, and p38. Activation of MAPKs proceeds through a three-tiered cas-
cade that begins with a MAP kinase kinase kinase (MEKK or MAP3K), MAP kinase
kinase (MEK or MAP2K), and ends with MAPK to elicit its respective effectors.
MAPKs have distinct functional roles; Erk1/2 mediates pro-survival events, whereas
JNK and p38 are mainly involved in stress-related responses (222, 223). The compo-
nents involved in redox regulation of MAPKs have been covered extensively in other
reviews (27). Therefore, specific examples emphasizing the functional role of cysteine







Figure 9: ASK1 Models for Oxidation


























Figure B.9: Two proposed models for redoxbased activation of ASK1. (a) Trx1 oxidation
model. In the cell, ASK1 assembles into multimers that interact with Trx1. Association of Trx1
with ASK1 sequesters the kinase in an inactive conformation that is released upon oxidation of
Trx1 by H2O2. Once released, activated ASK1 interacts with additional binding proteins (BPs)
to initiate downstream signaling. (b) ASK1 oxidation model. In this second model, H2O2 induces
intermolecular disulfide bond formation between ASK1 monomers to promote kinase activation and
multimerization. Trx1 is suggested to negatively regulate ASK1 signaling by maintaining the kinase
in its reduced state.
Early studies demonstrate that Erk1/2 is activated in response to H2O2 and en-
hances cell survival following oxidant injury (211, 224). H2O2 treatment increases
Erk1/2 phosphorylation levels 10-20 fold, and moderately for JNK and p38 (∼ 3-5
fold). RasN17 expression diminishes H2O2-induced Erk1/2 activation, and renders
cells more sensitive to apoptosis when compared to WT controls. Ras can undergo
S -nitrosylation at Cys118, and represents one mechanism by which redox regulation
of Erk1/2 can occur upstream (225). Additionally, overexpression of constitutively
active MEK promotes increased cellular resistance to H2O2 toxicity. These results
demonstrate stimulant-induced H2O2 production appears to affect protein targets
upstream of Erk1/2 to initiate kinase activity.
Distinct mechanisms have evolved to regulate redox-based responses of MAPK
family members. For example, c-Src mediates JNK activation by promoting Cas-Crk
complex formation in response to H2O2 (226). Cas is a c-Src substrate known to
trigger JNK signaling (227). Furthermore, JNK is inhibited in Src-deficient mice or
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when treated with Src inhibitors (PP2). This mechanism is unique to JNK, and is
not observed with respect to Erk1/2 or p38. Alternatively, Prxs represent another
regulatory component involved in JNK signaling. Although the major role of Prxs
is to catalyze H2O2 decomposition, one study provides mechanistic evidence demon-
strating direct JNK activation by Prx (228). Sty1, a JNK homologue found in fission
yeast, forms a H2O2-induced intermolecular disulfide bond with Tpx1 (2-Cys Prx).
This bond activates Sty1, and forms between the catalytic cysteine of Tpx1 (Cys48)
and Sty1 (Cys35). Both residues are conserved in their mammalian counterparts, and
suggest similar mechanisms may exist in other eukaryotes. In macrophages, JNK is
negatively modulated by S-nitrosylation at Cys116 (229).
Additionally, upstream elements of MAPKs are also subject to direct redox regu-
lation. The apoptosis signal-regulating kinase (ASK1)/Trx1 system is a well-known
complex explored by many researchers. ASK1 is a MAP3K responsible for activating
JNK and p38 pathways, and is required for tumor necrosis factor-α (TNF-α) me-
diated apoptosis (230). Two models have been proposed to describe H2O2-induced
ASK1 activation. In the first model (Figure B.9a), Trx1 sequesters ASK1 in an inac-
tive complex and undergoes intramolecular disulfide formation upon TNF-α or H2O2
stimulation. This releases ASK1, permits oligomerization, and leads to formation of
the active complex (231, 232). However, a later study (Figure B.9b) demonstrates
stable ASK1 oligomerization and activation is mediated by disulfide bond formation
between ASK1 monomers (233). This alternate model suggests Trx1 negatively regu-
lates ASK1 by maintaining its reduced state. Oxidation of ASK1 Cys250 is essential
for H2O2-dependent activation of JNK, albeit the exact details underlying this mod-
ification are unknown (234). ASK1 C250A mutants attenuate Trx1 association, but
do not activate JNK. These results suggest simple dissociation of Trx1 is not sufficient
to promote downstream signaling and that oxidative modification of C250 may in-
duce conformational changes in ASK1 to prompt pathway activation. Contrastingly,
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S -nitrosylation of ASK1 (Cys869) inactivates the kinase by interfering with MAP2K
binding (235).
MEKK1 is another MAP3K responsible for JNK activation, and forms a glu-
tathione adduct at Cys1238 upon H2O2 treatment (236). This residue is located in
the ATP binding domain, and represents one of many mechanisms utilized to obtain
signaling specificity in MAPK pathways. Interestingly, MKK6 (MAP2K activator of
p38) was recently identified to form an intramolecular disulfide bond (Cys109 and
Cys196) (237). Bond formation negatively regulates p38 by interfering with its ATP
binding ability. Sequence alignment of MKK6 reveals that these two residues are
conserved in all 7 human MAP2Ks. Similar experiments demonstrates that other
MAP2Ks (MKK1 and MKK4) undergo oxidative inactivation analogous to MKK6.
Another study demonstrates p38 may also contain redox-sensitive cysteines (Cys119
and Cys162) that reversibly inactivate the kinase upon oxidation (238). Non-reducing
gel analysis suggests these residues do not form an intramolecular disulfide, but the
exact identity of this modification remains unclear and further studies are necessary
to probe its functional relevance. Although many studies have reported H2O2-induced
activation of MAPK pathways, redox-based inactivation of upstream components also
serves to modulate MAPK signal duration.
c-Src
Cytoplasmic Src (c-Src) is a tyrosine kinase and a key regulator of proliferation,
survival, cytoskeletal organization, and integrin-dependent signaling responses (239,
240). Abnormal expression or hyperactivation of c-Src is present in several human
malignancies and has been linked to the development of human cancers (241). As
mentioned previously, c-Src interacts with many ligand-activated RTKs and affects
a number of substrates that include adaptor proteins, focal-adhesion proteins, and
transcription factors. The Src family of kinases (SFKs) is composed of nine mem-
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bers and can be mostly grouped into two subfamilies, namely the Src-related (Src,
Yes, Fyn, Fgr) and the Lyn-related (Lyn, Hck, Lck, Blk) kinases. c-Src and other
SFK members share a conserved domain architecture composed of an N-terminal
region with high variability among family members to enable distinct functionality,
followed by SH3, SH2, and tyrosine kinase (SH1) domains flanked by a C-terminal
tail (Figure B.10). c-Src contains two residues (Tyr416 and Tyr527) endowed with
opposing regulatory mechanisms. Phosphorylation of C-terminal Tyr527 locks Src
in an inactive conformation by binding to its SH2 domain, and is further clinched
by interactions between the SH2 and SH3 domains (242). In this conformation, the
activation loop (A-loop) adopts a compacted structure that precludes ATP access
and kinase activation through Tyr416. Concurrent dephosphorylation of Tyr527 and
disruption of SH2/SH3 interactions induces an open conformation to enable Tyr416































Figure B.10: Regulation of c-Src. Inactive c-Src exhibits a "closed" conformation, characterized
by binding of phosphorylated Tyr527 to its SH2 domain and interactions between its SH2/SH3
domains. Growth factors and cytokines initiate c-Src activation by promoting concurrent dephos-
phorylation of Tyr527 and disruption of SH2/SH3 interactions to induce an "open" conformation
for Tyr416 autophosphorylation. In the late phase of activation, signal-derived H2O2 mediates the
formation of an intramolecular disulfide bond between c-Src Cys245 and Cys487. Bond forma-
tion promotes kinase activation, Src-mediated cell adhesion, and cytoskeletal reorganization events.
Adapted from (243).
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Studies reporting H2O2-induced Src activation are typically accompanied by in-
creased Tyr416 phosphorylation (244, 245), whereas inactivation is invariably accom-
panied by increased Tyr527 phosphorylation (246, 247). These complications make
it difficult to ascertain whether these effects are due to direct or indirect regula-
tory mechanisms (243, 248). c-Src is involved in mediating redox-based responses
of many signaling components within the Ras/MAPK or PI3K/Akt pathways, and
Nox complexes. Suppression of c-Src activity with chemical inhibitors, antisense
oligonucleotides, or Src knockout mice interferes with the ability of these pathways
to effectively respond to oxidants during signaling and conditions of oxidative stress
(249–251). Negative regulation of Src is due to phosphorylation of Tyr527 by Csk
(C-terminal Src kinase). Csk is unique among other tyrosine kinases because it only
phosphorylates one class of substrate, the conserved Tyr residue located within the C-
terminal tail of SFKs (252). Interestingly, evidence suggests the relationship between
Src and Csk may be subject to redox regulation. The SH2 domain of Csk contains
two cysteine residues (Cys122 and Cys164) that form a unique intramolecular disul-
fide bond, and is not present in other known SH2 domains (253). Bond formation
induces a conformational change and is correlated to decreased Csk catalytic activ-
ity. Therefore, this disulfide may serve as a regulatory mechanism to suppress Src
inhibition through Csk-mediated phosphorylation. Crystal structures of the Csk-Src
complex reveal that disulfide formation occurs between Src Cys277 and Csk Cys290
(254). This does not form within the same kinase-substrate complex, but rather,
is composed from Src and Csk in two separate heterodimers. Structural analysis
demonstrates this disulfide is crucial in positioning the C-terminal tail of c-Src near
the Csk active site to promote Tyr527 phosphorylation. Many Tyr kinases contain a
canonical substrate binding site allowing for phosphorylation of several effectors that
is destabilized in Csk. Consequently, Csk solely phosphorylates SFK members due
to this. The two aforementioned studies demonstrate different functional roles that
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disulfide bond formation plays in modulating Src activation.
Cellular studies provide evidence that cysteine oxidation can directly affect c-Src
activity, albeit with contradictory conclusions. Evidence for both cases will be pre-
sented, but it is important to note contrasting results may be due to the cell types
used or sample manipulation. An initial study reports treatment of NIH 3T3 fibrob-
lasts or immunoprecipitated c-Src with exogenous NO donors (i.e. SNAP) promotes
kinase activation through S-nitrosylation (255). The sulfhydryl residues responsi-
ble for this were not identified, but seemingly enhanced Tyr416 autophosphorylation.
More recent work identifies c-Src Cys498, a conserved residue in SFK members, as the
target of NO-mediated kinase activation (256). H2O2 activation of c-Src has also been
reported to occur during cell adhesion events. Integrin ligation elicits production of
H2O2 by lipoxygenases (5-LipOX) to induce c-Src activation through an intramolecu-
lar disulfide bond (Cys245 and Cys487) (257). These residues are respectively located
within the SH2 and kinase domains of c-Src. During cell adhesion, evidence suggests
c-Src proceeds through a biphasic activation process that begins with an early phase
characterized by formation of focal adhesions and Tyr527 dephosphorylation. A late
phase quickly ensues and is distinguished by lipoxygenase-derived H2O2 and phospho-
rylation of Tyr416. c-Src cysteine mutants demonstrate that disulfide bond formation
is required to induce Tyr416 hyperactivation. These combined events demonstrate
H2O2 promotes kinase activation and Src-mediated cell adhesion and cytoskeletal re-
organization (Figure B.10). Lyn, another SFK member, contains a single cysteine
residue (Cys466) that functions as a redox senor to mediate leukocyte wound attrac-
tion in zebrafish (258). Alternatively, H2O2 has also been shown to suppress Src
activation in other studies. As discussed in detail in the FGFR section, a conserved
cysteine residue (Cys277) originally identified in c-Src promotes kinase inactivation
upon oxidative modification. The significance of this residue, homologous in SFK and
FGFR members, was similarly demonstrated with FGFR1. Therefore, it is reason-
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able to conclude that opposing regulatory redox mechanisms exist to modulate c-Src
activity akin to its phosphorylation sites.
IKK (Inhibitory κB kinase)
Inhibitory κB kinase (IKK) is a serine/threonine kinase primarily responsible for
activation of transcription factor nuclear factor-κB (NF-κB). IKK is composed of
two catalytic subunits, IKKα and IKKβ, and regulatory subunit IKKγ. Stimulation
with cytokines such as TNFα (tumor necrosis factor α) or interleukins induces Ser
phosphorylation of IKKα and IKKβ subunits by upstream kinases (i.e. MEKK1,
Akt). The activated IKK complex phosphorylates inhibitory κB (IκB) proteins, which
maintain and sequester NF-κB in its latent form in the cytoplasm. Phosphorylation
fosters inducible degradation of IκB proteins and unmasks the nuclear localization
signal (NLS) of NF-κB to promote nuclear translocation (Figure B.11). NF-κB binds
to recognition motifs and activates gene transcription of over ∼100 target genes that
mediate inflammatory response, proliferation, and survival. NF-κB can be directly
activated by ROS during TNFα signaling and has been extensively analyzed in a
number of studies (259).
ROS can also modulate activity of upstream components within the NF-κB path-
way. For example, IKK becomes inactivated upon stimulation with NO or H2O2.
Exposure of epithelial cells with exogenous NO donor SNAP inhibits IKK kinase ac-
tivity, but does not interfere with enzyme activation (260). These results suggest NO
directly modifies IKK rather than acting upon upstream components. MS analysis
identified IKKβ Cys179 as the major target for S -nitrosylation leading to kinase inac-
tivation. Repression of endogenous NO using NO synthase (NOS) inhibitors relieved
SNO-based IKK complex inactivation in Jurkat T cells. Cys179 is strategically lo-
cated between the two Ser residues (Ser177 and Ser181) required for IKKβ activation
by TNFα. Therefore, it is probable that IKK phosphorylation at its Ser residues
311





















Figure B.11: IKK activation of NF-κB. Stimulation with cytokines (i.e. TNFα or interleukins)
triggers Ser phosphorylation of the IKK complex by upstream kinases such as MEKK1 or Akt.
Once activated, IKK phosphorylates IκB proteins, which negatively regulate NF-κB and maintain
the latent transcription factor in the cytoplasm. Phosphorylation of IκB unmasks the nuclear local-
ization signal of NF-κB, and promotes nuclear translocation. Once NF-κB is released, IκB proteins
are subsequently degraded by proteasomes. In addition, IKK can be inactivated by endogenously
produced H2O2 or NO through direct modulation of Cys179.
may induce a negatively charged environment surrounding Cys179 to promote its
susceptibility to S -nitrosylation. Interestingly, IKKβ Cys179 undergoes inactivation
upon exposure to environmental toxins (261). IKK inhibition due to H2O2-induced
oxidation is also observed in TNFα stimulated epithelial cells (262). MS analysis and
dimedone-based experiments reveal that IKKβ Cys179 proceeds through a sulfenic
acid intermediate to form a glutathione adduct (263). S -glutathionylation of IKKβ
Cys179 is reversed by Grx to restore intrinsic kinase activity. Collectively, these re-
sults demonstrate S -glutathionylation is a physiologically relevant mechanism that
controls the magnitude of NF-κB activation. Multiple studies have identified a num-
ber of Cys179 modification states due to different oxidant sources, indicating redox
regulation of the IKK complex functions in a complex manner. In contrast, studies
have also reported H2O2-mediated activation of IKK; however, it is important to note
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Although PTPs were originally identified as the main targets of signal-derived
H2O2, direct modulation of protein kinases by reversible cysteine oxidation has been
identified in a continuously growing number of examples (Table B.2). For instance,
S -glutathionylation of c-Abl, a non-receptor Tyr kinase, serves to regulate kinase
activity under conditions of oxidation stress (266). Specific cysteine residues in two
other kinases, ataxia-telangiectasia mutated (ATM) kinase and pyruvate kinase M2
(PKM2), have recently been identified and exhibit distinct functional responses to
oxidation. ATM is activated by DNA double-strand breaks (DSBs) and orchestrates
signaling pathways that initiate DNA damage response. Upon exposure to H2O2,
ATM is activated through an intermolecular disulfide at Cys2991 (267, 268). Redox-
based ATM activation occurs separately from DNA damage-based kinase activation,
and represents a branch point wherein ATM can also act to modulate global cellular
responses to oxidative stress. Moreover, oxidation of PKM2 at Cys358 was shown
to inactivate the kinase in A549 lung cancer cells (269). PKM2 inactivation diverts
glucose flux into the pentose phosphate pathway and results in increased generation of
reducing equivalents (NADPH) for the detoxification of ROS through Prx, GSH, and
Trx systems. These recent discoveries demonstrate the likelihood that other kinases
may rely on redox-based mechanisms that remain to be unraveled.
The catalytic cysteine of PTPs serves as a well-established regulatory switch dur-
ing H2O2-mediated signaling to promote kinase activation and downstream signaling
in a controlled manner. Therefore, it is intriguing that similar mechanisms may
regulate PTKs containing conserved cysteine residues. Eight protein kinases, which
include SFK and FGFR members, share a cysteine residue located within a conserved
glycine-rich loop (194). This residue causes kinase inactivation in vitro, albeit the
cellular function of this modification remains unknown. Of the ∼95 receptor and
non-receptor PTKs in the human genome, nine additional members harbor a cys-
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Figure B.12: Abbreviated sequence alignment of EGFR and nine additional kinases that
harbor a cysteine residue structurally homologous to EGFR Cys797. This group includes
two erbB family members, HER2 and HER4.
teine residue that corresponds to EGFR Cys797, including two erbB family members
(HER2 and HER4) (Figure B.12). Cys797 and its structural homologues serve as the
N-terminal end of an alpha helix known as the Ncap position. Interestingly, cysteine
is the most sparsely occurring Ncap residue in proteins and comprises less than 1% of
these positions (270). Interaction of a cysteine residue with the helical dipole within
an Ncap context reduces the pKa of the residue, which inherently increases its reactiv-
ity (271). Efforts focused on delineating the molecular mechanisms by which protein
kinases are directly modulated by H2O2 could uncover general signaling mechanisms
that regulate kinases and their structural homologues.
Aberrant kinase activation has been identified in a number of human pathologies,
as referenced for each kinase within its respective section. This has stimulated efforts
to develop therapeutic strategies such as antibodies and reversible inhibitors to target
specific kinase classes. Many reversible inhibitors attenuate kinase activation by inter-
fering with the ATP binding site. Additionally, irreversible inhibitors have also been
developed for certain kinases (272, 273). For example, EGFR is mutated or amplified
in a number of human carcinomas such as breast and lung cancers. This has motivated
the development of a class of selective kinase inhibitors that covalently modify EGFR
Cys797 (274, 275). Several of these irreversible EGFR inhibitors are currently under-
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going preclinical or clinical trials (136, 137). Overexpression of EGFR and HER2 is
correlated to increased H2O2 levels and global protein oxidation in breast cancer cell
lines (276). When coupled to recent evidence that identifies sulfenic acid modifica-
tion of EGFR Cys797, these findings raise several fundamental questions regarding
cysteine modifications versus thiol-targeted covalent inhibitors. The aforementioned
irreversible EGFR inhibitors contain an acrylamide moiety that undergoes Michael
addition with Cys797 in its thiol form, but are not capable of reacting with sulfenic
acid or disulfide states. Oxidative modification of Cys797 could impact the potency
of these inhibitors, particularly in cancers characterized by high levels of stress and
aberrant H2O2 levels. Therefore, the sulfenyl form of EGFR Cys797 could be ex-
ploited to develop new classes of irreversible inhibitors that incorporate nucleophilic
warheads akin to chemical probes recently developed for PTPs (277). If success-
ful, redox-based EGFR inhibitors would exhibit enhanced selectively for cancerous
cells exhibiting high levels of oxidative stress, and may reduce the toxicity caused by
acrylamide-based compounds. Analogous approaches could be employed to generate
nucleophilic warheads for other classes of redox-modulated protein families as well.
Conclusions
The role of protein kinases in physiologic and pathological settings represents an
active and exciting area of research. The collective efforts of several individuals have
contributed tremendously towards uncovering the underlying mechanisms involved
in redox-regulation of protein kinases. These studies have expanded our knowledge
and demonstrate that kinases may be modulated both directly and indirectly upon
stimulant-induced H2O2 production. The continued efforts to dissect kinase function
will further our basic understanding of kinase redox-regulation, uncover new protein
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